[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Pharmaceutical Innovations, Inc.\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":397},{"warningLetters":4,"total":396},[5,32,52,74,95,112,127,153,174,195,213,230,250,269,287,310,328,346,363,380],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":27,"body_fetched_at":28,"delivery_method":29,"recipient_title":19,"reference_number":30,"action_taken_date":31,"medical_device_id":19,"response_letter_date":19},1068,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2025-02-11T05:00:00Z\">02\u002F11\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-02-05T05:00:00Z\">02\u002F05\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fchengdu-innovation-pharmaceutical-co-ltd-698786-02052025\">Chengdu Innovation Pharmaceutical Co., Ltd.\u003C\u002Fa>","Center for Drug Evaluation and Research (CDER)","CGMP\u002FActive Pharmaceutical Ingredient (API)\u002FAdulterated","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-25-40\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Ren Zhongju\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Chengdu Innovation Pharmaceutical Co., Ltd.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>No.123, 1st Floor, No 91 Zhongheng Street\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Jinniu Qu\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Chengdu Shi\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Sichuan Sheng\u003C\u002Fspan>, \u003Cspan>610036\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>China\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-25-40\u003C\u002Fp>\u003Cp>February 5, 2025\u003C\u002Fp>\u003Cp>Dear Ren Zhongju:\u003C\u002Fp>\u003Cp>Your facility was registered with the United States Food and Drug Administration (FDA) as a manufacturer of active pharmaceutical ingredients (APIs). FDA has reviewed the records you submitted in response to our April 29, 2024 request for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) for your facility, Chengdu Innovation Pharmaceutical Co., Ltd., FEI 3027222600, No.123, 1st Floor, No 91 Zhongheng Street, Jinniu District, Chengdu, Sichuan, China.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant deviations from Current Good Manufacturing Practice (CGMP) for API.\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding of drugs as described in your response to our 704(a)(4) request do not conform to CGMP, your APIs are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>Following review of records and other information provided pursuant to section 704(a)(4) of the FD&amp;C Act, significant deviations were observed including, but not limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cu>704(a)(4) Request for Records and Related CGMP Deviations\u003C\u002Fu>\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Failure to test the identity of each lot of incoming production material.\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You manufacture APIs that were distributed to \u003Cstrong>(b)(4)\u003C\u002Fstrong> in the United States. Based on the records and information you provided, you have not demonstrated that you are adequately testing each shipment of each lot of incoming materials. Specifically in response to our request, you state that you do not perform identity testing on each shipment of each lot of incoming material before they are released for use in drug manufacturing.\u003C\u002Fp>\u003Cp>Without adequate testing, you do not have scientific evidence that incoming materials conform to appropriate specifications prior to use in the manufacture of your drugs. As a manufacturer, you have a responsibility to sample, test, and examine incoming materials before use in production to assure adequate quality.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A description of how you will test each incoming material lot for conformity with all appropriate specifications for identity. If you intend to accept any results from your supplier’s certificate of analysis (COA) instead of testing each incoming material lot for other tests, specify how you will ensure that you have adequate evidence to establish that the supplier consistently provides material meeting specifications. In addition, include a commitment to always conduct at least one specific identity test for each incoming material lot.\u003C\u002Fli>\u003Cli>A comprehensive, independent review of your material system to determine whether all suppliers of incoming materials are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable materials.\u003C\u002Fli>\u003Cli>A summary of your program for qualifying and overseeing contract facilities that test the drugs you manufacture.\u003C\u002Fli>\u003Cli>A summary of results obtained from testing all incoming materials to evaluate the reliability of the COA from each incoming materials manufacturer. Include your standard operating procedure that describes this COA validation program.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Failure of your quality unit to establish a system to release or reject raw materials, intermediates, packaging, and labeling materials.\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The records and information you provided demonstrate that your quality unit (QU) did not effectively exercise its responsibilities to oversee the quality of your drug manufacturing operations. Specifically, your QU did not establish an appropriate system to approve or reject incoming materials.\u003C\u002Fp>\u003Cp>Your QU is responsible for fully exercising its authority and responsibilities.\u003C\u002Fp>\u003Cp>An adequate QU overseeing all elements of CGMP is necessary to consistently ensure drug quality. FDA considers the expectations outlined in ICH Q7 when determining whether API are manufactured in conformance with CGMP, including sections on quality oversight. See FDA’s guidance document \u003Cem>Q7 Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients\u003C\u002Fem> for guidance regarding CGMP for the manufacture of API at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71518\u002Fdownload.\">https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71518\u002Fdownload.\u003C\u002Fa>\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003Cbr>o A determination of whether procedures used by your firm are robust and appropriate.\u003Cbr>o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\u003Cbr>o A complete and final review of each batch and its related information before the QU disposition decision.\u003Cbr>o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, quality, and purity of all products.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based upon the nature of the deviations we identified at your firm, you should engage a consultant qualified to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions.\u003C\u002Fp>\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The deviations cited in this letter are not intended to be an all-inclusive list of deviations that exist at your facility. You are responsible for investigating and determining the causes of any deviations and for preventing their recurrence or the occurrence of other deviations.\u003C\u002Fp>\u003Cp>FDA placed products offered for import into the United States from your firm on Import Alert 66-40 on January 17, 2025.\u003C\u002Fp>\u003Cp>Correct any deviations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any deviations are completely addressed and we confirm your compliance with CGMP. We may inspect to verify that you have completed corrective actions to any deviations.\u003C\u002Fp>\u003Cp>Failure to address deviations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any deviations are completely addressed and we confirm your compliance with CGMP. We may inspect your facility to verify that you have completed corrective actions to address any deviations.\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 30 working days. Specify what you have done to address any deviations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003Cbr>\u003Cbr>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3027222600 and ATTN: William Yang.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nReference #:\n\n320-25-40\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nRen Zhongju\n\nChengdu Innovation Pharmaceutical Co., Ltd.\n\nNo.123, 1st Floor, No 91 Zhongheng Street\n\nJinniu Qu\n\nChengdu Shi\n\nSichuan Sheng, 610036\n\nChina\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-25-40\nFebruary 5, 2025\nDear Ren Zhongju:\nYour facility was registered with the United States Food and Drug Administration (FDA) as a manufacturer of active pharmaceutical ingredients (APIs). FDA has reviewed the records you submitted in response to our April 29, 2024 request for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) for your facility, Chengdu Innovation Pharmaceutical Co., Ltd., FEI 3027222600, No.123, 1st Floor, No 91 Zhongheng Street, Jinniu District, Chengdu, Sichuan, China.\nThis warning letter summarizes significant deviations from Current Good Manufacturing Practice (CGMP) for API.\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding of drugs as described in your response to our 704(a)(4) request do not conform to CGMP, your APIs are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nFollowing review of records and other information provided pursuant to section 704(a)(4) of the FD&C Act, significant deviations were observed including, but not limited to, the following:\n704(a)(4) Request for Records and Related CGMP Deviations\n1. Failure to test the identity of each lot of incoming production material.\nYou manufacture APIs that were distributed to (b)(4) in the United States. Based on the records and information you provided, you have not demonstrated that you are adequately testing each shipment of each lot of incoming materials. Specifically in response to our request, you state that you do not perform identity testing on each shipment of each lot of incoming material before they are released for use in drug manufacturing.\nWithout adequate testing, you do not have scientific evidence that incoming materials conform to appropriate specifications prior to use in the manufacture of your drugs. As a manufacturer, you have a responsibility to sample, test, and examine incoming materials before use in production to assure adequate quality.\nIn response to this letter, provide:\nA description of how you will test each incoming material lot for conformity with all appropriate specifications for identity. If you intend to accept any results from your supplier’s certificate of analysis (COA) instead of testing each incoming material lot for other tests, specify how you will ensure that you have adequate evidence to establish that the supplier consistently provides material meeting specifications. In addition, include a commitment to always conduct at least one specific identity test for each incoming material lot.\nA comprehensive, independent review of your material system to determine whether all suppliers of incoming materials are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable materials.\nA summary of your program for qualifying and overseeing contract facilities that test the drugs you manufacture.\nA summary of results obtained from testing all incoming materials to evaluate the reliability of the COA from each incoming materials manufacturer. Include your standard operating procedure that describes this COA validation program.\n2. Failure of your quality unit to establish a system to release or reject raw materials, intermediates, packaging, and labeling materials.\nThe records and information you provided demonstrate that your quality unit (QU) did not effectively exercise its responsibilities to oversee the quality of your drug manufacturing operations. Specifically, your QU did not establish an appropriate system to approve or reject incoming materials.\nYour QU is responsible for fully exercising its authority and responsibilities.\nAn adequate QU overseeing all elements of CGMP is necessary to consistently ensure drug quality. FDA considers the expectations outlined in ICH Q7 when determining whether API are manufactured in conformance with CGMP, including sections on quality oversight. See FDA’s guidance document Q7 Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients for guidance regarding CGMP for the manufacture of API at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71518\u002Fdownload.\nIn response to this letter, provide:\nA comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\no A determination of whether procedures used by your firm are robust and appropriate.\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\no A complete and final review of each batch and its related information before the QU disposition decision.\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, quality, and purity of all products.\nCGMP Consultant Recommended\nBased upon the nature of the deviations we identified at your firm, you should engage a consultant qualified to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions.\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\nConclusion\nThe deviations cited in this letter are not intended to be an all-inclusive list of deviations that exist at your facility. You are responsible for investigating and determining the causes of any deviations and for preventing their recurrence or the occurrence of other deviations.\nFDA placed products offered for import into the United States from your firm on Import Alert 66-40 on January 17, 2025.\nCorrect any deviations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any deviations are completely addressed and we confirm your compliance with CGMP. We may inspect to verify that you have completed corrective actions to any deviations.\nFailure to address deviations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any deviations are completely addressed and we confirm your compliance with CGMP. We may inspect your facility to verify that you have completed corrective actions to address any deviations.\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 30 working days. Specify what you have done to address any deviations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3027222600 and ATTN: William Yang.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research","Chengdu Innovation Pharmaceutical Co., Ltd.","chengdu-innovation-pharmaceutical-co-ltd-698786-02052025","2026-08-18T06:42:28.856152+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fchengdu-innovation-pharmaceutical-co-ltd-698786-02052025","2026-10-26T08:08:14.288167+00:00","Warning Letter","Issued","2025-02-11","698786","Drugs","Ren Zhongju","2026-08-19T17:02:27.799+00:00","VIA Electronic Mail","320-25-40","2025-02-05",{"id":33,"raw":34,"subject":39,"body_html":40,"body_text":41,"firm_name":42,"letter_id":43,"created_at":44,"fei_number":19,"letter_url":45,"updated_at":46,"action_type":22,"case_status":23,"posted_date":47,"marcs_cms_no":48,"product_type":26,"closeout_date":19,"issuing_office":38,"recipient_name":49,"body_fetched_at":50,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":51,"medical_device_id":19,"response_letter_date":19},2881,[35,36,37,38,39,13,13,13],"\u003Ctime datetime=\"2022-02-08T14:20:00Z\">02\u002F08\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-01-26T05:00:00Z\">01\u002F26\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Finnoveix-pharmaceuticals-inc-624782-01262022\">Innoveix Pharmaceuticals Inc \u003C\u002Fa>","Office of Pharmaceutical Quality Operations, Division II","Compounding Pharmacy\u002FAdulterated Drug Products","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Kevin P. Hogan\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President &amp; Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Innoveix Pharmaceuticals Inc \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>3790 Arapaho Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Addison\u003C\u002Fspan>, \u003Cspan>TX\u003C\u002Fspan> \u003Cspan>75001-4311\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:innoveix@gmail.com\"> innoveix@gmail.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Office of Pharmaceutical Quality Operations, Division II\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>January 26, 2022\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Case #624782\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Hogan:\u003C\u002Fp>\n\n\u003Cp>From May 11, 2021, to May 27, 2021, a U.S. Food and Drug Administration (FDA) investigator inspected your facility, Innoveix Pharmaceuticals, Inc., located at 3790 Arapaho Road, Addison, Texas 75001. During the inspection, the investigator noted serious deficiencies in your practices for producing sterile drug products, which put patients at risk.\u003C\u002Fp>\n\n\u003Cp>FDA issued a Form FDA 483 to your firm on May 27, 2021. FDA acknowledges receipt of your facility’s response, dated June 14, 2021. Additionally, FDA acknowledges that on July 9, 2021, your firm voluntarily recalled compounded \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;Semorelin\u002FIpamorelin 3 mg for subcutaneous or intramuscular injection and compounded \u003Cstrong>(b)(4)\u003C\u002Fstrong> AOD-9604, 3 mg for subcutaneous or intramuscular injection due to a lack of sterility assurance. Based on this inspection, it appears that you produced drug products that violate the Federal Food, Drug, and Cosmetic Act (FDCA).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>A. Compounded Drug Products Under the FDCA\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Section 503A of the FDCA describes the conditions under which human drug products compounded by a licensed pharmacist in a State licensed pharmacy or a Federal facility, or a licensed physician, qualify for exemptions from three sections of the FDCA: compliance with current good manufacturing practice (CGMP) (section 501(a)(2)(B)); labeling with adequate directions for use (section 502(f)(1)); and FDA approval prior to marketing (section 505) [21 U.S.C. §§ 351(a)(2)(B), 352(f)(1) and 355(a)].\u003Cbr>\n\u003Cbr>\n\u003Cstrong>B. Violations of the FDCA\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Adulterated Drug Products\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The FDA investigator noted that drug products intended or expected to be sterile were prepared, packed, or held under insanitary conditions, whereby they may have become contaminated with filth or rendered injurious to health, causing your drug products to be adulterated under section 501(a)(2)(A) of the FDCA. For example,\u003C\u002Fp>\n\n\u003Cp>1. Your firm used an unsuitable \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;unit to sterilize bulk drug solutions. The label on the \u003Cstrong>(b)(4)\u003C\u002Fstrong> unit states: “\u003Cem>This product is not intended for use in direct patient care or diagnostic procedures\u003C\u002Fem>.” In addition, your firm failed to perform post-use \u003Cstrong>(b)(4)\u003C\u002Fstrong> testing on the \u003Cstrong>(b)(4)\u003C\u002Fstrong> used to sterilize drug products. Therefore, you do not have assurance that the \u003Cstrong>(b)(4)\u003C\u002Fstrong> was integral throughout use.\u003C\u002Fp>\n\n\u003Cp>2. Your firm exposed \u003Cstrong>(b)(4)\u003C\u002Fstrong> vials that were used to produce drug products intended to be sterile to less than ISO 5 classified aseptic processing quality air. Specifically, trays of \u003Cstrong>(b)(4)\u003C\u002Fstrong> vials were improperly wrapped with foil and transferred from the ISO 8 area to the ISO 7 area without being disinfected. Therefore, sterile vials were exposed to less than ISO 5 quality air.\u003C\u002Fp>\n\n\u003Cp>3. The investigator observed that an operator blocked first air by placing gloved hands directly over open sterile containers that were used to fill drug products intended to be sterile.\u003C\u002Fp>\n\n\u003Cp>4. Your firm used a \u003Cstrong>(b)(4)\u003C\u002Fstrong> that is not part of a sanitation or sterilization process. The \u003Cstrong>(b)(4)\u003C\u002Fstrong> is not routinely cleaned and disinfected prior to use. The \u003Cstrong>(b)(4)\u003C\u002Fstrong> is not protected from contamination by \u003Cstrong>(b)(4)\u003C\u002Fstrong> on \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>5. Your media fills were not performed under the most challenging or stressful conditions and do not simulate your production process. Therefore, there is a lack of assurance that your firm can aseptically produce drug products within your facility.\u003C\u002Fp>\n\n\u003Cp>6. Your firm used household dish detergent to clean and sanitize glassware used in the production of sterile injectable drug products.\u003C\u002Fp>\n\n\u003Cp>7. Your firm used a non-sterile disinfectant within the ISO 5 aseptic processing area.\u003C\u002Fp>\n\n\u003Cp>Under section 301(a) of the FDCA [21 U.S.C. § 331(a)], the introduction or delivery for introduction into interstate commerce of any drug that is adulterated is a prohibited act. Further, it is a prohibited act under section 301(k) of the FDCA [21 U.S.C. § 331(k)] to do any act with respect to a drug, if such act is done while the drug is held for sale after shipment in interstate commerce and results in the drug being adulterated.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>C. Corrective Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>We have reviewed your firm’s response to the Form FDA 483.\u003C\u002Fp>\n\n\u003Cp>We acknowledge that on July 9, 2021, your firm voluntarily recalled compounded \u003Cstrong>(b)(4)\u003C\u002Fstrong> Semorelin\u002FIpamorelin 3 mg for subcutaneous or intramuscular injection and compounded \u003Cstrong>(b)(4)\u003C\u002Fstrong> AOD-9604, 3 mg for subcutaneous or intramuscular injection due to a lack of sterility assurance.\u003C\u002Fp>\n\n\u003Cp>Regarding your responses related to the insanitary conditions, some of your corrective actions appear adequate; however, we cannot fully evaluate the adequacy of the following corrective actions described in your response because you did not include sufficient information or supporting documentation:\u003C\u002Fp>\n\n\u003Cp>You stated that you will cease using the \u003Cstrong>(b)(4)\u003C\u002Fstrong> and return to using \u003Cstrong>(b)(4)\u003C\u002Fstrong> to \u003Cstrong>(b)(4)\u003C\u002Fstrong> sterilize your drug products that are intended to be sterile, but you did not provide any documentation to show which \u003Cstrong>(b)(4)\u003C\u002Fstrong> will be used in the future to \u003Cstrong>(b)(4)\u003C\u002Fstrong> your drug products that are intended to be sterile. In your response, you did not state whether post-use \u003Cstrong>(b)(4)\u003C\u002Fstrong> testing will be performed.\u003C\u002Fp>\n\n\u003Cp>Regarding your responses related to the insanitary conditions, the following corrective actions appear deficient:\u003C\u002Fp>\n\n\u003Cp>1. Your firm acknowledged the Pharmacist in Charge (PIC) briefly blocked first air by placing their gloves over sterile vials and stated less than five vials were impacted. These vials were not discarded and were used to prepare Sermorelin\u002FIpamorelin 3mg Injectable lot SIP225. Your firm stated the PIC is familiar with proper aseptic technique and reverted to correct aseptic technique after being notified during the inspection. No additional corrective actions were provided to prevent future lapses of aseptic technique from occurring.\u003C\u002Fp>\n\n\u003Cp>2. Your firm stated that the \u003Cstrong>(b)(4)\u003C\u002Fstrong> cycle is self-cleaning as it is designed to eliminate any microbes that may exist therefore sterilizing itself. The Agency is not aware of any evidence to support that \u003Cstrong>(b)(4)\u003C\u002Fstrong> cycles is equivalent to a sterilization cycle inside the \u003Cstrong>(b)(4)\u003C\u002Fstrong> chamber.\u003C\u002Fp>\n\n\u003Cp>Your firm stated that once the \u003Cstrong>(b)(4)\u003C\u002Fstrong> cycle is complete, the PIC cleans the interior of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> chamber with sterile \u003Cstrong>(b)(4)\u003C\u002Fstrong> wipes under ISO 5 conditions while wearing sterile garb. Your firm also stated that moving forward, a detergent and sporicidal agent will be used to clean the interior of the \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, there is no documentation or evidence to support that the \u003Cstrong>(b)(4)\u003C\u002Fstrong> chamber and its parts are cleaned and disinfected immediately prior to use.\u003C\u002Fp>\n\n\u003Cp>Your response also stated that you have not failed a sterility test in five years. However, a passing sterility test does not prove the sterility of each unit of each lot you produce and should not be solely relied upon as an indication of product sterility.\u003C\u002Fp>\n\n\u003Cp>3. Your response stated that USP &lt;797&gt; does not specify the number of media filled units required to verify an employee’s aseptic technique and requested guidance on how many vials should be filled. You also stated that the kit vials are not designed to be \u003Cstrong>(b)(4)\u003C\u002Fstrong>, but that you will \u003Cstrong>(b)(4)\u003C\u002Fstrong> the media filled vials going forward. Our expectation is that the media fill is used to evaluate the aseptic process in addition to operator technique. Media fills should simulate the most challenging operating conditions, including the number of units filled during routine production and \u003Cstrong>(b)(4)\u003C\u002Fstrong> to simulate the \u003Cstrong>(b)(4)\u003C\u002Fstrong> process. Units should not be frozen as this may adversely impact the media and potentially inhibit growth of microorganisms.\u003C\u002Fp>\n\n\u003Cp>Please be aware that section 501(a)(2)(A) of the FDCA concerning insanitary conditions applies regardless of whether drug products you compound meet the conditions of section 503A.\u003C\u002Fp>\n\n\u003Cp>FDA strongly recommends that your management undertake a comprehensive assessment of operations, including facility design, procedures, personnel, processes, maintenance, materials, and systems. In particular, this review should assess your aseptic processing operations. A third-party consultant with relevant sterile drug processing expertise should assist you in conducting this comprehensive evaluation.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>D. Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive statement of violations at your facility. You are responsible for investigating and determining the causes of the violations identified above and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>You should take prompt action to correct the violations cited in this letter. Failure to adequately address this matter may result in legal action without further notice, including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Within fifteen (15) working days of receipt of this letter, please notify this office in writing of the specific steps that you have taken to address any violations. Please include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. If you believe that your products are not in violation of the FDCA, include your reasoning and any supporting information for our consideration. If you cannot completely address this matter within fifteen (15) working days, state the reason for the delay and the time within which you will do so.\u003C\u002Fp>\n\n\u003Cp>Your written notification should refer to the Warning Letter Number above (Case # 624782). Please electronically submit your signed reply on your firm’s letterhead to CDR John W. Diehl, M.S., Director, Compliance Branch, at john.diehl@fda.hhs.gov and orapharm2_responses@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>If you have questions regarding the contents of this letter, you may contact Mr. Thao Ta, Compliance Officer, via phone at 214-253-5217 or e-mail at thao.ta@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Monica R. Maxwell\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Pharmaceutical Quality Operations, Division II\u003C\u002Fp>\n\n\u003Cp>cc: Via Electronic Mail\u003Cbr>\nDan Lype, Attorney\u003Cbr>\nLeichter Law Firm\u003Cbr>\n1602 East 7th Street\u003Cbr>\nAustin, Texas 78702\u003Cbr>\ndan@leichterlaw.com\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nKevin P. Hogan\n\nRecipient Title\n\nPresident & Owner\n\nInnoveix Pharmaceuticals Inc\n\n3790 Arapaho Road\n\nAddison, TX 75001-4311\n\nUnited States\n\ninnoveix@gmail.com\n\nIssuing Office:\n\nOffice of Pharmaceutical Quality Operations, Division II\n\nUnited States\n\nJanuary 26, 2022\n\nCase #624782\n\nWARNING LETTER\n\nDear Mr. Hogan:\n\nFrom May 11, 2021, to May 27, 2021, a U.S. Food and Drug Administration (FDA) investigator inspected your facility, Innoveix Pharmaceuticals, Inc., located at 3790 Arapaho Road, Addison, Texas 75001. During the inspection, the investigator noted serious deficiencies in your practices for producing sterile drug products, which put patients at risk.\n\nFDA issued a Form FDA 483 to your firm on May 27, 2021. FDA acknowledges receipt of your facility’s response, dated June 14, 2021. Additionally, FDA acknowledges that on July 9, 2021, your firm voluntarily recalled compounded (b)(4) Semorelin\u002FIpamorelin 3 mg for subcutaneous or intramuscular injection and compounded (b)(4) AOD-9604, 3 mg for subcutaneous or intramuscular injection due to a lack of sterility assurance. Based on this inspection, it appears that you produced drug products that violate the Federal Food, Drug, and Cosmetic Act (FDCA).\n\nA. Compounded Drug Products Under the FDCA\n\nSection 503A of the FDCA describes the conditions under which human drug products compounded by a licensed pharmacist in a State licensed pharmacy or a Federal facility, or a licensed physician, qualify for exemptions from three sections of the FDCA: compliance with current good manufacturing practice (CGMP) (section 501(a)(2)(B)); labeling with adequate directions for use (section 502(f)(1)); and FDA approval prior to marketing (section 505) [21 U.S.C. §§ 351(a)(2)(B), 352(f)(1) and 355(a)].\n\nB. Violations of the FDCA\n\nAdulterated Drug Products\n\nThe FDA investigator noted that drug products intended or expected to be sterile were prepared, packed, or held under insanitary conditions, whereby they may have become contaminated with filth or rendered injurious to health, causing your drug products to be adulterated under section 501(a)(2)(A) of the FDCA. For example,\n\n1. Your firm used an unsuitable (b)(4) unit to sterilize bulk drug solutions. The label on the (b)(4) unit states: “This product is not intended for use in direct patient care or diagnostic procedures.” In addition, your firm failed to perform post-use (b)(4) testing on the (b)(4) used to sterilize drug products. Therefore, you do not have assurance that the (b)(4) was integral throughout use.\n\n2. Your firm exposed (b)(4) vials that were used to produce drug products intended to be sterile to less than ISO 5 classified aseptic processing quality air. Specifically, trays of (b)(4) vials were improperly wrapped with foil and transferred from the ISO 8 area to the ISO 7 area without being disinfected. Therefore, sterile vials were exposed to less than ISO 5 quality air.\n\n3. The investigator observed that an operator blocked first air by placing gloved hands directly over open sterile containers that were used to fill drug products intended to be sterile.\n\n4. Your firm used a (b)(4) that is not part of a sanitation or sterilization process. The (b)(4) is not routinely cleaned and disinfected prior to use. The (b)(4) is not protected from contamination by (b)(4) on (b)(4).\n\n5. Your media fills were not performed under the most challenging or stressful conditions and do not simulate your production process. Therefore, there is a lack of assurance that your firm can aseptically produce drug products within your facility.\n\n6. Your firm used household dish detergent to clean and sanitize glassware used in the production of sterile injectable drug products.\n\n7. Your firm used a non-sterile disinfectant within the ISO 5 aseptic processing area.\n\nUnder section 301(a) of the FDCA [21 U.S.C. § 331(a)], the introduction or delivery for introduction into interstate commerce of any drug that is adulterated is a prohibited act. Further, it is a prohibited act under section 301(k) of the FDCA [21 U.S.C. § 331(k)] to do any act with respect to a drug, if such act is done while the drug is held for sale after shipment in interstate commerce and results in the drug being adulterated.\n\nC. Corrective Actions\n\nWe have reviewed your firm’s response to the Form FDA 483.\n\nWe acknowledge that on July 9, 2021, your firm voluntarily recalled compounded (b)(4) Semorelin\u002FIpamorelin 3 mg for subcutaneous or intramuscular injection and compounded (b)(4) AOD-9604, 3 mg for subcutaneous or intramuscular injection due to a lack of sterility assurance.\n\nRegarding your responses related to the insanitary conditions, some of your corrective actions appear adequate; however, we cannot fully evaluate the adequacy of the following corrective actions described in your response because you did not include sufficient information or supporting documentation:\n\nYou stated that you will cease using the (b)(4) and return to using (b)(4) to (b)(4) sterilize your drug products that are intended to be sterile, but you did not provide any documentation to show which (b)(4) will be used in the future to (b)(4) your drug products that are intended to be sterile. In your response, you did not state whether post-use (b)(4) testing will be performed.\n\nRegarding your responses related to the insanitary conditions, the following corrective actions appear deficient:\n\n1. Your firm acknowledged the Pharmacist in Charge (PIC) briefly blocked first air by placing their gloves over sterile vials and stated less than five vials were impacted. These vials were not discarded and were used to prepare Sermorelin\u002FIpamorelin 3mg Injectable lot SIP225. Your firm stated the PIC is familiar with proper aseptic technique and reverted to correct aseptic technique after being notified during the inspection. No additional corrective actions were provided to prevent future lapses of aseptic technique from occurring.\n\n2. Your firm stated that the (b)(4) cycle is self-cleaning as it is designed to eliminate any microbes that may exist therefore sterilizing itself. The Agency is not aware of any evidence to support that (b)(4) cycles is equivalent to a sterilization cycle inside the (b)(4) chamber.\n\nYour firm stated that once the (b)(4) cycle is complete, the PIC cleans the interior of the (b)(4) chamber with sterile (b)(4) wipes under ISO 5 conditions while wearing sterile garb. Your firm also stated that moving forward, a detergent and sporicidal agent will be used to clean the interior of the (b)(4). However, there is no documentation or evidence to support that the (b)(4) chamber and its parts are cleaned and disinfected immediately prior to use.\n\nYour response also stated that you have not failed a sterility test in five years. However, a passing sterility test does not prove the sterility of each unit of each lot you produce and should not be solely relied upon as an indication of product sterility.\n\n3. Your response stated that USP \u003C797> does not specify the number of media filled units required to verify an employee’s aseptic technique and requested guidance on how many vials should be filled. You also stated that the kit vials are not designed to be (b)(4), but that you will (b)(4) the media filled vials going forward. Our expectation is that the media fill is used to evaluate the aseptic process in addition to operator technique. Media fills should simulate the most challenging operating conditions, including the number of units filled during routine production and (b)(4) to simulate the (b)(4) process. Units should not be frozen as this may adversely impact the media and potentially inhibit growth of microorganisms.\n\nPlease be aware that section 501(a)(2)(A) of the FDCA concerning insanitary conditions applies regardless of whether drug products you compound meet the conditions of section 503A.\n\nFDA strongly recommends that your management undertake a comprehensive assessment of operations, including facility design, procedures, personnel, processes, maintenance, materials, and systems. In particular, this review should assess your aseptic processing operations. A third-party consultant with relevant sterile drug processing expertise should assist you in conducting this comprehensive evaluation.\n\nD. Conclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive statement of violations at your facility. You are responsible for investigating and determining the causes of the violations identified above and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nYou should take prompt action to correct the violations cited in this letter. Failure to adequately address this matter may result in legal action without further notice, including, without limitation, seizure and injunction.\n\nWithin fifteen (15) working days of receipt of this letter, please notify this office in writing of the specific steps that you have taken to address any violations. Please include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. If you believe that your products are not in violation of the FDCA, include your reasoning and any supporting information for our consideration. If you cannot completely address this matter within fifteen (15) working days, state the reason for the delay and the time within which you will do so.\n\nYour written notification should refer to the Warning Letter Number above (Case # 624782). Please electronically submit your signed reply on your firm’s letterhead to CDR John W. Diehl, M.S., Director, Compliance Branch, at john.diehl@fda.hhs.gov and orapharm2_responses@fda.hhs.gov.\n\nIf you have questions regarding the contents of this letter, you may contact Mr. Thao Ta, Compliance Officer, via phone at 214-253-5217 or e-mail at thao.ta@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nMonica R. Maxwell\n\nProgram Division Director\n\nOffice of Pharmaceutical Quality Operations, Division II\n\ncc: Via Electronic Mail\n\nDan Lype, Attorney\n\nLeichter Law Firm\n\n1602 East 7th Street\n\nAustin, Texas 78702\n\ndan@leichterlaw.com","Innoveix Pharmaceuticals Inc","innoveix-pharmaceuticals-inc-624782-01262022","2026-08-18T06:42:29.262718+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Finnoveix-pharmaceuticals-inc-624782-01262022","2026-10-26T08:08:59.168529+00:00","2022-02-08","624782","Kevin P. Hogan","2026-08-20T02:12:25.046+00:00","2022-01-26",{"id":53,"raw":54,"subject":60,"body_html":61,"body_text":62,"firm_name":63,"letter_id":64,"created_at":65,"fei_number":19,"letter_url":66,"updated_at":67,"action_type":22,"case_status":23,"posted_date":68,"marcs_cms_no":69,"product_type":26,"closeout_date":19,"issuing_office":58,"recipient_name":70,"body_fetched_at":71,"delivery_method":72,"recipient_title":19,"reference_number":19,"action_taken_date":73,"medical_device_id":19,"response_letter_date":19},1947,[55,56,57,58,59,13,13,13],"\u003Ctime datetime=\"2023-08-08T13:20:00Z\">08\u002F08\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-08-03T04:00:00Z\">08\u002F03\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fkm-pharmaceutical-co-ltd-663522-08032023\">KM Pharmaceutical Co. Ltd.\u003C\u002Fa>","Center for Drug Evaluation and Research | CDER","Refusal to Provide Access to and Copying of Records\u003Cbr \u002F>\r\n","Refusal to Provide Access to and Copying of Records","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>IL MO Kang\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>KM Pharmaceutical Co. Ltd.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>121 Pyeongtaekhang-ro 268 beon-gil\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Poseung-eup\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Pyeongtaek-si\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Gyeonggi-do\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>17953\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>South Korea\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-23-22\u003C\u002Fp>\n\n\u003Cp>August 3, 2023\u003C\u002Fp>\n\n\u003Cp>Reference FEI 3010164172\u003C\u002Fp>\n\n\u003Cp>Dear IL MO Kang:\u003C\u002Fp>\n\n\u003Cp>Your firm is registered with the United States Food and Drug Administration (FDA or Agency) as a manufacturer of over-the-counter (OTC) drug products, including \u003Cstrong>(b)(4)\u003C\u002Fstrong> and hand sanitizer. Ingredients of the drugs registered as manufactured at your firm include ingredients susceptible to Diethylene Glycol (DEG) and Ethylene Glycol (EG) substitution. A review of import records showed multiple shipments of drug products into the United States, which declared KM Pharmaceutical Co. Ltd. as the drug manufacturer. On March 3, 2023, the FDA sent an electronic request for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 374(a)(4), to the contact e-mail address provided in your registration file. This request ultimately went unanswered. A second request was sent via e-mail on March 16, 2023, followed by an attempted contact by telephone with your registered U.S. Agent on April 12, 2023, regarding this matter. The Agency sent a follow-up written request for such records and other information on April 17, 2023. Delivery to you was confirmed by the shipper, but you failed to respond to these attempted communications or otherwise provide the requested records or other information. Pursuant to section 704(a)(4), FDA’s request and follow-up communication included a sufficient and clear description of the records sought.\u003C\u002Fp>\n\n\u003Cp>It is a prohibited act under section 301(e) of the FD&amp;C Act (21 U.S.C. 331(e)) to refuse to permit access to or copying of any record as required by section 704(a).\u003C\u002Fp>\n\n\u003Cp>The use of ingredients contaminated with DEG or EG has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document Testing of \u003Cem>Glycerin, Propylene Glycol, Maltitol Solution, Hydrogenated Starch Hydrolysate, Sorbitol Solution, and Other High-Risk Drug Components for Diethylene Glycol and Ethylene Glycol\u003C\u002Fem> to help you meet the current good manufacturing practice (CGMP) requirements when manufacturing drugs containing ingredients at high-risk for DEG or EG contamination at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F167974\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>Because your firm failed to respond to the section 704(a)(4) records requests and associated communication attempts, we have no indication of the level of quality assurance for drugs registered as manufactured at your facility.\u003C\u002Fp>\n\n\u003Cp>Until FDA is able to confirm compliance with CGMP and other applicable requirements, we may withhold approval of any new applications or supplements listing your firm as a drug manufacturer. In addition, shipments of articles manufactured at KM Pharmaceutical Co. Ltd., 121 Pyeongtaekhang-ro, 268 beon-gil, Poseung-eup, Pyeongtaek Gyeonggi, 17953 South Korea, into the United States that appear to be adulterated or misbranded are subject to being detained or refused admission pursuant to section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3).\u003C\u002Fp>\n\n\u003Cp>FDA placed all drugs and drug products manufactured by your firm on Import Alert 66-79 on June 7, 2023.\u003C\u002Fp>\n\n\u003Cp>After you receive this letter, respond to this office in writing within 15 working days. In response to this letter, you may provide information for our consideration as we continue to assess your activities and practices, and\u002For submit a request to schedule an FDA inspection.\u003C\u002Fp>\n\n\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI #3010164172 and ATTN: Matthew R. Dionne, Pharm.D., Compliance Officer.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Francis Godwin\u003Cbr>\nDirector\u003Cbr>\nOffice of Manufacturing Quality\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research, FDA\u003C\u002Fp>\n\n\u003Cp>CC:\u003Cbr>\nKM Pharmaceutical Co. Ltd. POC\u003Cbr>\nIL MO Kang via email: gracejschem@hotmail.com\u003C\u002Fp>\n\n\u003Cp>Registered U.S. Agent:\u003Cbr>\nJ.S. Chem International Co.\u003Cbr>\nAhn3060@naver.com\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nIL MO Kang\n\nKM Pharmaceutical Co. Ltd.\n\n121 Pyeongtaekhang-ro 268 beon-gil\n\nPoseung-eup\n\nPyeongtaek-si\n\nGyeonggi-do\n\n17953\n\nSouth Korea\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nWarning Letter 320-23-22\n\nAugust 3, 2023\n\nReference FEI 3010164172\n\nDear IL MO Kang:\n\nYour firm is registered with the United States Food and Drug Administration (FDA or Agency) as a manufacturer of over-the-counter (OTC) drug products, including (b)(4) and hand sanitizer. Ingredients of the drugs registered as manufactured at your firm include ingredients susceptible to Diethylene Glycol (DEG) and Ethylene Glycol (EG) substitution. A review of import records showed multiple shipments of drug products into the United States, which declared KM Pharmaceutical Co. Ltd. as the drug manufacturer. On March 3, 2023, the FDA sent an electronic request for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 374(a)(4), to the contact e-mail address provided in your registration file. This request ultimately went unanswered. A second request was sent via e-mail on March 16, 2023, followed by an attempted contact by telephone with your registered U.S. Agent on April 12, 2023, regarding this matter. The Agency sent a follow-up written request for such records and other information on April 17, 2023. Delivery to you was confirmed by the shipper, but you failed to respond to these attempted communications or otherwise provide the requested records or other information. Pursuant to section 704(a)(4), FDA’s request and follow-up communication included a sufficient and clear description of the records sought.\n\nIt is a prohibited act under section 301(e) of the FD&C Act (21 U.S.C. 331(e)) to refuse to permit access to or copying of any record as required by section 704(a).\n\nThe use of ingredients contaminated with DEG or EG has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document Testing of Glycerin, Propylene Glycol, Maltitol Solution, Hydrogenated Starch Hydrolysate, Sorbitol Solution, and Other High-Risk Drug Components for Diethylene Glycol and Ethylene Glycol to help you meet the current good manufacturing practice (CGMP) requirements when manufacturing drugs containing ingredients at high-risk for DEG or EG contamination at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F167974\u002Fdownload.\n\nBecause your firm failed to respond to the section 704(a)(4) records requests and associated communication attempts, we have no indication of the level of quality assurance for drugs registered as manufactured at your facility.\n\nUntil FDA is able to confirm compliance with CGMP and other applicable requirements, we may withhold approval of any new applications or supplements listing your firm as a drug manufacturer. In addition, shipments of articles manufactured at KM Pharmaceutical Co. Ltd., 121 Pyeongtaekhang-ro, 268 beon-gil, Poseung-eup, Pyeongtaek Gyeonggi, 17953 South Korea, into the United States that appear to be adulterated or misbranded are subject to being detained or refused admission pursuant to section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3).\n\nFDA placed all drugs and drug products manufactured by your firm on Import Alert 66-79 on June 7, 2023.\n\nAfter you receive this letter, respond to this office in writing within 15 working days. In response to this letter, you may provide information for our consideration as we continue to assess your activities and practices, and\u002For submit a request to schedule an FDA inspection.\n\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI #3010164172 and ATTN: Matthew R. Dionne, Pharm.D., Compliance Officer.\n\nSincerely,\n\n\u002FS\u002F\n\nFrancis Godwin\n\nDirector\n\nOffice of Manufacturing Quality\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research, FDA\n\nCC:\n\nKM Pharmaceutical Co. Ltd. POC\n\nIL MO Kang via email: gracejschem@hotmail.com\n\nRegistered U.S. Agent:\n\nJ.S. Chem International Co.\n\nAhn3060@naver.com","KM Pharmaceutical Co. Ltd.","km-pharmaceutical-co-ltd-663522-08032023","2026-08-18T06:42:28.994808+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fkm-pharmaceutical-co-ltd-663522-08032023","2026-10-26T08:09:09.648472+00:00","2023-08-08","663522","IL MO Kang","2026-08-20T00:48:44.691+00:00","VIA UPS","2023-08-03",{"id":75,"raw":76,"subject":80,"body_html":81,"body_text":82,"firm_name":83,"letter_id":84,"created_at":85,"fei_number":19,"letter_url":86,"updated_at":87,"action_type":22,"case_status":23,"posted_date":88,"marcs_cms_no":89,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":90,"body_fetched_at":91,"delivery_method":92,"recipient_title":19,"reference_number":93,"action_taken_date":94,"medical_device_id":19,"response_letter_date":19},204,[77,78,79,11,80,13,13,13],"\u003Ctime datetime=\"2026-04-28T04:00:00Z\">04\u002F28\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-03-30T04:00:00Z\">03\u002F30\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fintas-pharmaceuticals-limited-721151-03302026\">Intas Pharmaceuticals Limited \u003C\u002Fa>","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA EMAIL WITH READ RECEIPT\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-26-57\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Kirti Maheshwari\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Operating Officer \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Intas Pharmaceuticals Limited \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Plot No. 255, Magnet Corporate Park\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Nr. Sola Bridge, S. G. Highway, Thaltej\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Ahmedabad\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>India\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-26-57\u003C\u002Fp>\u003Cp>March 30, 2026\u003C\u002Fp>\u003Cp>Dear Mr. Maheshwari:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Intas Pharmaceuticals Limited, FEI 3005890633, located at Camp Road, Selaqui, Dehradun, from September 8 to 17, 2025.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>We reviewed your October 8, 2025, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your investigations into out-of-specification (OOS) assay results were inadequate. Your corrective and preventive actions (CAPAs) to address your persistent OOS assay results for \u003Cstrong>(b)(4)\u003C\u002Fstrong> tablets were not robust, as evidenced by the continued trend of subpotent assay stability failures and multiple \u003Cstrong>(b)(4)\u003C\u002Fstrong> to drug product expiry period.\u003C\u002Fp>\u003Cp>For example, since 2023, your testing has shown multiple confirmed stability OOS results for \u003Cstrong>(b)(4)\u003C\u002Fstrong> batches. You \u003Cstrong>(b)(4)\u003C\u002Fstrong> your expiry period from \u003Cstrong>(b)(4)\u003C\u002Fstrong> to \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and then further \u003Cstrong>(b)(4)\u003C\u002Fstrong> it to the current \u003Cstrong>(b)(4)\u003C\u002Fstrong>. We acknowledge your decision to recall \u003Cstrong>(b)(4)\u003C\u002Fstrong> batches of \u003Cstrong>(b)(4)\u003C\u002Fstrong> tablets in response to stability OOS results since 2024.\u003C\u002Fp>\u003Cp>Multiple CAPAs included changes to batch processing to prevent further degradation of the active pharmaceutical ingredient. You also implemented modifications to your assay sample preparation procedures. However, you still experienced OOS assay results. For example, you tested 12-month long term stability batch \u003Cstrong>(b)(4)\u003C\u002Fstrong> and had a confirmed OOS result of \u003Cstrong>(b)(4)\u003C\u002Fstrong>% (specification is \u003Cstrong>(b)(4)\u003C\u002Fstrong>%). Your investigation of this 12-month stability failure was inadequate.\u003C\u002Fp>\u003Cp>You identified the root cause as “product behavior” and recalled this batch. You did not adequately evaluate the reserves of all distributed batches or reserve batches using the same API lot to determine if market action is warranted, as required.\u003C\u002Fp>\u003Cp>After the initial OOS result, you proceeded to test samples from the same batch and other previously OOS batches, using a revised analytical method with a different sample preparation and obtained different results. Despite using the revised analytical method, two batches (\u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>, \u003Cstrong>(b)(4)\u003C\u002Fstrong> tablets USP \u003Cstrong>(b)(4)\u003C\u002Fstrong> mcg and \u003Cstrong>(b)(4)\u003C\u002Fstrong> mcg) remained out of specification. Your investigation failed to evaluate why these batches still failed or assess whether the analytical method itself contributes to result variability. Attributing a failure to inherent drug product behaviors is not scientifically sound when a change in the test method yields a different outcome.\u003C\u002Fp>\u003Cp>Additionally, after you implemented your revised method in July 2025 you continued to experience low assay results. For example, you invalidated an assay result of \u003Cstrong>(b)(4)\u003C\u002Fstrong>% for a sample batch (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) used as a control due to “solution preparation error” without conclusive supporting evidence, despite the sample preparation analysis being deemed “satisfactory” during the laboratory Phase I investigation. You did not issue a CAPA plan for analyst training. You also discarded the initial OOS with insufficient supporting documentation and did not include it in your final reporting of the assay result.\u003C\u002Fp>\u003Cp>In your response, you attribute the low assay values to the analytical limitation in the assay method, specifically incomplete extraction of the active pharmaceutical ingredient. You state it is not “totally due to actual product degradation.” You discuss your submission of a \u003Cstrong>(b)(4)\u003C\u002Fstrong> to the Agency to address the assay OOS results. Using the revised method, your new assay results appeared to be closer to the lower specification end. The variability in the new results does not clearly explain why these results are outside of the target assay value.\u003C\u002Fp>\u003Cp>Additionally, you initiated testing of all \u003Cstrong>(b)(4)\u003C\u002Fstrong> distributed batches of \u003Cstrong>(b)(4)\u003C\u002Fstrong> tablets USP (all strengths) within their approved shelf-life for the U.S. market. All batches met the specification criteria.\u003C\u002Fp>\u003Cp>Your response is inadequate. Your response does not address why the extraction limitation was not identified during the original method validation or explain what failures in your method validation process allowed this critical deficiency. In addition, your impact assessment of the evaluation of the extraction method did not extend to all assay values specifically which were on the higher end of the specification. Your response does not review or correlate market complaints or adverse events with low assay batches, which would be critical for a patient safety assessment.\u003C\u002Fp>\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\u003Cul>\u003Cli>An impact assessment of \u003Cstrong>(b)(4)\u003C\u002Fstrong> tablet batches within expiry that showed assay results below your target assay. This assessment can coincide with your protocol for impact assessment for batches in the U.S. market that have stability testing assay results below \u003Cstrong>(b)(4)\u003C\u002Fstrong>%. Identify any common variables leading to the low assay values. Provide the OOS investigations for batch \u003Cstrong>(b)(4)\u003C\u002Fstrong> and all OOS assay failures for \u003Cstrong>(b)(4)\u003C\u002Fstrong> tablets since the FDA inspection.\u003C\u002Fli>\u003Cli>An assessment of each drug product process to ensure that there is a data-driven and scientifically sound program that identifies and controls all sources of variability, such that your production processes, and will consistently meet appropriate specifications and manufacturing standards. This includes, but is not limited to, evaluating suitability of equipment for its intended use, sufficiency of detectability in your monitoring and testing systems, quality of input materials, and reliability of each manufacturing process step and control.\u003C\u002Fli>\u003Cli>A comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, OOS results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, quality assurance oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\u003C\u002Fli>\u003Cli>An independent third-party assessment and remediation plan for your CAPA program. Provide a report that evaluates whether the program includes effective root cause analysis, ensures CAPA effectiveness, analyzes investigations trends, improves the CAPA program when needed, implements final quality assurance decisions, and is fully supported by executive management.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm lacks controls to assure the integrity of electronic batch record data. Your quality assurance employee instructed your software vendor to make changes to your electronic batch record which were not captured in the audit trail or managed through your quality system.\u003C\u002Fp>\u003Cp>During the inspection, you provided written communication from a quality assurance employee to the software vendor that discussed multiple changes and modifications made to the electronic batch record. One of the changes included the replacement of an employee identification number with another employee number for “Dispensed by” in \u003Cstrong>(b)(4)\u003C\u002Fstrong> tablets USP \u003Cstrong>(b)(4)\u003C\u002Fstrong> mcg batch record \u003Cstrong>(b)(4)\u003C\u002Fstrong>. The change was not recorded in the audit trail, nor was it noted in the electronic batch record. Additionally, your firm lacked detailed procedural controls to assure the integrity of electronic batch record data when modifications are made after completion of the batch record.\u003C\u002Fp>\u003Cp>In your response, you indicate that the changes the software vendor made in the electronic batch record corrected inaccuracies only. You state your requests to software vendors to modify data have been terminated. You commit to conducting formal interviews with employees who contacted the vendors to request the data changes and to initiating deviation investigations. You commit to performing a retrospective review of all group and individual email messages sent to the software vendor to determine which email messages contained CGMP instructions. You also commit to conducting a review of the audit trails of all U.S. batches.\u003C\u002Fp>\u003Cp>Your response is inadequate. You fail to provide documentation of the deviations, interview transcripts, or discussion held with the employees who requested changes to electronic batch record data. You fail to explain why Quality Assurance did not initiate a deviation upon finding discrepancies or why the batch record contained no comments or remarks about the employee identification change. Additionally, your retrospective review of email requests to software vendors for data changes did not include an assessment of communications with other software vendors such as \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\u003Cul>\u003Cli>A retrospective review of all software related communications and correlated audit trail between your Intas Dehradun facility and software support vendors. Provide any updated deviations and related CAPA reports.\u003C\u002Fli>\u003Cli>A product impact assessment for identified communications related to changes in batch record data and process parameters.\u003C\u002Fli>\u003Cli>Effectiveness checks for the CAPAs implemented in your “Data Integrity Risk Assessment” of software applications, conducted by third party consultants in 2024.\u003C\u002Fli>\u003Cli>Performance qualification deviations for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> filling machine (\u003Cstrong>(b)(4)\u003C\u002Fstrong>, Model \u003Cstrong>(b)(4)\u003C\u002Fstrong>, equipment ID: DP-38). Include a report discussing the discrepancies in entries in the data sheet versus audit trail data, including maximum \u003Cstrong>(b)(4)\u003C\u002Fstrong>. This equipment is related to a \u003Cstrong>(b)(4)\u003C\u002Fstrong> for \u003Cstrong>(b)(4)\u003C\u002Fstrong> solution \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fli>\u003Cli>A comprehensive assessment and remediation plan to ensure your quality unit (QU) is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003Cbr>o A determination of whether procedures used by your firm are robust and appropriate\u003Cbr>o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\u003Cbr>o A complete and final review of each batch and its related information before the QU disposition decision\u003Cbr>o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\u003Cbr>o Also describe how top management supports quality assurance and reliable operations, including but not limited to timely provision of resources to proactively address emerging manufacturing\u002Fquality issues and to assure a continuing state of control.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>If you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(b). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\u003C\u002Fp>\u003Cp>Correct any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\u003C\u002Fp>\u003Cp>Failure to address any violations may also result in the FDA refusing admission of articles manufactured at Intas Pharmaceuticals Limited located at Camp Road, Selaqui, Dehradun, into the United States under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3005890633 and ATTN: Erika V. Butler.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Under program enhancements for the Generic Drug User Fee Amendments (GDUFA) reauthorization for fiscal years (FYs) 2023-2027, also known as the GDUFA III Commitment Letter, your facility may be eligible for a Post-Warning Letter Meeting to obtain preliminary feedback from FDA on the adequacy and completeness of your corrective action plans.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA EMAIL WITH READ RECEIPT\n\nReference #:\n\n320-26-57\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Kirti Maheshwari\n\nRecipient Title\n\nChief Operating Officer\n\nIntas Pharmaceuticals Limited\n\nPlot No. 255, Magnet Corporate Park\n\nNr. Sola Bridge, S. G. Highway, Thaltej\n\nAhmedabad\n\nIndia\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-26-57\nMarch 30, 2026\nDear Mr. Maheshwari:\nThe United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Intas Pharmaceuticals Limited, FEI 3005890633, located at Camp Road, Selaqui, Dehradun, from September 8 to 17, 2025.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nWe reviewed your October 8, 2025, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n1. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\nYour investigations into out-of-specification (OOS) assay results were inadequate. Your corrective and preventive actions (CAPAs) to address your persistent OOS assay results for (b)(4) tablets were not robust, as evidenced by the continued trend of subpotent assay stability failures and multiple (b)(4) to drug product expiry period.\nFor example, since 2023, your testing has shown multiple confirmed stability OOS results for (b)(4) batches. You (b)(4) your expiry period from (b)(4) to (b)(4), and then further (b)(4) it to the current (b)(4). We acknowledge your decision to recall (b)(4) batches of (b)(4) tablets in response to stability OOS results since 2024.\nMultiple CAPAs included changes to batch processing to prevent further degradation of the active pharmaceutical ingredient. You also implemented modifications to your assay sample preparation procedures. However, you still experienced OOS assay results. For example, you tested 12-month long term stability batch (b)(4) and had a confirmed OOS result of (b)(4)% (specification is (b)(4)%). Your investigation of this 12-month stability failure was inadequate.\nYou identified the root cause as “product behavior” and recalled this batch. You did not adequately evaluate the reserves of all distributed batches or reserve batches using the same API lot to determine if market action is warranted, as required.\nAfter the initial OOS result, you proceeded to test samples from the same batch and other previously OOS batches, using a revised analytical method with a different sample preparation and obtained different results. Despite using the revised analytical method, two batches ((b)(4) and (b)(4), (b)(4) tablets USP (b)(4) mcg and (b)(4) mcg) remained out of specification. Your investigation failed to evaluate why these batches still failed or assess whether the analytical method itself contributes to result variability. Attributing a failure to inherent drug product behaviors is not scientifically sound when a change in the test method yields a different outcome.\nAdditionally, after you implemented your revised method in July 2025 you continued to experience low assay results. For example, you invalidated an assay result of (b)(4)% for a sample batch ((b)(4)) used as a control due to “solution preparation error” without conclusive supporting evidence, despite the sample preparation analysis being deemed “satisfactory” during the laboratory Phase I investigation. You did not issue a CAPA plan for analyst training. You also discarded the initial OOS with insufficient supporting documentation and did not include it in your final reporting of the assay result.\nIn your response, you attribute the low assay values to the analytical limitation in the assay method, specifically incomplete extraction of the active pharmaceutical ingredient. You state it is not “totally due to actual product degradation.” You discuss your submission of a (b)(4) to the Agency to address the assay OOS results. Using the revised method, your new assay results appeared to be closer to the lower specification end. The variability in the new results does not clearly explain why these results are outside of the target assay value.\nAdditionally, you initiated testing of all (b)(4) distributed batches of (b)(4) tablets USP (all strengths) within their approved shelf-life for the U.S. market. All batches met the specification criteria.\nYour response is inadequate. Your response does not address why the extraction limitation was not identified during the original method validation or explain what failures in your method validation process allowed this critical deficiency. In addition, your impact assessment of the evaluation of the extraction method did not extend to all assay values specifically which were on the higher end of the specification. Your response does not review or correlate market complaints or adverse events with low assay batches, which would be critical for a patient safety assessment.\nIn response to this letter, provide the following:\nAn impact assessment of (b)(4) tablet batches within expiry that showed assay results below your target assay. This assessment can coincide with your protocol for impact assessment for batches in the U.S. market that have stability testing assay results below (b)(4)%. Identify any common variables leading to the low assay values. Provide the OOS investigations for batch (b)(4) and all OOS assay failures for (b)(4) tablets since the FDA inspection.\nAn assessment of each drug product process to ensure that there is a data-driven and scientifically sound program that identifies and controls all sources of variability, such that your production processes, and will consistently meet appropriate specifications and manufacturing standards. This includes, but is not limited to, evaluating suitability of equipment for its intended use, sufficiency of detectability in your monitoring and testing systems, quality of input materials, and reliability of each manufacturing process step and control.\nA comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, OOS results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, quality assurance oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\nAn independent third-party assessment and remediation plan for your CAPA program. Provide a report that evaluates whether the program includes effective root cause analysis, ensures CAPA effectiveness, analyzes investigations trends, improves the CAPA program when needed, implements final quality assurance decisions, and is fully supported by executive management.\n2. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\nYour firm lacks controls to assure the integrity of electronic batch record data. Your quality assurance employee instructed your software vendor to make changes to your electronic batch record which were not captured in the audit trail or managed through your quality system.\nDuring the inspection, you provided written communication from a quality assurance employee to the software vendor that discussed multiple changes and modifications made to the electronic batch record. One of the changes included the replacement of an employee identification number with another employee number for “Dispensed by” in (b)(4) tablets USP (b)(4) mcg batch record (b)(4). The change was not recorded in the audit trail, nor was it noted in the electronic batch record. Additionally, your firm lacked detailed procedural controls to assure the integrity of electronic batch record data when modifications are made after completion of the batch record.\nIn your response, you indicate that the changes the software vendor made in the electronic batch record corrected inaccuracies only. You state your requests to software vendors to modify data have been terminated. You commit to conducting formal interviews with employees who contacted the vendors to request the data changes and to initiating deviation investigations. You commit to performing a retrospective review of all group and individual email messages sent to the software vendor to determine which email messages contained CGMP instructions. You also commit to conducting a review of the audit trails of all U.S. batches.\nYour response is inadequate. You fail to provide documentation of the deviations, interview transcripts, or discussion held with the employees who requested changes to electronic batch record data. You fail to explain why Quality Assurance did not initiate a deviation upon finding discrepancies or why the batch record contained no comments or remarks about the employee identification change. Additionally, your retrospective review of email requests to software vendors for data changes did not include an assessment of communications with other software vendors such as (b)(4).\nIn response to this letter, provide the following:\nA retrospective review of all software related communications and correlated audit trail between your Intas Dehradun facility and software support vendors. Provide any updated deviations and related CAPA reports.\nA product impact assessment for identified communications related to changes in batch record data and process parameters.\nEffectiveness checks for the CAPAs implemented in your “Data Integrity Risk Assessment” of software applications, conducted by third party consultants in 2024.\nPerformance qualification deviations for your (b)(4) filling machine ((b)(4), Model (b)(4), equipment ID: DP-38). Include a report discussing the discrepancies in entries in the data sheet versus audit trail data, including maximum (b)(4). This equipment is related to a (b)(4) for (b)(4) solution (b)(4).\nA comprehensive assessment and remediation plan to ensure your quality unit (QU) is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\no A determination of whether procedures used by your firm are robust and appropriate\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\no A complete and final review of each batch and its related information before the QU disposition decision\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\no Also describe how top management supports quality assurance and reliable operations, including but not limited to timely provision of resources to proactively address emerging manufacturing\u002Fquality issues and to assure a continuing state of control.\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nIf you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(b). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\nCorrect any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\nFailure to address any violations may also result in the FDA refusing admission of articles manufactured at Intas Pharmaceuticals Limited located at Camp Road, Selaqui, Dehradun, into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days1. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3005890633 and ATTN: Erika V. Butler.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research\n________________\n1 Under program enhancements for the Generic Drug User Fee Amendments (GDUFA) reauthorization for fiscal years (FYs) 2023-2027, also known as the GDUFA III Commitment Letter, your facility may be eligible for a Post-Warning Letter Meeting to obtain preliminary feedback from FDA on the adequacy and completeness of your corrective action plans.","Intas Pharmaceuticals Limited","intas-pharmaceuticals-limited-721151-03302026","2026-08-18T06:42:28.498414+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fintas-pharmaceuticals-limited-721151-03302026","2026-10-26T08:08:59.53451+00:00","2026-04-28","721151","Mr. Kirti Maheshwari","2026-08-19T04:45:36.862+00:00","VIA EMAIL WITH READ RECEIPT","320-26-57","2026-03-30",{"id":96,"raw":97,"subject":80,"body_html":101,"body_text":102,"firm_name":83,"letter_id":103,"created_at":65,"fei_number":19,"letter_url":104,"updated_at":105,"action_type":22,"case_status":23,"posted_date":106,"marcs_cms_no":107,"product_type":26,"closeout_date":19,"issuing_office":58,"recipient_name":108,"body_fetched_at":109,"delivery_method":110,"recipient_title":19,"reference_number":19,"action_taken_date":111,"medical_device_id":19,"response_letter_date":19},1722,[98,99,100,58,80,13,13,13],"\u003Ctime datetime=\"2023-11-28T14:20:00Z\">11\u002F28\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-11-21T05:00:00Z\">11\u002F21\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fintas-pharmaceuticals-limited-662868-11212023\">Intas Pharmaceuticals Limited\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Nimish Chudgar\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer &amp; Managing Director\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Intas Pharmaceuticals Limited\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Plot No. 255, Magnet Corporate Park, Near Sola Bridge, S.G. Highway\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Thaltej, Ahmedabad\u003C\u002Fspan> \u003Cspan>380054\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Gujarat\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>India\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter \u003C\u002Fstrong>320-24-12\u003C\u002Fp>\n\n\u003Cp>November 21, 2023\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Chudgar:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Intas Pharmaceuticals Limited, FEI 3003157498, at Plot No. 457- 458 &amp; 191\u002F218P, Sarkhej - Bavla Highway, Matoda - Sanand, Ahmedabad, from May 1 to May 12, 2023.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>We reviewed your June 05, 2023 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your Quality Assurance (QA) and production departments failed to provide adequate oversight and ensure the reliability of data related to the quality of finished drug products manufactured at your facility. Since 2021, visual inspectors manipulated particle and other defect counts on manual visual inspection records in many instances, in order to keep the finished product batches within rejection limits. More specifically, the investigation found that operators manipulated the defect quantities “to keep the category wise rejections within limits to avoid a deviation and investigation.”\u003C\u002Fp>\n\n\u003Cp>In addition, multiple operators manipulated the reported defects, including \u003Cstrong>(b)(4)\u003C\u002Fstrong> attributes and particle counts, on manual visual inspection records to have identical numbers. This practice was repeatedly performed by at least nine different manual visual inspectors on trays of \u003Cstrong>(b)(4)\u003C\u002Fstrong>. The records, filled out by multiple operators, had an identical number of defects listed for all drug product defect categories.\u003C\u002Fp>\n\n\u003Cp>Production managers including, but not limited to, front line supervisors failed to ensure reliable data, leading to significant data integrity deficiencies in your production records.\u003C\u002Fp>\n\n\u003Cp>In addition, there was a lack of QA department review and oversight of visual inspection records, and your firm continued this egregious pattern of recording and altering defect counts. These findings indicated that your QA department was not exercising its basic responsibilities including, but not limited to, oversight and control over the adequacy and reliability of all CGMP data at your facility.\u003C\u002Fp>\n\n\u003Cp>In your response, you acknowledge the discrepancies found in the visual inspection records and identify the contributing factors to these deviations as “inadequate data management processes, inadequate training and procedures, and inadequate quality oversight of the visual inspection operation.” You state that “all the visual inspectors in this area have been disqualified” and “operators have been moved to the secondary packaging area and are not participating in GMP activities.”\u003C\u002Fp>\n\n\u003Cp>In addition, you also commit to working with a qualified consultant to perform a “data governance and integrity audit” and to establish a remediation plan. You commit to perform an assessment to evaluate injectable products that are within shelf life and are on the market to identify similar discrepancies in the visual inspection records.\u003C\u002Fp>\n\n\u003Cp>We acknowledge your voluntary recall of batches of drug products due to particle contamination identified in product retain samples.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate because you have not conducted a comprehensive evaluation of other CGMP records in which data may have been reported inaccurately or otherwise manipulated by your employees. You do not provide a comprehensive corrective action and preventative action (CAPA) plan with a systematic approach to correct these oversight deficiencies. Furthermore, although you indicate that you have performed training for inspectors, QA, and managers, you fail to adequately address the managers’ failure to act on observed data integrity lapses. In particular, you lack a comprehensive review of the management of your operations, including but not limited to ineffective supervision and governance in your production department (i.e., encompassing frontline supervisors through top operations managers).\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>An explanation why disqualified visual inspectors relocated to secondary packaging operations were characterized as not being involved in CGMP activities. Secondary packaging functions in a production department are performed under good manufacturing practices.\u003C\u002Fli>\n\t\u003Cli>A comprehensive assessment and remediation plan to ensure your QA department is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o A determination of whether procedures used by your firm are robust and appropriate\u003Cbr>\n&nbsp; &nbsp; o Provisions for QA oversight throughout your operations to evaluate adherence to appropriate practices\u003Cbr>\n&nbsp; &nbsp; o A complete and final review of each batch and its related information before the QA disposition decision\u003Cbr>\n&nbsp; &nbsp; o Oversight and approval of investigations and discharging of all other QA duties to ensure identity, strength, quality, and purity of all products\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Describe how top management supports QA and reliable operations, including but not limited to, timely provision of resources to proactively address emerging manufacturing\u002Fquality issues and to assure a continuing state of control.\u003C\u002Fli>\n\t\u003Cli>A complete assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices to ensure you retain contemporaneous, attributable, legible, complete, original, and accurate (ALCOA) records throughout your operation.\u003C\u002Fli>\n\t\u003Cli>Describe your plans to prevent manipulation and enhance control of all CGMP records. Specifically, describe your reconciliation and integrity improvements for all CGMP records that may be in loose form or otherwise vulnerable to manipulation. Based on an independent review by a qualified consultant, provide a gap analysis and specific CAPA measures you will take to safeguard integrity of records (e.g., recording data in logbooks, pre-paginated documents, and validated electronic systems).\u003C\u002Fli>\n\t\u003Cli>Your corrective action and preventive action (CAPA) plan to implement routine, operations management oversight of facilities and equipment. This plan should include, at a minimum:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o Improved production management oversight that ensures prompt detection of equipment, facility, and process performance issues\u003Cbr>\n&nbsp; &nbsp; o Timely upgrades to equipment and facilities\u003Cbr>\n&nbsp; &nbsp; o Adherence to appropriate preventive maintenance schedules\u003Cbr>\n&nbsp; &nbsp; o Effective execution of repairs\u003Cbr>\n&nbsp; &nbsp; o Allocation of appropriate resources, staffing, and competencies\u003Cbr>\n&nbsp; &nbsp; o Appropriately qualified production supervisors and managers\u003Cbr>\n&nbsp; &nbsp; o Improved systems for ongoing management review\u003Cbr>\n&nbsp; &nbsp; o A provision(s) that appropriate actions are taken throughout the company network\u003Cbr>\n&nbsp; &nbsp; o A thorough evaluation and risk assessment that addresses the suitability of your equipment for its intended use. Include an evaluation whether equipment is of appropriate design and your ongoing control and maintenance program is effective.\u003Cbr>\n\u003Cbr>\n\u003Cstrong>2. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You failed to initiate or conduct adequate investigations into significant deviations in your aseptic processing manufacturing operations. You lacked investigations into visual inspection failures and non-viable particulates (NVP) exceeding your action levels. When investigations were conducted, they were often insufficient and lacked scientifically supported root cause(s).\u003C\u002Fp>\n\n\u003Cp>A. Several investigations were opened due to batches that failed visual inspection rejection rate limits. These investigations were closed without identifying the particles or their sources. There was no characterization of the particulates found in the batch to determine if they were intrinsic, extrinsic, or inherent to the product.\u003C\u002Fp>\n\n\u003Cp>For example, a deviation investigation was initiated for an \u003Cstrong>(b)(4)\u003C\u002Fstrong> injection batch intended for the European market, filled on the same aseptic processing line as that used to produce \u003Cstrong>(b)(4)\u003C\u002Fstrong> batches intended for the U.S. market. The batch exceeded the total rejection limit and the individual limits for white particles and glass particles. The investigation did not isolate or identify the white particles. In addition, there was no documented breakage of vials in the filling batch record. You closed the investigation without identifying the root cause or identifying the source of the white or glass particles.\u003C\u002Fp>\n\n\u003Cp>In your response, you acknowledge your deviation investigation failed to characterize the particulates when a batch failed to meet established limits. You commit to revise procedures for manual inspections of filled and sealed vials, to perform particle characterization, and to identify sources of particles during investigations.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate. Although you commit to perform particle characterization to identify the source of particulates during investigations, you do not commit to ensure appropriate definition and categorization of observed intrinsic and extrinsic particulates, and to fully evaluate visible particulate contamination.\u003C\u002Fp>\n\n\u003Cp>It is important that any visible particulate contamination is appropriately evaluated and investigated. Visible particulates in injectable products should be avoided through appropriate preventive measures built into your design and production controls. When categorizing any visible particles, extrinsic or foreign matter should receive special attention, as it may indicate possible microbial contamination. Extrinsic or foreign particulate contamination should occur very infrequently, and be thoroughly investigated and appropriate CAPA implemented.\u003C\u002Fp>\n\n\u003Cp>B. During aseptic filling, non-viable particle (NVP) count limits were exceeded in ISO 5 aseptic processing areas and no investigations were conducted because these excursions did not persist for more than \u003Cstrong>(b)(4)\u003C\u002Fstrong>, as stated in your procedure.\u003C\u002Fp>\n\n\u003Cp>You lacked an adequate system for handling NVP counts exceeding your action levels of NMT \u003Cstrong>(b)(4)\u003C\u002Fstrong> particles ≥ 0.5 μm\u002Fft\u003Csup>3\u003C\u002Fsup> during aseptic processing operations. Line \u003Cstrong>(b)(4)\u003C\u002Fstrong> frequently failed to meet these ISO 5 limits. You routinely failed to investigate these high particulate levels in the ISO 5 aseptic processing operation.\u003C\u002Fp>\n\n\u003Cp>For example, while manufacturing \u003Cstrong>(b)(4)\u003C\u002Fstrong> injection, a \u003Cstrong>(b)(4)\u003C\u002Fstrong> product produced for the U.S. market, the NVP probe at the filling station, the probe at the infeed \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and the probe at the stoppering station failed the NVP count limit multiple times. In one instance, the filling machine automatically stopped as a result of these NVP alarms. There was no procedural requirement to clear any open product containers present at the time of the excursion. Your firm determined that no investigation would be done because the ISO 5 alarms did not individually persist for \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>Excessive particulates in the ISO 5 environment can lead to non-viable or biological contamination of sterile drug products.\u003C\u002Fp>\n\n\u003Cp>In your response, you state for NVP count excursions, removal of open containers will be added to the relevant SOP(s) to address this observation.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate. There is no commitment to address the inappropriate \u003Cstrong>(b)(4)\u003C\u002Fstrong> timeframe to initiate a NVP deviation. The use of any timeframe-based criteria to initiate a NVP deviation is unacceptable. Any excursion or result outside of the classification limits should be investigated, and the intensity of those investigations should be consistent with the magnitude or frequency of the excursions. You should also trend data to identify and assess hazards and implement effective CAPA. In addition, you do not commit to perform a retrospective review of all batches with NVP levels outside the ISO 5 limits, including individual occurrences, as well as instances in which alarms occurred or the machine stopped during aseptic processing.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, out-of-specification (OOS) results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, quality assurance oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\u003C\u002Fli>\n\t\u003Cli>An independent, retrospective evaluation of all ISO 5 NVP deviations, root causes, and a relevant CAPA plan.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>3. Your firm failed to establish adequate written procedures for production and process controls designed to assure that the drug products have the identity, strength, purity, and quality that they are purported or represented to possess (21 CFR 211.100 (a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your personnel qualification for the visual inspection of injectable products is deficient.\u003C\u002Fp>\n\n\u003Cp>A. Your firm failed to provide adequate challenge test set vials to qualify your operators to perform the visual inspection of your drug products. The challenge test kit used to qualify manual visual inspectors was created using good and rejected vials from a previous batch, with unknown sizes of particles present in the vials. Additionally, a \u003Cstrong>(b)(4)\u003C\u002Fstrong> μm \u003Cstrong>(b)(4)\u003C\u002Fstrong> particle was added to the challenge kit but it is not representative of the types of particles found in your operation. You lacked assurance the test kit with unknown particle sizes can adequately assess if your inspectors have the competencies required to identify the particles that may be present in the vials. In addition, quality unit personnel have not maintained a defect library for training purposes or reference.\u003C\u002Fp>\n\n\u003Cp>In your response, you commit to create a new visual inspection kit with known sizes of certified particle defects and revise procedures for kit preparation (e.g., to include particles with known particle sizes) and the inclusion of a reference defect library.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate. You do not state how including the \u003Cstrong>(b)(4)\u003C\u002Fstrong> particle to your qualification kit is representative of your process to qualify visual inspectors.\u003C\u002Fp>\n\n\u003Cp>B. Your firm failed to adequately validate the manufacturing process for \u003Cstrong>(b)(4)\u003C\u002Fstrong> mg \u003Cstrong>(b)(4)\u003C\u002Fstrong> tablets. Specifically, your process validation lacked inter-batch and intra-batch evaluation of \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and process times for the \u003Cstrong>(b)(4)\u003C\u002Fstrong>. During production, \u003Cstrong>(b)(4)\u003C\u002Fstrong> processing times, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong> were left to operators’ discretion and variation of parameters were observed between batches.\u003C\u002Fp>\n\n\u003Cp>In addition, you lacked scientific justification for the sample sizes collected at the \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;operations to analyze for percent \u003Cstrong>(b)(4)\u003C\u002Fstrong>, dissolution, and appearance. Your firm has initiated deviations for OOS results of percent \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and rough surfaces were also observed during \u003Cstrong>(b)(4)\u003C\u002Fstrong> of \u003Cstrong>(b)(4)\u003C\u002Fstrong>mg \u003Cstrong>(b)(4)\u003C\u002Fstrong> tablets. The process validation study, and commercial manufacturing data, did not provide sufficient assurance of that process consistency is maintained throughout production batch operations.\u003C\u002Fp>\n\n\u003Cp>In your response, you acknowledge there is a lack of evaluation of inter- and intra-batch variability and insufficient guidance to the operators regarding process controls. You commit to performing an impact assessment on the \u003Cstrong>(b)(4)\u003C\u002Fstrong> on \u003Cstrong>(b)(4)\u003C\u002Fstrong> mg \u003Cstrong>(b)(4)\u003C\u002Fstrong> tablets \u003Cstrong>(b)(4)\u003C\u002Fstrong> and other drug products containing a \u003Cstrong>(b)(4)\u003C\u002Fstrong>. You also commit to revise your process validation procedures to ensure adequate samples are collected and performing statistical evaluations to understand the inter- and intra- batch variability with existing process validations. We acknowledge your firm’s commitment to perform process validation for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> stage of \u003Cstrong>(b)(4)\u003C\u002Fstrong> mg \u003Cstrong>(b)(4)\u003C\u002Fstrong> tablets.\u003C\u002Fp>\n\n\u003Cp>Process validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies determine whether an initial state of control has been established. Successful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure you maintain a stable manufacturing operation throughout the product lifecycle.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Provide a comprehensive, independent assessment of your validation program for ensuring an ongoing state of control throughout the product lifecycle, including the following elements:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o A description of the overall program (e.g., lifecycle process validation phases; equipment and facility qualification).\u003Cbr>\n&nbsp; &nbsp; o A detailed description of how you ensure a rigorous process performance qualification studies. Include specific quantitative approaches with intensified sampling plans to fully assess all significant process steps, and explain how these extensive levels of sampling characterize the intra-batch uniformity at these steps to provide a high level of assurance that supports a decision on readiness for marketing.\u003Cbr>\n&nbsp; &nbsp; o Vigilant ongoing monitoring of process performance and product quality throughout the lifecycle, with emphasis on:\u003Cbr>\n&nbsp; &nbsp;  Mechanisms to ensure ongoing attention to both intra-batch and inter-batch variation\u003Cbr>\n&nbsp; &nbsp;  Appropriate sampling methods and frequency throughout processing to ensure detection of process control lapses\u003Cbr>\n&nbsp; &nbsp;  Scrutiny of raw material variability from suppliers\u003Cbr>\n&nbsp; &nbsp;  Quality signals from both internal data and customers\u003Cbr>\n&nbsp; &nbsp;  How your quality system integrates this ongoing knowledge of signals from process performance and product quality monitoring to identify areas of variation that need improvement.\u003Cbr>\n&nbsp; &nbsp; o Based on this assessment, provide a CAPA to address any deficiencies in your process validation program.\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Improved in-process testing and monitoring to enhance detection of variation during production of each batch (including for both individual and average test limits). Include remediated in-process quality standards, including but not limited to enhanced sampling, that will more robustly monitor upstream process control. Describe how the improvements will ensure early detection of process variation and manufacturing defects, and prevent consumer exposure to substandard quality drug products.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>4. Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes (21 CFR 211.113 (b)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>A. Your procedures did not include a requirement for smoke studies to be performed in dynamic conditions in classified critical areas. There have been no smoke studies to determine whether the “\u003Cstrong>(b)(4)\u003C\u002Fstrong> LAF [laminar air flow]” can provide appropriate unidirectional air during dynamic activities, such as loading of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> into the \u003Cstrong>(b)(4)\u003C\u002Fstrong> restricted access barrier systems (\u003Cstrong>(b)(4)\u003C\u002Fstrong>RABS). The mobile LAF was not evaluated during the smoke studies under dynamic conditions. For example, the operator removes the \u003Cstrong>(b)(4)\u003C\u002Fstrong> tub from the mobile LAF and carries them under the “\u003Cstrong>(b)(4)\u003C\u002Fstrong> LAF” (which is classified as an ISO 7 area) and then into the \u003Cstrong>(b)(4)\u003C\u002Fstrong>RABS.\u003C\u002Fp>\n\n\u003Cp>Thorough smoke studies are essential to evaluate and qualify your aseptic processing operations and ensure appropriate implementation of needed design remediations.\u003C\u002Fp>\n\n\u003Cp>In your response, you indicate your procedures were revised to include instructions for conducting smoke studies under dynamic conditions. You state you have now performed smoke studies under dynamic conditions for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> tub loading process including the mobile LAF and “\u003Cstrong>(b)(4)\u003C\u002Fstrong> LAF.” You commit to an assessment for all filling lines of parenteral drug products to evaluate execution of smoke studies in static and dynamic conditions.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate. You do not provide the smoke study video and report evaluating unidirectional airflow patterns under dynamic conditions for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> tub loading process, including mobile LAF and “\u003Cstrong>(b)(4)\u003C\u002Fstrong> LAF.”\u003C\u002Fp>\n\n\u003Cp>B. The qualification of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> cycle of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> equipped with transport ports failed to ensure adequate decontamination and worst-case locations in the \u003Cstrong>(b)(4)\u003C\u002Fstrong> used in manufacturing. Specifically, the \u003Cstrong>(b)(4)\u003C\u002Fstrong> transport port \u003Cstrong>(b)(4)\u003C\u002Fstrong> used to transport components to the \u003Cstrong>(b)(4)\u003C\u002Fstrong> was not assessed with biological indicators at the \u003Cstrong>(b)(4)\u003C\u002Fstrong> of the \u003Cstrong>(b)(4)\u003C\u002Fstrong>. In addition, the investigator observed an overlap and fold in the \u003Cstrong>(b)(4)\u003C\u002Fstrong> of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> near the area where the \u003Cstrong>(b)(4)\u003C\u002Fstrong> attaches to the \u003Cstrong>(b)(4)\u003C\u002Fstrong> for which the qualification failed to address if this area can be reproducibly decontaminated by \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>In your response, you acknowledge the observation that chemical and biological indicators were not placed at the \u003Cstrong>(b)(4)\u003C\u002Fstrong> of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> transfer port and \u003Cstrong>(b)(4)\u003C\u002Fstrong> for \u003Cstrong>(b)(4)\u003C\u002Fstrong>. We note a requalification was performed on the \u003Cstrong>(b)(4)\u003C\u002Fstrong> cited during the inspection and a report was provided. You commit to evaluating all \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> for appropriate sample locations. You commit to reviewing the qualification protocols and reports for all remaining \u003Cstrong>(b)(4)\u003C\u002Fstrong> to ensure the \u003Cstrong>(b)(4)\u003C\u002Fstrong> are adequately sampled. As a result of this inspection, you conducted a retrospective review and discovered five other \u003Cstrong>(b)(4)\u003C\u002Fstrong> that did not have chemical and biological indicators at the \u003Cstrong>(b)(4)\u003C\u002Fstrong> of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> for \u003Cstrong>(b)(4)\u003C\u002Fstrong>-decontamination.\u003C\u002Fp>\n\n\u003Cp>As acknowledged in your response, further evaluations are needed to identify and assess the potential weak spots in your \u003Cstrong>(b)(4)\u003C\u002Fstrong> decontamination process. Your strategy appears to emphasize use of chemical indicators. However, biological indicators are essential to any evaluation to identify and evaluate locations that may lack assurance of sufficient \u003Cstrong>(b)(4)\u003C\u002Fstrong> exposure.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Comprehensive risk assessment of all contamination hazards with respect to your aseptic processes, equipment, and facilities, including an independent assessment that includes, but is not limited to:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o All human interactions within the ISO 5 area\u003Cbr>\n&nbsp; &nbsp; o Equipment placement and ergonomics\u003Cbr>\n&nbsp; &nbsp; o Air quality in the ISO 5 area and surrounding room\u003Cbr>\n&nbsp; &nbsp; o Facility layout\u003Cbr>\n&nbsp; &nbsp; o Personnel Flows and Material Flows (throughout all rooms used to conduct and support sterile operations)\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A detailed remediation plan with timelines to address the findings of the contamination hazards risk assessment. Describe specific tangible improvements to be made to aseptic processing operation design and control.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>Data Integrity Remediation\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture. See FDA’s guidance document \u003Cem>Data Integrity and Compliance With Drug CGMP\u003C\u002Fem> for guidance on establishing and following CGMP compliant data integrity practices at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fdata-integrity-and-compliance-drug-cgmp-questions-and-answers\u003C\u002Fp>\n\n\u003Cp>We acknowledge that you are using a consultant to audit your operation and assist in meeting FDA requirements. In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cp>A. A comprehensive investigation into the extent of the inaccuracies in data records and reporting. Your investigation should include:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A detailed investigation protocol and methodology; a summary of all laboratories, manufacturing operations, and systems to be covered by the assessment; and a justification for any part of your operation that you propose to exclude.\u003C\u002Fli>\n\t\u003Cli>Interviews of current and former employees to identify the nature, scope, and root cause of data inaccuracies. We recommend that these interviews be conducted by a qualified third party.\u003C\u002Fli>\n\t\u003Cli>An assessment of the extent of data integrity deficiencies at your facility. Identify omissions, alterations, deletions, record destruction, non-contemporaneous record completion, and other deficiencies. Describe all parts of your facility’s operations in which you discovered data integrity lapses.\u003C\u002Fli>\n\t\u003Cli>A comprehensive retrospective evaluation of the nature of the testing and manufacturing data integrity deficiencies. We recommend that a qualified third party with specific expertise in the area where potential breaches were identified should evaluate all data integrity lapses.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>B. A current risk assessment of the potential effects of the observed failures on the quality of your drugs. Your assessment should include analyses of the risks to patients caused by the release of drugs affected by a lapse of data integrity and analyses of the risks posed by ongoing operations.\u003C\u002Fp>\n\n\u003Cp>C. A management strategy for your firm that includes the details of your global corrective action and preventive action plan. Your strategy should include these elements:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A detailed corrective action plan that describes how you intend to ensure the reliability and completeness of all the data you generate including analytical data, manufacturing records, and all data submitted to FDA.\u003C\u002Fli>\n\t\u003Cli>A comprehensive description of the root causes of your data integrity lapses including evidence that the scope and depth of the current action plan is commensurate with the findings of the investigation and risk assessment. Indicate whether individuals responsible for data integrity lapses remain able to influence CGMP-related or drug application data at your firm.\u003C\u002Fli>\n\t\u003Cli>Interim measures describing the actions you have taken or will take to protect patients and to ensure the quality of your drugs, such as notifying your customers, recalling product, conducting additional testing, adding lots to your stability programs to assure stability, drug application actions, and enhanced complaint monitoring.\u003C\u002Fli>\n\t\u003Cli>Long-term measures describing any remediation efforts and enhancements to procedures, processes, methods, controls, systems, management oversight, and human resources (e.g., training, staffing improvements) designed to ensure the integrity of your company’s data.\u003C\u002Fli>\n\t\u003Cli>A commitment to have a qualified consultant conduct extensive annual audits, for at least two years, to assist in evaluating CAPA effectiveness after you have executed your data integrity remediation protocol.\u003C\u002Fli>\n\t\u003Cli>Inform FDA if you will be hiring a Chief Integrity Officer who is fully empowered to maintain anonymity of employees who report data integrity concerns and with authority to investigate potential breaches.\u003C\u002Fli>\n\t\u003Cli>A status report for any of the above activities already underway or completed.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>Repeat Observations at Facility\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>In a previous inspection, including the inspection of July 22 to August 02, 2019, FDA cited similar CGMP observations. You proposed specific remediations for these observations in your responses. Repeated failures demonstrate that executive management oversight and control over the manufacture of drugs is inadequate.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Ineffective Quality System\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Significant findings in this letter demonstrate that your firm does not operate an effective quality system in accord with CGMP. In addition to the lack of effective production and laboratory operations oversight, we found your quality unit is not enabled to exercise proper authority and\u002For has insufficiently implemented its responsibilities. Executive management should immediately and comprehensively assess your company’s global manufacturing operations to ensure that your systems, processes, and products conform to FDA requirements.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>If you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(b). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\u003C\u002Fp>\n\n\u003Cp>FDA placed your firm on Import Alert 66-40 on November 14, 2023.\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\u003C\u002Fp>\n\n\u003Cp>Failure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at, Intas Pharmaceuticals Limited, at Plot No. 457- 458 &amp; 191\u002F218P, Sarkhej - Bavla Highway, Matoda - Sanand, Ahmedabad, Gujarat, India into the United States under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>We request you email Temeka Moore, Temeka.Moore@fda.hhs.gov, within five days of receipt of this letter to schedule a regulatory meeting.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3003157498 and ATTN: Erika V. Butler.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Francis Godwin\u003Cbr>\nDirector\u003Cbr>\nOffice of Manufacturing Quality\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003C\u002Fp>\n\n\u003Cp>___________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Under program enhancements for the Generic Drug User Fee Amendments (GDUFA) reauthorization for fiscal years (FYs) 2023-2027, also known as the GDUFA III Commitment Letter, your facility may be eligible for a Post-Warning Letter Meeting to obtain preliminary feedback from FDA on the adequacy and completeness of your corrective action plans.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Nimish Chudgar\n\nRecipient Title\n\nChief Executive Officer & Managing Director\n\nIntas Pharmaceuticals Limited\n\nPlot No. 255, Magnet Corporate Park, Near Sola Bridge, S.G. Highway\n\nThaltej, Ahmedabad 380054\n\nGujarat\n\nIndia\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nWarning Letter 320-24-12\n\nNovember 21, 2023\n\nDear Mr. Chudgar:\n\nThe U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Intas Pharmaceuticals Limited, FEI 3003157498, at Plot No. 457- 458 & 191\u002F218P, Sarkhej - Bavla Highway, Matoda - Sanand, Ahmedabad, from May 1 to May 12, 2023.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\n\nWe reviewed your June 05, 2023 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\n\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n\n1. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\n\nYour Quality Assurance (QA) and production departments failed to provide adequate oversight and ensure the reliability of data related to the quality of finished drug products manufactured at your facility. Since 2021, visual inspectors manipulated particle and other defect counts on manual visual inspection records in many instances, in order to keep the finished product batches within rejection limits. More specifically, the investigation found that operators manipulated the defect quantities “to keep the category wise rejections within limits to avoid a deviation and investigation.”\n\nIn addition, multiple operators manipulated the reported defects, including (b)(4) attributes and particle counts, on manual visual inspection records to have identical numbers. This practice was repeatedly performed by at least nine different manual visual inspectors on trays of (b)(4). The records, filled out by multiple operators, had an identical number of defects listed for all drug product defect categories.\n\nProduction managers including, but not limited to, front line supervisors failed to ensure reliable data, leading to significant data integrity deficiencies in your production records.\n\nIn addition, there was a lack of QA department review and oversight of visual inspection records, and your firm continued this egregious pattern of recording and altering defect counts. These findings indicated that your QA department was not exercising its basic responsibilities including, but not limited to, oversight and control over the adequacy and reliability of all CGMP data at your facility.\n\nIn your response, you acknowledge the discrepancies found in the visual inspection records and identify the contributing factors to these deviations as “inadequate data management processes, inadequate training and procedures, and inadequate quality oversight of the visual inspection operation.” You state that “all the visual inspectors in this area have been disqualified” and “operators have been moved to the secondary packaging area and are not participating in GMP activities.”\n\nIn addition, you also commit to working with a qualified consultant to perform a “data governance and integrity audit” and to establish a remediation plan. You commit to perform an assessment to evaluate injectable products that are within shelf life and are on the market to identify similar discrepancies in the visual inspection records.\n\nWe acknowledge your voluntary recall of batches of drug products due to particle contamination identified in product retain samples.\n\nYour response is inadequate because you have not conducted a comprehensive evaluation of other CGMP records in which data may have been reported inaccurately or otherwise manipulated by your employees. You do not provide a comprehensive corrective action and preventative action (CAPA) plan with a systematic approach to correct these oversight deficiencies. Furthermore, although you indicate that you have performed training for inspectors, QA, and managers, you fail to adequately address the managers’ failure to act on observed data integrity lapses. In particular, you lack a comprehensive review of the management of your operations, including but not limited to ineffective supervision and governance in your production department (i.e., encompassing frontline supervisors through top operations managers).\n\nIn response to this letter, provide:\n\nAn explanation why disqualified visual inspectors relocated to secondary packaging operations were characterized as not being involved in CGMP activities. Secondary packaging functions in a production department are performed under good manufacturing practices.\n\nA comprehensive assessment and remediation plan to ensure your QA department is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\n\no A determination of whether procedures used by your firm are robust and appropriate\n\no Provisions for QA oversight throughout your operations to evaluate adherence to appropriate practices\n\no A complete and final review of each batch and its related information before the QA disposition decision\n\no Oversight and approval of investigations and discharging of all other QA duties to ensure identity, strength, quality, and purity of all products\n\nDescribe how top management supports QA and reliable operations, including but not limited to, timely provision of resources to proactively address emerging manufacturing\u002Fquality issues and to assure a continuing state of control.\n\nA complete assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices to ensure you retain contemporaneous, attributable, legible, complete, original, and accurate (ALCOA) records throughout your operation.\n\nDescribe your plans to prevent manipulation and enhance control of all CGMP records. Specifically, describe your reconciliation and integrity improvements for all CGMP records that may be in loose form or otherwise vulnerable to manipulation. Based on an independent review by a qualified consultant, provide a gap analysis and specific CAPA measures you will take to safeguard integrity of records (e.g., recording data in logbooks, pre-paginated documents, and validated electronic systems).\n\nYour corrective action and preventive action (CAPA) plan to implement routine, operations management oversight of facilities and equipment. This plan should include, at a minimum:\n\no Improved production management oversight that ensures prompt detection of equipment, facility, and process performance issues\n\no Timely upgrades to equipment and facilities\n\no Adherence to appropriate preventive maintenance schedules\n\no Effective execution of repairs\n\no Allocation of appropriate resources, staffing, and competencies\n\no Appropriately qualified production supervisors and managers\n\no Improved systems for ongoing management review\n\no A provision(s) that appropriate actions are taken throughout the company network\n\no A thorough evaluation and risk assessment that addresses the suitability of your equipment for its intended use. Include an evaluation whether equipment is of appropriate design and your ongoing control and maintenance program is effective.\n\n2. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\n\nYou failed to initiate or conduct adequate investigations into significant deviations in your aseptic processing manufacturing operations. You lacked investigations into visual inspection failures and non-viable particulates (NVP) exceeding your action levels. When investigations were conducted, they were often insufficient and lacked scientifically supported root cause(s).\n\nA. Several investigations were opened due to batches that failed visual inspection rejection rate limits. These investigations were closed without identifying the particles or their sources. There was no characterization of the particulates found in the batch to determine if they were intrinsic, extrinsic, or inherent to the product.\n\nFor example, a deviation investigation was initiated for an (b)(4) injection batch intended for the European market, filled on the same aseptic processing line as that used to produce (b)(4) batches intended for the U.S. market. The batch exceeded the total rejection limit and the individual limits for white particles and glass particles. The investigation did not isolate or identify the white particles. In addition, there was no documented breakage of vials in the filling batch record. You closed the investigation without identifying the root cause or identifying the source of the white or glass particles.\n\nIn your response, you acknowledge your deviation investigation failed to characterize the particulates when a batch failed to meet established limits. You commit to revise procedures for manual inspections of filled and sealed vials, to perform particle characterization, and to identify sources of particles during investigations.\n\nYour response is inadequate. Although you commit to perform particle characterization to identify the source of particulates during investigations, you do not commit to ensure appropriate definition and categorization of observed intrinsic and extrinsic particulates, and to fully evaluate visible particulate contamination.\n\nIt is important that any visible particulate contamination is appropriately evaluated and investigated. Visible particulates in injectable products should be avoided through appropriate preventive measures built into your design and production controls. When categorizing any visible particles, extrinsic or foreign matter should receive special attention, as it may indicate possible microbial contamination. Extrinsic or foreign particulate contamination should occur very infrequently, and be thoroughly investigated and appropriate CAPA implemented.\n\nB. During aseptic filling, non-viable particle (NVP) count limits were exceeded in ISO 5 aseptic processing areas and no investigations were conducted because these excursions did not persist for more than (b)(4), as stated in your procedure.\n\nYou lacked an adequate system for handling NVP counts exceeding your action levels of NMT (b)(4) particles ≥ 0.5 μm\u002Fft3 during aseptic processing operations. Line (b)(4) frequently failed to meet these ISO 5 limits. You routinely failed to investigate these high particulate levels in the ISO 5 aseptic processing operation.\n\nFor example, while manufacturing (b)(4) injection, a (b)(4) product produced for the U.S. market, the NVP probe at the filling station, the probe at the infeed (b)(4), and the probe at the stoppering station failed the NVP count limit multiple times. In one instance, the filling machine automatically stopped as a result of these NVP alarms. There was no procedural requirement to clear any open product containers present at the time of the excursion. Your firm determined that no investigation would be done because the ISO 5 alarms did not individually persist for (b)(4).\n\nExcessive particulates in the ISO 5 environment can lead to non-viable or biological contamination of sterile drug products.\n\nIn your response, you state for NVP count excursions, removal of open containers will be added to the relevant SOP(s) to address this observation.\n\nYour response is inadequate. There is no commitment to address the inappropriate (b)(4) timeframe to initiate a NVP deviation. The use of any timeframe-based criteria to initiate a NVP deviation is unacceptable. Any excursion or result outside of the classification limits should be investigated, and the intensity of those investigations should be consistent with the magnitude or frequency of the excursions. You should also trend data to identify and assess hazards and implement effective CAPA. In addition, you do not commit to perform a retrospective review of all batches with NVP levels outside the ISO 5 limits, including individual occurrences, as well as instances in which alarms occurred or the machine stopped during aseptic processing.\n\nIn response to this letter, provide:\n\nA comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, out-of-specification (OOS) results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, quality assurance oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\n\nAn independent, retrospective evaluation of all ISO 5 NVP deviations, root causes, and a relevant CAPA plan.\n\n3. Your firm failed to establish adequate written procedures for production and process controls designed to assure that the drug products have the identity, strength, purity, and quality that they are purported or represented to possess (21 CFR 211.100 (a)).\n\nYour personnel qualification for the visual inspection of injectable products is deficient.\n\nA. Your firm failed to provide adequate challenge test set vials to qualify your operators to perform the visual inspection of your drug products. The challenge test kit used to qualify manual visual inspectors was created using good and rejected vials from a previous batch, with unknown sizes of particles present in the vials. Additionally, a (b)(4) μm (b)(4) particle was added to the challenge kit but it is not representative of the types of particles found in your operation. You lacked assurance the test kit with unknown particle sizes can adequately assess if your inspectors have the competencies required to identify the particles that may be present in the vials. In addition, quality unit personnel have not maintained a defect library for training purposes or reference.\n\nIn your response, you commit to create a new visual inspection kit with known sizes of certified particle defects and revise procedures for kit preparation (e.g., to include particles with known particle sizes) and the inclusion of a reference defect library.\n\nYour response is inadequate. You do not state how including the (b)(4) particle to your qualification kit is representative of your process to qualify visual inspectors.\n\nB. Your firm failed to adequately validate the manufacturing process for (b)(4) mg (b)(4) tablets. Specifically, your process validation lacked inter-batch and intra-batch evaluation of (b)(4), and process times for the (b)(4). During production, (b)(4) processing times, (b)(4), and (b)(4) were left to operators’ discretion and variation of parameters were observed between batches.\n\nIn addition, you lacked scientific justification for the sample sizes collected at the (b)(4) operations to analyze for percent (b)(4), dissolution, and appearance. Your firm has initiated deviations for OOS results of percent (b)(4), and rough surfaces were also observed during (b)(4) of (b)(4)mg (b)(4) tablets. The process validation study, and commercial manufacturing data, did not provide sufficient assurance of that process consistency is maintained throughout production batch operations.\n\nIn your response, you acknowledge there is a lack of evaluation of inter- and intra-batch variability and insufficient guidance to the operators regarding process controls. You commit to performing an impact assessment on the (b)(4) on (b)(4) mg (b)(4) tablets (b)(4) and other drug products containing a (b)(4). You also commit to revise your process validation procedures to ensure adequate samples are collected and performing statistical evaluations to understand the inter- and intra- batch variability with existing process validations. We acknowledge your firm’s commitment to perform process validation for the (b)(4) stage of (b)(4) mg (b)(4) tablets.\n\nProcess validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies determine whether an initial state of control has been established. Successful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure you maintain a stable manufacturing operation throughout the product lifecycle.\n\nIn response to this letter, provide:\n\nProvide a comprehensive, independent assessment of your validation program for ensuring an ongoing state of control throughout the product lifecycle, including the following elements:\n\no A description of the overall program (e.g., lifecycle process validation phases; equipment and facility qualification).\n\no A detailed description of how you ensure a rigorous process performance qualification studies. Include specific quantitative approaches with intensified sampling plans to fully assess all significant process steps, and explain how these extensive levels of sampling characterize the intra-batch uniformity at these steps to provide a high level of assurance that supports a decision on readiness for marketing.\n\no Vigilant ongoing monitoring of process performance and product quality throughout the lifecycle, with emphasis on:\n\n Mechanisms to ensure ongoing attention to both intra-batch and inter-batch variation\n\n Appropriate sampling methods and frequency throughout processing to ensure detection of process control lapses\n\n Scrutiny of raw material variability from suppliers\n\n Quality signals from both internal data and customers\n\n How your quality system integrates this ongoing knowledge of signals from process performance and product quality monitoring to identify areas of variation that need improvement.\n\no Based on this assessment, provide a CAPA to address any deficiencies in your process validation program.\n\nImproved in-process testing and monitoring to enhance detection of variation during production of each batch (including for both individual and average test limits). Include remediated in-process quality standards, including but not limited to enhanced sampling, that will more robustly monitor upstream process control. Describe how the improvements will ensure early detection of process variation and manufacturing defects, and prevent consumer exposure to substandard quality drug products.\n\n4. Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes (21 CFR 211.113 (b)).\n\nA. Your procedures did not include a requirement for smoke studies to be performed in dynamic conditions in classified critical areas. There have been no smoke studies to determine whether the “(b)(4) LAF [laminar air flow]” can provide appropriate unidirectional air during dynamic activities, such as loading of the (b)(4) into the (b)(4) restricted access barrier systems ((b)(4)RABS). The mobile LAF was not evaluated during the smoke studies under dynamic conditions. For example, the operator removes the (b)(4) tub from the mobile LAF and carries them under the “(b)(4) LAF” (which is classified as an ISO 7 area) and then into the (b)(4)RABS.\n\nThorough smoke studies are essential to evaluate and qualify your aseptic processing operations and ensure appropriate implementation of needed design remediations.\n\nIn your response, you indicate your procedures were revised to include instructions for conducting smoke studies under dynamic conditions. You state you have now performed smoke studies under dynamic conditions for the (b)(4) tub loading process including the mobile LAF and “(b)(4) LAF.” You commit to an assessment for all filling lines of parenteral drug products to evaluate execution of smoke studies in static and dynamic conditions.\n\nYour response is inadequate. You do not provide the smoke study video and report evaluating unidirectional airflow patterns under dynamic conditions for the (b)(4) tub loading process, including mobile LAF and “(b)(4) LAF.”\n\nB. The qualification of the (b)(4) cycle of the (b)(4) equipped with transport ports failed to ensure adequate decontamination and worst-case locations in the (b)(4) used in manufacturing. Specifically, the (b)(4) transport port (b)(4) used to transport components to the (b)(4) was not assessed with biological indicators at the (b)(4) of the (b)(4). In addition, the investigator observed an overlap and fold in the (b)(4) of the (b)(4) near the area where the (b)(4) attaches to the (b)(4) for which the qualification failed to address if this area can be reproducibly decontaminated by (b)(4).\n\nIn your response, you acknowledge the observation that chemical and biological indicators were not placed at the (b)(4) of the (b)(4) transfer port and (b)(4) for (b)(4). We note a requalification was performed on the (b)(4) cited during the inspection and a report was provided. You commit to evaluating all (b)(4) and (b)(4) for appropriate sample locations. You commit to reviewing the qualification protocols and reports for all remaining (b)(4) to ensure the (b)(4) are adequately sampled. As a result of this inspection, you conducted a retrospective review and discovered five other (b)(4) that did not have chemical and biological indicators at the (b)(4) of the (b)(4) for (b)(4)-decontamination.\n\nAs acknowledged in your response, further evaluations are needed to identify and assess the potential weak spots in your (b)(4) decontamination process. Your strategy appears to emphasize use of chemical indicators. However, biological indicators are essential to any evaluation to identify and evaluate locations that may lack assurance of sufficient (b)(4) exposure.\n\nIn response to this letter, provide:\n\nComprehensive risk assessment of all contamination hazards with respect to your aseptic processes, equipment, and facilities, including an independent assessment that includes, but is not limited to:\n\no All human interactions within the ISO 5 area\n\no Equipment placement and ergonomics\n\no Air quality in the ISO 5 area and surrounding room\n\no Facility layout\n\no Personnel Flows and Material Flows (throughout all rooms used to conduct and support sterile operations)\n\nA detailed remediation plan with timelines to address the findings of the contamination hazards risk assessment. Describe specific tangible improvements to be made to aseptic processing operation design and control.\n\nData Integrity Remediation\n\nYour quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture. See FDA’s guidance document Data Integrity and Compliance With Drug CGMP for guidance on establishing and following CGMP compliant data integrity practices at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fdata-integrity-and-compliance-drug-cgmp-questions-and-answers\n\nWe acknowledge that you are using a consultant to audit your operation and assist in meeting FDA requirements. In response to this letter, provide:\n\nA. A comprehensive investigation into the extent of the inaccuracies in data records and reporting. Your investigation should include:\n\nA detailed investigation protocol and methodology; a summary of all laboratories, manufacturing operations, and systems to be covered by the assessment; and a justification for any part of your operation that you propose to exclude.\n\nInterviews of current and former employees to identify the nature, scope, and root cause of data inaccuracies. We recommend that these interviews be conducted by a qualified third party.\n\nAn assessment of the extent of data integrity deficiencies at your facility. Identify omissions, alterations, deletions, record destruction, non-contemporaneous record completion, and other deficiencies. Describe all parts of your facility’s operations in which you discovered data integrity lapses.\n\nA comprehensive retrospective evaluation of the nature of the testing and manufacturing data integrity deficiencies. We recommend that a qualified third party with specific expertise in the area where potential breaches were identified should evaluate all data integrity lapses.\n\nB. A current risk assessment of the potential effects of the observed failures on the quality of your drugs. Your assessment should include analyses of the risks to patients caused by the release of drugs affected by a lapse of data integrity and analyses of the risks posed by ongoing operations.\n\nC. A management strategy for your firm that includes the details of your global corrective action and preventive action plan. Your strategy should include these elements:\n\nA detailed corrective action plan that describes how you intend to ensure the reliability and completeness of all the data you generate including analytical data, manufacturing records, and all data submitted to FDA.\n\nA comprehensive description of the root causes of your data integrity lapses including evidence that the scope and depth of the current action plan is commensurate with the findings of the investigation and risk assessment. Indicate whether individuals responsible for data integrity lapses remain able to influence CGMP-related or drug application data at your firm.\n\nInterim measures describing the actions you have taken or will take to protect patients and to ensure the quality of your drugs, such as notifying your customers, recalling product, conducting additional testing, adding lots to your stability programs to assure stability, drug application actions, and enhanced complaint monitoring.\n\nLong-term measures describing any remediation efforts and enhancements to procedures, processes, methods, controls, systems, management oversight, and human resources (e.g., training, staffing improvements) designed to ensure the integrity of your company’s data.\n\nA commitment to have a qualified consultant conduct extensive annual audits, for at least two years, to assist in evaluating CAPA effectiveness after you have executed your data integrity remediation protocol.\n\nInform FDA if you will be hiring a Chief Integrity Officer who is fully empowered to maintain anonymity of employees who report data integrity concerns and with authority to investigate potential breaches.\n\nA status report for any of the above activities already underway or completed.\n\nRepeat Observations at Facility\n\nIn a previous inspection, including the inspection of July 22 to August 02, 2019, FDA cited similar CGMP observations. You proposed specific remediations for these observations in your responses. Repeated failures demonstrate that executive management oversight and control over the manufacture of drugs is inadequate.\n\nIneffective Quality System\n\nSignificant findings in this letter demonstrate that your firm does not operate an effective quality system in accord with CGMP. In addition to the lack of effective production and laboratory operations oversight, we found your quality unit is not enabled to exercise proper authority and\u002For has insufficiently implemented its responsibilities. Executive management should immediately and comprehensively assess your company’s global manufacturing operations to ensure that your systems, processes, and products conform to FDA requirements.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nIf you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(b). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\n\nFDA placed your firm on Import Alert 66-40 on November 14, 2023.\n\nCorrect any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\n\nFailure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at, Intas Pharmaceuticals Limited, at Plot No. 457- 458 & 191\u002F218P, Sarkhej - Bavla Highway, Matoda - Sanand, Ahmedabad, Gujarat, India into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).\n\nWe request you email Temeka Moore, Temeka.Moore@fda.hhs.gov, within five days of receipt of this letter to schedule a regulatory meeting.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days1. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3003157498 and ATTN: Erika V. Butler.\n\nSincerely,\n\n\u002FS\u002F\n\nFrancis Godwin\n\nDirector\n\nOffice of Manufacturing Quality\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\n___________________________\n\n1 Under program enhancements for the Generic Drug User Fee Amendments (GDUFA) reauthorization for fiscal years (FYs) 2023-2027, also known as the GDUFA III Commitment Letter, your facility may be eligible for a Post-Warning Letter Meeting to obtain preliminary feedback from FDA on the adequacy and completeness of your corrective action plans.","intas-pharmaceuticals-limited-662868-11212023","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fintas-pharmaceuticals-limited-662868-11212023","2026-10-26T08:08:59.489025+00:00","2023-11-28","662868","Mr. Nimish Chudgar","2026-08-20T00:28:57.09+00:00","Via Email","2023-11-21",{"id":113,"raw":114,"subject":80,"body_html":118,"body_text":119,"firm_name":83,"letter_id":120,"created_at":65,"fei_number":19,"letter_url":121,"updated_at":122,"action_type":22,"case_status":23,"posted_date":123,"marcs_cms_no":124,"product_type":26,"closeout_date":19,"issuing_office":58,"recipient_name":108,"body_fetched_at":125,"delivery_method":110,"recipient_title":19,"reference_number":19,"action_taken_date":126,"medical_device_id":19,"response_letter_date":19},1959,[115,116,117,58,80,13,13,13],"\u003Ctime datetime=\"2023-08-01T14:31:00Z\">08\u002F01\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-07-28T04:00:00Z\">07\u002F28\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fintas-pharmaceuticals-limited-652067-07282023\">Intas Pharmaceuticals Limited\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Nimish Chudgar\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer &amp; Managing Director\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Intas Pharmaceuticals Limited\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Plot No. 255, Magnet Corporate Park, Near Sola Bridge, S.G. Highway\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Thaltej, Ahmedabad\u003C\u002Fspan> \u003Cspan>382213\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Gujarat\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>India\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-23-20\u003C\u002Fp>\n\n\u003Cp>July 28, 2023\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Chudgar:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Intas Pharmaceuticals Limited, FEI 3004011473, at Plot No. 5 To 14, Pharmez, Near Village Matoda, Sarkhej-Bavla National Highway No. 8-A, Taluka, Sanand, India, from November 22 to December 02, 2022.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of current good manufacturing practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>We reviewed your December 27, 2022 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You failed to ensure reliability of data relating to the quality of medicines produced at your facility. Our inspection revealed serious deviations, including but not limited to, inadequate oversight of original CGMP documents, deficient controls over computerized systems, insufficient laboratory investigations, and aborted chromatographic sequences.\u003C\u002Fp>\n\n\u003Cp>Senior facility managers failed to exercise their authority and responsibility to ensure reliable data, leading to severe data integrity deficiencies in your production and laboratory departments. These findings also indicate that your quality assurance function is not exercising its responsibilities, including but not limited to, oversight and control over the adequacy and reliability of CGMP data used throughout your operation.\u003C\u002Fp>\n\n\u003Cp>A. You failed to assure integrity of analytical testing data. Some examples include:\u003C\u002Fp>\n\n\u003Cp>1. Our investigators observed plastic bags filled with torn and discarded original CGMP documents in your quality control (QC) scrap area under a stairwell, in your general parenteral scrap room, and on a truck outside your facility. Among these CGMP documents were engineering checklists associated with the Environmental Monitoring System (EMS), torn Karl Fischer (KF) analytical test reports, auto titration curves, and analytical balance weight slips for finished drug products.\u003C\u002Fp>\n\n\u003Cp>2. An analyst destroyed CGMP records by pouring acetic acid in a trash bin containing analytical balance slips for testing the standardization of \u003Cstrong>(b)(4)\u003C\u002Fstrong>. A QC employee stated he observed the same analyst destroy KF titration curves and balance printouts. The employee reported the incident to QC laboratory management on November 22, 2022. An investigation into the destruction of the torn CGMP documents and the impact to your drug product quality was not initiated until November 28, 2022.\u003C\u002Fp>\n\n\u003Cp>3. An analyst weighed out the same samples of amitriptyline hydrochloride tablets USP 100 mg batches multiple times for \u003Cstrong>(b)(4)\u003C\u002Fstrong> by \u003Cstrong>(b)(4)\u003C\u002Fstrong> test. The analyst stated to our investigator that he did not report all the test results, further stating that in some instances balance printouts were discarded in the trash. In addition, the time stamp on each of the analytical balance and \u003Cstrong>(b)(4)\u003C\u002Fstrong> printouts did not match your Laboratory Information Management System (LIMS) records.\u003C\u002Fp>\n\n\u003Cp>In your response, you commit to working with a qualified consultant to perform an overall baseline assessment of data integrity and governance controls, and to establish a remediation plan.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate in that it did not fully evaluate the scope of this deficiency and the impact to product quality. You did not adequately address the major failure of laboratory, operations, and quality assurance management to conduct proper oversight over documentation and prevent data integrity lapses.\u003C\u002Fp>\n\n\u003Cp>B. Your department failed to exercise appropriate controls over computerized systems. For example:\u003C\u002Fp>\n\n\u003Cp>1. Your electronic batch records allowed changes to be made to manual entries prior to saving. Our inspector observed a production employee manually alter the reported time that an operation was performed. QA did not review audit trails as part of their batch record review to identify discrepancies and compare the reported date and time against that which was originally logged.\u003C\u002Fp>\n\n\u003Cp>2. Analysts manually reprocessed chromatograms by adding integration events that were not approved by QC management. In addition, you lacked appropriate procedures describing when the analyst can manually input integration events, how these events should be used, or how they should be reviewed.\u003C\u002Fp>\n\n\u003Cp>3. Destroyed KF raw data paper printouts associated with drug products were discovered by our inspection team in a trash bag. The KF instrument used for water content testing and assay testing is capable of storing electronic data; however, this capacity was not utilized, and you did not save this data electronically.\u003C\u002Fp>\n\n\u003Cp>4. Your 2018 Process Equipment Assessment Report identified numerous gaps and deficiencies for electronic manufacturing equipment needing upgrades in access controls, audit trails, saving electronic data and preventing clock alterations. You had not documented closures of these corrective action and preventive action (CAPA) measures to support data integrity in your computerized systems. Your QA department had not performed a similar assessment in your QC laboratories.\u003C\u002Fp>\n\n\u003Cp>In your response, you acknowledge the inspection findings and you reference your standard operating procedure titled, “Data Integrity,” which stipulates the individuals permitted to make changes in an electronic record and requires audit trails to capture those actions. You also commit to obtaining expertise from a qualified consultant to systematically address the deviations, as part of the baseline assessment.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate. Although you established procedures, you did not explain the critical failure of laboratory and operations management in not providing adequate oversight of data integrity of computer systems. You also did not address the failure of the QA department to fully exercise its authority and responsibilities to ensure integrity of all data related to manufacturing and quality.\u003C\u002Fp>\n\n\u003Cp>C. You failed to have adequate oversight of laboratory investigations and to implement a systemic CAPA to address the high number of aborted chromatographic sequences. For example:\u003C\u002Fp>\n\n\u003Cp>1. You invalidated multiple out-of-specification (OOS) results for \u003Cstrong>(b)(4)\u003C\u002Fstrong> USP without adequate scientific justification. You then prepared new samples and reported passing results. You concluded the OOS results may be due to \u003Cstrong>(b)(4)\u003C\u002Fstrong> contamination during initial sample preparation. However, the laboratory investigation, which was approved by QA, did not discuss why other samples in the same analysis of lots, from the same material, prepared by the same analyst, under the same test conditions, were not affected by such contamination.\u003C\u002Fp>\n\n\u003Cp>2. You aborted hundreds of chromatographic sequences in your QC laboratories between January 2020 to November 2022. Each of the incidents were investigated by the quality control laboratory; however, you lacked adequate trending and CAPA systems to evaluate and identify recurring issues that should be targeted for laboratory improvements.\u003C\u002Fp>\n\n\u003Cp>In your response, you acknowledge the need to enhance your processes and practices for investigating laboratory deviations, applying CAPAs, and checking their effectiveness. In addition, you acknowledge the current trending procedures lack systematic tools for conducting evaluations and implementing effective corrective actions.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate. Your response did not adequately address how you will implement systems to identify and address adverse laboratory incident trends, or provide an overall management strategy for improving all phases of your laboratory investigations.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive assessment and remediation plan to ensure your QA department is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o A determination of whether procedures used by your firm are robust and appropriate.\u003Cbr>\n&nbsp; &nbsp; o Provisions for QA oversight throughout your operations to evaluate adherence to appropriate practices.\u003Cbr>\n&nbsp; &nbsp; o A complete and final review of each batch and its related information before the QA disposition decision.\u003Cbr>\n&nbsp; &nbsp; o Oversight and approval of investigations and discharging of all other QA duties to ensure identity, strength, quality, and purity of all products.\u003Cbr>\n&nbsp; &nbsp; o Also describe how top management supports quality assurance and reliable operations, including but not limited to timely provision of resources to proactively address emerging manufacturing\u002Fquality issues and to assure a continuing state of control.\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A retrospective, independent review of all invalidated OOS (including in-process and release\u002Fstability testing) results for U.S. products irrespective of whether the batch was ultimately distributed in the United States for the last three years from the initial date of inspection and a report summarizing the findings of the analysis, including the following for each OOS:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o Determine whether the scientific justification and evidence relating to the invalidated OOS result conclusively or inconclusively demonstrates causative laboratory error.\u003Cbr>\n&nbsp; &nbsp; o For investigations that conclusively establish laboratory root cause, provide rationale and ensure that all other laboratory methods vulnerable to the same or similar root cause are identified for remediation.\u003Cbr>\n&nbsp; &nbsp; o For all OOS results found by the retrospective review to have an inconclusive or no root cause identified in the laboratory, include a thorough review of production (e.g., batch manufacturing records, adequacy of the manufacturing steps, suitability of equipment\u002Ffacilities, variability of raw materials, process capability, deviation history, complaint history, batch failure history). Provide a summary of potential manufacturing root causes for each investigation, and any manufacturing operation improvements.\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive, independent assessment and CAPA plan for computer system security and integrity. Include a report that identifies design and control vulnerabilities, and appropriate remediations for each of your laboratory and manufacturing computer systems. This should include but not be limited to:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o A list of all hardware that includes all equipment, both standalone and network, in your laboratory and manufacturing.\u003Cbr>\n&nbsp; &nbsp; o Identification of vulnerabilities in hardware and software, encompassing both networked and non-networked systems (e.g., PLC).\u003Cbr>\n&nbsp; &nbsp; o A list of all software configurations (both equipment software and LIMS) and versions, details of all user privileges, and oversight responsibilities for your computerized systems. Regarding user privileges, specify user roles and associated user privileges (including the specific permissions allowed for anyone who has administrative rights) for all staff who have access to the laboratory and manufacturing computer systems, and their organizational affiliation and title. Also describe how you will ensure staff are not given administrative rights, or other permissions that compromise data retention or reliability.\u003Cbr>\n&nbsp; &nbsp; o System security provisions, including but not limited to whether unique usernames\u002Fpasswords are always used, and their confidentiality safeguarded.\u003Cbr>\n&nbsp; &nbsp; o Detailed procedures for robust use and review of audit trail data, and current status of audit trail implementation for each of your systems.\u003Cbr>\n&nbsp; &nbsp; o Interim control measures and procedural changes for the control, review, and full retention of laboratory data.\u003Cbr>\n&nbsp; &nbsp; o In addition to interim data retention measures, also provide more comprehensive and sustainable CAPA for retention of all CGMP data. This includes provisions that address not only the need to retain batch-related data for appropriate periods, but also the long-term retention of all source data from development studies that support design, qualification, validation, and application.\u003Cbr>\n&nbsp; &nbsp; o Technological improvements to increase the integration of data generated through electronic systems from standalone equipment (e.g., balances, pH meters, water content testing) into the LIMS network.\u003Cbr>\n&nbsp; &nbsp; o A detailed summary of your procedural updates and associated training, including but not limited to system security control to prevent unauthorized access, and ensure appropriate user role assignments, secondary review of all analyses, and other system controls.\u003Cbr>\n&nbsp; &nbsp; o Your remediated program for ensuring strict ongoing control over electronic and paper-based data to ensure that all additions, deletions, or modifications of information in your records are authorized, and all data is retained. Provide your full CAPA plan and any improvements made to date.\u003Cbr>\n&nbsp; &nbsp; o Provisions for oversight from QA managers, executives, and internal auditors with appropriate IT expertise (e.g., understanding of infrastructure, configuration, network requirements, strict segregation of administrative rights).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Your firm failed to ensure that laboratory records included complete data derived from all tests necessary to ensure compliance with established specifications and standards (21 CFR 211.194(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>A. Your laboratory records lacked complete and accurate data to support the analysis performed. Colony forming units (CFU) were not counted accurately in the laboratory's environmental monitoring (EM) data. Our investigators observed colony counts shortly after being read by your analyst for environmental and personnel monitoring that did not match your official records.\u003C\u002Fp>\n\n\u003Cp>Your analyst undercounted carboplatin injection batch EM data by recording two merged colonies as one CFU, despite your procedure stating, “If merged colonies are observed, count it as a separate colony.” Your laboratory identification instrument subsequently identified the joined colonies as two different species.\u003C\u002Fp>\n\n\u003Cp>Notably, you firm indicated no EM results were outside of action limits for Grade A (ISO 5) sample locations from January 2020 until our inspection in November 2022.\u003C\u002Fp>\n\n\u003Cp>B. Laboratory raw data was missing and could not be provided during the inspection. For example, analysts did not consistently include \u003Cstrong>(b)(4)\u003C\u002Fstrong> printout raw data in laboratory records. Paper printouts for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> determinations and pH printouts could not be reconciled for \u003Cstrong>(b)(4)\u003C\u002Fstrong> injection, \u003Cstrong>(b)(4)\u003C\u002Fstrong> mg, process validation batch \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>Because the \u003Cstrong>(b)(4)\u003C\u002Fstrong> instrument lacked audit trail capabilities, unreported raw data could not be detected during the QA review process.\u003C\u002Fp>\n\n\u003Cp>Failing to maintain complete records of the data and testing conditions associated with all tests significantly compromises the reliability of data and your QA’s ability to perform its obligation to assure quality through conformance with CGMP.\u003C\u002Fp>\n\n\u003Cp>In your response, you acknowledge EM samples are not counted accurately and that “laboratory practice was to count colonies that merge together with similar morphology, as one colony.” You opened EM investigations for action and alert samples and commit to working with an independent third-party consultant. We also acknowledge you provided modular training for microbiologists and revised standard operating procedures (SOPs).\u003C\u002Fp>\n\n\u003Cp>You also state you investigated the missing \u003Cstrong>(b)(4)\u003C\u002Fstrong> instrument print-outs but were unable to definitively determine the root cause of the missing laboratory data. You commit to improvements to the SOPs related to reconciliation of reported results with raw data.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate. You did not provide the opened investigations or updates to the investigations regarding the EM data or missing laboratory data. You did not commit to a retrospective review and risk assessment of personnel and environmental monitoring data. You did not commit to investigate the impact of missing laboratory data on the process validation batches.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A complete assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices to ensure you retain contemporaneous, attributable, legible, complete, original, and accurate (ALCOA) records throughout your operation.\u003C\u002Fli>\n\t\u003Cli>A comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, OOS results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, quality unit oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>3. Your firm failed to establish and follow required laboratory control mechanisms (21 CFR 211.160(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm failed to have appropriate procedures for the integration of chromatographic peaks and for the review of chromatographic data.\u003C\u002Fp>\n\n\u003Cp>Our inspection team identified examples of your analysts entering manual integration events that yielded passing results without adequate procedural controls or justification.\u003C\u002Fp>\n\n\u003Cp>In addition, your chromatographic data integration procedure is inadequate because it does not identify when it is appropriate for an analyst to input manual integration events. Your procedure lacked a requirement for supervisory approval and other controls such as data review and justification to consistently document when and why an analyst manually performs integration events.\u003C\u002Fp>\n\n\u003Cp>In your response, you acknowledge the observation and states you misunderstood the regulatory expectation of controls for manual integration. You commit to software upgrades which will maintain all processing parameters and methods. And you commit to working with a qualified third-party consultant to perform an overall baseline audit of the QC laboratories.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate. You did not commit to performing a retrospective review of all chromatographic data associated with manual integration. We acknowledge your commitment to work with a third-party to audit your QC laboratories; however, you did not provide details such as the scope of this audit or ongoing third-party laboratory activities. You also did not adequately address oversight of the QC laboratory by your QA department and any additional controls to be added to improve consistency of chromatographic practices.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Include an assessment of all test methods and procedures used by your firm to ensure they have appropriate instructions, method suitability criteria, and have been appropriately validated to determine whether they are fit for purpose. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\u003C\u002Fli>\n\t\u003Cli>A comprehensive review and remediation plan for your out-of-specification (OOS) result investigation systems. The corrective action and preventive action (CAPA) should include, but not be limited to, addressing the following:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o Quality unit oversight of laboratory investigations\u003Cbr>\n&nbsp; &nbsp; o Identification of adverse laboratory control trends\u003Cbr>\n&nbsp; &nbsp; o Resolution of causes of laboratory variation\u003Cbr>\n&nbsp; &nbsp; o Initiation of thorough investigations of potential manufacturing causes whenever a laboratory cause cannot be conclusively identified\u003Cbr>\n&nbsp; &nbsp; o Adequate scoping of each investigation and its CAPA\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Revised OOS investigation procedures with these and other remediations\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>4. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm failed to adequately validate the manufacturing process for \u003Cstrong>(b)(4)\u003C\u002Fstrong> injection \u003Cstrong>(b)(4)\u003C\u002Fstrong> mg. Specifically, your process validation lacked an evaluation of inter-batch and intra-batch variability observed for \u003Cstrong>(b)(4)\u003C\u002Fstrong> impurities and \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>A fourth process validation batch for \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;injection \u003Cstrong>(b)(4)\u003C\u002Fstrong> mg was initiated to evaluate related substances from different positions within the \u003Cstrong>(b)(4)\u003C\u002Fstrong> due to the incomplete impurity testing. This fourth process validation batch yielded a high OOS result for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> impurity. This OOS and failure of the fourth process validation batch was not referenced or discussed in the validation summary report or addendum. A fifth process validation batch was manufactured and included in the addendum report. You subsequently rejected a commercial batch for the U.S. market, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, due to a high OOS result for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> impurity.\u003C\u002Fp>\n\n\u003Cp>In your response you acknowledge the validation program does not evaluate inter-batch and intra-batch variability. You commit to revising your validation program to establish a process to analyze test data within and across batches and to consistently assess the variability of the production process. In addition, you state you will review equipment qualification to evaluate capabilities of the \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate. Your response did not address the omission of the failed fourth process validation batch for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> impurity in the approved QA validation report and addendum. Furthermore, your CAPA did not include evaluation of other drug product process validation studies that may be similarly deficient to ensure processes and equipment have adequate data to support their capabilities.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Provide a comprehensive, independent assessment of your validation program for ensuring an ongoing state of control throughout the product lifecycle, including the following elements:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o A description of the overall program (e.g., lifecycle process validation phases; equipment and facility qualification).\u003Cbr>\n&nbsp; &nbsp; o A detailed description of how you ensure a rigorous process performance qualification studies. Include specific quantitative approaches with intensified sampling plans to fully assess all significant process steps, and explain how these extensive levels of sampling characterize the intra-batch uniformity at these steps to provide a high level of assurance that supports a decision on readiness for marketing\u003Cbr>\n&nbsp; &nbsp; o Vigilant ongoing monitoring of process performance and product quality throughout the lifecycle, with emphasis on:\u003Cbr>\n&nbsp; &nbsp; &nbsp; &nbsp;  Mechanisms to ensure ongoing attention to both intra-batch and inter-batch variation\u003Cbr>\n&nbsp; &nbsp; &nbsp; &nbsp;  Appropriate sampling methods and frequency throughout processing to ensure detection of process control lapses\u003Cbr>\n&nbsp; &nbsp; &nbsp; &nbsp;  Scrutiny of raw material variability from suppliers\u003Cbr>\n&nbsp; &nbsp; &nbsp; &nbsp;  Quality signals from both internal data and customers\u003Cbr>\n&nbsp; &nbsp; &nbsp; &nbsp;  How your quality system integrates this ongoing knowledge of signals from process performance and product quality monitoring to identify areas of variation that need improvement.\u003Cbr>\n&nbsp; &nbsp; o Based on this assessment, provide a CAPA to address any deficiencies in your process validation program\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>5. Your firm failed to establish the accuracy, sensitivity, specificity, and reproducibility of its test methods (21 CFR 211.165(e)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your QA department did not ensure raw materials used in the manufacture of drug products were appropriately tested. Your firm failed to perform method validation (or verification, as appropriate) of test methods to ensure that they were suitable for their intended use. You provided a list of multiple in-house methods and compendial methods which have not been validated or verified, including for raw materials such as \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>Method validation and verification is necessary to support reliable determination of identity, strength, quality, purity, and potency of drugs. Without evaluating the validity of methods, you lack the basic assurance that your laboratory data accurately reflects drug product quality.\u003C\u002Fp>\n\n\u003Cp>In your response, you acknowledge all materials used for manufacturing need to be tested using methods that have been validated or verified. You commit to reviewing the procedures governing method validation and method verification as well as technical transfer to ensure that the procedures comply with FDA regulations.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A detailed, independent assessment of all test methods to evaluate if they include sufficiently specific instructions to ensure repeatability, are supported by adequate validation (or verification, for United States Pharmacopeia (USP) compendial methods) studies, and are appropriate for their intended use. The assessment should also determine whether test methods used in the stability program are stability-indicating. The scope of the assessment should encompass any tests conducted by your firm or its contract laboratories.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>Other Inspectional Findings\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>We acknowledge your plan to conduct new smoke studies under dynamic conditions to improve your evaluation of the effect of interventions and interactions (i.e., mobile cart transfers, other material transfers) on airflow within the \u003Cstrong>(b)(4)\u003C\u002Fstrong> Restricted Access Barrier System (\u003Cstrong>(b)(4)\u003C\u002Fstrong>RABS). In your response to this letter, provide updated static and dynamic smoke studies, or a commitment to provide these studies upon their completion.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Data Integrity Remediation\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture. See FDA’s guidance document \u003Cem>Data Integrity and Compliance With Drug CGMP\u003C\u002Fem> for guidance on establishing and following CGMP compliant data integrity practices at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fdata-integrity-and-compliance-drug-cgmp-questions-and-answers\u003C\u002Fp>\n\n\u003Cp>We acknowledge that you are using a consultant to audit your operation and assist in meeting FDA requirements. In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cp>A. A comprehensive investigation into the extent of the inaccuracies in data records and reporting. Your investigation should include:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A detailed investigation protocol and methodology; a summary of all laboratories, manufacturing operations, and systems to be covered by the assessment; and a justification for any part of your operation that you propose to exclude.\u003C\u002Fli>\n\t\u003Cli>Interviews of current and former employees to identify the nature, scope, and root cause of data inaccuracies. We recommend that these interviews be conducted by a qualified third party.\u003C\u002Fli>\n\t\u003Cli>An assessment of the extent of data integrity deficiencies at your facility. Identify omissions, alterations, deletions, record destruction, non-contemporaneous record completion, and other deficiencies. Describe all parts of your facility’s operations in which you discovered data integrity lapses.\u003C\u002Fli>\n\t\u003Cli>A comprehensive retrospective evaluation of the nature of the testing and manufacturing data integrity deficiencies. We recommend that a qualified third party with specific expertise in the area where potential breaches were identified should evaluate all data integrity lapses.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>B. A current risk assessment of the potential effects of the observed failures on the quality of your drugs. Your assessment should include analyses of the risks to patients caused by the release of drugs affected by a lapse of data integrity and analyses of the risks posed by ongoing operations.\u003C\u002Fp>\n\n\u003Cp>C. A management strategy for your firm that includes the details of your global corrective action and preventive action plan. Your strategy should include these elements:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A detailed corrective action plan that describes how you intend to ensure the reliability and completeness of all the data you generate including analytical data, manufacturing records, and all data submitted to FDA.\u003C\u002Fli>\n\t\u003Cli>A comprehensive description of the root causes of your data integrity lapses including evidence that the scope and depth of the current action plan is commensurate with the findings of the investigation and risk assessment. Indicate whether individuals responsible for data integrity lapses remain able to influence CGMP-related or drug application data at your firm.\u003C\u002Fli>\n\t\u003Cli>Interim measures describing the actions you have taken or will take to protect patients and to ensure the quality of your drugs, such as notifying your customers, recalling product, conducting additional testing, adding lots to your stability programs to assure stability, drug application actions, and enhanced complaint monitoring.\u003C\u002Fli>\n\t\u003Cli>Long-term measures describing any remediation efforts and enhancements to procedures, processes, methods, controls, systems, management oversight, and human resources (e.g., training, staffing improvements) designed to ensure the integrity of your company’s data.\u003C\u002Fli>\n\t\u003Cli>A commitment to have a qualified consultant conduct extensive annual audits, for at least two years, to assist in evaluating CAPA effectiveness after you have executed your data integrity remediation protocol.\u003C\u002Fli>\n\t\u003Cli>Inform FDA if you will be hiring a Chief Integrity Officer who is fully empowered to maintain anonymity of employees who report data integrity concerns and with authority to ensure any potential breach is investigated.\u003C\u002Fli>\n\t\u003Cli>A status report for any of the above activities already underway or completed.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>Repeat Observations at Facility\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>In previous inspections, including the inspection of May 20-28, 2019 FDA cited similar CGMP observations. You proposed specific remediation for these observations in your response. Repeated failures demonstrate that executive management oversight and control over the manufacture of drugs is inadequate.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Ineffective Quality System\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Significant findings in this letter demonstrate that your firm does not operate an effective quality system in accord with CGMP. In addition to the lack of effective production and laboratory operations oversight, we found your quality unit is not enabled to exercise proper authority and\u002For has insufficiently implemented its responsibilities. Executive management should immediately and comprehensively assess your company’s global manufacturing operations to ensure that your systems, processes, and products conform to FDA requirements.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Test Results Out-of-Specification\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>For more information about handling failing, out-of-specification, out-of-trend, or other unexpected results and documentation of your investigations, see FDA’s guidance document \u003Cem>Investigating Out-of-Specification (OOS) Test Results for Pharmaceutical Production\u003C\u002Fem> at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Finvestigating-out-specification-oos-test-results-pharmaceutical-production-level-2-revision. A possible laboratory error is insufficient to close an investigation at Phase 1. Whenever an investigation lacks conclusive evidence of laboratory error, a thorough investigation of potential manufacturing causes must be performed.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Process Validation\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Process validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies determine whether an initial state of control has been established. Successful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure you maintain a stable manufacturing operation throughout the product lifecycle.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>If you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(b). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\u003C\u002Fp>\n\n\u003Cp>FDA placed your firm on Import Alert 66-40 on June 1, 2023.\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\u003C\u002Fp>\n\n\u003Cp>Failure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at Intas Pharmaceutical Limited at Plot No. 5 To 14, Pharmez, Near Village Matoda, Sarkhej-Bavla National Highway No. 8-A, Taluka, Sanand, India into the United States under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3004011473 and ATTN: Erika V. Butler.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Francis Godwin\u003Cbr>\nDirector\u003Cbr>\nOffice of Manufacturing Quality\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003C\u002Fp>\n\n\u003Cp>__________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Under program enhancements for the Generic Drug User Fee Amendments (GDUFA) reauthorization for fiscal years (FYs) 2023-2027, also known as the GDUFA III Commitment Letter, your facility may be eligible for a Post-Warning Letter Meeting to obtain preliminary feedback from FDA on the adequacy and completeness of your corrective action plans.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Nimish Chudgar\n\nRecipient Title\n\nChief Executive Officer & Managing Director\n\nIntas Pharmaceuticals Limited\n\nPlot No. 255, Magnet Corporate Park, Near Sola Bridge, S.G. Highway\n\nThaltej, Ahmedabad 382213\n\nGujarat\n\nIndia\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nWarning Letter 320-23-20\n\nJuly 28, 2023\n\nDear Mr. Chudgar:\n\nThe U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Intas Pharmaceuticals Limited, FEI 3004011473, at Plot No. 5 To 14, Pharmez, Near Village Matoda, Sarkhej-Bavla National Highway No. 8-A, Taluka, Sanand, India, from November 22 to December 02, 2022.\n\nThis warning letter summarizes significant violations of current good manufacturing practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\n\nWe reviewed your December 27, 2022 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\n\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n\n1. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\n\nYou failed to ensure reliability of data relating to the quality of medicines produced at your facility. Our inspection revealed serious deviations, including but not limited to, inadequate oversight of original CGMP documents, deficient controls over computerized systems, insufficient laboratory investigations, and aborted chromatographic sequences.\n\nSenior facility managers failed to exercise their authority and responsibility to ensure reliable data, leading to severe data integrity deficiencies in your production and laboratory departments. These findings also indicate that your quality assurance function is not exercising its responsibilities, including but not limited to, oversight and control over the adequacy and reliability of CGMP data used throughout your operation.\n\nA. You failed to assure integrity of analytical testing data. Some examples include:\n\n1. Our investigators observed plastic bags filled with torn and discarded original CGMP documents in your quality control (QC) scrap area under a stairwell, in your general parenteral scrap room, and on a truck outside your facility. Among these CGMP documents were engineering checklists associated with the Environmental Monitoring System (EMS), torn Karl Fischer (KF) analytical test reports, auto titration curves, and analytical balance weight slips for finished drug products.\n\n2. An analyst destroyed CGMP records by pouring acetic acid in a trash bin containing analytical balance slips for testing the standardization of (b)(4). A QC employee stated he observed the same analyst destroy KF titration curves and balance printouts. The employee reported the incident to QC laboratory management on November 22, 2022. An investigation into the destruction of the torn CGMP documents and the impact to your drug product quality was not initiated until November 28, 2022.\n\n3. An analyst weighed out the same samples of amitriptyline hydrochloride tablets USP 100 mg batches multiple times for (b)(4) by (b)(4) test. The analyst stated to our investigator that he did not report all the test results, further stating that in some instances balance printouts were discarded in the trash. In addition, the time stamp on each of the analytical balance and (b)(4) printouts did not match your Laboratory Information Management System (LIMS) records.\n\nIn your response, you commit to working with a qualified consultant to perform an overall baseline assessment of data integrity and governance controls, and to establish a remediation plan.\n\nYour response is inadequate in that it did not fully evaluate the scope of this deficiency and the impact to product quality. You did not adequately address the major failure of laboratory, operations, and quality assurance management to conduct proper oversight over documentation and prevent data integrity lapses.\n\nB. Your department failed to exercise appropriate controls over computerized systems. For example:\n\n1. Your electronic batch records allowed changes to be made to manual entries prior to saving. Our inspector observed a production employee manually alter the reported time that an operation was performed. QA did not review audit trails as part of their batch record review to identify discrepancies and compare the reported date and time against that which was originally logged.\n\n2. Analysts manually reprocessed chromatograms by adding integration events that were not approved by QC management. In addition, you lacked appropriate procedures describing when the analyst can manually input integration events, how these events should be used, or how they should be reviewed.\n\n3. Destroyed KF raw data paper printouts associated with drug products were discovered by our inspection team in a trash bag. The KF instrument used for water content testing and assay testing is capable of storing electronic data; however, this capacity was not utilized, and you did not save this data electronically.\n\n4. Your 2018 Process Equipment Assessment Report identified numerous gaps and deficiencies for electronic manufacturing equipment needing upgrades in access controls, audit trails, saving electronic data and preventing clock alterations. You had not documented closures of these corrective action and preventive action (CAPA) measures to support data integrity in your computerized systems. Your QA department had not performed a similar assessment in your QC laboratories.\n\nIn your response, you acknowledge the inspection findings and you reference your standard operating procedure titled, “Data Integrity,” which stipulates the individuals permitted to make changes in an electronic record and requires audit trails to capture those actions. You also commit to obtaining expertise from a qualified consultant to systematically address the deviations, as part of the baseline assessment.\n\nYour response is inadequate. Although you established procedures, you did not explain the critical failure of laboratory and operations management in not providing adequate oversight of data integrity of computer systems. You also did not address the failure of the QA department to fully exercise its authority and responsibilities to ensure integrity of all data related to manufacturing and quality.\n\nC. You failed to have adequate oversight of laboratory investigations and to implement a systemic CAPA to address the high number of aborted chromatographic sequences. For example:\n\n1. You invalidated multiple out-of-specification (OOS) results for (b)(4) USP without adequate scientific justification. You then prepared new samples and reported passing results. You concluded the OOS results may be due to (b)(4) contamination during initial sample preparation. However, the laboratory investigation, which was approved by QA, did not discuss why other samples in the same analysis of lots, from the same material, prepared by the same analyst, under the same test conditions, were not affected by such contamination.\n\n2. You aborted hundreds of chromatographic sequences in your QC laboratories between January 2020 to November 2022. Each of the incidents were investigated by the quality control laboratory; however, you lacked adequate trending and CAPA systems to evaluate and identify recurring issues that should be targeted for laboratory improvements.\n\nIn your response, you acknowledge the need to enhance your processes and practices for investigating laboratory deviations, applying CAPAs, and checking their effectiveness. In addition, you acknowledge the current trending procedures lack systematic tools for conducting evaluations and implementing effective corrective actions.\n\nYour response is inadequate. Your response did not adequately address how you will implement systems to identify and address adverse laboratory incident trends, or provide an overall management strategy for improving all phases of your laboratory investigations.\n\nIn response to this letter, provide:\n\nA comprehensive assessment and remediation plan to ensure your QA department is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\n\no A determination of whether procedures used by your firm are robust and appropriate.\n\no Provisions for QA oversight throughout your operations to evaluate adherence to appropriate practices.\n\no A complete and final review of each batch and its related information before the QA disposition decision.\n\no Oversight and approval of investigations and discharging of all other QA duties to ensure identity, strength, quality, and purity of all products.\n\no Also describe how top management supports quality assurance and reliable operations, including but not limited to timely provision of resources to proactively address emerging manufacturing\u002Fquality issues and to assure a continuing state of control.\n\nA retrospective, independent review of all invalidated OOS (including in-process and release\u002Fstability testing) results for U.S. products irrespective of whether the batch was ultimately distributed in the United States for the last three years from the initial date of inspection and a report summarizing the findings of the analysis, including the following for each OOS:\n\no Determine whether the scientific justification and evidence relating to the invalidated OOS result conclusively or inconclusively demonstrates causative laboratory error.\n\no For investigations that conclusively establish laboratory root cause, provide rationale and ensure that all other laboratory methods vulnerable to the same or similar root cause are identified for remediation.\n\no For all OOS results found by the retrospective review to have an inconclusive or no root cause identified in the laboratory, include a thorough review of production (e.g., batch manufacturing records, adequacy of the manufacturing steps, suitability of equipment\u002Ffacilities, variability of raw materials, process capability, deviation history, complaint history, batch failure history). Provide a summary of potential manufacturing root causes for each investigation, and any manufacturing operation improvements.\n\nA comprehensive, independent assessment and CAPA plan for computer system security and integrity. Include a report that identifies design and control vulnerabilities, and appropriate remediations for each of your laboratory and manufacturing computer systems. This should include but not be limited to:\n\no A list of all hardware that includes all equipment, both standalone and network, in your laboratory and manufacturing.\n\no Identification of vulnerabilities in hardware and software, encompassing both networked and non-networked systems (e.g., PLC).\n\no A list of all software configurations (both equipment software and LIMS) and versions, details of all user privileges, and oversight responsibilities for your computerized systems. Regarding user privileges, specify user roles and associated user privileges (including the specific permissions allowed for anyone who has administrative rights) for all staff who have access to the laboratory and manufacturing computer systems, and their organizational affiliation and title. Also describe how you will ensure staff are not given administrative rights, or other permissions that compromise data retention or reliability.\n\no System security provisions, including but not limited to whether unique usernames\u002Fpasswords are always used, and their confidentiality safeguarded.\n\no Detailed procedures for robust use and review of audit trail data, and current status of audit trail implementation for each of your systems.\n\no Interim control measures and procedural changes for the control, review, and full retention of laboratory data.\n\no In addition to interim data retention measures, also provide more comprehensive and sustainable CAPA for retention of all CGMP data. This includes provisions that address not only the need to retain batch-related data for appropriate periods, but also the long-term retention of all source data from development studies that support design, qualification, validation, and application.\n\no Technological improvements to increase the integration of data generated through electronic systems from standalone equipment (e.g., balances, pH meters, water content testing) into the LIMS network.\n\no A detailed summary of your procedural updates and associated training, including but not limited to system security control to prevent unauthorized access, and ensure appropriate user role assignments, secondary review of all analyses, and other system controls.\n\no Your remediated program for ensuring strict ongoing control over electronic and paper-based data to ensure that all additions, deletions, or modifications of information in your records are authorized, and all data is retained. Provide your full CAPA plan and any improvements made to date.\n\no Provisions for oversight from QA managers, executives, and internal auditors with appropriate IT expertise (e.g., understanding of infrastructure, configuration, network requirements, strict segregation of administrative rights).\n\n2. Your firm failed to ensure that laboratory records included complete data derived from all tests necessary to ensure compliance with established specifications and standards (21 CFR 211.194(a)).\n\nA. Your laboratory records lacked complete and accurate data to support the analysis performed. Colony forming units (CFU) were not counted accurately in the laboratory's environmental monitoring (EM) data. Our investigators observed colony counts shortly after being read by your analyst for environmental and personnel monitoring that did not match your official records.\n\nYour analyst undercounted carboplatin injection batch EM data by recording two merged colonies as one CFU, despite your procedure stating, “If merged colonies are observed, count it as a separate colony.” Your laboratory identification instrument subsequently identified the joined colonies as two different species.\n\nNotably, you firm indicated no EM results were outside of action limits for Grade A (ISO 5) sample locations from January 2020 until our inspection in November 2022.\n\nB. Laboratory raw data was missing and could not be provided during the inspection. For example, analysts did not consistently include (b)(4) printout raw data in laboratory records. Paper printouts for the (b)(4) determinations and pH printouts could not be reconciled for (b)(4) injection, (b)(4) mg, process validation batch (b)(4).\n\nBecause the (b)(4) instrument lacked audit trail capabilities, unreported raw data could not be detected during the QA review process.\n\nFailing to maintain complete records of the data and testing conditions associated with all tests significantly compromises the reliability of data and your QA’s ability to perform its obligation to assure quality through conformance with CGMP.\n\nIn your response, you acknowledge EM samples are not counted accurately and that “laboratory practice was to count colonies that merge together with similar morphology, as one colony.” You opened EM investigations for action and alert samples and commit to working with an independent third-party consultant. We also acknowledge you provided modular training for microbiologists and revised standard operating procedures (SOPs).\n\nYou also state you investigated the missing (b)(4) instrument print-outs but were unable to definitively determine the root cause of the missing laboratory data. You commit to improvements to the SOPs related to reconciliation of reported results with raw data.\n\nYour response is inadequate. You did not provide the opened investigations or updates to the investigations regarding the EM data or missing laboratory data. You did not commit to a retrospective review and risk assessment of personnel and environmental monitoring data. You did not commit to investigate the impact of missing laboratory data on the process validation batches.\n\nIn response to this letter, provide:\n\nA complete assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices to ensure you retain contemporaneous, attributable, legible, complete, original, and accurate (ALCOA) records throughout your operation.\n\nA comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, OOS results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, quality unit oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\n\n3. Your firm failed to establish and follow required laboratory control mechanisms (21 CFR 211.160(a)).\n\nYour firm failed to have appropriate procedures for the integration of chromatographic peaks and for the review of chromatographic data.\n\nOur inspection team identified examples of your analysts entering manual integration events that yielded passing results without adequate procedural controls or justification.\n\nIn addition, your chromatographic data integration procedure is inadequate because it does not identify when it is appropriate for an analyst to input manual integration events. Your procedure lacked a requirement for supervisory approval and other controls such as data review and justification to consistently document when and why an analyst manually performs integration events.\n\nIn your response, you acknowledge the observation and states you misunderstood the regulatory expectation of controls for manual integration. You commit to software upgrades which will maintain all processing parameters and methods. And you commit to working with a qualified third-party consultant to perform an overall baseline audit of the QC laboratories.\n\nYour response is inadequate. You did not commit to performing a retrospective review of all chromatographic data associated with manual integration. We acknowledge your commitment to work with a third-party to audit your QC laboratories; however, you did not provide details such as the scope of this audit or ongoing third-party laboratory activities. You also did not adequately address oversight of the QC laboratory by your QA department and any additional controls to be added to improve consistency of chromatographic practices.\n\nIn response to this letter, provide:\n\nA comprehensive independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Include an assessment of all test methods and procedures used by your firm to ensure they have appropriate instructions, method suitability criteria, and have been appropriately validated to determine whether they are fit for purpose. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\n\nA comprehensive review and remediation plan for your out-of-specification (OOS) result investigation systems. The corrective action and preventive action (CAPA) should include, but not be limited to, addressing the following:\n\no Quality unit oversight of laboratory investigations\n\no Identification of adverse laboratory control trends\n\no Resolution of causes of laboratory variation\n\no Initiation of thorough investigations of potential manufacturing causes whenever a laboratory cause cannot be conclusively identified\n\no Adequate scoping of each investigation and its CAPA\n\nRevised OOS investigation procedures with these and other remediations\n\n4. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\n\nYour firm failed to adequately validate the manufacturing process for (b)(4) injection (b)(4) mg. Specifically, your process validation lacked an evaluation of inter-batch and intra-batch variability observed for (b)(4) impurities and (b)(4).\n\nA fourth process validation batch for (b)(4) injection (b)(4) mg was initiated to evaluate related substances from different positions within the (b)(4) due to the incomplete impurity testing. This fourth process validation batch yielded a high OOS result for the (b)(4) impurity. This OOS and failure of the fourth process validation batch was not referenced or discussed in the validation summary report or addendum. A fifth process validation batch was manufactured and included in the addendum report. You subsequently rejected a commercial batch for the U.S. market, (b)(4), due to a high OOS result for the (b)(4) impurity.\n\nIn your response you acknowledge the validation program does not evaluate inter-batch and intra-batch variability. You commit to revising your validation program to establish a process to analyze test data within and across batches and to consistently assess the variability of the production process. In addition, you state you will review equipment qualification to evaluate capabilities of the (b)(4).\n\nYour response is inadequate. Your response did not address the omission of the failed fourth process validation batch for the (b)(4) impurity in the approved QA validation report and addendum. Furthermore, your CAPA did not include evaluation of other drug product process validation studies that may be similarly deficient to ensure processes and equipment have adequate data to support their capabilities.\n\nIn response to this letter, provide:\n\nProvide a comprehensive, independent assessment of your validation program for ensuring an ongoing state of control throughout the product lifecycle, including the following elements:\n\no A description of the overall program (e.g., lifecycle process validation phases; equipment and facility qualification).\n\no A detailed description of how you ensure a rigorous process performance qualification studies. Include specific quantitative approaches with intensified sampling plans to fully assess all significant process steps, and explain how these extensive levels of sampling characterize the intra-batch uniformity at these steps to provide a high level of assurance that supports a decision on readiness for marketing\n\no Vigilant ongoing monitoring of process performance and product quality throughout the lifecycle, with emphasis on:\n\n Mechanisms to ensure ongoing attention to both intra-batch and inter-batch variation\n\n Appropriate sampling methods and frequency throughout processing to ensure detection of process control lapses\n\n Scrutiny of raw material variability from suppliers\n\n Quality signals from both internal data and customers\n\n How your quality system integrates this ongoing knowledge of signals from process performance and product quality monitoring to identify areas of variation that need improvement.\n\no Based on this assessment, provide a CAPA to address any deficiencies in your process validation program\n\n5. Your firm failed to establish the accuracy, sensitivity, specificity, and reproducibility of its test methods (21 CFR 211.165(e)).\n\nYour QA department did not ensure raw materials used in the manufacture of drug products were appropriately tested. Your firm failed to perform method validation (or verification, as appropriate) of test methods to ensure that they were suitable for their intended use. You provided a list of multiple in-house methods and compendial methods which have not been validated or verified, including for raw materials such as (b)(4).\n\nMethod validation and verification is necessary to support reliable determination of identity, strength, quality, purity, and potency of drugs. Without evaluating the validity of methods, you lack the basic assurance that your laboratory data accurately reflects drug product quality.\n\nIn your response, you acknowledge all materials used for manufacturing need to be tested using methods that have been validated or verified. You commit to reviewing the procedures governing method validation and method verification as well as technical transfer to ensure that the procedures comply with FDA regulations.\n\nIn response to this letter, provide:\n\nA detailed, independent assessment of all test methods to evaluate if they include sufficiently specific instructions to ensure repeatability, are supported by adequate validation (or verification, for United States Pharmacopeia (USP) compendial methods) studies, and are appropriate for their intended use. The assessment should also determine whether test methods used in the stability program are stability-indicating. The scope of the assessment should encompass any tests conducted by your firm or its contract laboratories.\n\nOther Inspectional Findings\n\nWe acknowledge your plan to conduct new smoke studies under dynamic conditions to improve your evaluation of the effect of interventions and interactions (i.e., mobile cart transfers, other material transfers) on airflow within the (b)(4) Restricted Access Barrier System ((b)(4)RABS). In your response to this letter, provide updated static and dynamic smoke studies, or a commitment to provide these studies upon their completion.\n\nData Integrity Remediation\n\nYour quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture. See FDA’s guidance document Data Integrity and Compliance With Drug CGMP for guidance on establishing and following CGMP compliant data integrity practices at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fdata-integrity-and-compliance-drug-cgmp-questions-and-answers\n\nWe acknowledge that you are using a consultant to audit your operation and assist in meeting FDA requirements. In response to this letter, provide:\n\nA. A comprehensive investigation into the extent of the inaccuracies in data records and reporting. Your investigation should include:\n\nA detailed investigation protocol and methodology; a summary of all laboratories, manufacturing operations, and systems to be covered by the assessment; and a justification for any part of your operation that you propose to exclude.\n\nInterviews of current and former employees to identify the nature, scope, and root cause of data inaccuracies. We recommend that these interviews be conducted by a qualified third party.\n\nAn assessment of the extent of data integrity deficiencies at your facility. Identify omissions, alterations, deletions, record destruction, non-contemporaneous record completion, and other deficiencies. Describe all parts of your facility’s operations in which you discovered data integrity lapses.\n\nA comprehensive retrospective evaluation of the nature of the testing and manufacturing data integrity deficiencies. We recommend that a qualified third party with specific expertise in the area where potential breaches were identified should evaluate all data integrity lapses.\n\nB. A current risk assessment of the potential effects of the observed failures on the quality of your drugs. Your assessment should include analyses of the risks to patients caused by the release of drugs affected by a lapse of data integrity and analyses of the risks posed by ongoing operations.\n\nC. A management strategy for your firm that includes the details of your global corrective action and preventive action plan. Your strategy should include these elements:\n\nA detailed corrective action plan that describes how you intend to ensure the reliability and completeness of all the data you generate including analytical data, manufacturing records, and all data submitted to FDA.\n\nA comprehensive description of the root causes of your data integrity lapses including evidence that the scope and depth of the current action plan is commensurate with the findings of the investigation and risk assessment. Indicate whether individuals responsible for data integrity lapses remain able to influence CGMP-related or drug application data at your firm.\n\nInterim measures describing the actions you have taken or will take to protect patients and to ensure the quality of your drugs, such as notifying your customers, recalling product, conducting additional testing, adding lots to your stability programs to assure stability, drug application actions, and enhanced complaint monitoring.\n\nLong-term measures describing any remediation efforts and enhancements to procedures, processes, methods, controls, systems, management oversight, and human resources (e.g., training, staffing improvements) designed to ensure the integrity of your company’s data.\n\nA commitment to have a qualified consultant conduct extensive annual audits, for at least two years, to assist in evaluating CAPA effectiveness after you have executed your data integrity remediation protocol.\n\nInform FDA if you will be hiring a Chief Integrity Officer who is fully empowered to maintain anonymity of employees who report data integrity concerns and with authority to ensure any potential breach is investigated.\n\nA status report for any of the above activities already underway or completed.\n\nRepeat Observations at Facility\n\nIn previous inspections, including the inspection of May 20-28, 2019 FDA cited similar CGMP observations. You proposed specific remediation for these observations in your response. Repeated failures demonstrate that executive management oversight and control over the manufacture of drugs is inadequate.\n\nIneffective Quality System\n\nSignificant findings in this letter demonstrate that your firm does not operate an effective quality system in accord with CGMP. In addition to the lack of effective production and laboratory operations oversight, we found your quality unit is not enabled to exercise proper authority and\u002For has insufficiently implemented its responsibilities. Executive management should immediately and comprehensively assess your company’s global manufacturing operations to ensure that your systems, processes, and products conform to FDA requirements.\n\nTest Results Out-of-Specification\n\nFor more information about handling failing, out-of-specification, out-of-trend, or other unexpected results and documentation of your investigations, see FDA’s guidance document Investigating Out-of-Specification (OOS) Test Results for Pharmaceutical Production at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Finvestigating-out-specification-oos-test-results-pharmaceutical-production-level-2-revision. A possible laboratory error is insufficient to close an investigation at Phase 1. Whenever an investigation lacks conclusive evidence of laboratory error, a thorough investigation of potential manufacturing causes must be performed.\n\nProcess Validation\n\nProcess validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies determine whether an initial state of control has been established. Successful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure you maintain a stable manufacturing operation throughout the product lifecycle.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nIf you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(b). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\n\nFDA placed your firm on Import Alert 66-40 on June 1, 2023.\n\nCorrect any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\n\nFailure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at Intas Pharmaceutical Limited at Plot No. 5 To 14, Pharmez, Near Village Matoda, Sarkhej-Bavla National Highway No. 8-A, Taluka, Sanand, India into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days1. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3004011473 and ATTN: Erika V. Butler.\n\nSincerely,\n\n\u002FS\u002F\n\nFrancis Godwin\n\nDirector\n\nOffice of Manufacturing Quality\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\n__________________\n\n1 Under program enhancements for the Generic Drug User Fee Amendments (GDUFA) reauthorization for fiscal years (FYs) 2023-2027, also known as the GDUFA III Commitment Letter, your facility may be eligible for a Post-Warning Letter Meeting to obtain preliminary feedback from FDA on the adequacy and completeness of your corrective action plans.","intas-pharmaceuticals-limited-652067-07282023","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fintas-pharmaceuticals-limited-652067-07282023","2026-10-26T08:08:59.43293+00:00","2023-08-01","652067","2026-08-20T00:49:55.281+00:00","2023-07-28",{"id":128,"raw":129,"subject":134,"body_html":136,"body_text":137,"firm_name":138,"letter_id":139,"created_at":140,"fei_number":19,"letter_url":141,"updated_at":142,"action_type":22,"case_status":143,"posted_date":144,"marcs_cms_no":145,"product_type":146,"closeout_date":147,"issuing_office":148,"recipient_name":149,"body_fetched_at":150,"delivery_method":151,"recipient_title":19,"reference_number":19,"action_taken_date":152,"medical_device_id":19,"response_letter_date":19},2053,[130,131,132,133,134,13,135,13],"\u003Ctime datetime=\"2023-06-13T13:20:00Z\">06\u002F13\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-06-01T04:00:00Z\">06\u002F01\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Faz-pharmaceutical-inc-645101-06012023\">A&amp;Z Pharmaceutical, Inc.\u003C\u002Fa>"," Division of Human and Animal Food Operations East I ","New Drug\u002FMisbranded","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Faz-pharmaceutical-inc-645101-05242024\">\u003Ctime datetime=\"2024-05-30T04:00:00Z\">05\u002F30\u002F2024\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>United Parcel Service\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Dietary Supplements\u003Cbr>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Emma Qingbo Li Xu\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chairwoman\u002FCEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>A&amp;Z Pharmaceutical, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>180 Oser Ave., Suite 300\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Hauppauge\u003C\u002Fspan>, \u003Cspan>NY\u003C\u002Fspan> \u003Cspan>11788-3709\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:emmaerwin@azpharmaceutical.com\"> emmaerwin@azpharmaceutical.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd> Division of Human and Animal Food Operations East I \u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003Cbr>\nCMS # 645101\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\nDear Ms. Li Xu:\u003C\u002Fp>\n\n\u003Cp>This is to advise you that the Food and Drug Administration (FDA) reviewed your website at the Internet address https:\u002F\u002Fd-calusa.com\u002F and your social media websites at https:\u002F\u002Fwww.facebook.com\u002Fdcalusa\u002F and https:\u002F\u002Fwww.facebook.com\u002Fmfitsupps\u002F in April 2023 and has determined that you take orders at https:\u002F\u002Fd-calusa.com\u002F for the product Chewable Calcium 600MG with Vitamin D for Kids in Orange Flavor. The claims on your websites establish that the product is a drug under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. 321(g)(1)(B)] because it is intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering this product for introduction into interstate commerce for such uses violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at \u003Ca>www.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>Examples of some of the website claims that provide evidence that your Chewable Calcium 600MG with Vitamin D for Kids in Orange Flavor product is intended for use as a drug include:\u003C\u002Fp>\n\n\u003Cp>On the website https:\u002F\u002Fd-calusa.com\u002F home page in the linked article titled: “VITAMIN D &amp; IT’S BENEFITS”:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“But, by upping your vitamin D levels, you can help re-mineralize bone structures, making them stronger…It could also help prevent osteoporosis, a condition affecting over 53 million people...Some studies have found that vitamin D can actually slow down bone loss, warding off osteoporosis and keeping you stronger for longer.”\u003C\u002Fli>\n\t\u003Cli>“[Vitamin D] can protect against gum disease…Researchers recently discovered that low vitamin D levels are linked to periodontitis, or gum disease. Their study found those with chronic gum disease also had very low levels of vitamin D in the blood.”\u003C\u002Fli>\n\t\u003Cli>“Vitamin D reduces depression…Research has shown that vitamin D might play an important role in regulating mood and warding off depression. In one study, scientists found that people with depression who received vitamin D supplements noticed an improvement in their symptoms.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>On the website https:\u002F\u002Fd-calusa.com\u002F Health &amp; Wellness page in the linked article titled: “CALCIUM DEFICIENCY|LOW CALCIUM SYMPTOMS”:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“How to Prevent Hypocalcemia?...The safest and easiest way to prevent hypocalcemia is by incorporating more calcium to your diet…For those who can’t meet their calcium recommended daily intake through their diets alone, calcium supplements are highly effective at maintaining healthy calcium levels…In addition, sometimes taking vitamin D supplements may be necessary to increase the absorption of calcium in the digestive tract.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>On the website https:\u002F\u002Fd-calusa.com\u002F Health &amp; Wellness page in the linked article titled: “WHAT IS CALCIUM? | CALCIUM BENEFITS”:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“[C]alcium supplements are tied to several health benefits including…lowering the risk of colon cancer…”\u003C\u002Fli>\n\t\u003Cli>“Calcium supplements are the standard defense-mechanism for treating and preventing bone-related diseases such as osteoporosis.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>On the website https:\u002F\u002Fd-calusa.com\u002F Health &amp; Wellness page in the linked article titled: “CONTROLLING BLOOD PRESSURE WITH THESE KEY MINERALS”:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Last, but not least, there’s a strong link between healthy calcium levels and controlled blood pressure. Besides being the cornerstone of bone health, calcium has many extended benefits, and lowering blood pressure is one of them. When combined with magnesium, calcium plays a critical role when it comes to regulating the constriction and dilatation of blood vessels. Research suggests calcium can help control high blood pressure, as it has been shown in several clinical trials that indicate increased calcium intake is linked to lower blood pressure and lower risk of hypertension. Previous studies have noted a reduction in systolic blood pressure as well as diastolic blood pressure per 100 mg of calcium consumed daily.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>On the website https:\u002F\u002Fd-calusa.com\u002F FAQs page:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“How much calcium do I need if I suffer from osteopenia?...If you suffer from osteopenia, you need between 1,000 and 1,200 milligrams of calcium per day, but, you also need 800 international units (IU) of vitamin D per day to help strengthen bones and treat your symptoms.”\u003C\u002Fli>\n\t\u003Cli>“Do I need calcium for hair growth?... Low levels of vitamin D are associated with alopecia or hair loss. Adding vitamin D and calcium supplements may help create new hair follicles, which can play a role in hair growth.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>On the social media site at https:\u002F\u002Fwww.facebook.com\u002Fdcalusa\u002F which directs consumers to your website to https:\u002F\u002Fd-calusa.com\u002F to purchase your products, including Chewable Calcium 600MG with Vitamin D for Kids in Orange Flavor:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Post dated June 28, 2021: “What happens if a child doesn't get enough vitamin D? Children who don't get enough vitamin D may not grow as much as others their age. They also have a chance of getting a rare disease called rickets, which causes bone pain and soft, weak bones that can lead to bone deformities…Follow us D-Cal for facts and tips about healthy lifestyles to stay strong!...#dcal#dcalkids”\u003C\u002Fli>\n\t\u003Cli>Post dated June 25, 2021: “What happens if a child doesn't get enough calcium?...Kids who don't get enough calcium will have increased risk of bone fractures, not able to reach potential height, and osteoporosis later in life. Make sure your kids get enough calcium through meals or supplements! Follow us D-Cal for facts and tips about healthy lifestyles to stay strong!#dcal #dcalkids”\u003C\u002Fli>\n\t\u003Cli>Post dated January 4, 2021: “Did you know vitamin D can help cut the risk of Covid-19? Remember to maintain a normal vitamin D intake level!...#covid19…#dcal…#dcalkids…”HOW VITAMIN D CUTSTHE RISK OF COVID-19…Covid-19 death rate by sunshine vitamin level…4.1% NORMAL***87.8%INSUFFICIENT…98.9% DEFICIENT...”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Your product is not generally recognized as safe and effective for the above referenced uses and, therefore, the product is a “new drug” under section 201(p) of the Act [21 U.S.C. 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\u003C\u002Fp>\n\n\u003Cp>A drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\u003C\u002Fp>\n\n\u003Cp>Your product Chewable Calcium 600MG with Vitamin D for Kids in Orange Flavor is intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your product safely for its intended purposes. Accordingly, Chewable Calcium 600MG with Vitamin D for Kids in Orange Flavor fails to bear adequate directions for its intended use and, therefore, the product is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of this misbranded drug violates section 301(a) of the Act [21 U.S.C. 331(a)].\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Please send your reply to the Food and Drug Administration, Attention: Lillian C. Aveta, Compliance Officer, 158-15 Liberty Ave., Jamaica, NY 11433 or via email at Lillian.aveta@fda.hhs.gov (preferred). If you have any questions about the content of this letter, please contact Ms. Aveta at 718-662-5576 or email atLillian.aveta@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ronald M. Pace\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Human and Animal Food Operations\u003Cbr>\nEast – Division 1\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nUnited Parcel Service\n\nProduct:\n\nDietary Supplements\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nEmma Qingbo Li Xu\n\nRecipient Title\n\nChairwoman\u002FCEO\n\nA&Z Pharmaceutical, Inc.\n\n180 Oser Ave., Suite 300\n\nHauppauge, NY 11788-3709\n\nUnited States\n\nemmaerwin@azpharmaceutical.com\n\nIssuing Office:\n\nDivision of Human and Animal Food Operations East I\n\nUnited States\n\nWARNING LETTER\n\nCMS # 645101\n\nDear Ms. Li Xu:\n\nThis is to advise you that the Food and Drug Administration (FDA) reviewed your website at the Internet address https:\u002F\u002Fd-calusa.com\u002F and your social media websites at https:\u002F\u002Fwww.facebook.com\u002Fdcalusa\u002F and https:\u002F\u002Fwww.facebook.com\u002Fmfitsupps\u002F in April 2023 and has determined that you take orders at https:\u002F\u002Fd-calusa.com\u002F for the product Chewable Calcium 600MG with Vitamin D for Kids in Orange Flavor. The claims on your websites establish that the product is a drug under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. 321(g)(1)(B)] because it is intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering this product for introduction into interstate commerce for such uses violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at www.fda.gov.\n\nExamples of some of the website claims that provide evidence that your Chewable Calcium 600MG with Vitamin D for Kids in Orange Flavor product is intended for use as a drug include:\n\nOn the website https:\u002F\u002Fd-calusa.com\u002F home page in the linked article titled: “VITAMIN D & IT’S BENEFITS”:\n\n“But, by upping your vitamin D levels, you can help re-mineralize bone structures, making them stronger…It could also help prevent osteoporosis, a condition affecting over 53 million people...Some studies have found that vitamin D can actually slow down bone loss, warding off osteoporosis and keeping you stronger for longer.”\n\n“[Vitamin D] can protect against gum disease…Researchers recently discovered that low vitamin D levels are linked to periodontitis, or gum disease. Their study found those with chronic gum disease also had very low levels of vitamin D in the blood.”\n\n“Vitamin D reduces depression…Research has shown that vitamin D might play an important role in regulating mood and warding off depression. In one study, scientists found that people with depression who received vitamin D supplements noticed an improvement in their symptoms.”\n\nOn the website https:\u002F\u002Fd-calusa.com\u002F Health & Wellness page in the linked article titled: “CALCIUM DEFICIENCY|LOW CALCIUM SYMPTOMS”:\n\n“How to Prevent Hypocalcemia?...The safest and easiest way to prevent hypocalcemia is by incorporating more calcium to your diet…For those who can’t meet their calcium recommended daily intake through their diets alone, calcium supplements are highly effective at maintaining healthy calcium levels…In addition, sometimes taking vitamin D supplements may be necessary to increase the absorption of calcium in the digestive tract.”\n\nOn the website https:\u002F\u002Fd-calusa.com\u002F Health & Wellness page in the linked article titled: “WHAT IS CALCIUM? | CALCIUM BENEFITS”:\n\n“[C]alcium supplements are tied to several health benefits including…lowering the risk of colon cancer…”\n\n“Calcium supplements are the standard defense-mechanism for treating and preventing bone-related diseases such as osteoporosis.”\n\nOn the website https:\u002F\u002Fd-calusa.com\u002F Health & Wellness page in the linked article titled: “CONTROLLING BLOOD PRESSURE WITH THESE KEY MINERALS”:\n\n“Last, but not least, there’s a strong link between healthy calcium levels and controlled blood pressure. Besides being the cornerstone of bone health, calcium has many extended benefits, and lowering blood pressure is one of them. When combined with magnesium, calcium plays a critical role when it comes to regulating the constriction and dilatation of blood vessels. Research suggests calcium can help control high blood pressure, as it has been shown in several clinical trials that indicate increased calcium intake is linked to lower blood pressure and lower risk of hypertension. Previous studies have noted a reduction in systolic blood pressure as well as diastolic blood pressure per 100 mg of calcium consumed daily.”\n\nOn the website https:\u002F\u002Fd-calusa.com\u002F FAQs page:\n\n“How much calcium do I need if I suffer from osteopenia?...If you suffer from osteopenia, you need between 1,000 and 1,200 milligrams of calcium per day, but, you also need 800 international units (IU) of vitamin D per day to help strengthen bones and treat your symptoms.”\n\n“Do I need calcium for hair growth?... Low levels of vitamin D are associated with alopecia or hair loss. Adding vitamin D and calcium supplements may help create new hair follicles, which can play a role in hair growth.”\n\nOn the social media site at https:\u002F\u002Fwww.facebook.com\u002Fdcalusa\u002F which directs consumers to your website to https:\u002F\u002Fd-calusa.com\u002F to purchase your products, including Chewable Calcium 600MG with Vitamin D for Kids in Orange Flavor:\n\nPost dated June 28, 2021: “What happens if a child doesn't get enough vitamin D? Children who don't get enough vitamin D may not grow as much as others their age. They also have a chance of getting a rare disease called rickets, which causes bone pain and soft, weak bones that can lead to bone deformities…Follow us D-Cal for facts and tips about healthy lifestyles to stay strong!...#dcal#dcalkids”\n\nPost dated June 25, 2021: “What happens if a child doesn't get enough calcium?...Kids who don't get enough calcium will have increased risk of bone fractures, not able to reach potential height, and osteoporosis later in life. Make sure your kids get enough calcium through meals or supplements! Follow us D-Cal for facts and tips about healthy lifestyles to stay strong!#dcal #dcalkids”\n\nPost dated January 4, 2021: “Did you know vitamin D can help cut the risk of Covid-19? Remember to maintain a normal vitamin D intake level!...#covid19…#dcal…#dcalkids…”HOW VITAMIN D CUTSTHE RISK OF COVID-19…Covid-19 death rate by sunshine vitamin level…4.1% NORMAL***87.8%INSUFFICIENT…98.9% DEFICIENT...”\n\nYour product is not generally recognized as safe and effective for the above referenced uses and, therefore, the product is a “new drug” under section 201(p) of the Act [21 U.S.C. 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\n\nA drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\n\nYour product Chewable Calcium 600MG with Vitamin D for Kids in Orange Flavor is intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your product safely for its intended purposes. Accordingly, Chewable Calcium 600MG with Vitamin D for Kids in Orange Flavor fails to bear adequate directions for its intended use and, therefore, the product is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of this misbranded drug violates section 301(a) of the Act [21 U.S.C. 331(a)].\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\n\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nPlease send your reply to the Food and Drug Administration, Attention: Lillian C. Aveta, Compliance Officer, 158-15 Liberty Ave., Jamaica, NY 11433 or via email at Lillian.aveta@fda.hhs.gov (preferred). If you have any questions about the content of this letter, please contact Ms. Aveta at 718-662-5576 or email atLillian.aveta@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nRonald M. Pace\n\nProgram Division Director\n\nOffice of Human and Animal Food Operations\n\nEast – Division 1","A&Z Pharmaceutical, Inc.","az-pharmaceutical-inc-645101-06012023","2026-08-18T06:42:29.145918+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Faz-pharmaceutical-inc-645101-06012023","2026-10-26T08:07:59.864348+00:00","Closed Out","2023-06-13","645101","Dietary SupplementsFood & Beverages","2024-05-30","Division of Human and Animal Food Operations East I","Emma Qingbo Li Xu","2026-08-20T01:03:01.454+00:00","United Parcel Service","2023-06-01",{"id":154,"raw":155,"subject":159,"body_html":160,"body_text":161,"firm_name":162,"letter_id":163,"created_at":85,"fei_number":19,"letter_url":164,"updated_at":165,"action_type":22,"case_status":23,"posted_date":166,"marcs_cms_no":167,"product_type":168,"closeout_date":19,"issuing_office":11,"recipient_name":169,"body_fetched_at":170,"delivery_method":171,"recipient_title":19,"reference_number":172,"action_taken_date":173,"medical_device_id":19,"response_letter_date":19},140,[156,157,158,11,159,13,13,13],"\u003Ctime datetime=\"2026-05-26T13:20:00Z\">05\u002F26\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-05-18T04:00:00Z\">05\u002F18\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsato-pharmaceutical-co-ltd-723059-05182026\">Sato Pharmaceutical Co., Ltd.\u003C\u002Fa>","CGMP\u002FDrugs\u002FAdulterated\u002FOTC","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email Return Receipt Requested\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-26-75\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n                          \u003Cbr>Over-the-Counter Drugs\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Seiichi Sato\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President and CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Sato Pharmaceutical Co., Ltd.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1-5-27 Moto-Akasaka Minato-ku\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Tokyo\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>107-0051\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Japan\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:seiichi@sato-seiyaku.co.jp\"> seiichi@sato-seiyaku.co.jp\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n  \u003Cdiv>\n    \u003Cdiv>Secondary Issuing Offices\u003C\u002Fdiv>\n          \u003Cdiv>\n              \u003Cdiv>    \u003Cbr>\n    \n     \n        \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n    \n    \n    \n    \n\u003C\u002Fdiv>\n              \u003C\u002Fdiv>\n      \u003C\u002Fdiv>\n\n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>May 18, 2026\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>&nbsp;\u003C\u002Fp>\u003Cp>Dear Mr. Sato:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Sato Pharmaceutical Co., Ltd., FEI 3004055563, located at 1468 Hazama-Machi, Hachioji, Tokyo, Japan, from November 13 to 21, 2025.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>We reviewed your December 12, 2025, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic processes (21 CFR 211.113(b)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your ISO 5 area used for aseptic filling of \u003Cstrong>(b)(4)\u003C\u002Fstrong> over-the-counter (OTC) \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug products is fundamentally unsuitable for its intended use. The design and capability of your aseptic filling line \u003Cstrong>(b)(4)\u003C\u002Fstrong> Line) were not sufficient to establish and maintain a state of control.\u003C\u002Fp>\u003Cp>Between November 2022 and February 2025, your attempts to validate your aseptic filling line resulted in at least six media fill failures. Notably, significant microbiological and foreign particulate contamination has been found in this line. The corrective actions you implemented appear insufficient to correct fundamental factors in aseptic process design that are essential to ensure reproducibility and ongoing contamination prevention. This line is used to manufacture \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug products intended for the U.S. market, including \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>. &nbsp;\u003C\u002Fp>\u003Cp>Your design of the ISO 5 area does not ensure unidirectional airflow protection of the aseptic processing line in the event of \u003Cstrong>(b)(4)\u003C\u002Fstrong> interventions. The air intake vents for the Grade A laminar airflow (\u003Cstrong>(b)(4)\u003C\u002Fstrong> RABS) are located \u003Cstrong>(b)(4)\u003C\u002Fstrong> the RABS \u003Cstrong>(b)(4)\u003C\u002Fstrong> near the \u003Cstrong>(b)(4)\u003C\u002Fstrong> level on your \u003Cstrong>(b)(4)\u003C\u002Fstrong> Filling Line. When a \u003Cstrong>(b)(4)\u003C\u002Fstrong>, air is drawn upward from the aseptic processing line. This fundamentally flawed design resulted in first-pass air not reaching the filling line, leaving the critical ISO 5 zone unprotected while sterile drug products were exposed.\u003C\u002Fp>\u003Cp>The airflow visualization studies you performed on the \u003Cstrong>(b)(4)\u003C\u002Fstrong> Filling Line failed to adequately demonstrate unidirectional airflow and were deficient in the following respects:\u003C\u002Fp>\u003Cp>• Your airflow visualization videos showed rapid manual movement of the smoke source.\u003C\u002Fp>\u003Cp>• The position of the smoke source prevented evaluation of airflow through the entire height of the operational area. At times, the technician obscured visibility of airflow with their body. &nbsp;\u003C\u002Fp>\u003Cp>Your response is inadequate. While you indicate plans to update the line prior to conducting media fills in October 2026 and resume commercial production after achieving \u003Cstrong>(b)(4)\u003C\u002Fstrong> successful media fills, your corrective actions are insufficient to address the fundamental design deficiencies in your aseptic processing operations.\u003C\u002Fp>\u003Cp>While you commit to replacing the bottle holders with \u003Cstrong>(b)(4)\u003C\u002Fstrong> holders and to revise your smoke study procedures, you do not address the broader systemic failures in aseptic process design, environmental control, and contamination prevention. &nbsp;\u003C\u002Fp>\u003Cp>These systemic issues pose an unacceptable risk to patients using your \u003Cstrong>(b)(4)\u003C\u002Fstrong> products.\u003C\u002Fp>\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\u003Cp>• A comprehensive, independent risk assessment of all contamination hazards with respect to your aseptic processes, equipment, and facilities, including but not limited to:\u003Cbr>o All human interactions within the ISO 5 area\u003Cbr>o Gowning in the aseptic processing room and ancillary clean areas&nbsp;\u003Cbr>o Equipment placement and ergonomics\u003Cbr>o Air quality in the ISO 5 area and surrounding room&nbsp;\u003Cbr>o Facility layout&nbsp;\u003Cbr>o Personnel flows and material flows (throughout all rooms used to conduct and support sterile operations)\u003C\u002Fp>\u003Cp>• A detailed remediation plan with timelines to address the findings of the contamination hazards risk assessment. Describe specific tangible improvements to be made to aseptic processing operation design and control at your facility and explain how this corrective action and preventive action (CAPA) plan will robustly remediate your deficient sterile manufacturing operations. Include comprehensive changes to the design of both your aseptic processing lines and cleanrooms. Also describe your plans for qualification and validation of your extensively remediated operations.\u003C\u002Fp>\u003Cp>\u003Cstrong>2. Your firm failed to conduct, for each batch of drug product, appropriate laboratory testing, as necessary, required to be free of objectionable microorganisms. Your firm also failed to establish and follow an adequate written testing program designed to assess the stability characteristics of drug products and to use results of stability testing to determine appropriate storage conditions and expiration dates (21 CFR 211.165(b) and 21 CFR 211.166(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm did not have an adequate stability program to demonstrate that the chemical and microbiological properties of your drug products met established specifications and that they remain acceptable throughout their labeled shelf-life.\u003C\u002Fp>\u003Cp>Your firm has not established stability-indicating methods for the OTC products you distribute to the U.S. market. During our review of stability data for multiple drug products, it was observed that your firm’s high performance liquid chromatographic (HPLC) analyses did not monitor or evaluate impurity peaks detected during testing. These impurity peaks were visible in the chromatograms but were not identified or adequately evaluated against established acceptance criteria. For example:\u003C\u002Fp>\u003Cp>• Twelve-month and 24-month stability data for \u003Cstrong>(b)(4)\u003C\u002Fstrong>, Lot #\u003Cstrong>(b)(4)\u003C\u002Fstrong>, showed an early eluting peak before the \u003Cstrong>(b)(4)\u003C\u002Fstrong> peak. This peak was not present during release testing. According to your firm, this peak is a degradation impurity but is not currently monitored or reported during stability studies.&nbsp;\u003Cbr>• Twelve-month stability data for \u003Cstrong>(b)(4)\u003C\u002Fstrong>, Lot #\u003Cstrong>(b)(4)\u003C\u002Fstrong>, showed early eluting peaks before the \u003Cstrong>(b)(4)\u003C\u002Fstrong> peak. These peaks were not present during release testing. Your firm has not identified these degradation impurities.\u003C\u002Fp>\u003Cp>The appearance of extraneous peaks during stability studies that were not present at release indicates potential product degradation, container-closure system interactions, or other impurities that could affect drug product safety and efficacy. The failure to monitor, identify, and control impurities throughout the drug product shelf life compromises your ability to ensure drug products maintain acceptable safety, identity, strength, purity, and quality throughout their expiration period.\u003C\u002Fp>\u003Cp>Your stability testing programs did not include complete test parameters necessary to adequately assess product stability characteristics. Review of stability protocols and testing records revealed that you omit critical quality attributes from routine stability testing. For example:\u003C\u002Fp>\u003Cp>• Your stability study program for \u003Cstrong>(b)(4) (b)(4)\u003C\u002Fstrong> expiry) does not include testing for viscosity, degradation products, \u003Cstrong>(b)(4)\u003C\u002Fstrong> content, and dose uniformity. &nbsp;\u003C\u002Fp>\u003Cp>• Your stability study program for \u003Cstrong>(b)(4) (b)(4)\u003C\u002Fstrong> expiry) does not include testing for \u003Cstrong>(b)(4)\u003C\u002Fstrong> content (\u003Cstrong>(b)(4)\u003C\u002Fstrong> testing ), degradation products, particulate matter, and weight loss, which are essential parameters for a \u003Cstrong>(b)(4)\u003C\u002Fstrong> formulation.\u003C\u002Fp>\u003Cp>Your response is inadequate. You indicate you are conducting a retrospective investigation of stability chromatograms and will establish new procedures requiring integration and monitoring of all chromatographic peaks. However, you have not provided stability-indicating methods for your OTC products, comprehensive identification of degradation products, or health hazard evaluations for products currently on the U.S. market that were released without adequate stability-indicating methods.\u003C\u002Fp>\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\u003Cp>• A comprehensive, independent assessment and CAPA plan to ensure the adequacy of your stability program. Your remediated program should address the above deficiencies and include, but not be limited to:\u003Cbr>o Stability indicating methods\u003Cbr>o Stability studies for each drug product in its marketed container-closure system before distribution is permitted\u003Cbr>o An ongoing program in which representative batches of each product are added each year to the program to determine whether the shelf-life claim remains valid\u003Cbr>o Detailed definition of the specific attributes to be tested at each station (timepoint)&nbsp;\u003Cbr>o All procedures that describe these and other elements of your remediated stability program\u003C\u002Fp>\u003Cp>\u003Cstrong>3. Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that your (b)(4) OTC drug products conform to appropriate standards of identity, strength, quality, and purity (21 CFR 211.160(b)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong> produces \u003Cstrong>(b)(4)\u003C\u002Fstrong> OTC drug products for the U.S. market, such as \u003Cstrong>(b)(4)\u003C\u002Fstrong>, that contain \u003Cstrong>(b)(4)\u003C\u002Fstrong> as an inactive ingredient. Your firm manufactured and released several OTC products to the U.S. market without conducting required microbiological testing, including testing for \u003Cem>Burkholderia cepacia \u003C\u002Fem>complex. These products include, but may not be limited to:\u003C\u002Fp>\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cem>Burkholderia cepacia \u003C\u002Fem>complex organisms are opportunistic pathogens of particular concern for patients with compromised immune systems or chronic lung conditions.\u003C\u002Fp>\u003Cp>Your response is inadequate. While you indicate you will conduct \u003Cem>Burkholderia cepacia \u003C\u002Fem>complex testing on reference samples and revise applicable procedures, you have not provided reserve sample testing results, health hazard evaluations for batches that were released without required microbiological testing, assessment of patient risk, or evaluation of the potential need for market action. You also have not provided evidence these products have passed \u003Cstrong>(b)(4)\u003C\u002Fstrong> testing at release and on stability to demonstrate the adequacy of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> systems. In addition, you did not provide evidence that the \u003Cstrong>(b)(4)\u003C\u002Fstrong> used in your drug products meets the requirements for \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\u003Cp>• A list of chemical and microbial specifications, including test methods, used to analyze each lot of your drug products before a lot disposition decision.&nbsp;\u003Cbr>o An action plan and timelines for conducting full chemical and microbiological testing (including impurities) of reserve samples to determine the quality of all batches of drug products distributed to the United States that are within expiry as of the date of this letter.&nbsp;\u003Cbr>o A summary of all results obtained from testing retain samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls. &nbsp;\u003C\u002Fp>\u003Cp>• For your \u003Cstrong>(b)(4)\u003C\u002Fstrong> OTC drug products that contain \u003Cstrong>(b)(4)\u003C\u002Fstrong>:\u003Cbr>o Test data and results showing whether each of the drug products has passed the requirements in \u003Cstrong>(b)(4)\u003C\u002Fstrong> Test with the lowest \u003Cstrong>(b)(4)\u003C\u002Fstrong> level allowed for release or stability, whichever is lower.&nbsp;\u003Cbr>o Results of testing for \u003Cstrong>(b)(4)\u003C\u002Fstrong> content at release and on the product stability program.\u003C\u002Fp>\u003Cp>\u003Cstrong>Pause in Production of Sterile Drug Products\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>We acknowledge that you halted production for the United States until corrective actions are made, and successful media fills completed. Given the fundamental flaws documented in your sterile production line, commit to not resuming production until corrective actions are made and you have discussed your CAPA plan with this office. Alternatively, if you no longer plan to make sterile drug products for the US market, provide a commitment to that effect in writing in response to this letter.\u003C\u002Fp>\u003Cp>\u003Cstrong>CGMP Consultant\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements if your firm intends to resume manufacturing drugs for the U.S. market. The qualified consultant should also perform a comprehensive six-system audit\u003Ca id=\"footnoteref1_l06p3ib\" href=\"#footnote1_l06p3ib\">\u003Csup>1\u003C\u002Fsup>\u003C\u002Fa>&nbsp;of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\u003C\u002Fp>\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>If you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(b). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\u003C\u002Fp>\u003Cp>Correct any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations. &nbsp;\u003C\u002Fp>\u003Cp>Failure to address any violations may also result in the FDA refusing admission of articles manufactured at Sato Pharmaceutical Co., Ltd., located at 1468, Hazama-Machi Hachioji, Tokyo, Japan, into the United States under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3004055563 and ATTN: Brian Nicholson.\u003C\u002Fp>\u003Cp>\u003Cbr>Sincerely,\u003Cbr>\u002FS\u002F\u003Cbr>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>\u003Cbr>Cc: Masakazu Miyashita, Factory Director\u003Cbr>masakazu.miyashita@sato-seiyaku.co.jp\u003Cbr>&nbsp;\u003C\u002Fp>\n\n\u003Col>\n                  \u003Cli id=\"footnote1_l06p3ib\">\u003Ca href=\"#footnoteref1_l06p3ib\">1\u003C\u002Fa>i.e. Quality System, Facilities &amp; Equipment System, Materials System, Production System, Packaging &amp; Labeling System, and Laboratory Control System per FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations.\u003C\u002Fli>\n      \u003C\u002Fol>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email Return Receipt Requested\n\nReference #:\n\n320-26-75\n\nProduct:\n\nDrugs\n\nOver-the-Counter Drugs\n\nRecipient:\n\nRecipient Name\n\nSeiichi Sato\n\nRecipient Title\n\nPresident and CEO\n\nSato Pharmaceutical Co., Ltd.\n\n1-5-27 Moto-Akasaka Minato-ku\n\nTokyo\n\n107-0051\n\nJapan\n\nseiichi@sato-seiyaku.co.jp\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nSecondary Issuing Offices\n\nUnited States\n\nMay 18, 2026\nWARNING LETTER\n\nDear Mr. Sato:\nThe United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Sato Pharmaceutical Co., Ltd., FEI 3004055563, located at 1468 Hazama-Machi, Hachioji, Tokyo, Japan, from November 13 to 21, 2025.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nWe reviewed your December 12, 2025, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n1. Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic processes (21 CFR 211.113(b)).\nYour ISO 5 area used for aseptic filling of (b)(4) over-the-counter (OTC) (b)(4) drug products is fundamentally unsuitable for its intended use. The design and capability of your aseptic filling line (b)(4) Line) were not sufficient to establish and maintain a state of control.\nBetween November 2022 and February 2025, your attempts to validate your aseptic filling line resulted in at least six media fill failures. Notably, significant microbiological and foreign particulate contamination has been found in this line. The corrective actions you implemented appear insufficient to correct fundamental factors in aseptic process design that are essential to ensure reproducibility and ongoing contamination prevention. This line is used to manufacture (b)(4) drug products intended for the U.S. market, including (b)(4) and (b)(4).\nYour design of the ISO 5 area does not ensure unidirectional airflow protection of the aseptic processing line in the event of (b)(4) interventions. The air intake vents for the Grade A laminar airflow ((b)(4) RABS) are located (b)(4) the RABS (b)(4) near the (b)(4) level on your (b)(4) Filling Line. When a (b)(4), air is drawn upward from the aseptic processing line. This fundamentally flawed design resulted in first-pass air not reaching the filling line, leaving the critical ISO 5 zone unprotected while sterile drug products were exposed.\nThe airflow visualization studies you performed on the (b)(4) Filling Line failed to adequately demonstrate unidirectional airflow and were deficient in the following respects:\n• Your airflow visualization videos showed rapid manual movement of the smoke source.\n• The position of the smoke source prevented evaluation of airflow through the entire height of the operational area. At times, the technician obscured visibility of airflow with their body.\nYour response is inadequate. While you indicate plans to update the line prior to conducting media fills in October 2026 and resume commercial production after achieving (b)(4) successful media fills, your corrective actions are insufficient to address the fundamental design deficiencies in your aseptic processing operations.\nWhile you commit to replacing the bottle holders with (b)(4) holders and to revise your smoke study procedures, you do not address the broader systemic failures in aseptic process design, environmental control, and contamination prevention.\nThese systemic issues pose an unacceptable risk to patients using your (b)(4) products.\nIn response to this letter, provide the following:\n• A comprehensive, independent risk assessment of all contamination hazards with respect to your aseptic processes, equipment, and facilities, including but not limited to:\no All human interactions within the ISO 5 area\no Gowning in the aseptic processing room and ancillary clean areas\no Equipment placement and ergonomics\no Air quality in the ISO 5 area and surrounding room\no Facility layout\no Personnel flows and material flows (throughout all rooms used to conduct and support sterile operations)\n• A detailed remediation plan with timelines to address the findings of the contamination hazards risk assessment. Describe specific tangible improvements to be made to aseptic processing operation design and control at your facility and explain how this corrective action and preventive action (CAPA) plan will robustly remediate your deficient sterile manufacturing operations. Include comprehensive changes to the design of both your aseptic processing lines and cleanrooms. Also describe your plans for qualification and validation of your extensively remediated operations.\n2. Your firm failed to conduct, for each batch of drug product, appropriate laboratory testing, as necessary, required to be free of objectionable microorganisms. Your firm also failed to establish and follow an adequate written testing program designed to assess the stability characteristics of drug products and to use results of stability testing to determine appropriate storage conditions and expiration dates (21 CFR 211.165(b) and 21 CFR 211.166(a)).\nYour firm did not have an adequate stability program to demonstrate that the chemical and microbiological properties of your drug products met established specifications and that they remain acceptable throughout their labeled shelf-life.\nYour firm has not established stability-indicating methods for the OTC products you distribute to the U.S. market. During our review of stability data for multiple drug products, it was observed that your firm’s high performance liquid chromatographic (HPLC) analyses did not monitor or evaluate impurity peaks detected during testing. These impurity peaks were visible in the chromatograms but were not identified or adequately evaluated against established acceptance criteria. For example:\n• Twelve-month and 24-month stability data for (b)(4), Lot #(b)(4), showed an early eluting peak before the (b)(4) peak. This peak was not present during release testing. According to your firm, this peak is a degradation impurity but is not currently monitored or reported during stability studies.\n• Twelve-month stability data for (b)(4), Lot #(b)(4), showed early eluting peaks before the (b)(4) peak. These peaks were not present during release testing. Your firm has not identified these degradation impurities.\nThe appearance of extraneous peaks during stability studies that were not present at release indicates potential product degradation, container-closure system interactions, or other impurities that could affect drug product safety and efficacy. The failure to monitor, identify, and control impurities throughout the drug product shelf life compromises your ability to ensure drug products maintain acceptable safety, identity, strength, purity, and quality throughout their expiration period.\nYour stability testing programs did not include complete test parameters necessary to adequately assess product stability characteristics. Review of stability protocols and testing records revealed that you omit critical quality attributes from routine stability testing. For example:\n• Your stability study program for (b)(4) (b)(4) expiry) does not include testing for viscosity, degradation products, (b)(4) content, and dose uniformity.\n• Your stability study program for (b)(4) (b)(4) expiry) does not include testing for (b)(4) content ((b)(4) testing ), degradation products, particulate matter, and weight loss, which are essential parameters for a (b)(4) formulation.\nYour response is inadequate. You indicate you are conducting a retrospective investigation of stability chromatograms and will establish new procedures requiring integration and monitoring of all chromatographic peaks. However, you have not provided stability-indicating methods for your OTC products, comprehensive identification of degradation products, or health hazard evaluations for products currently on the U.S. market that were released without adequate stability-indicating methods.\nIn response to this letter, provide the following:\n• A comprehensive, independent assessment and CAPA plan to ensure the adequacy of your stability program. Your remediated program should address the above deficiencies and include, but not be limited to:\no Stability indicating methods\no Stability studies for each drug product in its marketed container-closure system before distribution is permitted\no An ongoing program in which representative batches of each product are added each year to the program to determine whether the shelf-life claim remains valid\no Detailed definition of the specific attributes to be tested at each station (timepoint)\no All procedures that describe these and other elements of your remediated stability program\n3. Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that your (b)(4) OTC drug products conform to appropriate standards of identity, strength, quality, and purity (21 CFR 211.160(b)).\n(b)(4) produces (b)(4) OTC drug products for the U.S. market, such as (b)(4), that contain (b)(4) as an inactive ingredient. Your firm manufactured and released several OTC products to the U.S. market without conducting required microbiological testing, including testing for Burkholderia cepacia complex. These products include, but may not be limited to:\n(b)(4)\nBurkholderia cepacia complex organisms are opportunistic pathogens of particular concern for patients with compromised immune systems or chronic lung conditions.\nYour response is inadequate. While you indicate you will conduct Burkholderia cepacia complex testing on reference samples and revise applicable procedures, you have not provided reserve sample testing results, health hazard evaluations for batches that were released without required microbiological testing, assessment of patient risk, or evaluation of the potential need for market action. You also have not provided evidence these products have passed (b)(4) testing at release and on stability to demonstrate the adequacy of your (b)(4) systems. In addition, you did not provide evidence that the (b)(4) used in your drug products meets the requirements for (b)(4).\nIn response to this letter, provide the following:\n• A list of chemical and microbial specifications, including test methods, used to analyze each lot of your drug products before a lot disposition decision.\no An action plan and timelines for conducting full chemical and microbiological testing (including impurities) of reserve samples to determine the quality of all batches of drug products distributed to the United States that are within expiry as of the date of this letter.\no A summary of all results obtained from testing retain samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\n• For your (b)(4) OTC drug products that contain (b)(4):\no Test data and results showing whether each of the drug products has passed the requirements in (b)(4) Test with the lowest (b)(4) level allowed for release or stability, whichever is lower.\no Results of testing for (b)(4) content at release and on the product stability program.\nPause in Production of Sterile Drug Products\nWe acknowledge that you halted production for the United States until corrective actions are made, and successful media fills completed. Given the fundamental flaws documented in your sterile production line, commit to not resuming production until corrective actions are made and you have discussed your CAPA plan with this office. Alternatively, if you no longer plan to make sterile drug products for the US market, provide a commitment to that effect in writing in response to this letter.\nCGMP Consultant\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements if your firm intends to resume manufacturing drugs for the U.S. market. The qualified consultant should also perform a comprehensive six-system audit1 of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nIf you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(b). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\nCorrect any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\nFailure to address any violations may also result in the FDA refusing admission of articles manufactured at Sato Pharmaceutical Co., Ltd., located at 1468, Hazama-Machi Hachioji, Tokyo, Japan, into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3004055563 and ATTN: Brian Nicholson.\n\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research\n\nCc: Masakazu Miyashita, Factory Director\nmasakazu.miyashita@sato-seiyaku.co.jp\n\n1i.e. Quality System, Facilities & Equipment System, Materials System, Production System, Packaging & Labeling System, and Laboratory Control System per FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations.","Sato Pharmaceutical Co., Ltd.","sato-pharmaceutical-co-ltd-723059-05182026","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsato-pharmaceutical-co-ltd-723059-05182026","2026-10-26T08:09:54.1853+00:00","2026-05-26","723059","Drugs Over-the-Counter Drugs","Seiichi Sato","2026-08-19T04:40:00.541+00:00","Via Email Return Receipt Requested","320-26-75","2026-05-18",{"id":175,"raw":176,"subject":180,"body_html":181,"body_text":182,"firm_name":183,"letter_id":184,"created_at":185,"fei_number":19,"letter_url":186,"updated_at":187,"action_type":22,"case_status":23,"posted_date":188,"marcs_cms_no":189,"product_type":168,"closeout_date":19,"issuing_office":11,"recipient_name":190,"body_fetched_at":191,"delivery_method":192,"recipient_title":19,"reference_number":193,"action_taken_date":194,"medical_device_id":19,"response_letter_date":19},21921,[177,178,179,11,180,13,13,13],"\u003Ctime datetime=\"2026-10-20T04:00:00Z\">10\u002F20\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-10-14T04:00:00Z\">10\u002F14\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Frohto-pharmaceutical-co-ltd-733215-10142026\">Rohto Pharmaceutical Co., Ltd.\u003C\u002Fa>","CGMP\u002FFinished Pharmaceuticals\u002FUnapproved New Drug\u002FMisbranded\u002FAdulterated\u002FOTC","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-27-06\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n                          \u003Cbr>Over-the-Counter Drugs\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Kunio Yamada\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chairman and Representative Director\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Rohto Pharmaceutical Co., Ltd.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1-8-1 Tatsuminishi\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Ikuno-Ku\u003C\u002Fspan>, \u003Cspan>Osaka\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>544-8666\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Japan\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(4)\"> (b)(4)\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>October 14, 2026\u003C\u002Fp>\u003Cp>WARNING LETTER\u003Cbr>Reference number: 320-27-06\u003C\u002Fp>\u003Cp>To Mr. Kunio Yamada:\u003C\u002Fp>\u003Cp>This warning letter advises you of significant violations observed during a U.S. Food and Drug Administration (FDA) inspection of your facility. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that exist at your facility. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address violations may result in regulatory action without further notice.\u003C\u002Fp>\u003Cp>\u003Cstrong>FDA Inspection\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Violations were observed and documented during an inspection of your drug manufacturing facility, Rohto-Mentholatum (Vietnam) Co., Ltd., FDA Establishment Identifier (FEI) 3008808745, at No. 16 VSIP Street No. 5, Vietnam - Singapore Industrial Park, Thuan Giao Ward, Ho Chi Minh, Vietnam, from April 6 to 14, 2026. This inspection was conducted under FDA’s statutory authority and public health responsibilities to protect the public from unsafe, ineffective, and poor quality drugs.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>In addition, violations were identified and documented during a review of your product labeling and website at the internet address https:\u002F\u002Frohtoeyedrops.com\u002F and your Instagram account at https:\u002F\u002Fwww.instagram.com\u002Frohtoeyedrops\u002F in August 2026. Based on our review, your “ROHTO® Cooling Eye Drops COOL RELIEF,” “ROHTO® Cooling Eye Drops ALL-IN-ONE,” “ROHTO® Cooling Eye Drops MAX STRENGTH,” “ROHTO® Cooling Eye Drops DIGI EYE,” “ROHTO® Cooling Eye Drops OPTIC GLOW,” “ROHTO® Cooling Eye Drops DRY AID,” and “ROHTO® Cooling Eye Drops DUAL LIGHT RELIEF” are unapproved new drugs under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 355(a). In addition, these products are misbranded under sections 502(a) and 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(a) and 352(ee). As explained further below, introducing or delivering these products for introduction into interstate commerce is prohibited under sections 301(d) and (a) of the FD&amp;C Act, 21 U.S.C. 331(d) and (a).\u003C\u002Fp>\u003Cp>We reviewed your May 1, 2026, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\u003Cp>\u003Cstrong>Violations of the Federal Food, Drug, and Cosmetic Act\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>CGMP Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The following are violations identified during our inspection and review. As a reminder, this is not an all-inclusive list of violations at your facility.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to ensure that laboratory records included complete data derived from all tests necessary to ensure compliance with established specifications and standards. Your firm also failed to clean, maintain, and, as appropriate for the nature of the drug, sanitize and\u002For sterilize equipment and utensils at appropriate intervals to prevent malfunctions or contamination that would alter the safety, identity, strength, quality, or purity of the drug product beyond the official or other established requirements (21 CFR 211.194(a) and 21 CFR 211.67(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm manufactures over-the-counter (OTC) topical ophthalmic drug products using aseptic processing.\u003C\u002Fp>\u003Cp>Our inspection revealed systemic data falsification. Notably, we observed critical data integrity breaches in your environmental monitoring (EM), personnel monitoring (PM), and cleaning records.\u003C\u002Fp>\u003Cp>\u003Cem>Falsified Environmental Monitoring Records\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Our inspection identified critical discrepancies in your surface monitoring records. Your standard operating procedure (SOP) required post-batch surface sampling at \u003Cstrong>(b)(4)\u003C\u002Fstrong> locations. Your firm acknowledged repeatedly submitting unexposed plates to the laboratory and confirmed that you did not perform the actual sampling. In other instances, only partial sampling was performed.\u003C\u002Fp>\u003Cp>Similarly, personnel monitoring samples were not collected for production and engineering personnel who worked in the aseptic processing room. Instead, unexposed plates were submitted to the laboratory and the associated records reflected that personnel sampling had been performed.\u003C\u002Fp>\u003Cp>Further, in a separate instance, active air samples for a batch were collected at incorrect locations but falsely documented as having been collected at the required locations.\u003C\u002Fp>\u003Cp>These falsification practices fundamentally undermine any confidence in your microbiology data. Notably, you lacked reliable data indicating that environmental control existed in your aseptic processing operations and to support release of batches to the U.S. market. During this period, you reported 0 colony-forming unit findings across all EM and PM sampling with the exception of a single deviation following a water leakage event. In stark contrast, following discussion of deficiencies with firm management, actual plate readings conducted during the inspection (April 10 to 14, 2026) yielded numerous EM and PM samples with microbial growth, including approximately 25 ISO 5 excursions.\u003C\u002Fp>\u003Cp>\u003Cem>Falsified Cleaning Records\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Your SOP required cleaning ISO 5 surfaces \u003Cstrong>(b)(4)\u003C\u002Fstrong> decontamination of the room. Although cleaning records documented that these activities were completed on January 23, January 30, March 10, and March 21, 2026, our inspection found no evidence that the cleaning activities were performed. Your management confirmed that the documented cleaning activities were not performed and that the records reported false information.\u003C\u002Fp>\u003Cp>The profound data integrity breaches at your firm critically undermined assurance of sterility for U.S.-distributed drug products.\u003C\u002Fp>\u003Cp>In your response, you state that you suspended drug production for the U.S. market and notified your U.S. distributor of the need to halt distribution. You acknowledge that EM, PM, and cleaning records were falsified. You note several root causes, including a lack of independent oversight by quality assurance personnel and insufficient real-time supervision of cleaning execution. You state that you suspended all personnel involved and engaged an independent third-party to assess the scope of the data integrity issues. Notably, throughout your response, you reference your historical viable EM data, citing the absence of adverse trends, as a key “quality indicator data” source to support your initial product impact assessment.\u003C\u002Fp>\u003Cp>Your response is inadequate. Falsified EM data cannot be used for trending analysis. Therefore, your initial product impact assessment is not supportable as it relies on EM data confirmed to be unreliable. Furthermore, you have not sufficiently acknowledged the potential scope of the systemic data integrity breaches, which extended well beyond procedural gaps or individual misconduct. Widespread falsification across many staff members, multiple record types, and over an extended period of time went unchecked, reflecting a systemic quality failure and demonstrating a general failure of senior managers in your company to exercise their responsibility to ensure integrity of manufacturing and laboratory records.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, supervisory oversight, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\u003C\u002Fli>\u003Cli>A comprehensive, independent assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed corrective action and preventive action (CAPA) plan that comprehensively remediates your firm’s documentation practices to ensure you retain contemporaneous, attributable, legible, complete, original, and accurate records throughout your operation.\u003C\u002Fli>\u003Cli>A comprehensive CAPA, overseen by a qualified consultant, for handling microbiological sampling media to ensure robust and reliable data. Establish a system that ensures uncompromised and uninterrupted custody, with full reconciliation of all microbiological samples including, but not limited to, the following:\u003Cbr>o Unique labeling of each sample\u003Cbr>o Signatures of all staff who handle the sample\u003Cbr>o Complete tracking of uncompromised sample integrity and custody\u003Cbr>o Date and time of each activity (e.g., sample collection, transport, delivery, incubation, removal from incubator)\u003Cbr>o Digital time-stamped photos of all plates\u003Cbr>o Laboratory tools and methods to optimize visibility and detectability of colonies on plates\u003Cbr>o Signatures of personnel performing reading of microbial counts\u003Cbr>o Provisions for verifications and routine quality assurance oversight\u003C\u002Fli>\u003Cli>An independent assessment and remediation plan for your CAPA program. Provide a report that evaluates whether the program includes effective root cause analysis, ensures CAPA effectiveness, analyzes investigations trends, improves the CAPA program whenever needed, ensures final quality unit (QU) decision authority, and is fully supported by executive management.\u003C\u002Fli>\u003Cli>An independent review of your antimicrobial effectiveness testing (AET) program, including assuring that all \u003Cstrong>(b)(4)\u003C\u002Fstrong> products are evaluated using sound AET study protocols and that each formulation is suitable throughout its use period.\u003C\u002Fli>\u003Cli>A comprehensive assessment and CAPA, overseen by a qualified consultant, for your cleaning and disinfection program. Establish a system that ensures robust cleaning and disinfection and full verification and reconciliation of all related activities, including, but not limited to, provisions for meaningful independent verifications of cleaning and disinfection execution (using appropriate methods at required locations and frequencies) and effective routine quality assurance oversight.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes. Your firm also failed to use equipment in the manufacture, processing, packing, or holding of drug products that is of appropriate design, adequate size, and suitably located to facilitate operations for its intended use and for its cleaning and maintenance (21 CFR 211.113(b) and 21 CFR 211.63).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm failed to adequately design, control, and supervise your aseptic processing line.\u003C\u002Fp>\u003Cp>\u003Cem>Poor Aseptic Practices and Cleanroom Behavior\u003C\u002Fem>\u003C\u002Fp>\u003Cp>We observed numerous poor aseptic practices across multiple batches, operators, and dates during the manufacture of U.S.-marketed ophthalmic drug products including, but not limited to, the following:\u003C\u002Fp>\u003Cul>\u003Cli>A gowned operator stood inside the ISO 5 area near the \u003Cstrong>(b)(4)\u003C\u002Fstrong>, picking up exposed open sterile bottles with \u003Cstrong>(b)(4)\u003C\u002Fstrong> and reintroducing them into the bottle supply rather than rejecting them.\u003C\u002Fli>\u003Cli>Operators repeatedly used \u003Cstrong>(b)(4)\u003C\u002Fstrong> directly above and in contact with open bottles and critical surfaces during undocumented interventions without rejecting the exposed containers.\u003C\u002Fli>\u003Cli>Operators removed partially used open sterile \u003Cstrong>(b)(4)\u003C\u002Fstrong> packaging component bags from the ISO 5 area following batch manufacture, stored in the ISO 7 area for up to \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and reintroduced to future batches without following appropriate practices to ensure the contents remained sterile.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>These interventions were not documented in the batch record. Many interventions occurred in the \u003Cstrong>(b)(4)\u003C\u002Fstrong> area where equipment, including the \u003Cstrong>(b)(4)\u003C\u002Fstrong> and conveyer, directly contacted sterile open bottles. Despite the frequency of \u003Cstrong>(b)(4)\u003C\u002Fstrong> interventions in this area, you only performed infrequent decontamination (e.g., \u003Cstrong>(b)(4)\u003C\u002Fstrong>) of the sterile \u003Cstrong>(b)(4)\u003C\u002Fstrong> area of the aseptic processing line.\u003C\u002Fp>\u003Cp>In addition, we observed multiple deficiencies in aseptic processing operator gowning.\u003C\u002Fp>\u003Cp>These and other inspectional findings indicated a lack of adequate supervisory oversight of your aseptic processing operations.\u003C\u002Fp>\u003Cp>\u003Cem>Inadequate Equipment Design\u003C\u002Fem>\u003C\u002Fp>\u003Cp>We also noted equipment design deficiencies and a lack of unidirectional airflow. For example, the position of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> obstructed unidirectional airflow to the sterile \u003Cstrong>(b)(4)\u003C\u002Fstrong> in the \u003Cstrong>(b)(4)\u003C\u002Fstrong>, leading to inadequate ISO 5 protection of sterile \u003Cstrong>(b)(4)\u003C\u002Fstrong> packaging components.\u003C\u002Fp>\u003Cp>Your aseptic manufacturing processes should be designed, and operations executed, to prevent contamination hazards to your sterile product. Flaws in the design of cleanrooms and aseptic processing lines, or improper execution of aseptic operations, can promote influx of contamination into the critical processing area.\u003C\u002Fp>\u003Cp>These significant deviations in aseptic processes and disinfection are a further indication of insufficient control of aseptic processing operations to assure drug product sterility.\u003C\u002Fp>\u003Cp>In your response, you state that operator practices did not consistently align with your procedures, and that you will be remediating your qualification program for both operators and direct supervisors. You also acknowledge deficiencies in your smoke studies. To help address these deficiencies, you commit to engaging independent third-party experts to assess your operation, including aseptic practices. You also commit to conducting all future smoke studies using a qualified, neutrally buoyant smoke agent and to implementing corrective actions, including potential design modifications, based on the outcome of airflow evaluation. Your response also commits to working with the vendor to ensure the entire ISO 5 (grade A) zone for the sterile product can be decontaminated \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>Your response is inadequate because it does not adequately address the scope and root cause of the poor aseptic practices observed.\u003C\u002Fp>\u003Cp>See FDA’s guidance document \u003Cem>Sterile Drug Products Produced by Aseptic Processing—Current Good Manufacturing Practice\u003C\u002Fem> to help you meet the CGMP requirements when manufacturing sterile drugs using aseptic processing at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71026\u002Fdownload.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive, independent risk assessment of all contamination hazards with respect to your aseptic processes, equipment, and facilities, including but not limited to, the following:\u003Cbr>o All human interactions within the ISO 5 area (e.g., risk reduction or elimination of \u003Cstrong>(b)(4)\u003C\u002Fstrong> interventions wherever possible)\u003Cbr>o Equipment suitability (e.g., reliability, capability, ergonomics, placement) and sufficient cleanroom space\u003Cbr>o Air quality in the ISO 5 area and surrounding room including, but not limited to, air volume and flow\u003Cbr>o Facility layout\u003Cbr>o Personnel flow and material flow (movement throughout all rooms used to conduct and support sterile operations, and all material transfers)\u003Cbr>o Disinfection practices and procedures\u003Cbr>o Specific CAPA recommendations that will comprehensively address the design and control hazards identified in the risk assessment\u003C\u002Fli>\u003Cli>A detailed remediation plan with timelines to address the findings of the contamination hazards risk assessment. Describe specific tangible improvements to be made to aseptic processing operation design and control at your facility and explain how CAPA plan will robustly remediate your deficient sterile manufacturing operations. Include comprehensive changes to the design of both your aseptic processing lines and cleanrooms. Also, describe your plans for qualification and validation of your extensively remediated operations.\u003C\u002Fli>\u003Cli>Your systematic plan to assure adherence to appropriate aseptic practices, cleanroom behavior, and written procedures, including but not limited to an independent assessment of the following with accompanying CAPA:\u003Cbr>o Suitability of actual practices based on extensive retrospective review and prospective observation of aseptic processing operations\u003Cbr>o Deficiencies in production management oversight and identification of specific improvements to ensure effective and routine supervisory oversight for all batches\u003Cbr>o Frequency and depth of QU oversight (e.g., audit, ad hoc, daily interactions) of aseptic processing and its support operations\u003Cbr>o Adequacy of written procedures and operational ergonomics\u003Cbr>o The assessment should also evaluate how poor aseptic technique and cleanroom behavior may have affected the quality and sterility of your drugs.\u003C\u002Fli>\u003Cli>Perform a critical evaluation of airflow unidirectionality in your aseptic process with the assistance of a qualified consultant. Ensure smoke studies are conducted under dynamic conditions with thorough and complete evaluations of aseptic processing line airflow unidirectionality, including the impact of dynamic interactions and aseptic interventions. These thorough smoke studies should be performed after you remediate your aseptic operation and conducted using proper practices, including neutrally buoyant media, to appropriately visualize airflow.\u003C\u002Fli>\u003Cli>Your CAPA plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, enhanced production floor supervision, and improved systems for ongoing management review.\u003C\u002Fli>\u003Cli>A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function, that includes, but is not limited to, the following:\u003Cbr>o A determination of whether procedures used by your firm are robust and appropriate\u003Cbr>o Provisions for QU oversight throughout your operations to ensure satisfactory procedures and adherence to appropriate practices\u003Cbr>o A complete and final review of each batch and its related information before the QU disposition decision\u003Cbr>o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\u003Cbr>o Also, describe how executive management will support robust quality assurance at your firm, including but not limited to timely provision of resources that enable proactive detection and resolution of emerging manufacturing\u002Fquality issues to assure a continuing state of control.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>3. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm failed to adequately investigate out-of-limit 100% visual inspection findings for two batches of sterile ophthalmic drug products that exceeded the \u003Cstrong>(b)(4)\u003C\u002Fstrong>% total reject limit. Rather than conducting a full 100% re-inspection, only \u003Cstrong>(b)(4)\u003C\u002Fstrong> units per batch were re-inspected, and the investigations did not characterize the nature, composition, or source of the particles. Both batches were released and shipped to the U.S. market without determining whether the particles were intrinsic, extrinsic, or inherent.\u003C\u002Fp>\u003Cp>Ophthalmic products operations should be designed to prevent particle contamination and to protect consumers from the risk of instilling potentially harmful particles into the eye. In addition, when categorizing any visible particles, extrinsic or foreign matter should receive special attention, as it may indicate possible microbial contamination. Microbes introduced directly into the eye can pose a serious risk to consumers. Irreversible damage, including partial vision loss or blindness, can occur and, in some cases, may progress to life-threatening systemic infection.\u003C\u002Fp>\u003Cp>In your response, you acknowledge that your investigations were inadequate and that samples sent to an external laboratory for Fourier-Transform Infrared spectroscopic analysis could not conclusively determine the composition or source of the particles. While you identified a statistical correlation between high reject rates lots and a specific \u003Cstrong>(b)(4)\u003C\u002Fstrong> container supplier, the particle source(s) was not confirmed through analytical testing.\u003C\u002Fp>\u003Cp>Your response is inadequate. The identification of particles and their sources remained inconclusive and incomplete at the time of your initial response. Your response also did not address your decision to release batches despite your significant adverse quality defect trends.\u003C\u002Fp>\u003Cp>A substantial number of consumer complaints have been received since 2019, including reports of leakage, burning and stinging sensation, worsening eye redness, blurry vision, and reports of foreign matter or “floating matter.” Your firm recorded \"no need\" or “NA” for corrective action for those customer complaints.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, out-of-specification results, out-of-limit results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, QU oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\u003C\u002Fli>\u003Cli>A comprehensive, independent assessment and remediation plan for your visual inspection program to ensure compliance with CGMP. The assessment and remediation should include, but not be limited to, the following:\u003Cbr>o Implementing enhancements to your 100% visible inspection program, including defining critical, major, and minor defects and the individual defect limits for drug products.\u003Cbr>o Ensuring adequate methods, equipment, and personnel qualifications to reproducibly detect visible particulates, including particulates historically found in your operation.\u003Cbr>o Conducting rigorous qualification studies to ensure your \u003Cstrong>(b)(4)\u003C\u002Fstrong> visible particulate inspection systems consistently and reproducibly detect the variety of visible particulates encountered in your drug products.\u003Cbr>o Implementing destructive testing and other advanced technologies (e.g., \u003Cstrong>(b)(4)\u003C\u002Fstrong>) as appropriate, with statistically significant sample sizes, for drug products that are difficult to inspect (e.g., \u003Cstrong>(b)(4)\u003C\u002Fstrong> containers).\u003Cbr>o Incorporating product-specific knowledge, process experience, deviation investigation analysis, recall\u002Fcomplaint data, and quality risk management to improve the visual inspection program.\u003Cbr>o Remediating your visual inspection program, including establishing new written procedures, equipment, and methods. Include a summary of the review and recommendations made by your independent consultant.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>The following are violations identified during our review. As a reminder, this is not an all-inclusive list of violations that may exist in connection with your products or operations.\u003C\u002Fp>\u003Cp>\u003Cstrong>Unapproved New Drug Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based on a review of the product labeling, “ROHTO® Cooling Eye Drops COOL RELIEF,” “ROHTO® Cooling Eye Drops ALL-IN-ONE,” “ROHTO® Cooling Eye Drops MAX STRENGTH,” “ROHTO® Cooling Eye Drops DIGI EYE,” “ROHTO® Cooling Eye Drops OPTIC GLOW,” “ROHTO® Cooling Eye Drops DRY AID,” and “ROHTO® Cooling Eye Drops DUAL LIGHT RELIEF” (collectively, “ROHTO® Cooling Eye Drops products”) are drugs under section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For intended to affect the structure or any function of the body. Examples from your product labeling, including your website and social media, that provide evidence of the intended uses (as defined in 21 CFR 201.128) of these products as drugs include, but may not be limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cu>All ROHTO® Cooling Eye Drops products\u003C\u002Fu>\u003C\u002Fp>\u003Cp>““Our cooling eye drops additionally strengthen eye’s lipid film, promoting better stability of the tear film…” [from your “About” webpage, https:\u002F\u002Frohtoeyedrops.com\u002Fpages\u002Fabout]\u003C\u002Fp>\u003Cp>\u003Cu>“ROHTO® Cooling Eye Drops COOL RELIEF”\u003C\u002Fu>\u003C\u002Fp>\u003Cp>“ROHTO® Cooling Eye Drops COOL RELIEF . . . Drug Facts . . . Purpose…Redness reliever…Lubricant . . . soothes up to 8 hrs. with CoolSense™ Technology . . . Proprietary formula cools…eyes….” [from product label]\u003C\u002Fp>\u003Cp>\u003Cu>“ROHTO® Cooling Eye Drops ALL-IN-ONE”\u003C\u002Fu>\u003C\u002Fp>\u003Cp>“ROHTO® Cooling Eye Drops ALL-IN-ONE . . . Drug Facts . . . Purpose…Lubricant…Redness Reliever…Astringent . . . soothes up to 8 hrs. with CoolSense™ Technology . . . Proprietary formula cools…eyes…” [from product label]\u003C\u002Fp>\u003Cp>\u003Cu>“ROHTO® Cooling Eye Drops MAX STRENGTH”\u003C\u002Fu>\u003C\u002Fp>\u003Cp>“ROHTO® Cooling Eye Drops MAX STRENGTH . . . Drug Facts . . . Purpose…Redness reliever…Lubricant . . . soothes up to 8 hrs. with CoolSense™ Technology . . . Proprietary formula cools…eyes…” [from product label]\u003C\u002Fp>\u003Cp>\u003Cu>“ROHTO® Cooling Eye Drops DIGI EYE”\u003C\u002Fu>\u003C\u002Fp>\u003Cp>“ROHTO® Cooling Eye Drops DIGI EYE . . . Drug Facts . . Purpose…Lubricant…Redness reliever . . . soothes up to 8 hrs. . . . Proprietary formula cools…eyes. . . . Soothes Redness and Dryness due to Digital Eye Strain…” [from product label]\u003Cbr>“…specially designed to provide eye strain relief from the symptoms of Digital Eye Strain.” [from product webpage, https:\u002F\u002Frohtoeyedrops.com\u002Fproducts\u002Frohto-digi-eye-digital-eye-strain-eye-drops]\u003C\u002Fp>\u003Cp>\u003Cu>“ROHTO® Cooling Eye Drops OPTIC GLOW”\u003C\u002Fu>\u003C\u002Fp>\u003Cp>“ROHTO® Cooling Eye Drops OPTIC GLOW . . . Drug Facts . . . Purpose…Redness reliever…Lubricant . . . Soothes up to 8 hrs. . . . Proprietary formula cools…eyes…” [from product label]\u003C\u002Fp>\u003Cp>“Helps improve the health of the corneal surface….” [from product webpage, https:\u002F\u002Frohtoeyedrops.com\u002Fproducts\u002Frohto-eye-drops-optic-glow-eye-whitening-drops]\u003C\u002Fp>\u003Cp>\u003Cu>“ROHTO® Cooling Eye Drops DRY AID”\u003C\u002Fu>\u003C\u002Fp>\u003Cp>“ROHTO® Cooling Eye Drops DRY AID . . . Drug Facts . . . Purpose…Lubricant . . . Soothes up to 12 hrs. Long-Lasting . . . Repairs Natural Tear Film . . . Proprietary formula cools…eyes. . . . Repairs All Layers Of The Tear Film…” [from product label]\u003C\u002Fp>\u003Cp>“Rohto® Dry Aid® Eye Drops For Dry Eyes with Liquid Shield™ Technology . . . repairs the natural tear film over time . . . Unlike most over-the-counter eye drops that only work on one layer of the tear film, Rohto® Dry Aid® with Liquid Shield™ Technology works in a unique way to restore moisture to the tear film by working on all layers to mimic a stable, natural tear.” [from product webpage, https:\u002F\u002Frohtoeyedrops.com\u002Fproducts\u002Frohto-dry-aid-eye-drops-for-dry-eyes]\u003C\u002Fp>\u003Cp>\u003Cu>“ROHTO® Cooling Eye Drops DUAL LIGHT RELIEF”\u003C\u002Fu>\u003C\u002Fp>\u003Cp>“ROHTO® Cooling Eye Drops DUAL LIGHT RELIEF . . . Drug Facts . . . Purpose…Lubricant . . . Our eye drops…relieve symptoms of digital eye strain . . . protect your corneal cells from UV and Blue Light damage . . . HydroCorneal™ Protection Technology” [from product webpage, https:\u002F\u002Frohtoeyedrops.com\u002Fproducts\u002Frohto-dual-light-relief-hydrating-eye-drops]\u003C\u002Fp>\u003Cp>“ROHTO® Dual Light Relief . . . It employs HydroCorneal™ protection technology to protect corneal cells from UV damage.” [from your @rohtoeyedrops Instagram post, https:\u002F\u002Fwww.instagram.com\u002Fp\u002FDQb_GmTAD7c\u002F]\u003C\u002Fp>\u003Cp>Based on the above labeling evidence, “ROHTO® Cooling Eye Drops COOL RELIEF,” “ROHTO® Cooling Eye Drops ALL-IN-ONE,” “ROHTO® Cooling Eye Drops MAX STRENGTH,” “ROHTO® Cooling Eye Drops DIGI EYE,” “ROHTO® Cooling Eye Drops OPTIC GLOW,” “ROHTO® Cooling Eye Drops DRY AID,” and “ROHTO® Cooling Eye Drops DUAL LIGHT RELIEF” are intended for use as ophthalmic drug products. As described below, these drug products are unapproved new drugs marketed in violation of sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C 355(a) and 331(d).\u003C\u002Fp>\u003Cp>A drug product is a “new drug” within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), if it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a). No FDA-approved applications pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, are in effect for these drug products identified above.\u003C\u002Fp>\u003Cp>Under section 505G of the FD&amp;C Act, certain nonprescription drugs marketed without an approved application —commonly referred to as \"OTC monograph drugs\"—may be legally marketed if they meet applicable requirements. With respect to nonprescription ophthalmic drug products, such as your ROHTO® Cooling Eye Drops products, in order to be GRASE and not new drugs the products must, among other things, conform to the conditions in the applicable OTC monograph, here Over-the-Counter (OTC) Monograph M018: Ophthalmic Drug Products for Over-the-Counter Human Use (henceforth “M018”).\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> However, your nonprescription ROHTO® Cooling Eye Drops ophthalmic drug products do not conform to the conditions specified in M018 for the reasons described below.\u003C\u002Fp>\u003Cp>Claims on the product labeling for your ROHTO® Cooling Eye Drops products include intended uses that are not permitted in M018 for ophthalmic drug products. Specifically, the names of all of your ROHTO® Cooling Eye Drops products contain the term “Cooling.” Also, the “About” webpage of your website states that your ROHTO® Cooling Eye Drops products “strengthen eye’s lipid film, promoting better stability of the tear film.” In addition, your “ROHTO® Cooling Eye Drops COOL RELIEF,” “ROHTO® Cooling Eye Drops ALL-IN-ONE,” “ROHTO® Cooling Eye Drops MAX STRENGTH,” “ROHTO® Cooling Eye Drops OPTIC GLOW,” and “ROHTO® Cooling Eye Drops DUAL LIGHT RELIEF” product labels state that the product “cools eyes” and reference, “CoolSense™ Technology.” Such claims go beyond the allowed general intended uses for OTC ophthalmic drug products and do not conform to M018.\u003C\u002Fp>\u003Cp>Furthermore, your products “ROHTO® Cooling Eye Drops DIGI EYE,” “ROHTO® Cooling Eye Drops DUAL LIGHT RELIEF,” and “ROHTO® Cooling Eye Drops OPTIC GLOW” include additional intended uses that are not permitted in M018. For example, your product label for “ROHTO® Cooling Eye Drops DIGI EYE” states, “Soothes Redness and Dryness due to Digital Eye Strain,” and your website states that this product is “designed to provide eye strain relief from the symptoms of Digital Eye Strain.” Additionally, your website states that the product “ROHTO® Cooling Eye Drops DUAL LIGHT RELIEF” is intended to “…relieve symptoms of digital eye strain,” and “protect your corneal cells from UV and Blue Light damage.” Moreover, a post on your @rohtoeyedrops Instagram page states that this product “employs HydroCorneal™ protection technology to protect corneal cells from UV damage. In addition, your website states that the product, “ROHTO® Cooling Eye Drops OPTIC GLOW” “helps improve the health of the corneal surface….” Such claims go beyond the allowed general intended uses for ophthalmic drug products and do not conform to M018.\u003C\u002Fp>\u003Cp>The product labels for “ROHTO® Cooling Eye Drops COOL RELIEF,” “ROHTO® Cooling Eye Drops ALL-IN-ONE,” “ROHTO® Cooling Eye Drops MAX STRENGTH,” “ROHTO® Cooling Eye Drops DIGI EYE,” and “ROHTO® Cooling Eye Drops OPTIC GLOW” claim that these products “soothes up to 8 hrs.” and your product label for “ROHTO® Cooling Eye Drops DRY AID” claims that it “Soothes up to 12 hrs.” Time-specific extended efficacy claims such as these do not conform to M018.\u003C\u002Fp>\u003Cp>Thus, your “ROHTO® Cooling Eye Drops COOL RELIEF,” “ROHTO® Cooling Eye Drops ALL-IN-ONE,” “ROHTO® Cooling Eye Drops MAX STRENGTH,” “ROHTO® Cooling Eye Drops DIGI EYE,” “ROHTO® Cooling Eye Drops OPTIC GLOW,” “ROHTO® Cooling Eye Drops DRY AID,” and “ROHTO® Cooling Eye Drops DUAL LIGHT RELIEF” products do not comply with the applicable conditions specified in M018 and have not otherwise been found to be GRASE.\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> Accordingly, these products are new drugs within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), and there is no basis under section 505G of the FD&amp;C Act under which these products would be legally marketed without an approved application. Because there are no applications in effect for these products, these products are unapproved new drugs.\u003C\u002Fp>\u003Cp>The introduction or delivery for introduction of these unapproved new drug products into interstate commerce violates sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C. 355(a) and 331(d).\u003C\u002Fp>\u003Cp>\u003Cstrong>Misbranded Drug Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your ROHTO® Cooling Eye Drops products are misbranded under section 502(a) of the FD&amp;C Act, 21 U.S.C. 352(a), because the product labeling include statements that misleadingly suggest that the drug products are endorsed by FDA and are cGMP compliant. Specifically, on your “About” webpage, you display the acronym “FDA,” in a form that is similar to the FDA logo. Your use of the acronym FDA in a form that is similar to the FDA logo on your website misleadingly suggests that the drug products are approved or endorsed by FDA in some way. Your ROHTO® Cooling Eye Drops products are not the subject of an FDA-approved application. Additionally, on your website you claim, “Our manufacturing practices are US FDA GMP Compliant…,” and “GMP Compliance guarantees our eye drops are 100% sterile, 100% free from contamination, and meet rigorous quality standards….” Generally, current good manufacturing practice (CGMP) compliance cannot be implied or explicitly indicated on product labeling. Based solely on a determination of CGMP compliance at one point in time it would be unreasonable to assure permanent CGMP compliance, or to guarantee that products are 100% sterile or free from contamination at any given time. Moreover, when even a single aspect of a firm’s operations deviates from CGMP during the course of manufacturing a product, regardless of the significance of the deficiency, the product is deemed adulterated under section 501(a)(2)(B) of the FD&amp;C Act. Your firm cannot reliably guarantee that a product is sterile, free from contamination, or meets rigorous quality standards when it manufactures that product under conditions that fail to meet CGMP requirements, as described above. Such representation can mislead consumers into believing the product is safe despite the existence of serious manufacturing risks. Therefore, these products are misbranded under section 502(a) of the FD&amp;C Act, 21 U.S.C. 352(a), because your labeling representation suggesting that your products are FDA-approved and CGMP compliant is false or misleading.\u003C\u002Fp>\u003Cp>Additionally, your ROHTO® Cooling Eye Drops products are misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee), because these products are nonprescription drugs subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, but do not comply with the requirements for marketing under that section and are not the subject of an application approved under section 505 of the FD&amp;C Act, 21 U.S.C. 355.\u003C\u002Fp>\u003Cp>The introduction or delivery for introduction of a misbranded drug into interstate commerce violates section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\u003Cp>\u003Cstrong>Data Integrity Remediation\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture. See FDA’s guidance document \u003Cem>Data Integrity and Compliance with Drug CGMP: Questions and Answers\u003C\u002Fem> for guidance on establishing and following CGMP compliant data integrity practices at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F119267\u002Fdownload.\u003C\u002Fp>\u003Cp>We strongly recommend that you retain an independent, qualified third-party consultant to assist in your remediation. In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive investigation into the extent of the inaccuracies and inconsistencies in data, records, and reporting. Your investigation should include:\u003Cbr>o A detailed investigation protocol and methodology; a summary of all laboratories, manufacturing operations, and systems to be covered by the assessment; and a justification for any part of your operation that you propose to exclude.\u003Cbr>o Interviews of current and former employees to identify the nature, scope, and root cause of data inaccuracies. We recommend that these interviews be conducted by a qualified third party.\u003Cbr>o An assessment of the extent of data integrity deficiencies at your facility. Identify omissions, alterations, deletions, record destruction, non-contemporaneous record completion, and other deficiencies. Describe all parts of your facility’s operations in which you discovered data integrity deficiencies.\u003Cbr>o A comprehensive retrospective evaluation of the nature of the testing\u002Fmanufacturing\u002Fother data integrity deficiencies. We recommend that a qualified third party with specific expertise in the area where potential breaches were identified should evaluate all occurrences.\u003C\u002Fli>\u003Cli>A current risk assessment of the potential effects of the observed failures on the quality of your drugs. Your assessment should include analyses of the risks to patients caused by the release of drugs affected by a data integrity event and analyses of the risks posed by ongoing operations.\u003C\u002Fli>\u003Cli>A management strategy for your firm that includes the details of your global corrective action and preventive action plan. Your strategy should include:\u003Cbr>o A detailed corrective action plan that describes how you intend to ensure the reliability and completeness of all data, including analytical data, manufacturing records, and all data submitted to FDA.\u003Cbr>o A comprehensive description of the root causes of each data integrity deviation, including evidence that the scope and depth of the current action plan is commensurate with the findings of the investigation and risk assessment. Indicate whether individuals responsible for the data integrity breaches remain able to influence CGMP-related or drug application data at your firm.\u003Cbr>o Interim measures describing the actions you have taken or will take to ensure the quality of your drugs and protect patients, such as notifying your customers, recalling product(s), conducting additional testing, adding lots to your stability programs to assure stability, drug application actions, and enhanced complaint monitoring.\u003Cbr>o Long-term measures describing any remediation efforts and enhancements to procedures, processes, methods, controls, systems, management oversight, and human resources (e.g., training, staffing improvements) designed to ensure the integrity of your company’s data.\u003Cbr>o A commitment to have a qualified consultant conduct extensive annual audits, for at least two years, to assist in evaluating CAPA effectiveness after you have executed your data integrity remediation protocol.\u003Cbr>o Inform FDA if you will be hiring a chief integrity officer who is fully empowered to receive anonymous complaints from employees reporting data integrity concerns and with the authority to ensure any potential breach is promptly investigated (by an independent quality assurance function, along with expertise from outside entities whenever needed).\u003Cbr>o A status report for any of the above activities already underway or completed.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Drug Recall\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>On July 7, 2026, FDA held a teleconference with you recommending you recall all drug batches from the U.S. market. On July 8, 2026, you agreed to voluntary recall all drugs in current distribution in the United States.\u003C\u002Fp>\u003Cp>On July 14, 2026, you initiated a voluntary recall of all lots of Rohto Cool Relief, Rohto All-In-One, Rohto Max Strength, Rohto Digi-Eye, Rohto Optic Glow, and Rohto Dry Aid, due to lack of sterility assurance. The recalls were posted to the FDA’s Enforcement Report website at:\u003C\u002Fp>\u003Cp>https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fires\u002Findex.cfm?Product=221557\u003Cbr>https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fires\u002Findex.cfm?Product=221558\u003Cbr>https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fires\u002Findex.cfm?Product=221559\u003Cbr>https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fires\u002Findex.cfm?Product=221560\u003Cbr>https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fires\u002Findex.cfm?Product=221561\u003Cbr>https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fires\u002Findex.cfm?Product=221562\u003Cbr>https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fires\u002Findex.cfm?Product=221563\u003Cbr>https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fires\u002Findex.cfm?Product=221564\u003C\u002Fp>\u003Cp>\u003Cstrong>Drug Production Suspended\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>We acknowledge your commitment to suspend production of all drugs at this facility for the U.S. market. In response to this letter, clarify whether you intend to resume manufacturing drugs for the U.S. market at this facility in the future.\u003C\u002Fp>\u003Cp>If you plan to resume any manufacturing operations regulated under the FD&amp;C Act, notify this office before resuming your drug manufacturing operations. If you resume CGMP activities, you are responsible for resolving all deficiencies and systemic\u003Cbr>flaws to ensure your firm is capable of ongoing CGMP compliance. In your notification to the Agency, provide a summary of your remediations to demonstrate that you have appropriately completed all corrective action and preventive action (CAPA).\u003C\u002Fp>\u003Cp>\u003Cstrong>CGMP Consultant\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements if your firm intends to resume manufacturing drugs for the U.S. market. The qualified consultant should also perform a comprehensive six-system audit\u003Cem>\u003Cstrong>\u003Csup>3\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\u003C\u002Fp>\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur.\u003C\u002Fp>\u003Cp>FDA placed all drugs and drug products offered for import into the United States from your firm on Import Alert 66-40 on August 13, 2026.\u003C\u002Fp>\u003Cp>FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\u003C\u002Fp>\u003Cp>Failure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at Rohto-Mentholatum (Vietnam) Co., Ltd., FEI 3008808745, at No. 16 VSIP Street No. 5, Vietnam - Singapore Industrial Park, Thuan Giao Ward, Ho Chi Minh, Vietnam into the United States under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>Send your written response to CDER-OC-OMQ-Communications@fda.hhs.gov within fifteen (15) business days of receipt of this letter. Identify your written response with FEI 3008808745 and ATTN: Compliance officer Emily Wu in the subject line of the email.\u003C\u002Fp>\u003Cp>If you have information that you believe demonstrates that your products are not in violation of the FD&amp;C Act and FDA regulations, include that information for our consideration.\u003C\u002Fp>\u003Cp>FDA posts warning letters to www.FDA.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003C\u002Fp>\u003Cp>\u002FS\u002F\u003C\u002Fp>\u003Cp>Tina Smith\u003Cbr>Captain, U.S. Public Health Service\u003Cbr>Director\u003Cbr>Office of Unapproved Drugs &amp; Labeling Compliance\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003C\u002Fp>\u003Cp>cc:\u003Cbr>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Mr. Shiramatsu Hirofumi\u003Cbr>General Director\u003Cbr>Rohto-Mentholatum (Vietnam) Co., Ltd.,\u003Cbr>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Ms. Meryl Reis\u003Cbr>VP of US R&amp;D, Regulatory Affairs, QA\u002FQC\u003Cbr>The Mentholatum Company\u003Cbr>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>__________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> M018 reflects the conditions set forth in the relevant final order established and in effect under section 505G; see Order ID OTC000023, available at FDA’s website OTC Monographs@FDA, https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fomuf\u002F.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> FDA is not aware of any adequate and well-controlled clinical trials in the published literature that support a determination that your ROHTO® Cooling Eye Drops products are GRASE for use under the conditions prescribed, recommended, or suggested in their labeling, nor has FDA determined these drug products to be GRASE pursuant to an order issued under section 505G(b).\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> i.e. Quality System, Facilities &amp; Equipment System, Materials System, Production System, Packaging &amp; Labeling System, and Laboratory Control System per FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n\nReference #:\n\n320-27-06\n\nProduct:\n\nDrugs\n\nOver-the-Counter Drugs\n\nRecipient:\n\nRecipient Name\n\nMr. Kunio Yamada\n\nRecipient Title\n\nChairman and Representative Director\n\nRohto Pharmaceutical Co., Ltd.\n\n1-8-1 Tatsuminishi\n\nIkuno-Ku, Osaka\n\n544-8666\n\nJapan\n\n(b)(4)\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nOctober 14, 2026\nWARNING LETTER\nReference number: 320-27-06\nTo Mr. Kunio Yamada:\nThis warning letter advises you of significant violations observed during a U.S. Food and Drug Administration (FDA) inspection of your facility. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that exist at your facility. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address violations may result in regulatory action without further notice.\nFDA Inspection\nViolations were observed and documented during an inspection of your drug manufacturing facility, Rohto-Mentholatum (Vietnam) Co., Ltd., FDA Establishment Identifier (FEI) 3008808745, at No. 16 VSIP Street No. 5, Vietnam - Singapore Industrial Park, Thuan Giao Ward, Ho Chi Minh, Vietnam, from April 6 to 14, 2026. This inspection was conducted under FDA’s statutory authority and public health responsibilities to protect the public from unsafe, ineffective, and poor quality drugs.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nIn addition, violations were identified and documented during a review of your product labeling and website at the internet address https:\u002F\u002Frohtoeyedrops.com\u002F and your Instagram account at https:\u002F\u002Fwww.instagram.com\u002Frohtoeyedrops\u002F in August 2026. Based on our review, your “ROHTO® Cooling Eye Drops COOL RELIEF,” “ROHTO® Cooling Eye Drops ALL-IN-ONE,” “ROHTO® Cooling Eye Drops MAX STRENGTH,” “ROHTO® Cooling Eye Drops DIGI EYE,” “ROHTO® Cooling Eye Drops OPTIC GLOW,” “ROHTO® Cooling Eye Drops DRY AID,” and “ROHTO® Cooling Eye Drops DUAL LIGHT RELIEF” are unapproved new drugs under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a). In addition, these products are misbranded under sections 502(a) and 502(ee) of the FD&C Act, 21 U.S.C. 352(a) and 352(ee). As explained further below, introducing or delivering these products for introduction into interstate commerce is prohibited under sections 301(d) and (a) of the FD&C Act, 21 U.S.C. 331(d) and (a).\nWe reviewed your May 1, 2026, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\nViolations of the Federal Food, Drug, and Cosmetic Act\nCGMP Violations\nThe following are violations identified during our inspection and review. As a reminder, this is not an all-inclusive list of violations at your facility.\n1. Your firm failed to ensure that laboratory records included complete data derived from all tests necessary to ensure compliance with established specifications and standards. Your firm also failed to clean, maintain, and, as appropriate for the nature of the drug, sanitize and\u002For sterilize equipment and utensils at appropriate intervals to prevent malfunctions or contamination that would alter the safety, identity, strength, quality, or purity of the drug product beyond the official or other established requirements (21 CFR 211.194(a) and 21 CFR 211.67(a)).\nYour firm manufactures over-the-counter (OTC) topical ophthalmic drug products using aseptic processing.\nOur inspection revealed systemic data falsification. Notably, we observed critical data integrity breaches in your environmental monitoring (EM), personnel monitoring (PM), and cleaning records.\nFalsified Environmental Monitoring Records\nOur inspection identified critical discrepancies in your surface monitoring records. Your standard operating procedure (SOP) required post-batch surface sampling at (b)(4) locations. Your firm acknowledged repeatedly submitting unexposed plates to the laboratory and confirmed that you did not perform the actual sampling. In other instances, only partial sampling was performed.\nSimilarly, personnel monitoring samples were not collected for production and engineering personnel who worked in the aseptic processing room. Instead, unexposed plates were submitted to the laboratory and the associated records reflected that personnel sampling had been performed.\nFurther, in a separate instance, active air samples for a batch were collected at incorrect locations but falsely documented as having been collected at the required locations.\nThese falsification practices fundamentally undermine any confidence in your microbiology data. Notably, you lacked reliable data indicating that environmental control existed in your aseptic processing operations and to support release of batches to the U.S. market. During this period, you reported 0 colony-forming unit findings across all EM and PM sampling with the exception of a single deviation following a water leakage event. In stark contrast, following discussion of deficiencies with firm management, actual plate readings conducted during the inspection (April 10 to 14, 2026) yielded numerous EM and PM samples with microbial growth, including approximately 25 ISO 5 excursions.\nFalsified Cleaning Records\nYour SOP required cleaning ISO 5 surfaces (b)(4) decontamination of the room. Although cleaning records documented that these activities were completed on January 23, January 30, March 10, and March 21, 2026, our inspection found no evidence that the cleaning activities were performed. Your management confirmed that the documented cleaning activities were not performed and that the records reported false information.\nThe profound data integrity breaches at your firm critically undermined assurance of sterility for U.S.-distributed drug products.\nIn your response, you state that you suspended drug production for the U.S. market and notified your U.S. distributor of the need to halt distribution. You acknowledge that EM, PM, and cleaning records were falsified. You note several root causes, including a lack of independent oversight by quality assurance personnel and insufficient real-time supervision of cleaning execution. You state that you suspended all personnel involved and engaged an independent third-party to assess the scope of the data integrity issues. Notably, throughout your response, you reference your historical viable EM data, citing the absence of adverse trends, as a key “quality indicator data” source to support your initial product impact assessment.\nYour response is inadequate. Falsified EM data cannot be used for trending analysis. Therefore, your initial product impact assessment is not supportable as it relies on EM data confirmed to be unreliable. Furthermore, you have not sufficiently acknowledged the potential scope of the systemic data integrity breaches, which extended well beyond procedural gaps or individual misconduct. Widespread falsification across many staff members, multiple record types, and over an extended period of time went unchecked, reflecting a systemic quality failure and demonstrating a general failure of senior managers in your company to exercise their responsibility to ensure integrity of manufacturing and laboratory records.\nIn response to this letter, provide:\nA comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, supervisory oversight, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\nA comprehensive, independent assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed corrective action and preventive action (CAPA) plan that comprehensively remediates your firm’s documentation practices to ensure you retain contemporaneous, attributable, legible, complete, original, and accurate records throughout your operation.\nA comprehensive CAPA, overseen by a qualified consultant, for handling microbiological sampling media to ensure robust and reliable data. Establish a system that ensures uncompromised and uninterrupted custody, with full reconciliation of all microbiological samples including, but not limited to, the following:\no Unique labeling of each sample\no Signatures of all staff who handle the sample\no Complete tracking of uncompromised sample integrity and custody\no Date and time of each activity (e.g., sample collection, transport, delivery, incubation, removal from incubator)\no Digital time-stamped photos of all plates\no Laboratory tools and methods to optimize visibility and detectability of colonies on plates\no Signatures of personnel performing reading of microbial counts\no Provisions for verifications and routine quality assurance oversight\nAn independent assessment and remediation plan for your CAPA program. Provide a report that evaluates whether the program includes effective root cause analysis, ensures CAPA effectiveness, analyzes investigations trends, improves the CAPA program whenever needed, ensures final quality unit (QU) decision authority, and is fully supported by executive management.\nAn independent review of your antimicrobial effectiveness testing (AET) program, including assuring that all (b)(4) products are evaluated using sound AET study protocols and that each formulation is suitable throughout its use period.\nA comprehensive assessment and CAPA, overseen by a qualified consultant, for your cleaning and disinfection program. Establish a system that ensures robust cleaning and disinfection and full verification and reconciliation of all related activities, including, but not limited to, provisions for meaningful independent verifications of cleaning and disinfection execution (using appropriate methods at required locations and frequencies) and effective routine quality assurance oversight.\n2. Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes. Your firm also failed to use equipment in the manufacture, processing, packing, or holding of drug products that is of appropriate design, adequate size, and suitably located to facilitate operations for its intended use and for its cleaning and maintenance (21 CFR 211.113(b) and 21 CFR 211.63).\nYour firm failed to adequately design, control, and supervise your aseptic processing line.\nPoor Aseptic Practices and Cleanroom Behavior\nWe observed numerous poor aseptic practices across multiple batches, operators, and dates during the manufacture of U.S.-marketed ophthalmic drug products including, but not limited to, the following:\nA gowned operator stood inside the ISO 5 area near the (b)(4), picking up exposed open sterile bottles with (b)(4) and reintroducing them into the bottle supply rather than rejecting them.\nOperators repeatedly used (b)(4) directly above and in contact with open bottles and critical surfaces during undocumented interventions without rejecting the exposed containers.\nOperators removed partially used open sterile (b)(4) packaging component bags from the ISO 5 area following batch manufacture, stored in the ISO 7 area for up to (b)(4), and reintroduced to future batches without following appropriate practices to ensure the contents remained sterile.\nThese interventions were not documented in the batch record. Many interventions occurred in the (b)(4) area where equipment, including the (b)(4) and conveyer, directly contacted sterile open bottles. Despite the frequency of (b)(4) interventions in this area, you only performed infrequent decontamination (e.g., (b)(4)) of the sterile (b)(4) area of the aseptic processing line.\nIn addition, we observed multiple deficiencies in aseptic processing operator gowning.\nThese and other inspectional findings indicated a lack of adequate supervisory oversight of your aseptic processing operations.\nInadequate Equipment Design\nWe also noted equipment design deficiencies and a lack of unidirectional airflow. For example, the position of the (b)(4) obstructed unidirectional airflow to the sterile (b)(4) in the (b)(4), leading to inadequate ISO 5 protection of sterile (b)(4) packaging components.\nYour aseptic manufacturing processes should be designed, and operations executed, to prevent contamination hazards to your sterile product. Flaws in the design of cleanrooms and aseptic processing lines, or improper execution of aseptic operations, can promote influx of contamination into the critical processing area.\nThese significant deviations in aseptic processes and disinfection are a further indication of insufficient control of aseptic processing operations to assure drug product sterility.\nIn your response, you state that operator practices did not consistently align with your procedures, and that you will be remediating your qualification program for both operators and direct supervisors. You also acknowledge deficiencies in your smoke studies. To help address these deficiencies, you commit to engaging independent third-party experts to assess your operation, including aseptic practices. You also commit to conducting all future smoke studies using a qualified, neutrally buoyant smoke agent and to implementing corrective actions, including potential design modifications, based on the outcome of airflow evaluation. Your response also commits to working with the vendor to ensure the entire ISO 5 (grade A) zone for the sterile product can be decontaminated (b)(4).\nYour response is inadequate because it does not adequately address the scope and root cause of the poor aseptic practices observed.\nSee FDA’s guidance document Sterile Drug Products Produced by Aseptic Processing—Current Good Manufacturing Practice to help you meet the CGMP requirements when manufacturing sterile drugs using aseptic processing at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71026\u002Fdownload.\nIn response to this letter, provide:\nA comprehensive, independent risk assessment of all contamination hazards with respect to your aseptic processes, equipment, and facilities, including but not limited to, the following:\no All human interactions within the ISO 5 area (e.g., risk reduction or elimination of (b)(4) interventions wherever possible)\no Equipment suitability (e.g., reliability, capability, ergonomics, placement) and sufficient cleanroom space\no Air quality in the ISO 5 area and surrounding room including, but not limited to, air volume and flow\no Facility layout\no Personnel flow and material flow (movement throughout all rooms used to conduct and support sterile operations, and all material transfers)\no Disinfection practices and procedures\no Specific CAPA recommendations that will comprehensively address the design and control hazards identified in the risk assessment\nA detailed remediation plan with timelines to address the findings of the contamination hazards risk assessment. Describe specific tangible improvements to be made to aseptic processing operation design and control at your facility and explain how CAPA plan will robustly remediate your deficient sterile manufacturing operations. Include comprehensive changes to the design of both your aseptic processing lines and cleanrooms. Also, describe your plans for qualification and validation of your extensively remediated operations.\nYour systematic plan to assure adherence to appropriate aseptic practices, cleanroom behavior, and written procedures, including but not limited to an independent assessment of the following with accompanying CAPA:\no Suitability of actual practices based on extensive retrospective review and prospective observation of aseptic processing operations\no Deficiencies in production management oversight and identification of specific improvements to ensure effective and routine supervisory oversight for all batches\no Frequency and depth of QU oversight (e.g., audit, ad hoc, daily interactions) of aseptic processing and its support operations\no Adequacy of written procedures and operational ergonomics\no The assessment should also evaluate how poor aseptic technique and cleanroom behavior may have affected the quality and sterility of your drugs.\nPerform a critical evaluation of airflow unidirectionality in your aseptic process with the assistance of a qualified consultant. Ensure smoke studies are conducted under dynamic conditions with thorough and complete evaluations of aseptic processing line airflow unidirectionality, including the impact of dynamic interactions and aseptic interventions. These thorough smoke studies should be performed after you remediate your aseptic operation and conducted using proper practices, including neutrally buoyant media, to appropriately visualize airflow.\nYour CAPA plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, enhanced production floor supervision, and improved systems for ongoing management review.\nA comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function, that includes, but is not limited to, the following:\no A determination of whether procedures used by your firm are robust and appropriate\no Provisions for QU oversight throughout your operations to ensure satisfactory procedures and adherence to appropriate practices\no A complete and final review of each batch and its related information before the QU disposition decision\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\no Also, describe how executive management will support robust quality assurance at your firm, including but not limited to timely provision of resources that enable proactive detection and resolution of emerging manufacturing\u002Fquality issues to assure a continuing state of control.\n3. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\nYour firm failed to adequately investigate out-of-limit 100% visual inspection findings for two batches of sterile ophthalmic drug products that exceeded the (b)(4)% total reject limit. Rather than conducting a full 100% re-inspection, only (b)(4) units per batch were re-inspected, and the investigations did not characterize the nature, composition, or source of the particles. Both batches were released and shipped to the U.S. market without determining whether the particles were intrinsic, extrinsic, or inherent.\nOphthalmic products operations should be designed to prevent particle contamination and to protect consumers from the risk of instilling potentially harmful particles into the eye. In addition, when categorizing any visible particles, extrinsic or foreign matter should receive special attention, as it may indicate possible microbial contamination. Microbes introduced directly into the eye can pose a serious risk to consumers. Irreversible damage, including partial vision loss or blindness, can occur and, in some cases, may progress to life-threatening systemic infection.\nIn your response, you acknowledge that your investigations were inadequate and that samples sent to an external laboratory for Fourier-Transform Infrared spectroscopic analysis could not conclusively determine the composition or source of the particles. While you identified a statistical correlation between high reject rates lots and a specific (b)(4) container supplier, the particle source(s) was not confirmed through analytical testing.\nYour response is inadequate. The identification of particles and their sources remained inconclusive and incomplete at the time of your initial response. Your response also did not address your decision to release batches despite your significant adverse quality defect trends.\nA substantial number of consumer complaints have been received since 2019, including reports of leakage, burning and stinging sensation, worsening eye redness, blurry vision, and reports of foreign matter or “floating matter.” Your firm recorded \"no need\" or “NA” for corrective action for those customer complaints.\nIn response to this letter, provide:\nA comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, out-of-specification results, out-of-limit results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, QU oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\nA comprehensive, independent assessment and remediation plan for your visual inspection program to ensure compliance with CGMP. The assessment and remediation should include, but not be limited to, the following:\no Implementing enhancements to your 100% visible inspection program, including defining critical, major, and minor defects and the individual defect limits for drug products.\no Ensuring adequate methods, equipment, and personnel qualifications to reproducibly detect visible particulates, including particulates historically found in your operation.\no Conducting rigorous qualification studies to ensure your (b)(4) visible particulate inspection systems consistently and reproducibly detect the variety of visible particulates encountered in your drug products.\no Implementing destructive testing and other advanced technologies (e.g., (b)(4)) as appropriate, with statistically significant sample sizes, for drug products that are difficult to inspect (e.g., (b)(4) containers).\no Incorporating product-specific knowledge, process experience, deviation investigation analysis, recall\u002Fcomplaint data, and quality risk management to improve the visual inspection program.\no Remediating your visual inspection program, including establishing new written procedures, equipment, and methods. Include a summary of the review and recommendations made by your independent consultant.\nThe following are violations identified during our review. As a reminder, this is not an all-inclusive list of violations that may exist in connection with your products or operations.\nUnapproved New Drug Violations\nBased on a review of the product labeling, “ROHTO® Cooling Eye Drops COOL RELIEF,” “ROHTO® Cooling Eye Drops ALL-IN-ONE,” “ROHTO® Cooling Eye Drops MAX STRENGTH,” “ROHTO® Cooling Eye Drops DIGI EYE,” “ROHTO® Cooling Eye Drops OPTIC GLOW,” “ROHTO® Cooling Eye Drops DRY AID,” and “ROHTO® Cooling Eye Drops DUAL LIGHT RELIEF” (collectively, “ROHTO® Cooling Eye Drops products”) are drugs under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For intended to affect the structure or any function of the body. Examples from your product labeling, including your website and social media, that provide evidence of the intended uses (as defined in 21 CFR 201.128) of these products as drugs include, but may not be limited to, the following:\nAll ROHTO® Cooling Eye Drops products\n““Our cooling eye drops additionally strengthen eye’s lipid film, promoting better stability of the tear film…” [from your “About” webpage, https:\u002F\u002Frohtoeyedrops.com\u002Fpages\u002Fabout]\n“ROHTO® Cooling Eye Drops COOL RELIEF”\n“ROHTO® Cooling Eye Drops COOL RELIEF . . . Drug Facts . . . Purpose…Redness reliever…Lubricant . . . soothes up to 8 hrs. with CoolSense™ Technology . . . Proprietary formula cools…eyes….” [from product label]\n“ROHTO® Cooling Eye Drops ALL-IN-ONE”\n“ROHTO® Cooling Eye Drops ALL-IN-ONE . . . Drug Facts . . . Purpose…Lubricant…Redness Reliever…Astringent . . . soothes up to 8 hrs. with CoolSense™ Technology . . . Proprietary formula cools…eyes…” [from product label]\n“ROHTO® Cooling Eye Drops MAX STRENGTH”\n“ROHTO® Cooling Eye Drops MAX STRENGTH . . . Drug Facts . . . Purpose…Redness reliever…Lubricant . . . soothes up to 8 hrs. with CoolSense™ Technology . . . Proprietary formula cools…eyes…” [from product label]\n“ROHTO® Cooling Eye Drops DIGI EYE”\n“ROHTO® Cooling Eye Drops DIGI EYE . . . Drug Facts . . Purpose…Lubricant…Redness reliever . . . soothes up to 8 hrs. . . . Proprietary formula cools…eyes. . . . Soothes Redness and Dryness due to Digital Eye Strain…” [from product label]\n“…specially designed to provide eye strain relief from the symptoms of Digital Eye Strain.” [from product webpage, https:\u002F\u002Frohtoeyedrops.com\u002Fproducts\u002Frohto-digi-eye-digital-eye-strain-eye-drops]\n“ROHTO® Cooling Eye Drops OPTIC GLOW”\n“ROHTO® Cooling Eye Drops OPTIC GLOW . . . Drug Facts . . . Purpose…Redness reliever…Lubricant . . . Soothes up to 8 hrs. . . . Proprietary formula cools…eyes…” [from product label]\n“Helps improve the health of the corneal surface….” [from product webpage, https:\u002F\u002Frohtoeyedrops.com\u002Fproducts\u002Frohto-eye-drops-optic-glow-eye-whitening-drops]\n“ROHTO® Cooling Eye Drops DRY AID”\n“ROHTO® Cooling Eye Drops DRY AID . . . Drug Facts . . . Purpose…Lubricant . . . Soothes up to 12 hrs. Long-Lasting . . . Repairs Natural Tear Film . . . Proprietary formula cools…eyes. . . . Repairs All Layers Of The Tear Film…” [from product label]\n“Rohto® Dry Aid® Eye Drops For Dry Eyes with Liquid Shield™ Technology . . . repairs the natural tear film over time . . . Unlike most over-the-counter eye drops that only work on one layer of the tear film, Rohto® Dry Aid® with Liquid Shield™ Technology works in a unique way to restore moisture to the tear film by working on all layers to mimic a stable, natural tear.” [from product webpage, https:\u002F\u002Frohtoeyedrops.com\u002Fproducts\u002Frohto-dry-aid-eye-drops-for-dry-eyes]\n“ROHTO® Cooling Eye Drops DUAL LIGHT RELIEF”\n“ROHTO® Cooling Eye Drops DUAL LIGHT RELIEF . . . Drug Facts . . . Purpose…Lubricant . . . Our eye drops…relieve symptoms of digital eye strain . . . protect your corneal cells from UV and Blue Light damage . . . HydroCorneal™ Protection Technology” [from product webpage, https:\u002F\u002Frohtoeyedrops.com\u002Fproducts\u002Frohto-dual-light-relief-hydrating-eye-drops]\n“ROHTO® Dual Light Relief . . . It employs HydroCorneal™ protection technology to protect corneal cells from UV damage.” [from your @rohtoeyedrops Instagram post, https:\u002F\u002Fwww.instagram.com\u002Fp\u002FDQb_GmTAD7c\u002F]\nBased on the above labeling evidence, “ROHTO® Cooling Eye Drops COOL RELIEF,” “ROHTO® Cooling Eye Drops ALL-IN-ONE,” “ROHTO® Cooling Eye Drops MAX STRENGTH,” “ROHTO® Cooling Eye Drops DIGI EYE,” “ROHTO® Cooling Eye Drops OPTIC GLOW,” “ROHTO® Cooling Eye Drops DRY AID,” and “ROHTO® Cooling Eye Drops DUAL LIGHT RELIEF” are intended for use as ophthalmic drug products. As described below, these drug products are unapproved new drugs marketed in violation of sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C 355(a) and 331(d).\nA drug product is a “new drug” within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p), if it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a). No FDA-approved applications pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, are in effect for these drug products identified above.\nUnder section 505G of the FD&C Act, certain nonprescription drugs marketed without an approved application —commonly referred to as \"OTC monograph drugs\"—may be legally marketed if they meet applicable requirements. With respect to nonprescription ophthalmic drug products, such as your ROHTO® Cooling Eye Drops products, in order to be GRASE and not new drugs the products must, among other things, conform to the conditions in the applicable OTC monograph, here Over-the-Counter (OTC) Monograph M018: Ophthalmic Drug Products for Over-the-Counter Human Use (henceforth “M018”).1 However, your nonprescription ROHTO® Cooling Eye Drops ophthalmic drug products do not conform to the conditions specified in M018 for the reasons described below.\nClaims on the product labeling for your ROHTO® Cooling Eye Drops products include intended uses that are not permitted in M018 for ophthalmic drug products. Specifically, the names of all of your ROHTO® Cooling Eye Drops products contain the term “Cooling.” Also, the “About” webpage of your website states that your ROHTO® Cooling Eye Drops products “strengthen eye’s lipid film, promoting better stability of the tear film.” In addition, your “ROHTO® Cooling Eye Drops COOL RELIEF,” “ROHTO® Cooling Eye Drops ALL-IN-ONE,” “ROHTO® Cooling Eye Drops MAX STRENGTH,” “ROHTO® Cooling Eye Drops OPTIC GLOW,” and “ROHTO® Cooling Eye Drops DUAL LIGHT RELIEF” product labels state that the product “cools eyes” and reference, “CoolSense™ Technology.” Such claims go beyond the allowed general intended uses for OTC ophthalmic drug products and do not conform to M018.\nFurthermore, your products “ROHTO® Cooling Eye Drops DIGI EYE,” “ROHTO® Cooling Eye Drops DUAL LIGHT RELIEF,” and “ROHTO® Cooling Eye Drops OPTIC GLOW” include additional intended uses that are not permitted in M018. For example, your product label for “ROHTO® Cooling Eye Drops DIGI EYE” states, “Soothes Redness and Dryness due to Digital Eye Strain,” and your website states that this product is “designed to provide eye strain relief from the symptoms of Digital Eye Strain.” Additionally, your website states that the product “ROHTO® Cooling Eye Drops DUAL LIGHT RELIEF” is intended to “…relieve symptoms of digital eye strain,” and “protect your corneal cells from UV and Blue Light damage.” Moreover, a post on your @rohtoeyedrops Instagram page states that this product “employs HydroCorneal™ protection technology to protect corneal cells from UV damage. In addition, your website states that the product, “ROHTO® Cooling Eye Drops OPTIC GLOW” “helps improve the health of the corneal surface….” Such claims go beyond the allowed general intended uses for ophthalmic drug products and do not conform to M018.\nThe product labels for “ROHTO® Cooling Eye Drops COOL RELIEF,” “ROHTO® Cooling Eye Drops ALL-IN-ONE,” “ROHTO® Cooling Eye Drops MAX STRENGTH,” “ROHTO® Cooling Eye Drops DIGI EYE,” and “ROHTO® Cooling Eye Drops OPTIC GLOW” claim that these products “soothes up to 8 hrs.” and your product label for “ROHTO® Cooling Eye Drops DRY AID” claims that it “Soothes up to 12 hrs.” Time-specific extended efficacy claims such as these do not conform to M018.\nThus, your “ROHTO® Cooling Eye Drops COOL RELIEF,” “ROHTO® Cooling Eye Drops ALL-IN-ONE,” “ROHTO® Cooling Eye Drops MAX STRENGTH,” “ROHTO® Cooling Eye Drops DIGI EYE,” “ROHTO® Cooling Eye Drops OPTIC GLOW,” “ROHTO® Cooling Eye Drops DRY AID,” and “ROHTO® Cooling Eye Drops DUAL LIGHT RELIEF” products do not comply with the applicable conditions specified in M018 and have not otherwise been found to be GRASE.2 Accordingly, these products are new drugs within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p), and there is no basis under section 505G of the FD&C Act under which these products would be legally marketed without an approved application. Because there are no applications in effect for these products, these products are unapproved new drugs.\nThe introduction or delivery for introduction of these unapproved new drug products into interstate commerce violates sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C. 355(a) and 331(d).\nMisbranded Drug Violations\nYour ROHTO® Cooling Eye Drops products are misbranded under section 502(a) of the FD&C Act, 21 U.S.C. 352(a), because the product labeling include statements that misleadingly suggest that the drug products are endorsed by FDA and are cGMP compliant. Specifically, on your “About” webpage, you display the acronym “FDA,” in a form that is similar to the FDA logo. Your use of the acronym FDA in a form that is similar to the FDA logo on your website misleadingly suggests that the drug products are approved or endorsed by FDA in some way. Your ROHTO® Cooling Eye Drops products are not the subject of an FDA-approved application. Additionally, on your website you claim, “Our manufacturing practices are US FDA GMP Compliant…,” and “GMP Compliance guarantees our eye drops are 100% sterile, 100% free from contamination, and meet rigorous quality standards….” Generally, current good manufacturing practice (CGMP) compliance cannot be implied or explicitly indicated on product labeling. Based solely on a determination of CGMP compliance at one point in time it would be unreasonable to assure permanent CGMP compliance, or to guarantee that products are 100% sterile or free from contamination at any given time. Moreover, when even a single aspect of a firm’s operations deviates from CGMP during the course of manufacturing a product, regardless of the significance of the deficiency, the product is deemed adulterated under section 501(a)(2)(B) of the FD&C Act. Your firm cannot reliably guarantee that a product is sterile, free from contamination, or meets rigorous quality standards when it manufactures that product under conditions that fail to meet CGMP requirements, as described above. Such representation can mislead consumers into believing the product is safe despite the existence of serious manufacturing risks. Therefore, these products are misbranded under section 502(a) of the FD&C Act, 21 U.S.C. 352(a), because your labeling representation suggesting that your products are FDA-approved and CGMP compliant is false or misleading.\nAdditionally, your ROHTO® Cooling Eye Drops products are misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee), because these products are nonprescription drugs subject to section 505G of the FD&C Act, 21 U.S.C. 355h, but do not comply with the requirements for marketing under that section and are not the subject of an application approved under section 505 of the FD&C Act, 21 U.S.C. 355.\nThe introduction or delivery for introduction of a misbranded drug into interstate commerce violates section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\nData Integrity Remediation\nYour quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture. See FDA’s guidance document Data Integrity and Compliance with Drug CGMP: Questions and Answers for guidance on establishing and following CGMP compliant data integrity practices at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F119267\u002Fdownload.\nWe strongly recommend that you retain an independent, qualified third-party consultant to assist in your remediation. In response to this letter, provide:\nA comprehensive investigation into the extent of the inaccuracies and inconsistencies in data, records, and reporting. Your investigation should include:\no A detailed investigation protocol and methodology; a summary of all laboratories, manufacturing operations, and systems to be covered by the assessment; and a justification for any part of your operation that you propose to exclude.\no Interviews of current and former employees to identify the nature, scope, and root cause of data inaccuracies. We recommend that these interviews be conducted by a qualified third party.\no An assessment of the extent of data integrity deficiencies at your facility. Identify omissions, alterations, deletions, record destruction, non-contemporaneous record completion, and other deficiencies. Describe all parts of your facility’s operations in which you discovered data integrity deficiencies.\no A comprehensive retrospective evaluation of the nature of the testing\u002Fmanufacturing\u002Fother data integrity deficiencies. We recommend that a qualified third party with specific expertise in the area where potential breaches were identified should evaluate all occurrences.\nA current risk assessment of the potential effects of the observed failures on the quality of your drugs. Your assessment should include analyses of the risks to patients caused by the release of drugs affected by a data integrity event and analyses of the risks posed by ongoing operations.\nA management strategy for your firm that includes the details of your global corrective action and preventive action plan. Your strategy should include:\no A detailed corrective action plan that describes how you intend to ensure the reliability and completeness of all data, including analytical data, manufacturing records, and all data submitted to FDA.\no A comprehensive description of the root causes of each data integrity deviation, including evidence that the scope and depth of the current action plan is commensurate with the findings of the investigation and risk assessment. Indicate whether individuals responsible for the data integrity breaches remain able to influence CGMP-related or drug application data at your firm.\no Interim measures describing the actions you have taken or will take to ensure the quality of your drugs and protect patients, such as notifying your customers, recalling product(s), conducting additional testing, adding lots to your stability programs to assure stability, drug application actions, and enhanced complaint monitoring.\no Long-term measures describing any remediation efforts and enhancements to procedures, processes, methods, controls, systems, management oversight, and human resources (e.g., training, staffing improvements) designed to ensure the integrity of your company’s data.\no A commitment to have a qualified consultant conduct extensive annual audits, for at least two years, to assist in evaluating CAPA effectiveness after you have executed your data integrity remediation protocol.\no Inform FDA if you will be hiring a chief integrity officer who is fully empowered to receive anonymous complaints from employees reporting data integrity concerns and with the authority to ensure any potential breach is promptly investigated (by an independent quality assurance function, along with expertise from outside entities whenever needed).\no A status report for any of the above activities already underway or completed.\nDrug Recall\nOn July 7, 2026, FDA held a teleconference with you recommending you recall all drug batches from the U.S. market. On July 8, 2026, you agreed to voluntary recall all drugs in current distribution in the United States.\nOn July 14, 2026, you initiated a voluntary recall of all lots of Rohto Cool Relief, Rohto All-In-One, Rohto Max Strength, Rohto Digi-Eye, Rohto Optic Glow, and Rohto Dry Aid, due to lack of sterility assurance. The recalls were posted to the FDA’s Enforcement Report website at:\nhttps:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fires\u002Findex.cfm?Product=221557\nhttps:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fires\u002Findex.cfm?Product=221558\nhttps:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fires\u002Findex.cfm?Product=221559\nhttps:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fires\u002Findex.cfm?Product=221560\nhttps:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fires\u002Findex.cfm?Product=221561\nhttps:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fires\u002Findex.cfm?Product=221562\nhttps:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fires\u002Findex.cfm?Product=221563\nhttps:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fires\u002Findex.cfm?Product=221564\nDrug Production Suspended\nWe acknowledge your commitment to suspend production of all drugs at this facility for the U.S. market. In response to this letter, clarify whether you intend to resume manufacturing drugs for the U.S. market at this facility in the future.\nIf you plan to resume any manufacturing operations regulated under the FD&C Act, notify this office before resuming your drug manufacturing operations. If you resume CGMP activities, you are responsible for resolving all deficiencies and systemic\nflaws to ensure your firm is capable of ongoing CGMP compliance. In your notification to the Agency, provide a summary of your remediations to demonstrate that you have appropriately completed all corrective action and preventive action (CAPA).\nCGMP Consultant\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements if your firm intends to resume manufacturing drugs for the U.S. market. The qualified consultant should also perform a comprehensive six-system audit3 of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\nConclusion\nYou are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur.\nFDA placed all drugs and drug products offered for import into the United States from your firm on Import Alert 66-40 on August 13, 2026.\nFDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\nFailure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at Rohto-Mentholatum (Vietnam) Co., Ltd., FEI 3008808745, at No. 16 VSIP Street No. 5, Vietnam - Singapore Industrial Park, Thuan Giao Ward, Ho Chi Minh, Vietnam into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).\nSend your written response to CDER-OC-OMQ-Communications@fda.hhs.gov within fifteen (15) business days of receipt of this letter. Identify your written response with FEI 3008808745 and ATTN: Compliance officer Emily Wu in the subject line of the email.\nIf you have information that you believe demonstrates that your products are not in violation of the FD&C Act and FDA regulations, include that information for our consideration.\nFDA posts warning letters to www.FDA.gov.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration\n\u002FS\u002F\nTina Smith\nCaptain, U.S. Public Health Service\nDirector\nOffice of Unapproved Drugs & Labeling Compliance\nOffice of Compliance\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration\ncc:\n(b)(4)\nMr. Shiramatsu Hirofumi\nGeneral Director\nRohto-Mentholatum (Vietnam) Co., Ltd.,\n(b)(4)\nMs. Meryl Reis\nVP of US R&D, Regulatory Affairs, QA\u002FQC\nThe Mentholatum Company\n(b)(4)\n__________________\n1 M018 reflects the conditions set forth in the relevant final order established and in effect under section 505G; see Order ID OTC000023, available at FDA’s website OTC Monographs@FDA, https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fomuf\u002F.\n2 FDA is not aware of any adequate and well-controlled clinical trials in the published literature that support a determination that your ROHTO® Cooling Eye Drops products are GRASE for use under the conditions prescribed, recommended, or suggested in their labeling, nor has FDA determined these drug products to be GRASE pursuant to an order issued under section 505G(b).\n3 i.e. Quality System, Facilities & Equipment System, Materials System, Production System, Packaging & Labeling System, and Laboratory Control System per FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations.","Rohto Pharmaceutical Co., Ltd.","rohto-pharmaceutical-co-ltd-733215-10142026","2026-10-27T01:18:54.544251+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Frohto-pharmaceutical-co-ltd-733215-10142026","2026-11-17T01:02:03.701861+00:00","2026-10-20","733215","Mr. Kunio Yamada","2026-10-27T01:19:17.38+00:00","VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED","320-27-06","2026-10-14",{"id":196,"raw":197,"subject":201,"body_html":202,"body_text":203,"firm_name":204,"letter_id":205,"created_at":85,"fei_number":19,"letter_url":206,"updated_at":207,"action_type":22,"case_status":23,"posted_date":208,"marcs_cms_no":209,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":210,"body_fetched_at":211,"delivery_method":110,"recipient_title":19,"reference_number":19,"action_taken_date":212,"medical_device_id":19,"response_letter_date":19},466,[198,199,200,11,201,13,13,13],"\u003Ctime datetime=\"2025-11-18T05:00:00Z\">11\u002F18\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-11-12T05:00:00Z\">11\u002F12\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsinsin-pharmaceutical-co-ltd-718720-11122025\">Sinsin Pharmaceutical Co., Ltd.\u003C\u002Fa>","Nonprescription\u002FOTC","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Hyun Kwang Dan\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Senior Managing Director \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Sinsin Pharmaceutical Co., Ltd.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>9 Sojeongsandandong-Ro\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Sojeong-myeon\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Sejong\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>30002\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>South Korea\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:hktan@sinsin.com\"> hktan@sinsin.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>November 12, 2025\u003C\u002Fp>\u003Cp>\u003Cstrong>RE: 718720\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Hyun-Kwang Dan:\u003C\u002Fp>\u003Cp>This letter is to advise you that on April 15, 2025, the U.S. Food and Drug Administration (FDA) reviewed your product labeling, including your website at www.sinsinpas.us\u002F, which directs consumers to your Amazon storefront where your SINSINPAS AREX INSTANT PAIN RELIEF and SINSINPAS Pain Relieving Liquid MULPAS drug products are available for purchase in the United States without a prescription. We also reviewed your social media on Facebook and Instagram at https:\u002F\u002Fwww.facebook.com\u002Fsearch\u002Ftop?q=sinsinpas_us and https:\u002F\u002Fwww.instagram.com\u002Fsinsinpas_us, which also direct consumers to your Amazon storefront.\u003C\u002Fp>\u003Cp>SINSINPAS AREX INSTANT PAIN RELIEF and SINSINPAS Pain Relieving Liquid MULPAS are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 355(a), 331(d). In addition, these products are misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee). Introduction or delivery for introduction of misbranded products into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a). These violations are described in more detail below.\u003C\u002Fp>\u003Cp>\u003Cstrong>Unapproved New Drug and Misbranded Drug Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>SINSINPAS AREX INSTANT PAIN RELIEF and SINSINPAS Pain Relieving Liquid MULPAS are drugs as defined by section 201(g)(1)(B) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(B), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(C), because they are intended to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>Examples from the SINSINPAS AREX INSTANT PAIN RELIEF and SINSINPAS Pain Relieving Liquid MULPAS product labeling, including your website listed above, that provide evidence of the intended uses (as defined in 21 CFR 201.128) of the product as a drug include, but may not be limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cu>SINSINPAS AREX INSTANT PAIN RELIEF\u003C\u002Fu>\u003Cbr>“\u003Cstrong>Drug Facts\u003C\u002Fstrong> . . . Purpose: Topical Analgesic . . . \u003Cstrong>Uses\u003C\u002Fstrong> For temporary relief of minor aches and pains of muscles and joints associated with: ■ Arthritis ■ Simple Backache ■ Strains ■ Bruises ■ Sprains,” “- Joint Pain – Muscle pain – Sprains – Backache” [from the product label]\u003C\u002Fp>\u003Cp>\u003Cu>SINSINPAS Pain Relieving Liquid MULPAS\u003C\u002Fu>\u003Cbr>“\u003Cstrong>Drug Facts\u003C\u002Fstrong> . . . Purpose: Topical Analgesic . . . \u003Cstrong>Uses\u003C\u002Fstrong> For temporary relief of minor aches and pains associated with: ■ arthritis ■ simple backache ■ sprains ■ strains ■ bruises” ; “Muscle Pain Arthritis Strains Insect Bites” [from the product label]\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Unapproved New Drug Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based on the above labeling evidence SINSINPAS AREX INSTANT PAIN RELIEF and SINSINPAS Pain Relieving Liquid MULPAS are intended for use as external analgesic drug products. As described below, these drug products are unapproved new drugs marketed in violation of sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C. 355(a) and 331(d).\u003C\u002Fp>\u003Cp>A drug product is a “new drug” within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), if it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a). No FDA-approved applications pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, are in effect for these drug products identified above.\u003C\u002Fp>\u003Cp>Under section 505G of the FD&amp;C Act, certain nonprescription drugs marketed without an approved application —commonly referred to as “over-the-counter (OTC) monograph drugs”—may be legally marketed if they meet applicable requirements. With respect to nonprescription external analgesic drug products, such as your SINSINPAS AREX INSTANT PAIN RELIEF and SINSINPAS Pain Relieving Liquid MULPAS, in order to be GRASE and not new drugs, the products must, among other things, conform to the conditions in the applicable OTC monograph, here External Analgesic Drug Products for Over-the-Counter Human Use (hereafter M017).\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> However, SINSINPAS AREX INSTANT PAIN RELIEF and SINSINPAS Pain Relieving Liquid MULPAS do not conform to the conditions specified in M017 for the reasons described below.\u003C\u002Fp>\u003Cp>Your SINSINPAS AREX INSTANT PAIN RELIEF and SINSINPAS Pain Relieving Liquid MULPAS are formulated with active ingredients that are not permitted for OTC external analgesic drug products under M017.12. Specifically, according to your product’s labeling, your SINSINPAS AREX INSTANT PAIN RELIEF product is formulated with the active ingredients zinc oxide and mentha oil. However, zinc oxide and mentha oil are not permitted active ingredients under M017.12 when used in combination, or as sole ingredients, for any OTC external analgesic drug product.\u003C\u002Fp>\u003Cp>In addition, your SINSINPAS Pain Relieving Liquid MULPAS is formulated with the active ingredients chlorpheniramine maleate and thymol. However, chlorpheniramine maleate and thymol are not permitted active ingredients under M017.12 when used in combination, or as sole ingredients, for any OTC external analgesic drug product. Furthermore, FDA has also determined that OTC external analgesic and anesthetic drug products with the active ingredient thymol are not generally recognized as safe and effective (GRASE) under a final determination issued under 21 CFR par 330.\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Thus, your SINSINPAS AREX INSTANT PAIN RELIEF and SINSINPAS Pain Relieving Liquid MULPAS products do not comply with the applicable conditions specified in M017 and have not otherwise been found GRASE.\u003Cem>\u003Cstrong>\u003Csup>3\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> Accordingly, these products are new drugs within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), and there is no basis under section 505G of the FD&amp;C Act under which these products would be legally marketed without an approved application. Because there are no approved applications in effect for these products, these products are unapproved new drugs. The introduction or delivery for introduction into interstate commerce of these unapproved new drug products violates sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C. 355(a) and 331(d).\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Misbranded Drug Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Additionally, SINSINPAS AREX INSTANT PAIN RELIEF and SINSINPAS Pain Relieving Liquid MULPAS are misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee), because these products are nonprescription drugs subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, but do not comply with the requirements for marketing under that section and are not the subject of an application approved under section 505 of the FD&amp;C Act, 21 U.S.C. 355.\u003C\u002Fp>\u003Cp>The introduction or delivery for introduction of a misbranded drug into interstate commerce violates section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within 15 working days, state the reason for the delay and the time within which you will complete the correction. Your response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov. Please include your firm name and the unique identifier “718720” in the subject line of the email.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Tina Smith, M.S.\u003Cbr>Captain, U.S. Public Health Service\u003Cbr>Director\u003Cbr>Office of Unapproved Drugs and Labeling Compliance\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003C\u002Fp>\u003Cp>____________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> M017 reflects the conditions as set forth in the relevant final orders established and in effect under section 505G; see Order OTC000033, available at FDA’s website OTC Monographs@FDA https:\u002F\u002Fdps.fda.gov\u002Fomuf.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Non-Monograph Conditions NM900: Drug Products Containing Certain Active Ingredients Offered Over-the-Counter for Certain Uses. See Order ID OTC000007, available at FDA’s website OTC Monographs@FDA, https:\u002F\u002Fdps.fda.gov\u002Fomuf.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> FDA is not aware of any adequate and well-controlled clinical trials in the published literature that support a determination that SINSINPAS AREX INSTANT PAIN RELIEF and SINSINPAS Pain Relieving Liquid MULPAS are GRASE for use under the conditions prescribed, recommended, or suggested in their labeling, nor has FDA determined these drug products to be GRASE pursuant to an order issued under section 505G(b).\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nHyun Kwang Dan\n\nRecipient Title\n\nSenior Managing Director\n\nSinsin Pharmaceutical Co., Ltd.\n\n9 Sojeongsandandong-Ro\n\nSojeong-myeon\n\nSejong\n\n30002\n\nSouth Korea\n\nhktan@sinsin.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWARNING LETTER\nNovember 12, 2025\nRE: 718720\nHyun-Kwang Dan:\nThis letter is to advise you that on April 15, 2025, the U.S. Food and Drug Administration (FDA) reviewed your product labeling, including your website at www.sinsinpas.us\u002F, which directs consumers to your Amazon storefront where your SINSINPAS AREX INSTANT PAIN RELIEF and SINSINPAS Pain Relieving Liquid MULPAS drug products are available for purchase in the United States without a prescription. We also reviewed your social media on Facebook and Instagram at https:\u002F\u002Fwww.facebook.com\u002Fsearch\u002Ftop?q=sinsinpas_us and https:\u002F\u002Fwww.instagram.com\u002Fsinsinpas_us, which also direct consumers to your Amazon storefront.\nSINSINPAS AREX INSTANT PAIN RELIEF and SINSINPAS Pain Relieving Liquid MULPAS are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a), 331(d). In addition, these products are misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee). Introduction or delivery for introduction of misbranded products into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a). These violations are described in more detail below.\nUnapproved New Drug and Misbranded Drug Violations\nSINSINPAS AREX INSTANT PAIN RELIEF and SINSINPAS Pain Relieving Liquid MULPAS are drugs as defined by section 201(g)(1)(B) of the FD&C Act, 21 U.S.C. 321(g)(1)(B), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&C Act, 21 U.S.C. 321(g)(1)(C), because they are intended to affect the structure or any function of the body.\nExamples from the SINSINPAS AREX INSTANT PAIN RELIEF and SINSINPAS Pain Relieving Liquid MULPAS product labeling, including your website listed above, that provide evidence of the intended uses (as defined in 21 CFR 201.128) of the product as a drug include, but may not be limited to, the following:\nSINSINPAS AREX INSTANT PAIN RELIEF\n“Drug Facts . . . Purpose: Topical Analgesic . . . Uses For temporary relief of minor aches and pains of muscles and joints associated with: ■ Arthritis ■ Simple Backache ■ Strains ■ Bruises ■ Sprains,” “- Joint Pain – Muscle pain – Sprains – Backache” [from the product label]\nSINSINPAS Pain Relieving Liquid MULPAS\n“Drug Facts . . . Purpose: Topical Analgesic . . . Uses For temporary relief of minor aches and pains associated with: ■ arthritis ■ simple backache ■ sprains ■ strains ■ bruises” ; “Muscle Pain Arthritis Strains Insect Bites” [from the product label]\nUnapproved New Drug Violations\nBased on the above labeling evidence SINSINPAS AREX INSTANT PAIN RELIEF and SINSINPAS Pain Relieving Liquid MULPAS are intended for use as external analgesic drug products. As described below, these drug products are unapproved new drugs marketed in violation of sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C. 355(a) and 331(d).\nA drug product is a “new drug” within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p), if it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a). No FDA-approved applications pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, are in effect for these drug products identified above.\nUnder section 505G of the FD&C Act, certain nonprescription drugs marketed without an approved application —commonly referred to as “over-the-counter (OTC) monograph drugs”—may be legally marketed if they meet applicable requirements. With respect to nonprescription external analgesic drug products, such as your SINSINPAS AREX INSTANT PAIN RELIEF and SINSINPAS Pain Relieving Liquid MULPAS, in order to be GRASE and not new drugs, the products must, among other things, conform to the conditions in the applicable OTC monograph, here External Analgesic Drug Products for Over-the-Counter Human Use (hereafter M017).1 However, SINSINPAS AREX INSTANT PAIN RELIEF and SINSINPAS Pain Relieving Liquid MULPAS do not conform to the conditions specified in M017 for the reasons described below.\nYour SINSINPAS AREX INSTANT PAIN RELIEF and SINSINPAS Pain Relieving Liquid MULPAS are formulated with active ingredients that are not permitted for OTC external analgesic drug products under M017.12. Specifically, according to your product’s labeling, your SINSINPAS AREX INSTANT PAIN RELIEF product is formulated with the active ingredients zinc oxide and mentha oil. However, zinc oxide and mentha oil are not permitted active ingredients under M017.12 when used in combination, or as sole ingredients, for any OTC external analgesic drug product.\nIn addition, your SINSINPAS Pain Relieving Liquid MULPAS is formulated with the active ingredients chlorpheniramine maleate and thymol. However, chlorpheniramine maleate and thymol are not permitted active ingredients under M017.12 when used in combination, or as sole ingredients, for any OTC external analgesic drug product. Furthermore, FDA has also determined that OTC external analgesic and anesthetic drug products with the active ingredient thymol are not generally recognized as safe and effective (GRASE) under a final determination issued under 21 CFR par 330.2\nThus, your SINSINPAS AREX INSTANT PAIN RELIEF and SINSINPAS Pain Relieving Liquid MULPAS products do not comply with the applicable conditions specified in M017 and have not otherwise been found GRASE.3 Accordingly, these products are new drugs within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p), and there is no basis under section 505G of the FD&C Act under which these products would be legally marketed without an approved application. Because there are no approved applications in effect for these products, these products are unapproved new drugs. The introduction or delivery for introduction into interstate commerce of these unapproved new drug products violates sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C. 355(a) and 331(d).\nMisbranded Drug Violations\nAdditionally, SINSINPAS AREX INSTANT PAIN RELIEF and SINSINPAS Pain Relieving Liquid MULPAS are misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee), because these products are nonprescription drugs subject to section 505G of the FD&C Act, 21 U.S.C. 355h, but do not comply with the requirements for marketing under that section and are not the subject of an application approved under section 505 of the FD&C Act, 21 U.S.C. 355.\nThe introduction or delivery for introduction of a misbranded drug into interstate commerce violates section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within 15 working days, state the reason for the delay and the time within which you will complete the correction. Your response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov. Please include your firm name and the unique identifier “718720” in the subject line of the email.\nSincerely,\n\u002FS\u002F\nTina Smith, M.S.\nCaptain, U.S. Public Health Service\nDirector\nOffice of Unapproved Drugs and Labeling Compliance\nOffice of Compliance\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration\n____________________\n1 M017 reflects the conditions as set forth in the relevant final orders established and in effect under section 505G; see Order OTC000033, available at FDA’s website OTC Monographs@FDA https:\u002F\u002Fdps.fda.gov\u002Fomuf.\n2 Non-Monograph Conditions NM900: Drug Products Containing Certain Active Ingredients Offered Over-the-Counter for Certain Uses. See Order ID OTC000007, available at FDA’s website OTC Monographs@FDA, https:\u002F\u002Fdps.fda.gov\u002Fomuf.\n3 FDA is not aware of any adequate and well-controlled clinical trials in the published literature that support a determination that SINSINPAS AREX INSTANT PAIN RELIEF and SINSINPAS Pain Relieving Liquid MULPAS are GRASE for use under the conditions prescribed, recommended, or suggested in their labeling, nor has FDA determined these drug products to be GRASE pursuant to an order issued under section 505G(b).","Sinsin Pharmaceutical Co., Ltd.","sinsin-pharmaceutical-co-ltd-718720-11122025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsinsin-pharmaceutical-co-ltd-718720-11122025","2026-10-26T08:09:58.178315+00:00","2025-11-18","718720","Hyun Kwang Dan","2026-08-19T14:55:28.603+00:00","2025-11-12",{"id":214,"raw":215,"subject":80,"body_html":219,"body_text":220,"firm_name":221,"letter_id":222,"created_at":65,"fei_number":19,"letter_url":223,"updated_at":224,"action_type":22,"case_status":23,"posted_date":225,"marcs_cms_no":226,"product_type":26,"closeout_date":19,"issuing_office":58,"recipient_name":227,"body_fetched_at":228,"delivery_method":72,"recipient_title":19,"reference_number":19,"action_taken_date":229,"medical_device_id":19,"response_letter_date":19},1876,[216,217,218,58,80,13,13,13],"\u003Ctime datetime=\"2023-09-05T13:20:00Z\">09\u002F05\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-08-23T04:00:00Z\">08\u002F23\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fgreen-pharmaceutical-co-ltd-663544-08232023\">Green Pharmaceutical Co. Ltd.\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Jang Hyun-pill\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Green Pharmaceutical Co. Ltd.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1098 Nongdari-ro\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Munbaek-myeon\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Jincheon\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>27863\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>South Korea\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:green_qc@greenpharma.co.kr\"> green_qc@greenpharma.co.kr\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-23-36\u003C\u002Fp>\n\n\u003Cp>August 23, 2023\u003Cbr>\n\u003Cbr>\nDear Jang Hyun-pill:\u003C\u002Fp>\n\n\u003Cp>Your facility was registered with the United States Food and Drug Administration (FDA) as a manufacturer of over-the-counter (OTC) drug products. FDA has reviewed the records you submitted in response to our March 3, 2023 request for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) for your facility, Green Pharmaceutical Co. Ltd., FEI 3013338037, 1098 Nongdari-ro, Munbaek-myeon, Jincheon 27863.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations, parts 210 and 211 (21 CFR, parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding of drugs as described in your response to our 704(a)(4) request do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the FD&amp;C Act (21 U.S.C. 351(a)(2)(B)).\u003C\u002Fp>\n\n\u003Cp>Following review of records and other information provided pursuant to section 704(a)(4) of the FD&amp;C Act, significant violations were observed including, but not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm failed to conduct at least one test to verify the identity of each component of a drug product (21 CFR 211.84(d)(1)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You manufactured over-the-counter (OTC) drug products, including \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Based on the records and information you provided, you did not demonstrate that you adequately tested each shipment of each lot of the incoming component at high-risk of \u003Cstrong>(b)(4)\u003C\u002Fstrong> contamination. These include, but were not limited to, testing of \u003Cstrong>(b)(4)\u003C\u002Fstrong>, you used in manufacturing drug products to determine their appropriate identity. Identity testing for these and certain other high-risk drug components\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> includes a limit test in the United States Pharmacopeia (USP) to ensure that the component meets the relevant safety limits for levels of \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Because you did not perform identity testing on each shipment of each lot using the USP identification test that detects these hazardous impurities, you failed to assure the acceptability of these components for use in the manufacture of your drug products.\u003C\u002Fp>\n\n\u003Cp>The use of ingredients contaminated with \u003Cstrong>(b)(4)\u003C\u002Fstrong> has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document \u003Cstrong>(b)(4)\u003C\u002Fstrong> to help you meet the CGMP requirements when manufacturing drugs containing ingredients at high-risk for \u003Cstrong>(b)(4)\u003C\u002Fstrong> contamination at \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A commitment to provide \u003Cstrong>(b)(4)\u003C\u002Fstrong> test results, no later than 30 calendar days from the date of this letter, from testing retains for all lots of high-risk drug components used in the manufacture of drug products. Alternatively, if a retain of a component lot is unavailable, perform retain sample testing of all implicated finished drug product batches for the presence of \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fli>\n\t\u003Cli>A full risk assessment for drug products that are within expiry which contain any ingredient at risk for \u003Cstrong>(b)(4)\u003C\u002Fstrong> contamination. Take prompt and appropriate actions to determine the safety of all lots of the components and any related drug product that could contain&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>, including customer notifications and product recalls for any contaminated lots. Identify additional appropriate corrective action and preventive action (CAPA) that secure supply chains in the future, including, but not limited to, ensuring that all incoming raw material lots are from fully qualified manufacturers and free from unsafe impurities. Detail these actions in your response to this letter.\u003C\u002Fli>\n\t\u003Cli>A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s certificate of analysis (COA) instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic revalidation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot. In the case of \u003Cstrong>(b)(4)\u003C\u002Fstrong>, propylene glycol, and certain additional high-risk components we note that this includes the performance of parts A, B, and C of the USP monograph.\u003C\u002Fli>\n\t\u003Cli>The chemical quality control specifications you use to test each incoming lot of high-risk drug components to determine acceptability for use in manufacturing.\u003C\u002Fli>\n\t\u003Cli>A comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>2. Your firm failed to establish an adequate quality control unit with the responsibility and authority to approve or reject all components, drug product containers, closures, in-process materials, packaging materials, labeling, and drug products (21 CFR 211.22(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The records and information you provided demonstrate that your quality unit (QU) did not effectively exercise its responsibilities to oversee the quality of your drug manufacturing operations. Specifically, your QU did not adequately exercise its authority in the approval or rejection of components in your Materials System.\u003C\u002Fp>\n\n\u003Cp>Your QU is responsible for fully exercising its authority and responsibilities. FDA is concerned that your QU may also not be conducting appropriate oversight regarding other CGMP operations, including Production, Facilities &amp; Equipment, Laboratory Controls, and Packaging &amp; Labelling Systems.\u003C\u002Fp>\n\n\u003Cp>See FDA’s guidance document \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem> for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o A determination of whether procedures used by your firm are robust and appropriate\u003Cbr>\n&nbsp; &nbsp; o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\u003Cbr>\n&nbsp; &nbsp; o A complete and final review of each batch and its related information before the QU disposition decision\u003Cbr>\n&nbsp; &nbsp; o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements if your firm intends to resume manufacturing drugs for the U.S. market. The qualified consultant should also perform a comprehensive six-system audit\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> of your entire operation for CGMP compliance and evaluate the completion and efficacy of your CAPA before you pursue resolution of your firm’s compliance status with FDA.\u003C\u002Fp>\n\n\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>FDA placed your firm on Import Alert 66-40 on July 17, 2023.\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\u003C\u002Fp>\n\n\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may inspect your facility to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 30 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3013338037 and ATTN: Matthew R. Dionne, Pharm.D., Compliance Officer.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Francis Godwin\u003Cbr>\nDirector\u003Cbr>\nOffice of Manufacturing Quality\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003C\u002Fp>\n\n\u003Cp>CC (U.S. Agent via email):\u003Cbr>\nRegistrar Corp\u003Cbr>\ndrugs@registrarcorp.com\u003C\u002Fp>\n\n\u003Cp>______________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Components with higher risk of \u003Cstrong>(b)(4)\u003C\u002Fstrong> contamination compared to other drug components.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> i.e., Quality System, Facilities &amp; Equipment System, Materials System, Production System, Packaging &amp; Labeling System, and Laboratory Control System per FDA’s guidance document \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem>.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nJang Hyun-pill\n\nGreen Pharmaceutical Co. Ltd.\n\n1098 Nongdari-ro\n\nMunbaek-myeon\n\nJincheon\n\n27863\n\nSouth Korea\n\ngreen_qc@greenpharma.co.kr\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nWarning Letter 320-23-36\n\nAugust 23, 2023\n\nDear Jang Hyun-pill:\n\nYour facility was registered with the United States Food and Drug Administration (FDA) as a manufacturer of over-the-counter (OTC) drug products. FDA has reviewed the records you submitted in response to our March 3, 2023 request for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) for your facility, Green Pharmaceutical Co. Ltd., FEI 3013338037, 1098 Nongdari-ro, Munbaek-myeon, Jincheon 27863.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations, parts 210 and 211 (21 CFR, parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding of drugs as described in your response to our 704(a)(4) request do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act (21 U.S.C. 351(a)(2)(B)).\n\nFollowing review of records and other information provided pursuant to section 704(a)(4) of the FD&C Act, significant violations were observed including, but not limited to, the following:\n\n1. Your firm failed to conduct at least one test to verify the identity of each component of a drug product (21 CFR 211.84(d)(1)).\n\nYou manufactured over-the-counter (OTC) drug products, including (b)(4). Based on the records and information you provided, you did not demonstrate that you adequately tested each shipment of each lot of the incoming component at high-risk of (b)(4) contamination. These include, but were not limited to, testing of (b)(4), you used in manufacturing drug products to determine their appropriate identity. Identity testing for these and certain other high-risk drug components1 includes a limit test in the United States Pharmacopeia (USP) to ensure that the component meets the relevant safety limits for levels of (b)(4). Because you did not perform identity testing on each shipment of each lot using the USP identification test that detects these hazardous impurities, you failed to assure the acceptability of these components for use in the manufacture of your drug products.\n\nThe use of ingredients contaminated with (b)(4) has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document (b)(4) to help you meet the CGMP requirements when manufacturing drugs containing ingredients at high-risk for (b)(4) contamination at (b)(4).\n\nIn response to this letter, provide:\n\nA commitment to provide (b)(4) test results, no later than 30 calendar days from the date of this letter, from testing retains for all lots of high-risk drug components used in the manufacture of drug products. Alternatively, if a retain of a component lot is unavailable, perform retain sample testing of all implicated finished drug product batches for the presence of (b)(4).\n\nA full risk assessment for drug products that are within expiry which contain any ingredient at risk for (b)(4) contamination. Take prompt and appropriate actions to determine the safety of all lots of the components and any related drug product that could contain (b)(4), including customer notifications and product recalls for any contaminated lots. Identify additional appropriate corrective action and preventive action (CAPA) that secure supply chains in the future, including, but not limited to, ensuring that all incoming raw material lots are from fully qualified manufacturers and free from unsafe impurities. Detail these actions in your response to this letter.\n\nA description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s certificate of analysis (COA) instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic revalidation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot. In the case of (b)(4), propylene glycol, and certain additional high-risk components we note that this includes the performance of parts A, B, and C of the USP monograph.\n\nThe chemical quality control specifications you use to test each incoming lot of high-risk drug components to determine acceptability for use in manufacturing.\n\nA comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\n\n2. Your firm failed to establish an adequate quality control unit with the responsibility and authority to approve or reject all components, drug product containers, closures, in-process materials, packaging materials, labeling, and drug products (21 CFR 211.22(a)).\n\nThe records and information you provided demonstrate that your quality unit (QU) did not effectively exercise its responsibilities to oversee the quality of your drug manufacturing operations. Specifically, your QU did not adequately exercise its authority in the approval or rejection of components in your Materials System.\n\nYour QU is responsible for fully exercising its authority and responsibilities. FDA is concerned that your QU may also not be conducting appropriate oversight regarding other CGMP operations, including Production, Facilities & Equipment, Laboratory Controls, and Packaging & Labelling Systems.\n\nSee FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\n\nIn response to this letter, provide:\n\nA comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\n\no A determination of whether procedures used by your firm are robust and appropriate\n\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\n\no A complete and final review of each batch and its related information before the QU disposition decision\n\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\n\nCGMP Consultant Recommended\n\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements if your firm intends to resume manufacturing drugs for the U.S. market. The qualified consultant should also perform a comprehensive six-system audit2 of your entire operation for CGMP compliance and evaluate the completion and efficacy of your CAPA before you pursue resolution of your firm’s compliance status with FDA.\n\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nFDA placed your firm on Import Alert 66-40 on July 17, 2023.\n\nCorrect any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\n\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may inspect your facility to verify that you have completed corrective actions to address any violations.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 30 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3013338037 and ATTN: Matthew R. Dionne, Pharm.D., Compliance Officer.\n\nSincerely,\n\n\u002FS\u002F\n\nFrancis Godwin\n\nDirector\n\nOffice of Manufacturing Quality\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nCC (U.S. Agent via email):\n\nRegistrar Corp\n\ndrugs@registrarcorp.com\n\n______________________\n\n1 Components with higher risk of (b)(4) contamination compared to other drug components.\n\n2 i.e., Quality System, Facilities & Equipment System, Materials System, Production System, Packaging & Labeling System, and Laboratory Control System per FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations.","Green Pharmaceutical Co. Ltd.","green-pharmaceutical-co-ltd-663544-08232023","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fgreen-pharmaceutical-co-ltd-663544-08232023","2026-10-26T08:08:49.939898+00:00","2023-09-05","663544","Jang Hyun-pill","2026-08-20T00:42:53.861+00:00","2023-08-23",{"id":231,"raw":232,"subject":39,"body_html":237,"body_text":238,"firm_name":239,"letter_id":240,"created_at":241,"fei_number":19,"letter_url":242,"updated_at":243,"action_type":22,"case_status":23,"posted_date":244,"marcs_cms_no":245,"product_type":26,"closeout_date":19,"issuing_office":236,"recipient_name":246,"body_fetched_at":247,"delivery_method":248,"recipient_title":19,"reference_number":19,"action_taken_date":249,"medical_device_id":19,"response_letter_date":19},3176,[233,234,235,236,39,13,13,13],"\u003Ctime datetime=\"2021-08-31T13:20:00Z\">08\u002F31\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-08-02T04:00:00Z\">08\u002F02\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fpharmaceutical-care-solutions-dba-pharmacy-solutions-610201-08022021\">Pharmaceutical Care Solutions dba Pharmacy Solutions\u003C\u002Fa>","Division of Pharmaceutical Quality Operations III","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>UPS Next Day\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Sahar Z. Swidan\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Pharmaceutical Care Solutions dba Pharmacy Solutions\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>5402 Jackson Road, Suite C\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Ann Arbor\u003C\u002Fspan>, \u003Cspan>MI\u003C\u002Fspan> \u003Cspan>48103-1866\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of Pharmaceutical Quality Operations III\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>August 2, 2021\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>\nCase# 610201\u003C\u002Fp>\n\n\u003Cp>Dear Ms. Swidan:\u003C\u002Fp>\n\n\u003Cp>From January 15, 2020, to January 24, 2020, U.S. Food and Drug Administration (FDA) investigators inspected your facility, Pharmaceutical Care Solutions dba Pharmacy Solutions, located at 5204 Jackson Road, Suite C, Ann Arbor, MI 48103. During the inspection, the investigators collected evidence indicating that drug products you produced failed to meet the conditions of section 503A of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. § 353a] for exemption from certain provisions of the FDCA. Based on this inspection, it appears that you produced drug products that violate the FDCA.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>A. Compounded Drug Products Under the FDCA\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Section 503A of the FDCA describes the conditions under which human drug products compounded by a licensed pharmacist in a State licensed pharmacy or a Federal facility, or a licensed physician, qualify for exemptions from three sections of the FDCA: compliance with current good manufacturing practice (CGMP) (section 501(a)(2)(B)); labeling with adequate directions for use (section 502(f)(1)); and FDA approval prior to marketing (section 505) [21 U.S.C. §§ 351(a)(2)(B), 352(f)(1) and 355(a)].\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Receipt of valid prescriptions for individually-identified patients is one of the conditions for the exemptions under section 503A.\u003C\u002Fp>\n\n\u003Cp>In addition, for a compounded drug product to qualify for the exemptions under section 503A, bulk drug substances used to compound it must: (I) comply with the standards of an applicable United States Pharmacopeia (USP) or National Formulary (NF) monograph, if a monograph exists, and the USP chapter on pharmacy compounding; (II) if such a monograph does not exist, be components of drugs approved by the Secretary; or (III) if such a monograph does not exist and the drug substance is not a component of a drug approved by the Secretary, appear on a list developed by the Secretary through regulation (“503A bulks list”) (section 503A(b)(1)(A)(i) of the FDCA).\u003C\u002Fp>\n\n\u003Cp>Further, each bulk drug substance used to compound a drug product must be manufactured by an establishment that is registered under section 510 of the FDCA [21 U.S.C § 360] (section 503A(b)(1)(A)(ii) of the FDCA).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>B. Failure to Meet the Conditions of Section 503A\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>During the inspection, the FDA investigators collected evidence indicating that drug products produced by your firm failed to meet the conditions of section 503A. For example, the evidence collected indicates that:\u003C\u002Fp>\n\n\u003Cp>1. Your firm compounded drug products using ammonium tetrathiomolybdate. Drug products compounded using ammonium tetrathiomolybdate are not eligible for the exemptions provided by section 503A(a), because ammonium tetrathiomolybdate is not the subject of an applicable USP or NF monograph, is not a component of an FDA-approved human drug and does not appear on the 503A bulks list.\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>2. Your firm compounded drug products using a bulk drug substance manufactured by \u003Cstrong>(b)(4)\u003C\u002Fstrong>, which is not a registered establishment under section 510 of the FDCA.\u003C\u002Fp>\n\n\u003Cp>Therefore, you compounded drug products that do not meet the conditions of section 503A and are not eligible for the exemptions in that section, including the FDA approval requirement of section 505 of the FDCA, the requirement under section 502(f)(1) of the FDCA that labeling bear adequate directions for use, and the requirement of compliance with CGMP under section 501(a)(2)(B) of the FDCA. In the remainder of this letter, we refer to your drug products that do not qualify for exemptions under section 503A as the “ineligible drug products.”\u003C\u002Fp>\n\n\u003Cp>Specific violations are described below.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>C. Violations of the FDCA\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved New Drug Products\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You do not have any FDA-approved applications on file for the ineligible drug products that you compounded.\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Under sections 505(a) and 301(d) of the FDCA [21 U.S.C. § 331(d)], a new drug may not be introduced into or delivered for introduction into interstate commerce unless an application approved by FDA under section 505 of the FDCA is in effect for the drug. Marketing of these products, or other applicable products, without an approved application violates these provisions of the FDCA.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Misbranded Drug Products\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The ineligible drug products you compounded are intended for conditions not amenable to self-diagnosis and treatment by individuals who are not medical practitioners; therefore, adequate directions for use cannot be written so that a layman can use these products safely for their intended uses. Consequently, their labeling fails to bear adequate directions for their intended uses.\u003Csup>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Accordingly, these ineligible drug products are misbranded under section 502(f)(1) of the FDCA.\u003C\u002Fp>\n\n\u003Cp>The introduction or delivery for introduction into interstate commerce of these ineligible drug products violates section 301(a) of the FDCA. It is also a prohibited act under section 301(k) of the FDCA to do any act with respect to a drug, if such act is done while the drug is held for sale after shipment in interstate commerce and results in the drug being misbranded.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>D. Corrective Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>We have reviewed your firm’s letter, dated February 14, 2020, in response to FDA’s inspection of your facility. Regarding issues related to the conditions of section 503A of the FDCA, the following corrective action appears deficient: you have not agreed to cease compounding with ammonium tetrathiomolybdate. In your letter you requested that FDA review ammonium tetrathiomolybdate bulk drug substance for addition to Category 1. Ammonium tetrathiomolybdate was nominated for inclusion on the 503A bulks list, but its nomination was later withdrawn. If you would like FDA to evaluate this bulk drug substance, ammonium tetrathiomolybdate may be renominated for inclusion on the 503A bulks list by submitting a nomination to docket number FDA-2015-N-3534 at \u003Ca>www.regulations.gov\u003C\u002Fa>. For more information on how to submit a nomination, please see the instructions in the Federal Register notice titled, \u003Cem>Bulk Drug Substances That Can Be Used To Compound Drug Products in&nbsp;\u003C\u002Fem>\u003Cem>Accordance With Section 503A of the Federal Food, Drug, and Cosmetic Act; Establishment of a Public Docket\u003C\u002Fem>.\u003Csup>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>In addition, you have not addressed your use of bulk drug substances from establishments that are not registered under section 510 of the FDCA. As stated above, to qualify for the exemptions under section 503A of the FDCA, only bulk drug substances manufactured by an establishment that is registered under section 510 of the FDCA may be used in compounding.\u003C\u002Fp>\n\n\u003Cp>Should you continue to compound and distribute drug products that do not meet the conditions of section 503A, the compounding and distribution of such drugs would be subject to the new drug approval requirement, the requirement to label drug products with adequate directions for use, and the drug CGMP regulations.\u003C\u002Fp>\n\n\u003Cp>In addition, we also note that during the inspection, the FDA investigators collected evidence indicating that your firm had tranilast in inventory. As noted above, for a compounded drug product to qualify for the exemptions under section 503A of the FDCA, bulk drug substances used to compound it must: (I) comply with the standards of an applicable USP or NF monograph, if a monograph exists, and the USP chapter on pharmacy compounding; (II) if such a monograph does not exist, be components of drugs approved by the Secretary; or (III) if such a monograph does not exist and the drug substance is not a component of a drug approved by the Secretary, appear on a list developed by the Secretary through regulation (“503A bulks list”) (section 503A(b)(1)(A)(i) of the FDCA). Tranilast was nominated for inclusion on the 503A bulks list, was evaluated by Pharmacy Compounding Advisory Committee and by FDA and FDA determined not to include tranilast on the list of bulk drug substances that can be used in compounding under section 503A, found at 21 C.F.R. 216.23(a). \u003Cem>See\u003C\u002Fem> 21 C.F.R. 216.23(b)(4). Accordingly, drug products compounded using tranilast are not eligible for the exemptions provided by section 503A(a).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>E. Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive statement of violations at your facility. You are responsible for investigating and determining the causes of the violations identified above and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>You should take prompt action to correct the violations cited in this letter. Failure to adequately address this matter may result in legal action without further notice, including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Within fifteen (15) working days of receipt of this letter, please notify this office in writing of the specific steps that you have taken to correct violations. Please include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. This letter notifies you of our concerns and provides an opportunity to address them. If you believe your products are not in violation of the FDCA, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within fifteen (15) working days, state the reason for the delay and the time within which you will complete the correction.\u003C\u002Fp>\n\n\u003Cp>Please address your reply via email to: ORAPHARM3_RESPONSES@fda.hhs.gov\u003C\u002Fp>\n\n\u003Cp>Attention: Brian D. Garthwaite, Ph. D.\u003Cbr>\nCompliance Officer\u003Cbr>\nU.S. Food and Drug Administration\u003Cbr>\nDivision of Pharmaceutical Quality Operations Division III\u003C\u002Fp>\n\n\u003Cp>Your written notification should refer to the Warning Letter Number above (Case # 610201). If you have questions about the contents of this letter, please contact Dr. Garthwaite at (612) 758-7132.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Art O. Czabaniuk\u003Cbr>\nProgram Division Director\u003Cbr>\nDivision of Pharmaceutical Quality Operations III\u003C\u002Fp>\n\n\u003Cp>__________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> We remind you that there are conditions other than those discussed in this letter that must be satisfied to qualify for the exemptions in section 503A of the FDCA.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> On June 9, 2016, FDA issued a final guidance titled, \u003Cem>Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the Federal Food, Drug, and Cosmetic Act\u003C\u002Fem>. This guidance describes FDA’s interim regulatory policy for State-licensed pharmacies, Federal facilities, and licensed physicians that compound human drug products using bulk drug substances that do not otherwise meet the conditions of section 503A(b)(1)(A)(i) while the 503A bulks list is being developed. Specifically, the guidance sets out the conditions under which FDA does not intend to take action against a State-licensed pharmacy, Federal facility, or licensed physician for compounding a drug product using a bulk drug substance that is not the subject of an applicable USP or NF monograph or a component of an FDA-approved drug, until the substance is identified in a final rule as included or not included on the 503A bulks list. These conditions include that the substance may be eligible for inclusion on the 503A bulks list, was nominated with adequate support for FDA to evaluate it, and has not been identified by FDA as a substance that appears to present significant safety risks pending further evaluation. Ammonium tetrathiomolybdate was nominated for inclusion on the 503A bulks list, but its nomination was later withdrawn. For additional information, see the guidance at \u003Ca href=\"http:\u002F\u002Fwww.fda.gov\u002Fdownloads\u002FDrugs\u002FGuidanceComplianceRegulatoryInformation\u002FGuidances\u002FUCM469120.pdf\">http:\u002F\u002Fwww.fda.gov\u002Fdownloads\u002FDrugs\u002FGuidanceComplianceRegulatoryInformation\u002FGuidances\u002FUCM469120.pdf\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> The specific products made by your firm are drugs within the meaning of section 201(g) of the Act, [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases and\u002For because they are intended to affect the structure or any function of the body. Further, they are “new drugs” within the meaning of section 201(p) [21 U.S.C. 321(p)] of the FDCA because they are not generally recognized as safe and effective for their labeled uses.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> Your ineligible drug products are not exempted from the requirements of section 502(f)(1) of the FDCA by regulations issued by the FDA (see, e.g., 21 CFR 201.115).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem> See \u003Ca href=\"https:\u002F\u002Fwww.govinfo.gov\u002Fcontent\u002Fpkg\u002FFR-2015-10-27\u002Fpdf\u002F2015-27271.pdf\">https:\u002F\u002Fwww.govinfo.gov\u002Fcontent\u002Fpkg\u002FFR-2015-10-27\u002Fpdf\u002F2015-27271.pdf\u003C\u002Fa>.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nUPS Next Day\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nSahar Z. Swidan\n\nRecipient Title\n\nCEO\n\nPharmaceutical Care Solutions dba Pharmacy Solutions\n\n5402 Jackson Road, Suite C\n\nAnn Arbor, MI 48103-1866\n\nUnited States\n\nIssuing Office:\n\nDivision of Pharmaceutical Quality Operations III\n\nUnited States\n\nAugust 2, 2021\n\nWARNING LETTER\n\nCase# 610201\n\nDear Ms. Swidan:\n\nFrom January 15, 2020, to January 24, 2020, U.S. Food and Drug Administration (FDA) investigators inspected your facility, Pharmaceutical Care Solutions dba Pharmacy Solutions, located at 5204 Jackson Road, Suite C, Ann Arbor, MI 48103. During the inspection, the investigators collected evidence indicating that drug products you produced failed to meet the conditions of section 503A of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. § 353a] for exemption from certain provisions of the FDCA. Based on this inspection, it appears that you produced drug products that violate the FDCA.\n\nA. Compounded Drug Products Under the FDCA\n\nSection 503A of the FDCA describes the conditions under which human drug products compounded by a licensed pharmacist in a State licensed pharmacy or a Federal facility, or a licensed physician, qualify for exemptions from three sections of the FDCA: compliance with current good manufacturing practice (CGMP) (section 501(a)(2)(B)); labeling with adequate directions for use (section 502(f)(1)); and FDA approval prior to marketing (section 505) [21 U.S.C. §§ 351(a)(2)(B), 352(f)(1) and 355(a)].1 Receipt of valid prescriptions for individually-identified patients is one of the conditions for the exemptions under section 503A.\n\nIn addition, for a compounded drug product to qualify for the exemptions under section 503A, bulk drug substances used to compound it must: (I) comply with the standards of an applicable United States Pharmacopeia (USP) or National Formulary (NF) monograph, if a monograph exists, and the USP chapter on pharmacy compounding; (II) if such a monograph does not exist, be components of drugs approved by the Secretary; or (III) if such a monograph does not exist and the drug substance is not a component of a drug approved by the Secretary, appear on a list developed by the Secretary through regulation (“503A bulks list”) (section 503A(b)(1)(A)(i) of the FDCA).\n\nFurther, each bulk drug substance used to compound a drug product must be manufactured by an establishment that is registered under section 510 of the FDCA [21 U.S.C § 360] (section 503A(b)(1)(A)(ii) of the FDCA).\n\nB. Failure to Meet the Conditions of Section 503A\n\nDuring the inspection, the FDA investigators collected evidence indicating that drug products produced by your firm failed to meet the conditions of section 503A. For example, the evidence collected indicates that:\n\n1. Your firm compounded drug products using ammonium tetrathiomolybdate. Drug products compounded using ammonium tetrathiomolybdate are not eligible for the exemptions provided by section 503A(a), because ammonium tetrathiomolybdate is not the subject of an applicable USP or NF monograph, is not a component of an FDA-approved human drug and does not appear on the 503A bulks list.2\n\n2. Your firm compounded drug products using a bulk drug substance manufactured by (b)(4), which is not a registered establishment under section 510 of the FDCA.\n\nTherefore, you compounded drug products that do not meet the conditions of section 503A and are not eligible for the exemptions in that section, including the FDA approval requirement of section 505 of the FDCA, the requirement under section 502(f)(1) of the FDCA that labeling bear adequate directions for use, and the requirement of compliance with CGMP under section 501(a)(2)(B) of the FDCA. In the remainder of this letter, we refer to your drug products that do not qualify for exemptions under section 503A as the “ineligible drug products.”\n\nSpecific violations are described below.\n\nC. Violations of the FDCA\n\nUnapproved New Drug Products\n\nYou do not have any FDA-approved applications on file for the ineligible drug products that you compounded.3 Under sections 505(a) and 301(d) of the FDCA [21 U.S.C. § 331(d)], a new drug may not be introduced into or delivered for introduction into interstate commerce unless an application approved by FDA under section 505 of the FDCA is in effect for the drug. Marketing of these products, or other applicable products, without an approved application violates these provisions of the FDCA.\n\nMisbranded Drug Products\n\nThe ineligible drug products you compounded are intended for conditions not amenable to self-diagnosis and treatment by individuals who are not medical practitioners; therefore, adequate directions for use cannot be written so that a layman can use these products safely for their intended uses. Consequently, their labeling fails to bear adequate directions for their intended uses.4 Accordingly, these ineligible drug products are misbranded under section 502(f)(1) of the FDCA.\n\nThe introduction or delivery for introduction into interstate commerce of these ineligible drug products violates section 301(a) of the FDCA. It is also a prohibited act under section 301(k) of the FDCA to do any act with respect to a drug, if such act is done while the drug is held for sale after shipment in interstate commerce and results in the drug being misbranded.\n\nD. Corrective Actions\n\nWe have reviewed your firm’s letter, dated February 14, 2020, in response to FDA’s inspection of your facility. Regarding issues related to the conditions of section 503A of the FDCA, the following corrective action appears deficient: you have not agreed to cease compounding with ammonium tetrathiomolybdate. In your letter you requested that FDA review ammonium tetrathiomolybdate bulk drug substance for addition to Category 1. Ammonium tetrathiomolybdate was nominated for inclusion on the 503A bulks list, but its nomination was later withdrawn. If you would like FDA to evaluate this bulk drug substance, ammonium tetrathiomolybdate may be renominated for inclusion on the 503A bulks list by submitting a nomination to docket number FDA-2015-N-3534 at www.regulations.gov. For more information on how to submit a nomination, please see the instructions in the Federal Register notice titled, Bulk Drug Substances That Can Be Used To Compound Drug Products in Accordance With Section 503A of the Federal Food, Drug, and Cosmetic Act; Establishment of a Public Docket.5\n\nIn addition, you have not addressed your use of bulk drug substances from establishments that are not registered under section 510 of the FDCA. As stated above, to qualify for the exemptions under section 503A of the FDCA, only bulk drug substances manufactured by an establishment that is registered under section 510 of the FDCA may be used in compounding.\n\nShould you continue to compound and distribute drug products that do not meet the conditions of section 503A, the compounding and distribution of such drugs would be subject to the new drug approval requirement, the requirement to label drug products with adequate directions for use, and the drug CGMP regulations.\n\nIn addition, we also note that during the inspection, the FDA investigators collected evidence indicating that your firm had tranilast in inventory. As noted above, for a compounded drug product to qualify for the exemptions under section 503A of the FDCA, bulk drug substances used to compound it must: (I) comply with the standards of an applicable USP or NF monograph, if a monograph exists, and the USP chapter on pharmacy compounding; (II) if such a monograph does not exist, be components of drugs approved by the Secretary; or (III) if such a monograph does not exist and the drug substance is not a component of a drug approved by the Secretary, appear on a list developed by the Secretary through regulation (“503A bulks list”) (section 503A(b)(1)(A)(i) of the FDCA). Tranilast was nominated for inclusion on the 503A bulks list, was evaluated by Pharmacy Compounding Advisory Committee and by FDA and FDA determined not to include tranilast on the list of bulk drug substances that can be used in compounding under section 503A, found at 21 C.F.R. 216.23(a). See 21 C.F.R. 216.23(b)(4). Accordingly, drug products compounded using tranilast are not eligible for the exemptions provided by section 503A(a).\n\nE. Conclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive statement of violations at your facility. You are responsible for investigating and determining the causes of the violations identified above and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nYou should take prompt action to correct the violations cited in this letter. Failure to adequately address this matter may result in legal action without further notice, including, without limitation, seizure and injunction.\n\nWithin fifteen (15) working days of receipt of this letter, please notify this office in writing of the specific steps that you have taken to correct violations. Please include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. This letter notifies you of our concerns and provides an opportunity to address them. If you believe your products are not in violation of the FDCA, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within fifteen (15) working days, state the reason for the delay and the time within which you will complete the correction.\n\nPlease address your reply via email to: ORAPHARM3_RESPONSES@fda.hhs.gov\n\nAttention: Brian D. Garthwaite, Ph. D.\n\nCompliance Officer\n\nU.S. Food and Drug Administration\n\nDivision of Pharmaceutical Quality Operations Division III\n\nYour written notification should refer to the Warning Letter Number above (Case # 610201). If you have questions about the contents of this letter, please contact Dr. Garthwaite at (612) 758-7132.\n\nSincerely,\n\n\u002FS\u002F\n\nArt O. Czabaniuk\n\nProgram Division Director\n\nDivision of Pharmaceutical Quality Operations III\n\n__________________________\n\n1 We remind you that there are conditions other than those discussed in this letter that must be satisfied to qualify for the exemptions in section 503A of the FDCA.\n\n2 On June 9, 2016, FDA issued a final guidance titled, Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the Federal Food, Drug, and Cosmetic Act. This guidance describes FDA’s interim regulatory policy for State-licensed pharmacies, Federal facilities, and licensed physicians that compound human drug products using bulk drug substances that do not otherwise meet the conditions of section 503A(b)(1)(A)(i) while the 503A bulks list is being developed. Specifically, the guidance sets out the conditions under which FDA does not intend to take action against a State-licensed pharmacy, Federal facility, or licensed physician for compounding a drug product using a bulk drug substance that is not the subject of an applicable USP or NF monograph or a component of an FDA-approved drug, until the substance is identified in a final rule as included or not included on the 503A bulks list. These conditions include that the substance may be eligible for inclusion on the 503A bulks list, was nominated with adequate support for FDA to evaluate it, and has not been identified by FDA as a substance that appears to present significant safety risks pending further evaluation. Ammonium tetrathiomolybdate was nominated for inclusion on the 503A bulks list, but its nomination was later withdrawn. For additional information, see the guidance at http:\u002F\u002Fwww.fda.gov\u002Fdownloads\u002FDrugs\u002FGuidanceComplianceRegulatoryInformation\u002FGuidances\u002FUCM469120.pdf.\n\n3 The specific products made by your firm are drugs within the meaning of section 201(g) of the Act, [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases and\u002For because they are intended to affect the structure or any function of the body. Further, they are “new drugs” within the meaning of section 201(p) [21 U.S.C. 321(p)] of the FDCA because they are not generally recognized as safe and effective for their labeled uses.\n\n4 Your ineligible drug products are not exempted from the requirements of section 502(f)(1) of the FDCA by regulations issued by the FDA (see, e.g., 21 CFR 201.115).\n\n5 See https:\u002F\u002Fwww.govinfo.gov\u002Fcontent\u002Fpkg\u002FFR-2015-10-27\u002Fpdf\u002F2015-27271.pdf.","Pharmaceutical Care Solutions dba Pharmacy Solutions","pharmaceutical-care-solutions-dba-pharmacy-solutions-610201-08022021","2026-08-18T06:42:29.386127+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fpharmaceutical-care-solutions-dba-pharmacy-solutions-610201-08022021","2026-10-26T08:09:41.17307+00:00","2021-08-31","610201","Sahar Z. Swidan","2026-08-20T02:39:10.736+00:00","UPS Next Day","2021-08-02",{"id":251,"raw":252,"subject":80,"body_html":256,"body_text":257,"firm_name":258,"letter_id":259,"created_at":260,"fei_number":19,"letter_url":261,"updated_at":262,"action_type":22,"case_status":23,"posted_date":263,"marcs_cms_no":264,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":265,"body_fetched_at":266,"delivery_method":110,"recipient_title":19,"reference_number":267,"action_taken_date":268,"medical_device_id":19,"response_letter_date":19},768,[253,254,255,11,80,13,13,13],"\u003Ctime datetime=\"2025-07-15T04:00:00Z\">07\u002F15\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-07-02T04:00:00Z\">07\u002F02\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fdaewoo-pharmaceutical-co-ltd-706371-07022025\">Daewoo Pharmaceutical Co., Ltd.\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-25-86\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Jin Soo Baek\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Managing Director\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Daewoo Pharmaceutical Co., Ltd.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>153, Dadae-ro, Saha-gu\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Busan\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>49393\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>South Korea\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-25-86\u003C\u002Fp>\u003Cp>July 2, 2025\u003C\u002Fp>\u003Cp>\u003Cstrong>AMENDED\u003C\u002Fstrong>\u003Cbr>(This letter replaces Warning Letter No. 320-25-86 dated June 26, 2025)\u003C\u002Fp>\u003Cp>\u003Cbr>Dear Mr. Baek:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Daewoo Pharmaceuticals Co., Ltd., FEI 1000448124, at 153, Dadae-ro, Saha-gu, Busan, from January 6 to 15, 2025.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug product are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>We reviewed your February 12, 2025 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes (21 CFR 211.113(b)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cem>Inadequate Smoke Studies\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Smoke studies showed a lack of unidirectional airflow in your ISO 5 aseptic processing operation. Multiple instances of turbulent airflow in critical areas of filling line \u003Cstrong>(b)(4)\u003C\u002Fstrong> were noted, including above the \u003Cstrong>(b)(4)\u003C\u002Fstrong>. In addition, smoke study videos did not include set-up of the aseptic processing line or filling line interventions that sufficiently represent your commercial manufacturing process.\u003C\u002Fp>\u003Cp>In your response, you commit to repeat smoke studies with defined set-up and interventions. Your response is inadequate as you do not provide details, such as how you will address line deficiencies, when you will perform the smoke studies, and what interventions will be included.\u003C\u002Fp>\u003Cp>\u003Cem>Inadequate Media Fill Program\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Your media fills failed to accurately simulate commercial operations. Our inspection found that the aseptic operations simulated during your media fills were not sufficiently representative of aseptic manufacturing operations. We observed significantly more interventions performed during routine batch manufacturing that were either not simulated or reduced in quantity in media fills, as compared to what was observed during production. Notably, a substantial number of these interventions during routine production were unplanned.\u003C\u002Fp>\u003Cp>In addition, the type, frequency, and time of interventions are not routinely documented in production batch records.\u003C\u002Fp>\u003Cp>Your firm also did not require operators to participate in a media fill prior to working in the aseptic processing operation.\u003C\u002Fp>\u003Cp>Your response is inadequate. You commit to documenting routine interventions during manufacturing but fail to evaluate the interventions used in your media fill program and their inadequate representation of routine production. Your operators performed numerous, manually intensive interventions during aseptic operations. As such, the quantity of process simulation interventions and the duration of the media fill should closely resemble the actual manufacturing process. If a media fill program fails to incorporate contamination risk factors and closely simulate actual drug product exposure, the state of process control and assurance of sterility cannot be accurately assessed.\u003C\u002Fp>\u003Cp>\u003Cem>Poor Practices in the Aseptic Processing Areas\u003C\u002Fem>\u003C\u002Fp>\u003Cp>During the inspection of your facility, we observed poor practices in ISO 5 areas during the aseptic processing of sterile drug products. These poor practices included, but are not limited to:\u003C\u002Fp>\u003Cul>\u003Cli>Exposed skin in the ISO 5 area (e.g., forehead).\u003C\u002Fli>\u003Cli>Use of non-sterile tape on the filling line.\u003C\u002Fli>\u003Cli>Storage of machine tools and spare parts, for use on the filling line, in a \u003Cstrong>(b)(4)\u003C\u002Fstrong> of the ISO 5 area.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Your response is inadequate because it does not address the lack of oversight of the operators’ aseptic practices and evaluate the insufficiencies in their training. Further, these poor aseptic practices were not evaluated to determine the impact to aseptic processing operations.\u003C\u002Fp>\u003Cp>\u003Cem>Insufficient Personnel Monitoring\u003C\u002Fem>\u003C\u002Fp>\u003Cp>The personnel monitoring for operators working in the ISO 5 area was not sufficient to assure sterility. For example, the locations chosen for personnel monitoring were not scientifically justified, nor was the practice of using \u003Cstrong>(b)(4)\u003C\u002Fstrong> plates for one hand and \u003Cstrong>(b)(4)\u003C\u002Fstrong> for the other. In addition, there was no written procedure for gowning qualification.\u003C\u002Fp>\u003Cp>Your response is inadequate, as you fail to conduct a retrospective review of your aseptic personnel monitoring practices.\u003C\u002Fp>\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\u003Cul>\u003Cli>Comprehensive risk assessment of all contamination hazards with respect to your aseptic processes, equipment, and facilities, including an independent assessment that includes, but is not limited to:\u003Cbr>o All human interactions within the ISO 5 area\u003Cbr>o Equipment placement and ergonomics\u003Cbr>o Air quality in the ISO 5 area and surrounding room\u003Cbr>o Facility layout\u003Cbr>o Personnel Flows and Material Flows (throughout all rooms used to conduct and support sterile operations)\u003C\u002Fli>\u003Cli>A detailed remediation plan with timelines to address the findings of the contamination hazards risk assessment. Describe specific tangible improvements to be made to aseptic processing operation design and control.\u003C\u002Fli>\u003Cli>Your plan to ensure appropriate aseptic practices and cleanroom behavior during production. Include steps to ensure routine and effective supervisory oversight for all production batches. Also describe the frequency of quality unit (QU) oversight (e.g., audit) during aseptic processing and its support-operations.\u003C\u002Fli>\u003Cli>A thorough retrospective review and risk assessment that evaluates how poor aseptic technique and cleanroom behavior may have affected the quality and sterility of your drugs.\u003C\u002Fli>\u003Cli>Smoke studies under dynamic conditions, with thorough and complete evaluations of aseptic interventions and operator positioning within the critical filling areas. After you remediate your aseptic operation, provide smoke studies that visualize airflow and critically evaluate unidirectional airflow. Include a video of your dynamic smoke studies.\u003C\u002Fli>\u003Cli>A comprehensive summary of your remediated media fill program that ensures appropriate simulations of worst-case conditions in commercial manufacturing.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Your firm failed to perform operations within specifically defined areas of adequate size and to have separate or defined areas or such other control systems necessary to prevent contamination or mix-ups in aseptic processing areas (21 CFR 211.42(c)(10)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cem>Equipment as a Route of Contamination\u003C\u002Fem>\u003C\u002Fp>\u003Cp>The design of the aseptic processing line used to manufacture over-the-counter \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug products was inadequate. Line \u003Cstrong>(b)(4)\u003C\u002Fstrong> is a traditional filling line consisting of an ISO 5 area \u003Cstrong>(b)(4)\u003C\u002Fstrong> and a surrounding ISO 7 area. The line involves manually intensive \u003Cstrong>(b)(4)\u003C\u002Fstrong> interventions, and the HEPA filter layout leaves approximately 10-centimeter gaps due to overhead lights in between the filters that appear to affect unidirectional airflow.\u003C\u002Fp>\u003Cp>Furthermore, you did not sterilize direct product contact equipment that holds primary container and closure components for your sterile drug products. These equipment were disinfected with \u003Cstrong>(b)(4)\u003C\u002Fstrong>, which are not sterilants. You also use \u003Cstrong>(b)(4)\u003C\u002Fstrong> approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong>, which is a decontaminating agent.\u003C\u002Fp>\u003Cp>Your response is inadequate. You commit to turning Line \u003Cstrong>(b)(4)\u003C\u002Fstrong> into an \u003Cstrong>(b)(4)\u003C\u002Fstrong> restricted access barrier (\u003Cstrong>(b)(4)\u003C\u002Fstrong>RAB) filling line. However, you did not provide detailed plans for how you will redesign your filling line and conduct a risk assessment for products currently released to the U.S. Market.\u003C\u002Fp>\u003Cp>\u003Cem>Environmental Monitoring (EM)\u003C\u002Fem>\u003C\u002Fp>\u003Cp>The EM of your aseptic processing operations was inadequate. The locations identified for EM in ISO 5 and ISO 7 areas lacked scientific justification and were not sufficiently located where the aseptic operations are taking place.\u003C\u002Fp>\u003Cp>The consistent and meaningful contamination level in ISO 7, along with frequent manually intensive interventions, posed a high risk to sterile products on your aseptic processing line.\u003C\u002Fp>\u003Cp>Your response is inadequate. You commit to repeating the EM risk assessment and trending EM data but fail to include plans for how you will assess your line after redesign.\u003C\u002Fp>\u003Cp>A vigilant, ongoing EM program is essential to detect and respond to potential product contamination hazards in your manufacturing environment in a timely manner. Loss of environmental control in an aseptic manufacturing facility can ultimately pose a serious hazard to patients.\u003C\u002Fp>\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\u003Cul>\u003Cli>Your corrective action and preventive action (CAPA) plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, and improved systems for ongoing management review.\u003C\u002Fli>\u003Cli>An independent assessment of your EM program including, but not limited to, establishing appropriate limits, sampling locations and frequencies, investigating deviations, and trend analysis. Also, ensure the implementation of a comprehensive CAPA plan.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>3. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cem>Visual Inspection\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Your post-fill visual inspection of aseptically filled drug products was insufficient to identify defects which may be present. For example, bottles were only inspected against a \u003Cstrong>(b)(4)\u003C\u002Fstrong> background to identify visible defects, particulates, and cloudiness. Individual defect limits were not set. Further, an Acceptable Quality Limit (AQL) sample is not obtained for quality assurance evaluation.\u003C\u002Fp>\u003Cp>In addition, your visual inspector qualification process is inadequate. For example, you lack a procedure for inspector training, and the \u003Cstrong>(b)(4)\u003C\u002Fstrong> challenge kit is used for each of \u003Cstrong>(b)(4)\u003C\u002Fstrong> runs where it is not required that inspectors identify the correct defect, only the correct bottle.\u003C\u002Fp>\u003Cp>Your response is inadequate. You commit to evaluating the visual inspection program and replacing the \u003Cstrong>(b)(4)\u003C\u002Fstrong> process with an \u003Cstrong>(b)(4)\u003C\u002Fstrong> one, instead of a \u003Cstrong>(b)(4)\u003C\u002Fstrong> inspection methods. Your program should include an appropriate combination of these techniques to ensure detection of the wide array of potential visible product defects.\u003C\u002Fp>\u003Cp>In addition, you fail to provide details regarding the qualification and creation of a defect library, challenge kits, appropriate inspection protocols (including use of a \u003Cstrong>(b)(4)\u003C\u002Fstrong> background), and inspector training.\u003C\u002Fp>\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\u003Cul>\u003Cli>A formalized 100% visual inspection program designed to reliably detect particulate contamination and other visible defects. Your program should detail the inspection methods, identify categories of defects and their associated acceptance and rejection limits for each batch, and include inspector training and qualification.\u003C\u002Fli>\u003Cli>A retrospective review of drug product batches released without having undergone a complete and appropriate visual inspection by qualified inspectors.\u003C\u002Fli>\u003Cli>Perform a visual inspection of retain samples for all batches already in distribution and provide the results.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>4. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The QU failed to maintain adequate CGMP oversight. For example:\u003C\u002Fp>\u003Cp>\u003Cem>Lack of Written Procedures (211.100)\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Numerous written procedures were either missing or lacked sufficient detail to ensure consistent repeatability between operators. For example, the following critical processes were not contained in a written procedure: set-up of the filling line, performing interventions on the filling line, personnel monitoring, and how to perform \u003Cstrong>(b)(4)\u003C\u002Fstrong> decontamination of aseptic processing rooms.\u003C\u002Fp>\u003Cp>In addition, written procedures lacked sufficient detail, including those for cleaning of the filling line and cleaning of the filling room.\u003C\u002Fp>\u003Cp>Your response is inadequate. You commit to writing procedures for the critical items described above, however you fail to perform a comprehensive review to ensure appropriate procedures are established and followed as part of your quality system. In addition, you did not provide a comprehensive risk assessment of the product impact of the lack of sufficient procedures.\u003C\u002Fp>\u003Cp>\u003Cem>Investigations (211.192)\u003C\u002Fem>\u003C\u002Fp>\u003Cp>We noted multiple instances where thorough investigations were not completed. For example, a viable air monitoring plate dated January 22, 2024, had a significant microbial recovery for the ISO 7 area of Line \u003Cstrong>(b)(4)\u003C\u002Fstrong>, identified as \u003Cem>Cladosporium\u003C\u002Fem>, a mold. The available documentation of the \u003Cem>Cladosporium\u003C\u002Fem> recovery noted that the same mold was found in multiple areas of the facility. You lacked a meaningful investigation into this trend.\u003C\u002Fp>\u003Cp>Your response is inadequate as you did not commit to opening an investigation to examine this and other potentially adverse trends.\u003C\u002Fp>\u003Cp>\u003Cem>Complaint Handling (211.198(a))\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Your complaint handling and investigation process is inadequate. Retain samples are not always evaluated for sterility unless requested by your distributor, even when the complaint indicates potential contamination. For example, you received a substantial number of complaints for burning or redness but did not perform sterility testing on retain samples until the fourth complaint was received.\u003C\u002Fp>\u003Cp>Your response is inadequate. You commit to reviewing past complaints and updating your current procedure but fail to provide details for how you will incorporate testing, including but not limited to, sterility, into your complaint handling process in the future.\u003C\u002Fp>\u003Cp>\u003Cem>Raw Material Testing for \u003Cstrong>(b)(4)\u003C\u002Fstrong> (211.84(d)(2))\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Your incoming raw material sampling and testing plan for \u003Cstrong>(b)(4)\u003C\u002Fstrong>, which is a component at high-risk of contamination with \u003Cstrong>(b)(4)\u003C\u002Fstrong>, is inadequate.\u003C\u002Fp>\u003Cp>Your response is inadequate. While you commit to testing each container of every lot moving forward, you did not commit to testing of finished products that previously used these raw materials to verify that \u003Cstrong>(b)(4)\u003C\u002Fstrong> are not present above specified levels.\u003C\u002Fp>\u003Cp>The use of ingredients contaminated with \u003Cstrong>(b)(4)\u003C\u002Fstrong> has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document Testing of \u003Cstrong>(b)(4)\u003C\u002Fstrong> to help you meet the CGMP requirements when manufacturing drugs containing ingredients at high-risk for \u003Cstrong>(b)(4)\u003C\u002Fstrong> contamination at \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A commitment to provide \u003Cstrong>(b)(4)\u003C\u002Fstrong> test results, no later than 30 calendar days from the date of this letter, from testing retains for all lots of high-risk drug components used in the manufacture of drug products. Alternatively, if a retain of a component lot is unavailable, perform retain sample testing of all implicated finished drug product batches for the presence of \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fli>\u003Cli>A full risk assessment for drug products that are within expiry which contain any ingredient at risk for \u003Cstrong>(b)(4)\u003C\u002Fstrong> contamination (including, but not limited to, \u003Cstrong>(b)(4)\u003C\u002Fstrong>). Take prompt and appropriate actions to determine the safety of all lots of the component(s) and any related drug product that could contain \u003Cstrong>(b)(4)\u003C\u002Fstrong>, including customer notifications and product recalls for any contaminated lots. Identify additional appropriate CAPAs that secure supply chains in the future, including, but not limited to, ensuring that all incoming raw material lots are from fully qualified manufacturers and free from unsafe impurities. Detail these actions in your response to this letter.\u003C\u002Fli>\u003Cli>A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s certificate of analysis instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic revalidation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot. In the case of \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and certain additional high-risk components we note that this includes the performance of parts \u003Cstrong>(b)(4)\u003C\u002Fstrong> of the United States Pharmacopeia (USP) monograph.\u003C\u002Fli>\u003Cli>The chemical quality control specifications you use to test each incoming lot of high-risk drug components to determine acceptability for use in manufacturing.\u003C\u002Fli>\u003Cli>A comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\u003C\u002Fli>\u003Cli>A comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, out-of-specification (OOS) results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, QU oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\u003C\u002Fli>\u003Cli>A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003Cbr>o A determination of whether procedures used by your firm are robust and appropriate.\u003Cbr>o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\u003Cbr>o A complete and final review of each batch and its related information before the QU disposition decision.\u003Cbr>o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>5. Your firm failed to establish and follow adequate written procedures for cleaning and maintenance of equipment (21 CFR 211.67(b)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your cleaning procedures lack sufficient detail to ensure repeatability between operators. We observed cleaning deficiencies and variability between operators, including wiping technique, using the same cleaning cloths for multiple areas, and failure to clean on top of the overhead light casings of the filling line.\u003C\u002Fp>\u003Cp>Further, the disinfection efficacy studies for \u003Cstrong>(b)(4)\u003C\u002Fstrong> did not adequately address all materials of the filling line, including but not limited to, \u003Cstrong>(b)(4)\u003C\u002Fstrong> (filling equipment), \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong> hose).\u003C\u002Fp>\u003Cp>In addition, your \u003Cstrong>(b)(4)\u003C\u002Fstrong> room decontamination validation is deficient (e.g., biological indicator locations are not adequately justified).\u003C\u002Fp>\u003Cp>Your response is inadequate. You commit to conduct a comprehensive review and assessment of cleaning and disinfection practices; however, you fail to investigate the impact on the products in the U.S. Market. In addition, a retrospective review for only extraneous chromatographic peaks is not sufficient to determine if deficient cleaning practices contribute to finished product that does not meet established specifications.\u003C\u002Fp>\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\u003Cul>\u003Cli>A CAPA plan, based on the retrospective assessment of your cleaning and disinfection program, that includes appropriate remediations to your cleaning and disinfection processes and practices, and timelines for completion. Provide a detailed summary of vulnerabilities in your process for lifecycle management of equipment cleaning and disinfection. Describe improvements to your cleaning and disinfection program, including enhancements to cleaning and disinfection effectiveness; improved ongoing verification of proper cleaning and disinfection execution for all products and equipment; and all other needed remediations.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Additional Guidance on Aseptic Processing\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>See FDA’s guidance document \u003Cem>Sterile Drug Products Produced by Aseptic Processing—Current Good Manufacturing Practice\u003C\u002Fem> to help you meet the CGMP requirements when manufacturing sterile drugs using aseptic processing at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71026\u002Fdownload.\u003C\u002Fp>\u003Cp>\u003Cstrong>Quality Systems\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm’s quality systems are inadequate. For guidance on establishing and maintaining CGMP-compliant quality systems, see FDA’s guidances: Q9 Quality Risk Management at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F167721\u002Fdownload and Q10 Pharmaceutical Quality System at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71553\u002Fdownload.\u003C\u002Fp>\u003Cp>\u003Cstrong>Drug Production Suspended\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>We acknowledge your commitment to suspend production of all drugs and that you deregistered your facility as a drug manufacturer. In response to this letter, clarify whether you intend to resume manufacturing drugs for the U.S. market at this facility in the future.\u003C\u002Fp>\u003Cp>If you plan to resume any manufacturing operations regulated under the FD&amp;C Act, notify this office before resuming your drug manufacturing operations. If your firm intends to resume manufacturing drugs, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations to assist your firm in meeting CGMP requirements. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance. In your notification to the Agency, provide a summary of your remediations to demonstrate that you have appropriately completed all CAPAs.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>Correct any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\u003C\u002Fp>\u003Cp>Failure to address any violations may also result in the FDA refusing admission of articles manufactured at Daewoo Pharmaceutical Co. Ltd, 153, Dadae-ro, Saha-gu, Busan, into the United States under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 1000448124 and ATTN: Sarah Rhoades.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nReference #:\n\n320-25-86\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Jin Soo Baek\n\nRecipient Title\n\nManaging Director\n\nDaewoo Pharmaceutical Co., Ltd.\n\n153, Dadae-ro, Saha-gu\n\nBusan\n\n49393\n\nSouth Korea\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-25-86\nJuly 2, 2025\nAMENDED\n(This letter replaces Warning Letter No. 320-25-86 dated June 26, 2025)\n\nDear Mr. Baek:\nThe United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Daewoo Pharmaceuticals Co., Ltd., FEI 1000448124, at 153, Dadae-ro, Saha-gu, Busan, from January 6 to 15, 2025.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug product are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nWe reviewed your February 12, 2025 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n1. Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes (21 CFR 211.113(b)).\nInadequate Smoke Studies\nSmoke studies showed a lack of unidirectional airflow in your ISO 5 aseptic processing operation. Multiple instances of turbulent airflow in critical areas of filling line (b)(4) were noted, including above the (b)(4). In addition, smoke study videos did not include set-up of the aseptic processing line or filling line interventions that sufficiently represent your commercial manufacturing process.\nIn your response, you commit to repeat smoke studies with defined set-up and interventions. Your response is inadequate as you do not provide details, such as how you will address line deficiencies, when you will perform the smoke studies, and what interventions will be included.\nInadequate Media Fill Program\nYour media fills failed to accurately simulate commercial operations. Our inspection found that the aseptic operations simulated during your media fills were not sufficiently representative of aseptic manufacturing operations. We observed significantly more interventions performed during routine batch manufacturing that were either not simulated or reduced in quantity in media fills, as compared to what was observed during production. Notably, a substantial number of these interventions during routine production were unplanned.\nIn addition, the type, frequency, and time of interventions are not routinely documented in production batch records.\nYour firm also did not require operators to participate in a media fill prior to working in the aseptic processing operation.\nYour response is inadequate. You commit to documenting routine interventions during manufacturing but fail to evaluate the interventions used in your media fill program and their inadequate representation of routine production. Your operators performed numerous, manually intensive interventions during aseptic operations. As such, the quantity of process simulation interventions and the duration of the media fill should closely resemble the actual manufacturing process. If a media fill program fails to incorporate contamination risk factors and closely simulate actual drug product exposure, the state of process control and assurance of sterility cannot be accurately assessed.\nPoor Practices in the Aseptic Processing Areas\nDuring the inspection of your facility, we observed poor practices in ISO 5 areas during the aseptic processing of sterile drug products. These poor practices included, but are not limited to:\nExposed skin in the ISO 5 area (e.g., forehead).\nUse of non-sterile tape on the filling line.\nStorage of machine tools and spare parts, for use on the filling line, in a (b)(4) of the ISO 5 area.\nYour response is inadequate because it does not address the lack of oversight of the operators’ aseptic practices and evaluate the insufficiencies in their training. Further, these poor aseptic practices were not evaluated to determine the impact to aseptic processing operations.\nInsufficient Personnel Monitoring\nThe personnel monitoring for operators working in the ISO 5 area was not sufficient to assure sterility. For example, the locations chosen for personnel monitoring were not scientifically justified, nor was the practice of using (b)(4) plates for one hand and (b)(4) for the other. In addition, there was no written procedure for gowning qualification.\nYour response is inadequate, as you fail to conduct a retrospective review of your aseptic personnel monitoring practices.\nIn response to this letter, provide the following:\nComprehensive risk assessment of all contamination hazards with respect to your aseptic processes, equipment, and facilities, including an independent assessment that includes, but is not limited to:\no All human interactions within the ISO 5 area\no Equipment placement and ergonomics\no Air quality in the ISO 5 area and surrounding room\no Facility layout\no Personnel Flows and Material Flows (throughout all rooms used to conduct and support sterile operations)\nA detailed remediation plan with timelines to address the findings of the contamination hazards risk assessment. Describe specific tangible improvements to be made to aseptic processing operation design and control.\nYour plan to ensure appropriate aseptic practices and cleanroom behavior during production. Include steps to ensure routine and effective supervisory oversight for all production batches. Also describe the frequency of quality unit (QU) oversight (e.g., audit) during aseptic processing and its support-operations.\nA thorough retrospective review and risk assessment that evaluates how poor aseptic technique and cleanroom behavior may have affected the quality and sterility of your drugs.\nSmoke studies under dynamic conditions, with thorough and complete evaluations of aseptic interventions and operator positioning within the critical filling areas. After you remediate your aseptic operation, provide smoke studies that visualize airflow and critically evaluate unidirectional airflow. Include a video of your dynamic smoke studies.\nA comprehensive summary of your remediated media fill program that ensures appropriate simulations of worst-case conditions in commercial manufacturing.\n2. Your firm failed to perform operations within specifically defined areas of adequate size and to have separate or defined areas or such other control systems necessary to prevent contamination or mix-ups in aseptic processing areas (21 CFR 211.42(c)(10)).\nEquipment as a Route of Contamination\nThe design of the aseptic processing line used to manufacture over-the-counter (b)(4) drug products was inadequate. Line (b)(4) is a traditional filling line consisting of an ISO 5 area (b)(4) and a surrounding ISO 7 area. The line involves manually intensive (b)(4) interventions, and the HEPA filter layout leaves approximately 10-centimeter gaps due to overhead lights in between the filters that appear to affect unidirectional airflow.\nFurthermore, you did not sterilize direct product contact equipment that holds primary container and closure components for your sterile drug products. These equipment were disinfected with (b)(4), which are not sterilants. You also use (b)(4) approximately (b)(4), which is a decontaminating agent.\nYour response is inadequate. You commit to turning Line (b)(4) into an (b)(4) restricted access barrier ((b)(4)RAB) filling line. However, you did not provide detailed plans for how you will redesign your filling line and conduct a risk assessment for products currently released to the U.S. Market.\nEnvironmental Monitoring (EM)\nThe EM of your aseptic processing operations was inadequate. The locations identified for EM in ISO 5 and ISO 7 areas lacked scientific justification and were not sufficiently located where the aseptic operations are taking place.\nThe consistent and meaningful contamination level in ISO 7, along with frequent manually intensive interventions, posed a high risk to sterile products on your aseptic processing line.\nYour response is inadequate. You commit to repeating the EM risk assessment and trending EM data but fail to include plans for how you will assess your line after redesign.\nA vigilant, ongoing EM program is essential to detect and respond to potential product contamination hazards in your manufacturing environment in a timely manner. Loss of environmental control in an aseptic manufacturing facility can ultimately pose a serious hazard to patients.\nIn response to this letter, provide the following:\nYour corrective action and preventive action (CAPA) plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, and improved systems for ongoing management review.\nAn independent assessment of your EM program including, but not limited to, establishing appropriate limits, sampling locations and frequencies, investigating deviations, and trend analysis. Also, ensure the implementation of a comprehensive CAPA plan.\n3. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\nVisual Inspection\nYour post-fill visual inspection of aseptically filled drug products was insufficient to identify defects which may be present. For example, bottles were only inspected against a (b)(4) background to identify visible defects, particulates, and cloudiness. Individual defect limits were not set. Further, an Acceptable Quality Limit (AQL) sample is not obtained for quality assurance evaluation.\nIn addition, your visual inspector qualification process is inadequate. For example, you lack a procedure for inspector training, and the (b)(4) challenge kit is used for each of (b)(4) runs where it is not required that inspectors identify the correct defect, only the correct bottle.\nYour response is inadequate. You commit to evaluating the visual inspection program and replacing the (b)(4) process with an (b)(4) one, instead of a (b)(4) inspection methods. Your program should include an appropriate combination of these techniques to ensure detection of the wide array of potential visible product defects.\nIn addition, you fail to provide details regarding the qualification and creation of a defect library, challenge kits, appropriate inspection protocols (including use of a (b)(4) background), and inspector training.\nIn response to this letter, provide the following:\nA formalized 100% visual inspection program designed to reliably detect particulate contamination and other visible defects. Your program should detail the inspection methods, identify categories of defects and their associated acceptance and rejection limits for each batch, and include inspector training and qualification.\nA retrospective review of drug product batches released without having undergone a complete and appropriate visual inspection by qualified inspectors.\nPerform a visual inspection of retain samples for all batches already in distribution and provide the results.\n4. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\nThe QU failed to maintain adequate CGMP oversight. For example:\nLack of Written Procedures (211.100)\nNumerous written procedures were either missing or lacked sufficient detail to ensure consistent repeatability between operators. For example, the following critical processes were not contained in a written procedure: set-up of the filling line, performing interventions on the filling line, personnel monitoring, and how to perform (b)(4) decontamination of aseptic processing rooms.\nIn addition, written procedures lacked sufficient detail, including those for cleaning of the filling line and cleaning of the filling room.\nYour response is inadequate. You commit to writing procedures for the critical items described above, however you fail to perform a comprehensive review to ensure appropriate procedures are established and followed as part of your quality system. In addition, you did not provide a comprehensive risk assessment of the product impact of the lack of sufficient procedures.\nInvestigations (211.192)\nWe noted multiple instances where thorough investigations were not completed. For example, a viable air monitoring plate dated January 22, 2024, had a significant microbial recovery for the ISO 7 area of Line (b)(4), identified as Cladosporium, a mold. The available documentation of the Cladosporium recovery noted that the same mold was found in multiple areas of the facility. You lacked a meaningful investigation into this trend.\nYour response is inadequate as you did not commit to opening an investigation to examine this and other potentially adverse trends.\nComplaint Handling (211.198(a))\nYour complaint handling and investigation process is inadequate. Retain samples are not always evaluated for sterility unless requested by your distributor, even when the complaint indicates potential contamination. For example, you received a substantial number of complaints for burning or redness but did not perform sterility testing on retain samples until the fourth complaint was received.\nYour response is inadequate. You commit to reviewing past complaints and updating your current procedure but fail to provide details for how you will incorporate testing, including but not limited to, sterility, into your complaint handling process in the future.\nRaw Material Testing for (b)(4) (211.84(d)(2))\nYour incoming raw material sampling and testing plan for (b)(4), which is a component at high-risk of contamination with (b)(4), is inadequate.\nYour response is inadequate. While you commit to testing each container of every lot moving forward, you did not commit to testing of finished products that previously used these raw materials to verify that (b)(4) are not present above specified levels.\nThe use of ingredients contaminated with (b)(4) has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document Testing of (b)(4) to help you meet the CGMP requirements when manufacturing drugs containing ingredients at high-risk for (b)(4) contamination at (b)(4).\nIn response to this letter, provide:\nA commitment to provide (b)(4) test results, no later than 30 calendar days from the date of this letter, from testing retains for all lots of high-risk drug components used in the manufacture of drug products. Alternatively, if a retain of a component lot is unavailable, perform retain sample testing of all implicated finished drug product batches for the presence of (b)(4).\nA full risk assessment for drug products that are within expiry which contain any ingredient at risk for (b)(4) contamination (including, but not limited to, (b)(4)). Take prompt and appropriate actions to determine the safety of all lots of the component(s) and any related drug product that could contain (b)(4), including customer notifications and product recalls for any contaminated lots. Identify additional appropriate CAPAs that secure supply chains in the future, including, but not limited to, ensuring that all incoming raw material lots are from fully qualified manufacturers and free from unsafe impurities. Detail these actions in your response to this letter.\nA description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s certificate of analysis instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic revalidation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot. In the case of (b)(4), and certain additional high-risk components we note that this includes the performance of parts (b)(4) of the United States Pharmacopeia (USP) monograph.\nThe chemical quality control specifications you use to test each incoming lot of high-risk drug components to determine acceptability for use in manufacturing.\nA comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\nA comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, out-of-specification (OOS) results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, QU oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\nA comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\no A determination of whether procedures used by your firm are robust and appropriate.\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\no A complete and final review of each batch and its related information before the QU disposition decision.\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\n5. Your firm failed to establish and follow adequate written procedures for cleaning and maintenance of equipment (21 CFR 211.67(b)).\nYour cleaning procedures lack sufficient detail to ensure repeatability between operators. We observed cleaning deficiencies and variability between operators, including wiping technique, using the same cleaning cloths for multiple areas, and failure to clean on top of the overhead light casings of the filling line.\nFurther, the disinfection efficacy studies for (b)(4) did not adequately address all materials of the filling line, including but not limited to, (b)(4) (filling equipment), (b)(4) and (b)(4), and (b)(4) hose).\nIn addition, your (b)(4) room decontamination validation is deficient (e.g., biological indicator locations are not adequately justified).\nYour response is inadequate. You commit to conduct a comprehensive review and assessment of cleaning and disinfection practices; however, you fail to investigate the impact on the products in the U.S. Market. In addition, a retrospective review for only extraneous chromatographic peaks is not sufficient to determine if deficient cleaning practices contribute to finished product that does not meet established specifications.\nIn response to this letter, provide the following:\nA CAPA plan, based on the retrospective assessment of your cleaning and disinfection program, that includes appropriate remediations to your cleaning and disinfection processes and practices, and timelines for completion. Provide a detailed summary of vulnerabilities in your process for lifecycle management of equipment cleaning and disinfection. Describe improvements to your cleaning and disinfection program, including enhancements to cleaning and disinfection effectiveness; improved ongoing verification of proper cleaning and disinfection execution for all products and equipment; and all other needed remediations.\nAdditional Guidance on Aseptic Processing\nSee FDA’s guidance document Sterile Drug Products Produced by Aseptic Processing—Current Good Manufacturing Practice to help you meet the CGMP requirements when manufacturing sterile drugs using aseptic processing at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71026\u002Fdownload.\nQuality Systems\nYour firm’s quality systems are inadequate. For guidance on establishing and maintaining CGMP-compliant quality systems, see FDA’s guidances: Q9 Quality Risk Management at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F167721\u002Fdownload and Q10 Pharmaceutical Quality System at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71553\u002Fdownload.\nDrug Production Suspended\nWe acknowledge your commitment to suspend production of all drugs and that you deregistered your facility as a drug manufacturer. In response to this letter, clarify whether you intend to resume manufacturing drugs for the U.S. market at this facility in the future.\nIf you plan to resume any manufacturing operations regulated under the FD&C Act, notify this office before resuming your drug manufacturing operations. If your firm intends to resume manufacturing drugs, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations to assist your firm in meeting CGMP requirements. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance. In your notification to the Agency, provide a summary of your remediations to demonstrate that you have appropriately completed all CAPAs.\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nCorrect any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\nFailure to address any violations may also result in the FDA refusing admission of articles manufactured at Daewoo Pharmaceutical Co. Ltd, 153, Dadae-ro, Saha-gu, Busan, into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 1000448124 and ATTN: Sarah Rhoades.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research","Daewoo Pharmaceutical Co., Ltd.","daewoo-pharmaceutical-co-ltd-706371-07022025","2026-08-18T06:42:28.676509+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fdaewoo-pharmaceutical-co-ltd-706371-07022025","2026-10-26T08:08:20.933262+00:00","2025-07-15","706371","Mr. Jin Soo Baek","2026-08-19T16:35:33.122+00:00","320-25-86","2025-07-02",{"id":270,"raw":271,"subject":80,"body_html":275,"body_text":276,"firm_name":277,"letter_id":278,"created_at":260,"fei_number":19,"letter_url":279,"updated_at":280,"action_type":22,"case_status":23,"posted_date":281,"marcs_cms_no":282,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":283,"body_fetched_at":284,"delivery_method":110,"recipient_title":19,"reference_number":285,"action_taken_date":286,"medical_device_id":19,"response_letter_date":19},844,[272,273,274,11,80,13,13,13],"\u003Ctime datetime=\"2025-06-03T04:00:00Z\">06\u002F03\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-03-27T04:00:00Z\">03\u002F27\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fyiling-pharmaceutical-ltd-699738-03272025\">Yiling Pharmaceutical Ltd. \u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-25-58\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Hongzhi Li\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Yiling Pharmaceutical Ltd. \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>No. 36 Zhujiang Street\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Shijiazhuang Shi\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Hebei Sheng\u003C\u002Fspan>, \u003Cspan>050035\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>China\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-25-58\u003C\u002Fp>\u003Cp>March 27, 2025\u003C\u002Fp>\u003Cp>Dear Mr. Li:\u003C\u002Fp>\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Yiling Pharmaceutical Ltd., FEI 3011640199, located at No. 36 Zhujiang Street, Shijiazhuang, Hebei, China, from October 7 to 11, 2024.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>We reviewed your October 31, 2024 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\u003Cp>During our inspection, our investigator observed specific violations including, but not limited to, the following.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to use equipment in the manufacture, processing, packing, or holding of drug products that is of appropriate design, adequate size, and suitably located to facilitate operations for its intended use and for its cleaning and maintenance (21 CFR 211.63).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your non-dedicated manufacturing equipment was not designed and maintained appropriately to prevent potential cross-contamination of drug products.\u003C\u002Fp>\u003Cp>For example, \u003Cstrong>(b)(4)\u003C\u002Fstrong> were not designed and maintained to ensure that the \u003Cstrong>(b)(4)\u003C\u002Fstrong> consistently closes tightly, to prevent backflow of bulk drug powder into the \u003Cstrong>(b)(4)\u003C\u002Fstrong> duct. Residues were observed in the \u003Cstrong>(b)(4)\u003C\u002Fstrong> duct of \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>Numerous drug substance residues, including \u003Cstrong>(b)(4)\u003C\u002Fstrong>, were recovered upon swabbing of \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your \u003Cstrong>(b)(4)\u003C\u002Fstrong>, are used to manufacture multiple drug products, including \u003Cstrong>(b)(4)\u003C\u002Fstrong> therapeutics such as \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>In addition, junctions on the \u003Cstrong>(b)(4)\u003C\u002Fstrong> duct had degraded seals and were covered with tape.\u003C\u002Fp>\u003Cp>In your response, you state you will replace the \u003Cstrong>(b)(4)\u003C\u002Fstrong> on \u003Cstrong>(b)(4)\u003C\u002Fstrong> to prohibit backflow into the \u003Cstrong>(b)(4)\u003C\u002Fstrong> ducting and replace the \u003Cstrong>(b)(4)\u003C\u002Fstrong> ducting on \u003Cstrong>(b)(4)\u003C\u002Fstrong> for ease of cleaning and sanitization. You further state you are identifying all batches of U.S. product within expiry from these \u003Cstrong>(b)(4)\u003C\u002Fstrong> and have initiated testing reserve samples for possible cross-contamination.\u003C\u002Fp>\u003Cp>Your response is inadequate. Your assessment is limited to testing reserve samples of each finished drug product only for the presence of the preceding drug substance processed on the same non-dedicated equipment, instead of testing each reserve sample for all drug substances processed on the equipment. You do not adequately address how you intend to maintain this equipment to ensure the integrity of the seals.\u003C\u002Fp>\u003Cp>Equipment used in pharmaceutical manufacturing operations should be designed to protect drug products from contamination. Air flow over dirty surfaces can cause contamination of the drug being processed in a \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Robust design, cleaning, and maintenance of this and other equipment are critical to prevent cross-contamination.\u003C\u002Fp>\u003Cp>Contamination is generally not uniformly distributed. Data obtained from retrospectively testing a small proportion of a batch (e.g., reserve samples for the presence of previous active ingredient) is limited in its ability to retrospectively assess the extent of contamination in other portions of a batch. The lowest or highest results obtained from testing a small sample size is unlikely to reveal the true range of minimum and maximum contamination level that exists in a batch exposed to the contamination hazards identified at your firm. Consequently, the range of variability of contamination levels in batches produced by your firm remain characterized by substantial residual uncertainty.\u003C\u002Fp>\u003Cp>Because of the limitations of retrospective testing in gaining a representative understanding of the entire lot, testing reserve samples alone is insufficient to determine the scope of the contamination issues and mitigate the associated risks. Further evaluation and scientific rationale are needed in your firm’s risk assessment to reflect the nature of cross-contamination events and determine the degree of cross-contamination risk that may be posed to portion of marketed batches.\u003C\u002Fp>\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\u003Cp>Your corrective action and preventive action (CAPA) plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, and improved systems for ongoing management review.\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive retrospective risk assessment that addresses all possible cross-contamination, including but not limited to, highly potent substances such as \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fli>\u003Cli>A comprehensive risk assessment from analysis of adverse drug events for all affected drug products. Any side effects possibly attributable to cross-contamination with \u003Cstrong>(b)(4)\u003C\u002Fstrong> should be reported.\u003C\u002Fli>\u003Cli>A detailed CAPA plan to implement segregation of highly potent substances such as \u003Cstrong>(b)(4)\u003C\u002Fstrong> from equipment shared with other drug products.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your quality unit (QU) failed to adequately implement the facility’s quality function and ensure quality oversight. For example:\u003C\u002Fp>\u003Cp>You failed to have an adequate procedure to clean \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your approved procedure did not include sufficient directions to clean the \u003Cstrong>(b)(4)\u003C\u002Fstrong> ducts, including directions on disassembly and visual inspection for cleanliness. Thus, you failed to identify visible residue with the possibility of cross-contaminated drug products being released to the market.\u003C\u002Fp>\u003Cp>In your response you identify \u003Cstrong>(b)(4)\u003C\u002Fstrong>, was not designed to facilitate appropriate cleaning. You acknowledge this resulted in residual drug substances inside the \u003Cstrong>(b)(4)\u003C\u002Fstrong> duct of your \u003Cstrong>(b)(4)\u003C\u002Fstrong>. You indicate that you are updating your cleaning procedures to require disassembly and post cleaning inspection.\u003C\u002Fp>\u003Cp>Your response is inadequate. You do not provide a written approved procedure that would ensure adequate disassembly and cleaning of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> duct. And you fail to provide evidence you have implemented CAPA measures ensuring QU oversight of cross-contamination risks from highly potent substances, such as \u003Cstrong>(b)(4)\u003C\u002Fstrong>, on shared equipment.\u003C\u002Fp>\u003Cp>You also manufacture \u003Cstrong>(b)(4)\u003C\u002Fstrong>, a highly potent drug on the same shared equipment. \u003Cstrong>(b)(4)\u003C\u002Fstrong> is a hazardous drug that can cause \u003Cstrong>(b)(4)\u003C\u002Fstrong> if administered outside of its therapeutic range.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive, independent assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003Cbr>o A determination of whether procedures used by your firm are robust and appropriate.\u003Cbr>o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\u003Cbr>o A complete and final review of each batch and its related information before the QU disposition decision.\u003Cbr>o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\u003C\u002Fli>\u003Cli>A comprehensive, independent retrospective assessment of your cleaning effectiveness to evaluate the scope of cross-contamination hazards. Include the identity of residues, other manufacturing equipment that may have been improperly cleaned, and an assessment whether cross-contaminated products may have been released for distribution. The assessment should identify any inadequacies of cleaning procedures and practices, and encompass each piece of manufacturing equipment used to manufacture more than one product.\u003C\u002Fli>\u003Cli>A CAPA plan, based on the retrospective assessment of your cleaning program, that includes appropriate remediations to your cleaning processes and practices, and timelines for completion. Provide a detailed summary of vulnerabilities in your process for lifecycle management of equipment cleaning. Describe improvements to your cleaning program, including enhancements to cleaning effectiveness; improved ongoing verification of proper cleaning execution for all products and equipment; and all other needed remediations.\u003C\u002Fli>\u003Cli>A comprehensive assessment of your overall system for investigating deviations, discrepancies, complaints, out-of-specification results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, QU oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\u003C\u002Fli>\u003Cli>A complete assessment of all investigations where unknown impurities or unknown peaks were detected in marketed product and a determination if these are associated with potential cross-contamination events.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Your firm’s quality systems are inadequate. See FDA’s guidance document \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem> for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>If you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(b). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\u003C\u002Fp>\u003Cp>Correct any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\u003C\u002Fp>\u003Cp>Failure to address any violations may also result in the FDA refusing admission of articles manufactured at Yiling Pharmaceutical Ltd., located at No. 36 Zhujiang Street, Shijiazhuang, Hebei, China, into the United States under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3011640199 and ATTN: Brian Nicholson.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>____________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Under program enhancements for the Generic Drug User Fee Amendments (GDUFA) reauthorization for fiscal years (FYs) 2023-2027, also known as the GDUFA III Commitment Letter, your facility may be eligible for a Post-Warning Letter Meeting to obtain preliminary feedback from FDA on the adequacy and completeness of your corrective action plans.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nReference #:\n\n320-25-58\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Hongzhi Li\n\nRecipient Title\n\nCEO\n\nYiling Pharmaceutical Ltd.\n\nNo. 36 Zhujiang Street\n\nShijiazhuang Shi\n\nHebei Sheng, 050035\n\nChina\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-25-58\nMarch 27, 2025\nDear Mr. Li:\nThe U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Yiling Pharmaceutical Ltd., FEI 3011640199, located at No. 36 Zhujiang Street, Shijiazhuang, Hebei, China, from October 7 to 11, 2024.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nWe reviewed your October 31, 2024 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\nDuring our inspection, our investigator observed specific violations including, but not limited to, the following.\n1. Your firm failed to use equipment in the manufacture, processing, packing, or holding of drug products that is of appropriate design, adequate size, and suitably located to facilitate operations for its intended use and for its cleaning and maintenance (21 CFR 211.63).\nYour non-dedicated manufacturing equipment was not designed and maintained appropriately to prevent potential cross-contamination of drug products.\nFor example, (b)(4) were not designed and maintained to ensure that the (b)(4) consistently closes tightly, to prevent backflow of bulk drug powder into the (b)(4) duct. Residues were observed in the (b)(4) duct of (b)(4).\nNumerous drug substance residues, including (b)(4), were recovered upon swabbing of (b)(4). Your (b)(4), are used to manufacture multiple drug products, including (b)(4) therapeutics such as (b)(4).\nIn addition, junctions on the (b)(4) duct had degraded seals and were covered with tape.\nIn your response, you state you will replace the (b)(4) on (b)(4) to prohibit backflow into the (b)(4) ducting and replace the (b)(4) ducting on (b)(4) for ease of cleaning and sanitization. You further state you are identifying all batches of U.S. product within expiry from these (b)(4) and have initiated testing reserve samples for possible cross-contamination.\nYour response is inadequate. Your assessment is limited to testing reserve samples of each finished drug product only for the presence of the preceding drug substance processed on the same non-dedicated equipment, instead of testing each reserve sample for all drug substances processed on the equipment. You do not adequately address how you intend to maintain this equipment to ensure the integrity of the seals.\nEquipment used in pharmaceutical manufacturing operations should be designed to protect drug products from contamination. Air flow over dirty surfaces can cause contamination of the drug being processed in a (b)(4). Robust design, cleaning, and maintenance of this and other equipment are critical to prevent cross-contamination.\nContamination is generally not uniformly distributed. Data obtained from retrospectively testing a small proportion of a batch (e.g., reserve samples for the presence of previous active ingredient) is limited in its ability to retrospectively assess the extent of contamination in other portions of a batch. The lowest or highest results obtained from testing a small sample size is unlikely to reveal the true range of minimum and maximum contamination level that exists in a batch exposed to the contamination hazards identified at your firm. Consequently, the range of variability of contamination levels in batches produced by your firm remain characterized by substantial residual uncertainty.\nBecause of the limitations of retrospective testing in gaining a representative understanding of the entire lot, testing reserve samples alone is insufficient to determine the scope of the contamination issues and mitigate the associated risks. Further evaluation and scientific rationale are needed in your firm’s risk assessment to reflect the nature of cross-contamination events and determine the degree of cross-contamination risk that may be posed to portion of marketed batches.\nIn response to this letter, provide the following:\nYour corrective action and preventive action (CAPA) plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, and improved systems for ongoing management review.\nA comprehensive retrospective risk assessment that addresses all possible cross-contamination, including but not limited to, highly potent substances such as (b)(4).\nA comprehensive risk assessment from analysis of adverse drug events for all affected drug products. Any side effects possibly attributable to cross-contamination with (b)(4) should be reported.\nA detailed CAPA plan to implement segregation of highly potent substances such as (b)(4) from equipment shared with other drug products.\n2. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\nYour quality unit (QU) failed to adequately implement the facility’s quality function and ensure quality oversight. For example:\nYou failed to have an adequate procedure to clean (b)(4). Your approved procedure did not include sufficient directions to clean the (b)(4) ducts, including directions on disassembly and visual inspection for cleanliness. Thus, you failed to identify visible residue with the possibility of cross-contaminated drug products being released to the market.\nIn your response you identify (b)(4), was not designed to facilitate appropriate cleaning. You acknowledge this resulted in residual drug substances inside the (b)(4) duct of your (b)(4). You indicate that you are updating your cleaning procedures to require disassembly and post cleaning inspection.\nYour response is inadequate. You do not provide a written approved procedure that would ensure adequate disassembly and cleaning of the (b)(4) duct. And you fail to provide evidence you have implemented CAPA measures ensuring QU oversight of cross-contamination risks from highly potent substances, such as (b)(4), on shared equipment.\nYou also manufacture (b)(4), a highly potent drug on the same shared equipment. (b)(4) is a hazardous drug that can cause (b)(4) if administered outside of its therapeutic range.\nIn response to this letter, provide:\nA comprehensive, independent assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\no A determination of whether procedures used by your firm are robust and appropriate.\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\no A complete and final review of each batch and its related information before the QU disposition decision.\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\nA comprehensive, independent retrospective assessment of your cleaning effectiveness to evaluate the scope of cross-contamination hazards. Include the identity of residues, other manufacturing equipment that may have been improperly cleaned, and an assessment whether cross-contaminated products may have been released for distribution. The assessment should identify any inadequacies of cleaning procedures and practices, and encompass each piece of manufacturing equipment used to manufacture more than one product.\nA CAPA plan, based on the retrospective assessment of your cleaning program, that includes appropriate remediations to your cleaning processes and practices, and timelines for completion. Provide a detailed summary of vulnerabilities in your process for lifecycle management of equipment cleaning. Describe improvements to your cleaning program, including enhancements to cleaning effectiveness; improved ongoing verification of proper cleaning execution for all products and equipment; and all other needed remediations.\nA comprehensive assessment of your overall system for investigating deviations, discrepancies, complaints, out-of-specification results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, QU oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\nA complete assessment of all investigations where unknown impurities or unknown peaks were detected in marketed product and a determination if these are associated with potential cross-contamination events.\nYour firm’s quality systems are inadequate. See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nIf you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(b). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\nCorrect any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\nFailure to address any violations may also result in the FDA refusing admission of articles manufactured at Yiling Pharmaceutical Ltd., located at No. 36 Zhujiang Street, Shijiazhuang, Hebei, China, into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days1. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3011640199 and ATTN: Brian Nicholson.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research\n____________________\n1 Under program enhancements for the Generic Drug User Fee Amendments (GDUFA) reauthorization for fiscal years (FYs) 2023-2027, also known as the GDUFA III Commitment Letter, your facility may be eligible for a Post-Warning Letter Meeting to obtain preliminary feedback from FDA on the adequacy and completeness of your corrective action plans.","Yiling Pharmaceutical Ltd.","yiling-pharmaceutical-ltd-699738-03272025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fyiling-pharmaceutical-ltd-699738-03272025","2026-10-26T08:10:36.435917+00:00","2025-06-03","699738","Mr. Hongzhi Li","2026-08-19T16:43:45.805+00:00","320-25-58","2025-03-27",{"id":288,"raw":289,"subject":296,"body_html":297,"body_text":298,"firm_name":299,"letter_id":300,"created_at":18,"fei_number":19,"letter_url":301,"updated_at":302,"action_type":22,"case_status":143,"posted_date":303,"marcs_cms_no":304,"product_type":305,"closeout_date":306,"issuing_office":293,"recipient_name":307,"body_fetched_at":308,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":309,"medical_device_id":19,"response_letter_date":19},1019,[290,291,292,293,294,13,295,13],"\u003Ctime datetime=\"2025-03-11T04:00:00Z\">03\u002F11\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-02-07T05:00:00Z\">02\u002F07\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Faurora-pharmaceutical-698797-02072025\">Aurora Pharmaceutical\u003C\u002Fa>","Center for Veterinary Medicine","False &amp; Misleading Claims\u002FMisbranded","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Faurora-pharmaceutical-inc-698797-09112025\">\u003Ctime datetime=\"2025-09-19T04:00:00Z\">09\u002F19\u002F2025\u003C\u002Ftime>\n\u003C\u002Fa>","False & Misleading Claims\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Animal &amp; Veterinary\u003Cbr>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Michael Strobel\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Aurora Pharmaceutical\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1196 Highway 3 South\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Northfield\u003C\u002Fspan>, \u003Cspan>MN\u003C\u002Fspan> \u003Cspan>55057\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Veterinary Medicine\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>February 7, 2025\u003C\u002Fp>\u003Cp>Re: ANADAs 200-620 Altren® (altrenogest), 200-621 SwineMate® (altrenogest), 200-718 Barrier™ for dogs (imidacloprid and moxidectin)\u003C\u002Fp>\u003Cp>\u003Cstrong>CMS #: 698797\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Dear Dr. Strobel:\u003C\u002Fp>\u003Cp>The U.S. Food and Drug Administration (FDA) has reviewed your promotional communications for your FDA-approved products including your company website\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> and linked webpages and noted false or misleading claims and representations about the safety and effectiveness of these products. These promotional communications misbrand your products within the meaning of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) section 502(a) [21 U.S.C. 352(a)] and section 502(n) [21 U.S.C. 352(n)]; section 201(n) [21 U.S.C. 321(n)]; and 21 CFR 202.1(e)(5). It is a prohibited act to distribute a misbranded product in interstate commerce. Section 301(a) [21 U.S.C. 331(a)]. This violation is especially concerning from a public health perspective because your products Altren® (altrenogest) and SwineMate® (altrenogest) have serious user safety warnings and your product Barrier™ for dogs (imidacloprid and moxidectin) has a boxed warning regarding oral exposure in dogs and topical exposure in children.\u003C\u002Fp>\u003Cp>\u003Cstrong>Product Information\u003C\u002Fstrong>\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>\u003Cem>Altren\u003C\u002Fem>®\u003C\u002Fp>\u003Cp>Altren® is indicated for:\u003C\u002Fp>\u003Cp>“[S]uppression of estrus in mares. Suppression of estrus allows for a predictable occurrence of estrus following drug withdrawal. This facilitates the attainment of regular cyclicity during the transition from winter anestrus to the physiological breeding season. Suppression of estrus will also facilitate management of prolonged estrus conditions. Suppression of estrus may be used to facilitate scheduled breeding during the physiological breeding season.”\u003Cem>\u003Cstrong>\u003Csup>3\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Due to human user safety risks, the package insert (PI) for Altren® contains user safety warning language: “Not for use in humans. Keep out of reach of children. Avoid skin contact. Altren® is absorbed through unbroken skin, and exposure may result in serious side effects to both women and men. \u003Cstrong>Wear vinyl, neoprene, or nitrile gloves when handling or administering Altren®, or when touching contaminated surfaces or equipment. Latex gloves are not protective.”\u003C\u002Fstrong> [Emphasis original].\u003C\u002Fp>\u003Cp>Additional warning language includes:\u003C\u002Fp>\u003Cp>\u003Cstrong>“PREGNANT WOMEN OR WOMEN WHO MAY BE PREGNANT SHOULD NOT HANDLE ALTREN®. WOMEN OF CHILDBEARING AGE SHOULD EXERCISE EXTREME CAUTION WHEN HANDLING THIS PRODUCT.\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Accidental absorption, such as via direct contact with the skin, could lead to a disruption of the menstrual cycle or prolongation of pregnancy….”\u003C\u002Fp>\u003Cp>[Emphasis original].\u003C\u002Fp>\u003Cp>The PI also contains a list of people who should not handle Altren®, instructions on what to do in case of accidental exposure, and reported human effects from exposure.\u003C\u002Fp>\u003Cp>The PI for Altren® further contains, among other things, additional adverse event, warning, precaution, and contraindication information.\u003C\u002Fp>\u003Cp>SwineMate®\u003C\u002Fp>\u003Cp>SwineMate® is indicated for:\u003C\u002Fp>\u003Cp>“[S]ynchronization of estrus in sexually mature gilts that have had at least one estrous cycle. Treatment with SwineMate® results in estrus (standing heat) 4 to 9 days after completion of the 14-day treatment period.”\u003Cem>\u003Cstrong>\u003Csup>4\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Due to human user safety risks, the PI for SwineMate® contains user safety warning language stating: “Skin contact must be avoided as SwineMate® is readily absorbed through unbroken skin, and exposure may result in serious side effects to both women and men.\u003Cstrong> Always wear vinyl, neoprene or nitrile protective gloves when handling SwineMate\u003C\u002Fstrong> or when in contact with equipment or surfaces contaminated by this product. \u003Cstrong>Latex gloves are not protective.”\u003C\u002Fstrong> [Emphasis original].\u003C\u002Fp>\u003Cp>Additional warning language includes:\u003C\u002Fp>\u003Cp>\u003Cstrong>“PREGNANT WOMEN OR WOMEN WHO MAY BE PREGNANT SHOULD NOT HANDLE SwineMate® (altrenogest). WOMEN OF CHILDBEARING AGE SHOULD EXERCISE EXTREME CAUTION WHEN HANDLING THIS PRODUCT.\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Accidental absorption, such as absorption through the skin, could lead to a disruption of the menstrual cycle or prolongation of pregnancy....”\u003C\u002Fp>\u003Cp>[Emphasis original].\u003C\u002Fp>\u003Cp>The PI also contains a list of people who should not handle the product, instructions on what to do in case of accidental exposure, and information on reported human effects from exposure.\u003C\u002Fp>\u003Cp>The PI for SwineMate® further contains, among other things, additional adverse event, warning, precaution, and contraindication information.\u003C\u002Fp>\u003Cp>\u003Cem>Barrier™ for dogs\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Barrier™ for dogs is indicated for:\u003C\u002Fp>\u003Cp>“[T]he prevention of heartworm disease caused by \u003Cem>Dirofilaria immitis\u003C\u002Fem> and the treatment of \u003Cem>Dirofilaria immitis\u003C\u002Fem> circulating microfilariae in heartworm-positive dogs. \u003Cem>Barrier for Dogs\u003C\u002Fem> kills adult fleas and is indicated for the treatment of flea infestations \u003Cem>(Ctenocephalides felis)\u003C\u002Fem>. \u003Cem>Barrier for Dogs\u003C\u002Fem> is indicated for the treatment and control of sarcoptic mange caused by \u003Cem>Sarcoptes scabiei var. canis.\u003C\u002Fem>”\u003Cem>\u003Cstrong>\u003Csup>5\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>The PI also contains a chart detailing the intestinal parasites and the associated stages Barrier™ for dogs is indicated to treat or control.\u003C\u002Fp>\u003Cp>The PI contains a boxed warning stating:\u003C\u002Fp>\u003Cul>\u003Cli>\u003Cstrong>“DO NOT ADMINISTER THIS PRODUCT ORALLY”\u003C\u002Fstrong>\u003C\u002Fli>\u003Cli>\u003Cstrong>“For the first 30 minutes after application ensure that dogs cannot lick the product from application sites on themselves or other treated animals.”\u003C\u002Fstrong>\u003C\u002Fli>\u003Cli>\u003Cstrong>“Children should not come in contact with application sites for two (2) hours after application.\u003C\u002Fstrong>\u003Cbr>\u003Cstrong>(See Contraindications, Warnings, Human Warnings, and Adverse Reactions, for more information)”\u003C\u002Fstrong>\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Boxed warnings are the most significant type of warning in a product’s labeling and are used to emphasize serious or life-threatening risks.\u003Cem>\u003Cstrong>\u003Csup>6\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>The Warnings section of the PI states that oral ingestion of this product by dogs may cause “serious adverse reactions including depression, salivation, dilated pupils, incoordination, panting, and generalized muscle tremors.” The Human Warnings section states that human exposure to this product has been reported to cause “headache; dizziness; and redness, burning, tingling or numbness of the skin.”\u003C\u002Fp>\u003Cp>In addition to the boxed warning, the PI contains, among other things, additional adverse event, warning, precaution, and contraindication information.\u003C\u002Fp>\u003Cp>\u003Cstrong>False or Misleading Claims\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Prescription drug advertisements and labeling (promotional communications) misbrand a drug if they are false or misleading in any particular. See FD&amp;C Act section 502(a),(n) (21 U.S.C 352(a),(n)). The determination of whether a promotional communication is misleading includes, among other things, not only representations made or suggested in the promotional communication, but also the extent to which the promotional communication fails to reveal facts material in the light of its representations or material with respect to consequences that may result from the use of the drug as recommended or suggested in the promotional communication. See FD&amp;C Act section 201(n) (21 U.S.C 321(n)) and 21 CFR 202.1(e)(5).\u003C\u002Fp>\u003Cp>The website for Aurora Pharmaceutical mentioned above\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> includes a tab at the top of the page titled “Species,” which contains links to product-specific webpages for each product the firm markets. The webpage for Altren®\u003Cem>\u003Cstrong>\u003Csup>7\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> can be found under “Equine;” the webpage for SwineMate®\u003Cem>\u003Cstrong>\u003Csup>8\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> can be found under “Porcine;” and the webpage for Barrier™\u003Cem>\u003Cstrong>\u003Csup>9\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> can be found under “Pets.”\u003C\u002Fp>\u003Cp>\u003Cem>Altren®\u003C\u002Fem>\u003C\u002Fp>\u003Cp>The product webpage is misleading because it prominently features benefit information about the product in the center of the page, but fails to contain any risk information. See 21 CFR 202.1(e)(5)(ii). The webpage for Altren® omits information from the PI about the significant risks to humans from potential product exposure, as well as important animal safety warning language. This omission of risk information creates a misleading impression about the potential consequences associated with using the drug.\u003C\u002Fp>\u003Cp>The webpage for Altren® also contains a link to a “Product Sheet”\u003Cem>\u003Cstrong>\u003Csup>10\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> which lacks fair balance because the first page contains information regarding benefits and effectiveness in a larger font and bulleted format, whereas risk information is presented only in a smaller font on the second page.\u003Cem>\u003Cstrong>\u003Csup>11\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> See 21 CFR 202.1(e)(5)(ii). The Product Sheet fails to present information relating to side effects and contraindications with a prominence and readability reasonably comparable with the presentation of information relating to effectiveness of the drug and fails to include on each page the information relating to side effects and contraindications or a prominent reference to its presence and location. 21 CFR 202.1(e)(7)(viii), (e)(7)(xii). Further, at the bottom of the webpage for Altren® there are links to print advertisements\u003Cem>\u003Cstrong>\u003Csup>12 \u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>which contain benefit information but omit important risk information about human user safety, such as that users should wear vinyl, neoprene, or nitrile gloves when handling or administering Altren®; latex gloves are not protective. Additionally, the risk information that is present on the advertisements, such as “Pregnant women, or women who suspect they are pregnant, should not handle Altren,” is presented in a small, lightweight font which is not reasonably comparable to the presentation of information relating to effectiveness in terms of prominence and readability. See 21 CFR 202.1(e)(7)(viii). It also does not explain that women of childbearing age should exercise extreme caution when handling Altren® because it is readily absorbed through the skin and can disrupt the menstrual cycle or prolong pregnancy.\u003C\u002Fp>\u003Cp>\u003Cem>SwineMate®\u003C\u002Fem>\u003C\u002Fp>\u003Cp>The product webpage is misleading because it prominently features benefit information about the product in the center of the page but fails to contain any risk information. See 21 CFR 202.1(e)(5)(ii). The webpage for SwineMate® omits information from the PI about the significant risks to humans from potential product exposure, as well as important animal safety warning language. This omission of risk information creates a misleading impression about the potential consequences associated with using the drug. Further, the webpage for SwineMate® fails to include adequate information for use, such as the effects, routes, methods of administration, and any relevant warnings, hazards, contraindications, side effects, and precautions. See 21 CFR 201.105(d)(1).\u003C\u002Fp>\u003Cp>The webpage for SwineMate® also contains a link to a “Product Sheet”\u003Cem>\u003Cstrong>\u003Csup>13\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> which lacks fair balance because the first page contains information regarding benefits and effectiveness in a larger font and bulleted format, whereas risk information is presented only in a smaller font on the second page.\u003Cem>\u003Cstrong>\u003Csup>14\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> See 21 CFR 202.1(e)(5)(ii). The Product Sheet fails to present information relating to side effects and contraindications with a prominence and readability\u003Cbr>reasonably comparable with the presentation of information relating to effectiveness of the drug and fails to include on each page the information relating to side effects and contraindications or a prominent reference to its presence and location. 21 CFR 202.1(e)(7)(viii), (e)(7)(xii). Further, the print advertisement linked at the bottom of the SwineMate® webpage\u003Cem>\u003Cstrong>\u003Csup>15\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> contains no risk information although there is benefit information presented. See 21 CFR 202.1(e)(1).\u003C\u002Fp>\u003Cp>\u003Cem>Barrier™ for dogs\u003C\u002Fem>\u003C\u002Fp>\u003Cp>The product webpage is misleading because it prominently features benefit information about the product in the center of the page, but fails to contain any risk information. See 21 CFR 202.1(e)(5)(ii). The webpage for Barrier™ for dogs omits the boxed warning from the PI, as well as other important animal and human safety information. This omission of risk information creates a misleading impression about the potential consequences associated with using the drug.\u003C\u002Fp>\u003Cp>The ”Product Sheet”\u003Cem>\u003Cstrong>\u003Csup>16\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> linked on the Barrier™ for dogs webpage lacks fair balance because the first seven pages contain information regarding benefits and effectiveness in a larger font and with numerous charts, images, and visuals, whereas risk information is presented only in a smaller font on a single page at the end of the brochure. See 21 CFR 202.1(e)(5)(ii). The Product Sheet fails to present information relating to side effects and contraindications with a prominence and readability reasonably comparable with the presentation of information relating to effectiveness of the drug and fails to include on each page the information relating to side effects and contraindications or a prominent reference to its presence and location. 21 CFR 202.1(e)(7)(viii), (e)(7)(xii).\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion and Requested Response\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>For the reasons discussed above, your website misbrands Altren®, SwineMate®, and Barrier™ for dogs within the meaning of the FD&amp;C Act and make their distribution violative.\u003Cem>\u003Cstrong>\u003Csup>17 \u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>FD&amp;C Act section 502(a), (21 U.S.C. 352(a)); section 502(n) [21 U.S.C. 352(n)]; section 201(n) (21 U.S.C. 321(n)); section 301(a) (21 U.S.C. 331(a)), and 21 CFR 202.1(e)(5).\u003C\u002Fp>\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may lead to legal action, including without limitation, seizure, and injunction.\u003C\u002Fp>\u003Cp>Within fifteen (15) working days of receipt of this letter, please submit a written response addressing the concerns described in this letter, listing all promotional communications for Altren®, SwineMate®, and Barrier™ for dogs that contain representations like those described above, and explaining any plan for discontinuing use of such communications, or for ceasing distribution of Altren®, SwineMate®, and Barrier™ for dogs. If you cannot complete the above requested actions within fifteen (15) working days, state the reason for the delay and the time within which you will complete them.\u003C\u002Fp>\u003Cp>If you believe that your products are not in violation of the FD&amp;C Act, please include in your submission to us your reasoning and any supporting information for our consideration within 15 working days from the date of receipt of this letter.\u003C\u002Fp>\u003Cp>Please direct your response to the undersigned at the Food and Drug Administration, Center for Veterinary Medicine, Division of Pharmacovigilance and Surveillance, 12225 Wilkins Ave, MPN II Room E436, Rockville, Maryland 20852. Please send a courtesy copy by email to CVMSurveillance@fda.hhs.gov. All correspondence should include a subject line that clearly identifies the submission as a Response to Warning Letter # 698797.\u003C\u002Fp>\u003Cp>If you have any questions, please contact Dr. Christopher Loss by email at christopher.loss@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Linda Walter-Grimm, DVM\u003Cbr>Director, Division of Pharmacovigilance and\u003Cbr>Surveillance\u003Cbr>Office of Surveillance and Compliance\u003Cbr>Center for Veterinary Medicine\u003C\u002Fp>\u003Cp>________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Veterinary Pharmaceuticals for Livestock, Dogs and Cats https:\u002F\u002Faurorapharmaceutical.com\u002F last viewed on 2.6.2025\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> This section does not include all the safety and risk information in the package insert for each product and does not necessarily represent the risk information that should be included in the promotional communication(s) cited in this letter.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> FDA-approved package insert (PI) for Altren®\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> FDA-approved PI for SwineMate®\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem> FDA-approved PI for Barrier™ for Dogs\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>6\u003C\u002Fstrong>\u003C\u002Fem> See, e.g., “Boxed Warning”, https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fprescription-drug-advertising\u002Fdrug-advertisingglossary-terms\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>7\u003C\u002Fstrong>\u003C\u002Fem> EQUINE – Altren® (altrenogest) | Aurora Pharmaceutical\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>8\u003C\u002Fstrong>\u003C\u002Fem> Porcine – SwineMate® (altrenogest) | Aurora Pharmaceutical\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>9\u003C\u002Fstrong>\u003C\u002Fem> Barrier Pets Demo | Aurora Pharmaceutical. This webpage contains information about both Barrier™ for Dogs and Barrier™ for Cats\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>10\u003C\u002Fstrong>\u003C\u002Fem> Identified as “ss000026 04\u002F2020” for Altren®\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>11\u003C\u002Fstrong>\u003C\u002Fem> We also note that the PI on the second page of the Product Sheet is not the currently approved PI with the updated user safety information.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>12\u003C\u002Fstrong>\u003C\u002Fem> Identified as: Altren Aurora Ad 1 jpeg (ad000040 05\u002F2018), Altren Aurora Ad 2 jpeg (000041 05\u002F2018), Aurora Altren Ad-Florida (Ad000069 10\u002F2019)\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>13\u003C\u002Fstrong>\u003C\u002Fem> Identified as “ss000025 04\u002F2020” for SwineMate®\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>14\u003C\u002Fstrong>\u003C\u002Fem> We also note that the PI on the second page of the Product Sheet is not the currently approved PI with the updated user safety information.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>15\u003C\u002Fstrong>\u003C\u002Fem> Identified as “ad000048 10\u002F2018”\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>16\u003C\u002Fstrong>\u003C\u002Fem> Identified as “ad000174 12\u002F2022” and “br000051 12\u002F2022”\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>17\u003C\u002Fstrong>\u003C\u002Fem> We note that the website for Aurora Pharmaceuticals contains other product-specific webpages that are misleading because they omit risk information including, but not limited to, EQUISUL-SDT® (sulfadiazine\u002Ftrimethoprim) found at EQUINE – EQUISUL-SDT® (Sulfadiazine\u002FTrimethoprim) | Aurora Pharmaceutical, EquiCoxib™ (firocoxib) found at EQUINE – EQUICOXIB™ | Aurora Pharmaceutical and Revolt® (selamectin) found at Revolt for Pets | Aurora Pharmaceutical.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nAnimal & Veterinary\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMichael Strobel\n\nRecipient Title\n\nCEO\n\nAurora Pharmaceutical\n\n1196 Highway 3 South\n\nNorthfield, MN 55057\n\nUnited States\n\nIssuing Office:\n\nCenter for Veterinary Medicine\n\nUnited States\n\nFebruary 7, 2025\nRe: ANADAs 200-620 Altren® (altrenogest), 200-621 SwineMate® (altrenogest), 200-718 Barrier™ for dogs (imidacloprid and moxidectin)\nCMS #: 698797\nWARNING LETTER\nDear Dr. Strobel:\nThe U.S. Food and Drug Administration (FDA) has reviewed your promotional communications for your FDA-approved products including your company website1 and linked webpages and noted false or misleading claims and representations about the safety and effectiveness of these products. These promotional communications misbrand your products within the meaning of the Federal Food, Drug, and Cosmetic Act (FD&C Act) section 502(a) [21 U.S.C. 352(a)] and section 502(n) [21 U.S.C. 352(n)]; section 201(n) [21 U.S.C. 321(n)]; and 21 CFR 202.1(e)(5). It is a prohibited act to distribute a misbranded product in interstate commerce. Section 301(a) [21 U.S.C. 331(a)]. This violation is especially concerning from a public health perspective because your products Altren® (altrenogest) and SwineMate® (altrenogest) have serious user safety warnings and your product Barrier™ for dogs (imidacloprid and moxidectin) has a boxed warning regarding oral exposure in dogs and topical exposure in children.\nProduct Information2\nAltren®\nAltren® is indicated for:\n“[S]uppression of estrus in mares. Suppression of estrus allows for a predictable occurrence of estrus following drug withdrawal. This facilitates the attainment of regular cyclicity during the transition from winter anestrus to the physiological breeding season. Suppression of estrus will also facilitate management of prolonged estrus conditions. Suppression of estrus may be used to facilitate scheduled breeding during the physiological breeding season.”3\nDue to human user safety risks, the package insert (PI) for Altren® contains user safety warning language: “Not for use in humans. Keep out of reach of children. Avoid skin contact. Altren® is absorbed through unbroken skin, and exposure may result in serious side effects to both women and men. Wear vinyl, neoprene, or nitrile gloves when handling or administering Altren®, or when touching contaminated surfaces or equipment. Latex gloves are not protective.” [Emphasis original].\nAdditional warning language includes:\n“PREGNANT WOMEN OR WOMEN WHO MAY BE PREGNANT SHOULD NOT HANDLE ALTREN®. WOMEN OF CHILDBEARING AGE SHOULD EXERCISE EXTREME CAUTION WHEN HANDLING THIS PRODUCT.\nAccidental absorption, such as via direct contact with the skin, could lead to a disruption of the menstrual cycle or prolongation of pregnancy….”\n[Emphasis original].\nThe PI also contains a list of people who should not handle Altren®, instructions on what to do in case of accidental exposure, and reported human effects from exposure.\nThe PI for Altren® further contains, among other things, additional adverse event, warning, precaution, and contraindication information.\nSwineMate®\nSwineMate® is indicated for:\n“[S]ynchronization of estrus in sexually mature gilts that have had at least one estrous cycle. Treatment with SwineMate® results in estrus (standing heat) 4 to 9 days after completion of the 14-day treatment period.”4\nDue to human user safety risks, the PI for SwineMate® contains user safety warning language stating: “Skin contact must be avoided as SwineMate® is readily absorbed through unbroken skin, and exposure may result in serious side effects to both women and men. Always wear vinyl, neoprene or nitrile protective gloves when handling SwineMate or when in contact with equipment or surfaces contaminated by this product. Latex gloves are not protective.” [Emphasis original].\nAdditional warning language includes:\n“PREGNANT WOMEN OR WOMEN WHO MAY BE PREGNANT SHOULD NOT HANDLE SwineMate® (altrenogest). WOMEN OF CHILDBEARING AGE SHOULD EXERCISE EXTREME CAUTION WHEN HANDLING THIS PRODUCT.\nAccidental absorption, such as absorption through the skin, could lead to a disruption of the menstrual cycle or prolongation of pregnancy....”\n[Emphasis original].\nThe PI also contains a list of people who should not handle the product, instructions on what to do in case of accidental exposure, and information on reported human effects from exposure.\nThe PI for SwineMate® further contains, among other things, additional adverse event, warning, precaution, and contraindication information.\nBarrier™ for dogs\nBarrier™ for dogs is indicated for:\n“[T]he prevention of heartworm disease caused by Dirofilaria immitis and the treatment of Dirofilaria immitis circulating microfilariae in heartworm-positive dogs. Barrier for Dogs kills adult fleas and is indicated for the treatment of flea infestations (Ctenocephalides felis). Barrier for Dogs is indicated for the treatment and control of sarcoptic mange caused by Sarcoptes scabiei var. canis.”5\nThe PI also contains a chart detailing the intestinal parasites and the associated stages Barrier™ for dogs is indicated to treat or control.\nThe PI contains a boxed warning stating:\n“DO NOT ADMINISTER THIS PRODUCT ORALLY”\n“For the first 30 minutes after application ensure that dogs cannot lick the product from application sites on themselves or other treated animals.”\n“Children should not come in contact with application sites for two (2) hours after application.\n(See Contraindications, Warnings, Human Warnings, and Adverse Reactions, for more information)”\nBoxed warnings are the most significant type of warning in a product’s labeling and are used to emphasize serious or life-threatening risks.6\nThe Warnings section of the PI states that oral ingestion of this product by dogs may cause “serious adverse reactions including depression, salivation, dilated pupils, incoordination, panting, and generalized muscle tremors.” The Human Warnings section states that human exposure to this product has been reported to cause “headache; dizziness; and redness, burning, tingling or numbness of the skin.”\nIn addition to the boxed warning, the PI contains, among other things, additional adverse event, warning, precaution, and contraindication information.\nFalse or Misleading Claims\nPrescription drug advertisements and labeling (promotional communications) misbrand a drug if they are false or misleading in any particular. See FD&C Act section 502(a),(n) (21 U.S.C 352(a),(n)). The determination of whether a promotional communication is misleading includes, among other things, not only representations made or suggested in the promotional communication, but also the extent to which the promotional communication fails to reveal facts material in the light of its representations or material with respect to consequences that may result from the use of the drug as recommended or suggested in the promotional communication. See FD&C Act section 201(n) (21 U.S.C 321(n)) and 21 CFR 202.1(e)(5).\nThe website for Aurora Pharmaceutical mentioned above1 includes a tab at the top of the page titled “Species,” which contains links to product-specific webpages for each product the firm markets. The webpage for Altren®7 can be found under “Equine;” the webpage for SwineMate®8 can be found under “Porcine;” and the webpage for Barrier™9 can be found under “Pets.”\nAltren®\nThe product webpage is misleading because it prominently features benefit information about the product in the center of the page, but fails to contain any risk information. See 21 CFR 202.1(e)(5)(ii). The webpage for Altren® omits information from the PI about the significant risks to humans from potential product exposure, as well as important animal safety warning language. This omission of risk information creates a misleading impression about the potential consequences associated with using the drug.\nThe webpage for Altren® also contains a link to a “Product Sheet”10 which lacks fair balance because the first page contains information regarding benefits and effectiveness in a larger font and bulleted format, whereas risk information is presented only in a smaller font on the second page.11 See 21 CFR 202.1(e)(5)(ii). The Product Sheet fails to present information relating to side effects and contraindications with a prominence and readability reasonably comparable with the presentation of information relating to effectiveness of the drug and fails to include on each page the information relating to side effects and contraindications or a prominent reference to its presence and location. 21 CFR 202.1(e)(7)(viii), (e)(7)(xii). Further, at the bottom of the webpage for Altren® there are links to print advertisements12 which contain benefit information but omit important risk information about human user safety, such as that users should wear vinyl, neoprene, or nitrile gloves when handling or administering Altren®; latex gloves are not protective. Additionally, the risk information that is present on the advertisements, such as “Pregnant women, or women who suspect they are pregnant, should not handle Altren,” is presented in a small, lightweight font which is not reasonably comparable to the presentation of information relating to effectiveness in terms of prominence and readability. See 21 CFR 202.1(e)(7)(viii). It also does not explain that women of childbearing age should exercise extreme caution when handling Altren® because it is readily absorbed through the skin and can disrupt the menstrual cycle or prolong pregnancy.\nSwineMate®\nThe product webpage is misleading because it prominently features benefit information about the product in the center of the page but fails to contain any risk information. See 21 CFR 202.1(e)(5)(ii). The webpage for SwineMate® omits information from the PI about the significant risks to humans from potential product exposure, as well as important animal safety warning language. This omission of risk information creates a misleading impression about the potential consequences associated with using the drug. Further, the webpage for SwineMate® fails to include adequate information for use, such as the effects, routes, methods of administration, and any relevant warnings, hazards, contraindications, side effects, and precautions. See 21 CFR 201.105(d)(1).\nThe webpage for SwineMate® also contains a link to a “Product Sheet”13 which lacks fair balance because the first page contains information regarding benefits and effectiveness in a larger font and bulleted format, whereas risk information is presented only in a smaller font on the second page.14 See 21 CFR 202.1(e)(5)(ii). The Product Sheet fails to present information relating to side effects and contraindications with a prominence and readability\nreasonably comparable with the presentation of information relating to effectiveness of the drug and fails to include on each page the information relating to side effects and contraindications or a prominent reference to its presence and location. 21 CFR 202.1(e)(7)(viii), (e)(7)(xii). Further, the print advertisement linked at the bottom of the SwineMate® webpage15 contains no risk information although there is benefit information presented. See 21 CFR 202.1(e)(1).\nBarrier™ for dogs\nThe product webpage is misleading because it prominently features benefit information about the product in the center of the page, but fails to contain any risk information. See 21 CFR 202.1(e)(5)(ii). The webpage for Barrier™ for dogs omits the boxed warning from the PI, as well as other important animal and human safety information. This omission of risk information creates a misleading impression about the potential consequences associated with using the drug.\nThe ”Product Sheet”16 linked on the Barrier™ for dogs webpage lacks fair balance because the first seven pages contain information regarding benefits and effectiveness in a larger font and with numerous charts, images, and visuals, whereas risk information is presented only in a smaller font on a single page at the end of the brochure. See 21 CFR 202.1(e)(5)(ii). The Product Sheet fails to present information relating to side effects and contraindications with a prominence and readability reasonably comparable with the presentation of information relating to effectiveness of the drug and fails to include on each page the information relating to side effects and contraindications or a prominent reference to its presence and location. 21 CFR 202.1(e)(7)(viii), (e)(7)(xii).\nConclusion and Requested Response\nFor the reasons discussed above, your website misbrands Altren®, SwineMate®, and Barrier™ for dogs within the meaning of the FD&C Act and make their distribution violative.17 FD&C Act section 502(a), (21 U.S.C. 352(a)); section 502(n) [21 U.S.C. 352(n)]; section 201(n) (21 U.S.C. 321(n)); section 301(a) (21 U.S.C. 331(a)), and 21 CFR 202.1(e)(5).\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may lead to legal action, including without limitation, seizure, and injunction.\nWithin fifteen (15) working days of receipt of this letter, please submit a written response addressing the concerns described in this letter, listing all promotional communications for Altren®, SwineMate®, and Barrier™ for dogs that contain representations like those described above, and explaining any plan for discontinuing use of such communications, or for ceasing distribution of Altren®, SwineMate®, and Barrier™ for dogs. If you cannot complete the above requested actions within fifteen (15) working days, state the reason for the delay and the time within which you will complete them.\nIf you believe that your products are not in violation of the FD&C Act, please include in your submission to us your reasoning and any supporting information for our consideration within 15 working days from the date of receipt of this letter.\nPlease direct your response to the undersigned at the Food and Drug Administration, Center for Veterinary Medicine, Division of Pharmacovigilance and Surveillance, 12225 Wilkins Ave, MPN II Room E436, Rockville, Maryland 20852. Please send a courtesy copy by email to CVMSurveillance@fda.hhs.gov. All correspondence should include a subject line that clearly identifies the submission as a Response to Warning Letter # 698797.\nIf you have any questions, please contact Dr. Christopher Loss by email at christopher.loss@fda.hhs.gov.\nSincerely,\n\u002FS\u002F\nLinda Walter-Grimm, DVM\nDirector, Division of Pharmacovigilance and\nSurveillance\nOffice of Surveillance and Compliance\nCenter for Veterinary Medicine\n________________\n1 Veterinary Pharmaceuticals for Livestock, Dogs and Cats https:\u002F\u002Faurorapharmaceutical.com\u002F last viewed on 2.6.2025\n2 This section does not include all the safety and risk information in the package insert for each product and does not necessarily represent the risk information that should be included in the promotional communication(s) cited in this letter.\n3 FDA-approved package insert (PI) for Altren®\n4 FDA-approved PI for SwineMate®\n5 FDA-approved PI for Barrier™ for Dogs\n6 See, e.g., “Boxed Warning”, https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fprescription-drug-advertising\u002Fdrug-advertisingglossary-terms\n7 EQUINE – Altren® (altrenogest) | Aurora Pharmaceutical\n8 Porcine – SwineMate® (altrenogest) | Aurora Pharmaceutical\n9 Barrier Pets Demo | Aurora Pharmaceutical. This webpage contains information about both Barrier™ for Dogs and Barrier™ for Cats\n10 Identified as “ss000026 04\u002F2020” for Altren®\n11 We also note that the PI on the second page of the Product Sheet is not the currently approved PI with the updated user safety information.\n12 Identified as: Altren Aurora Ad 1 jpeg (ad000040 05\u002F2018), Altren Aurora Ad 2 jpeg (000041 05\u002F2018), Aurora Altren Ad-Florida (Ad000069 10\u002F2019)\n13 Identified as “ss000025 04\u002F2020” for SwineMate®\n14 We also note that the PI on the second page of the Product Sheet is not the currently approved PI with the updated user safety information.\n15 Identified as “ad000048 10\u002F2018”\n16 Identified as “ad000174 12\u002F2022” and “br000051 12\u002F2022”\n17 We note that the website for Aurora Pharmaceuticals contains other product-specific webpages that are misleading because they omit risk information including, but not limited to, EQUISUL-SDT® (sulfadiazine\u002Ftrimethoprim) found at EQUINE – EQUISUL-SDT® (Sulfadiazine\u002FTrimethoprim) | Aurora Pharmaceutical, EquiCoxib™ (firocoxib) found at EQUINE – EQUICOXIB™ | Aurora Pharmaceutical and Revolt® (selamectin) found at Revolt for Pets | Aurora Pharmaceutical.","Aurora Pharmaceutical","aurora-pharmaceutical-698797-02072025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Faurora-pharmaceutical-698797-02072025","2026-10-26T08:07:59.207703+00:00","2025-03-11","698797","Animal & VeterinaryDrugs","2025-09-19","Michael Strobel","2026-08-19T16:58:07.742+00:00","2025-02-07",{"id":311,"raw":312,"subject":201,"body_html":316,"body_text":317,"firm_name":318,"letter_id":319,"created_at":85,"fei_number":19,"letter_url":320,"updated_at":321,"action_type":22,"case_status":23,"posted_date":322,"marcs_cms_no":323,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":324,"body_fetched_at":325,"delivery_method":326,"recipient_title":19,"reference_number":19,"action_taken_date":327,"medical_device_id":19,"response_letter_date":19},127,[313,314,315,11,201,13,13,13],"\u003Ctime datetime=\"2026-06-09T04:00:00Z\">06\u002F09\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-05-29T04:00:00Z\">05\u002F29\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmacau-union-pharmaceutical-limited-724506-05292026\">Macau-Union Pharmaceutical Limited\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Electronic Mail - Return Receipt Requested\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Kin Va Choi\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>General Manager\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Macau-Union Pharmaceutical Limited\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>3 - 3A Rua Cinco Do Bairro Da Areia Preta\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Room B 1\u002FF, Industrial Veng Fong\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Macao SAR China\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-26-83\u003C\u002Fp>\u003Cp>May 29, 2026\u003C\u002Fp>\u003Cp>Dear Mr. Choi:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Macau-Union Pharmaceutical Limited, FEI 3011219786, at 3-3A Rua Cinco Do Bairro Da Areia Preta, Room B 1\u002FF, Industrial Veng Fong, from December 15 to 17, 2025.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>In addition, “Bamboo Pharmacy® Mobility penetrating muscle &amp; joint rub” and “Bamboo Pharmacy® Relief + Recovery deep tissue pain relieving rub” are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of section 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C. 355(a), 331(d). Additionally, these products are misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee). Introduction or delivery for introduction of misbranded products into interstate commerce is prohibited under section 301(d) and (a) of the FD&amp;C Act, 21 U.S.C. 331(d) and (a). These violations are described in more detail below.\u003C\u002Fp>\u003Cp>We reviewed your February 2, 2026, response to our Form FDA 483 in detail.\u003C\u002Fp>\u003Cp>\u003Cstrong>CGMP Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release, and for each batch of drug product required to be free of objectionable microorganisms, appropriate laboratory testing, as necessary (21 CFR 211.165(a) and 211.165(b)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm did not adequately test your over-the-counter (OTC) drug products prior to release and distribution to the U.S. market. Specifically, your firm failed to test the identity and strength of each active ingredient before releasing the drug products. Your firm also failed to perform adequate microbiological testing on each batch of your drug products prior to release. You confirmed to our investigator that you lacked procedures for testing your finished drug products, and you could only provide evidence of finished drug product testing for appearance and weight.\u003C\u002Fp>\u003Cp>In your response, you commit to requiring testing for all drug products for the U.S. market, including identity verification, assay, microbial limits, and critical quality attributes. You also included summary test reports for batches shipped to the U.S. These reports contained both chemical and microbial test results.\u003C\u002Fp>\u003Cp>Your response is inadequate because you failed to provide supporting documentation for corrective actions. Additionally, the analytical reports provided lack specifications and show results for your active ingredients \u003Cstrong>(b)(4)\u003C\u002Fstrong>. The analyses found that these active ingredients were below the drug product labeled concentrations but offered no scientific justification or explanation. Sub potency versus the labeled concentration is also a violation of section 501(c) in that the drug product’s quality falls below that which it purports to possess. Further, your microbiological reports reference “Modified United States Pharmacopeia” (USP) methods (e.g. &lt;61&gt; and &lt;62&gt;); however, your response lacks adequate documentation describing the specific modifications made to the compendial USP methods.\u003C\u002Fp>\u003Cp>Testing is essential to ensure that the drug products you manufacture conform to all pre-determined quality attributes appropriate for their intended use. Because your firm lacked adequate testing of each batch of your drug products, you do not know whether the drug products conform to all appropriate finished drug product specifications and are suitable for release to consumers.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A list of chemical and microbial specifications, including test methods used to analyze each batch of your drug products before a batch disposition decision.\u003Cbr>o An action plan and timelines for conducting full chemical and microbiological testing of retain samples to determine the quality of all batches of drug product distributed to the United States that are within expiry as of the date of this letter.\u003Cbr>o A summary of all results obtained from testing retain samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and drug product recalls.\u003Cbr>o Complete microbiological testing results per USP &lt;61&gt; and &lt;62&gt; as written. Provide justification for any modified microbiological test method with validation data.\u003Cbr>o A comprehensive objectionable organism testing panel appropriate for topical OTC drug products including scientific rationale for microbiological specifications\u003Cbr>o Corrective actions to ensure no drug product is released without complete finished drug product testing.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm failed to test incoming active pharmaceutical ingredients (APIs) (e.g. \u003Cstrong>(b)(4)\u003C\u002Fstrong>) and other components used to manufacture your OTC drug products to determine their identity, purity, strength, and other appropriate quality attributes. Additionally, you relied on your suppliers’ certificates of analysis (COA) without verifying your supplier’s test results at appropriate intervals.\u003C\u002Fp>\u003Cp>In your response, you committed to implementing an identity testing program for all incoming components to align with USP requirements and to retrospectively verify the identity of the active ingredients \u003Cstrong>(b)(4)\u003C\u002Fstrong>. In addition, you will establish a supplier audit procedure to verify that suppliers’ test methods and COA results to ensure compliance with USP standards.\u003C\u002Fp>\u003Cp>Your response is inadequate because you failed to provide supporting documentation demonstrating adequate implementation of the proposed corrective actions. You also do not mention retrospective testing for the active ingredients \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Additionally, you did not include your interim plans to mitigate risks to drug products during the implementation of these corrective actions.\u003C\u002Fp>\u003Cp>Without adequate testing, you do not have scientific evidence that the components conform to appropriate specifications prior to use in the manufacture of your drug products. As a manufacturer, you have a responsibility to sample, test, and examine drug components before use in production to assure adequate quality.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive, independent review of your material system including, but not limited to:\u003Cbr>o evaluating all suppliers of materials (components, containers, and closures) to determine if they are reliable and appropriately qualified\u003Cbr>o an assessment of all materials to determine if they are consistently of acceptable quality\u003Cbr>o a review to ensure assigned expiration or retest dates are appropriate (supported by data)\u003Cbr>o adequacy of the supplier qualification program and its selection, qualification, and disqualification provisions.\u003C\u002Fli>\u003Cli>Based on a thorough review, provide a summary of your systems corrective action and preventive action (CAPA) plan to remediate the vendor qualification program and prevent use of unsuitable components, containers, and closures.\u003C\u002Fli>\u003Cli>The chemical and microbiological quality control specifications you use to test and release each incoming batch of component for use in manufacturing.\u003C\u002Fli>\u003Cli>A description of how you will test each component batch for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COA instead of testing each component batch for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component batch.\u003C\u002Fli>\u003Cli>A summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your SOP that describes this COA validation program.\u003C\u002Fli>\u003Cli>A summary of your program for qualifying and overseeing contract facilities that test the components and drug products you manufacture.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>3. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess, and your firm’s quality control unit did not review and approve those procedures, including any changes (21 CFR 211.100(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm lacks process validation studies to demonstrate reproducibility and control of your manufacturing processes to ensure uniform drug product quality. Additionally, your cleaning procedures for shared equipment are inadequate. You have not demonstrated that they enable operators to clean each equipment type reproducibly and effectively.\u003C\u002Fp>\u003Cp>In your response, you committed to conducting full process validation for U.S. drug products along with establishing a comprehensive in-process testing program. You will develop a shared equipment cleaning validation protocol to validate cleaning effectiveness. Additionally, you will install a new \u003Cstrong>(b)(4)\u003C\u002Fstrong> system with monitoring capabilities and revise your \u003Cstrong>(b)(4)\u003C\u002Fstrong> management procedure to ensure that cleaning water meets \u003Cstrong>(b)(4)\u003C\u002Fstrong> USP standards.\u003C\u002Fp>\u003Cp>Your response is inadequate because you failed to provide supporting documentation demonstrating adequate implementation of the proposed corrective actions. Additionally, you did not include a risk assessment of released drug products or provide any interim manufacturing plans to mitigate risks to drug products during the implementation of your corrective actions.\u003C\u002Fp>\u003Cp>Process validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies include intensive monitoring and testing throughout each significant process stage to characterize intra-batch variation and evaluate batches to determine whether an initial state of control has been established.\u003C\u002Fp>\u003Cp>See FDA’s guidance document Process Validation: General Principles and Practices for general principles and approaches that FDA considers appropriate elements of process validation at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A detailed summary of your validation program for ensuring a state of control throughout the drug product lifecycle, along with associated procedures. Describe your program for process performance qualification (PPQ), and ongoing monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control.\u003C\u002Fli>\u003Cli>A timeline for performing appropriate PPQ for each of your marketed drug products. Also provide a risk assessment and any follow-up actions to be taken for the distributed drug products produced without performing any process validation studies.\u003C\u002Fli>\u003Cli>Process performance protocol(s) and written procedures for qualification of equipment and facilities.\u003C\u002Fli>\u003Cli>A detailed program for designing, validating, maintaining, controlling and monitoring each of your manufacturing processes that include vigilant monitoring of intra-batch and inter-batch variation to ensure an ongoing state of control. Also, include your program for qualification of your equipment and facility.\u003C\u002Fli>\u003Cli>Appropriate improvements to your cleaning validation program, with special emphasis on incorporating conditions identified as worst case in your drug manufacturing operation. This should include but not be limited to identification and evaluation of all worst-case:\u003Cbr>o Drugs with higher toxicities\u003Cbr>o Drugs with higher drug potencies\u003Cbr>o Drugs of lower solubility in their cleaning solvents\u003Cbr>o Drugs with characteristics that make them difficult to clean\u003Cbr>o Swabbing locations for areas that are most difficult to clean\u003Cbr>o Maximum hold times before cleaning\u003C\u002Fli>\u003Cli>In addition, describe the steps that must be taken in your change management system before introduction of new manufacturing equipment or a new drug product.\u003C\u002Fli>\u003Cli>A summary of updated standard operating procedures that ensure an appropriate program is in place for verification and validation of cleaning procedures for drug products, processes, and equipment.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>4. Your firm failed to assure that the drug product bore an expiration date that was supported by appropriate stability testing (21 CFR 211.137(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You failed to establish an adequate stability testing program to support the labeled expiration date on your distributed drug products in the U.S. market. There is no assurance that your OTC drug products will remain acceptable throughout the labeled \u003Cstrong>(b)(4)\u003C\u002Fstrong> expiry period without an ongoing stability program.\u003C\u002Fp>\u003Cp>In your response, you committed to establishing a stability testing program “in compliance with USP &lt;1150&gt;.” You also commit to test identity and strength of the active ingredients, related substances, microbial limits, appearance, and viscosity at designated time intervals.\u003C\u002Fp>\u003Cp>Your response is inadequate because your it lacked sufficient scientific evidence to ensure that your drug products will meet proposed specifications and retain their quality attributes throughout labeled expiry. Additionally, you did not conduct or provide a risk assessment for drug products currently on the market without adequate stability testing to support the labeled expiration date.\u003C\u002Fp>\u003Cp>Without appropriate stability data, you cannot ensure your drug products meet established specifications and all pre-determined quality criteria throughout their assigned shelf-life.\u003C\u002Fp>\u003Cp>In response to this letter, provide a comprehensive, independent assessment CAPA plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\u003C\u002Fp>\u003Cul>\u003Cli>Stability-indicating methods\u003C\u002Fli>\u003Cli>Stability studies for each drug product in its marketed container-closure system before distribution is permitted\u003C\u002Fli>\u003Cli>An ongoing program in which representative batches of each drug product are added each year to the program to determine if the shelf-life claim remains valid\u003C\u002Fli>\u003Cli>Detailed definition of the specific attributes to be tested at each station (timepoint)\u003C\u002Fli>\u003Cli>All procedures that describe these and other elements of your remediated stability program\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your CAPAs before you pursue resolution of your firm’s compliance status with FDA.\u003C\u002Fp>\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\u003Cp>\u003Cstrong>Unapproved New Drug and Misbranding Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>“Bamboo Pharmacy® Mobility penetrating muscle &amp; joint rub” and “Bamboo Pharmacy® Relief + Recovery deep tissue pain relieving rub” are drugs as defined by section 201(g)(1)(B) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(B) because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(C) because they are intended to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>Examples from the product labels that provide evidence of the intended uses (as defined in 21 CFR 201.128) of the products as drugs include, but may not be limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cu>“Bamboo Pharmacy® Mobility penetrating muscle &amp; joint rub”\u003C\u002Fu>\u003C\u002Fp>\u003Cul>\u003Cli>“\u003Cstrong>DRUG FACTS . . . Uses:\u003C\u002Fstrong> For the temporary relief of minor aches and pains of muscles and joints due to ■arthritis ■strains ■bruises ■sprains ■simple backache” [from the product label]\u003C\u002Fli>\u003Cli>“Natural herbs to Promote Healing Improve Circulation Reduce Inflammation” [from the product label]\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cu>“Bamboo Pharmacy® Relief + Recovery deep tissue pain relieving rub”\u003C\u002Fu>\u003C\u002Fp>\u003Cul>\u003Cli>“\u003Cstrong>DRUG FACTS . . . Uses:\u003C\u002Fstrong> For the temporary relief of minor aches and pains of muscles and joints due to■¦arthritis ■strains ■bruises ■sprains ■simple backache” [from the product label]\u003C\u002Fli>\u003Cli>“Natural herbs to Promote Healing Improve Circulation Reduce Inflammation” [from the product label]\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Unapproved New Drug Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based on the above labeling evidence, “Bamboo Pharmacy® Mobility penetrating muscle &amp; joint rub” and “Bamboo Pharmacy® Relief + Recovery deep tissue pain relieving rub” are intended for use as external analgesic drug products, among other intended uses. As described below, these drug products are unapproved new drugs marketed in violation of sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C 355(a) and 331(d).\u003C\u002Fp>\u003Cp>A drug product is a “new drug” within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), if it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a). No FDA-approved applications pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, are in effect for these drug products identified above.\u003C\u002Fp>\u003Cp>Under section 505G of the FD&amp;C Act, certain nonprescription drugs marketed without an approved application —commonly referred to as \"OTC monograph drugs\"—may be legally marketed if they meet applicable requirements. With respect to nonprescription external analgesic drug products, such as your “Bamboo Pharmacy® Mobility penetrating muscle &amp; joint rub” and “Bamboo Pharmacy® Relief + Recovery deep tissue pain relieving rub,” in order to be GRASE and not new drugs, the products must, among other things, conform to the conditions in the applicable OTC monograph, here M017: External Analgesic Drug Products for Over-the-Counter Human Use.\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> However, “Bamboo Pharmacy® Mobility penetrating muscle &amp; joint rub” and “Bamboo Pharmacy® Relief + Recovery deep tissue pain relieving rub” do not conform to the conditions specified in M017 for the reasons described below.\u003C\u002Fp>\u003Cp>Specifically, the labeling for “Bamboo Pharmacy® Mobility penetrating muscle &amp; joint rub” and “Bamboo Pharmacy® Relief + Recovery deep tissue pain relieving rub” includes intended use claims that are not permitted under M017. For example, claims that the products “…Promote Healing Improve Circulation Reduce Inflammation” go beyond the allowed general intended uses for an external analgesic drug product and do not conform with M017.50(b).\u003C\u002Fp>\u003Cp>Furthermore, as formulated “Bamboo Pharmacy® Mobility penetrating muscle &amp; joint rub” and “Bamboo Pharmacy® Relief + Recovery deep tissue pain relieving rub” includes active ingredients that are not permitted by M017.\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> For example, the product labels for “Bamboo Pharmacy® Mobility penetrating muscle &amp; joint rub” and “Bamboo Pharmacy® Relief + Recovery deep tissue pain relieving rub” state that the products are formulated with “Natural herbs to Promote Healing Improve Circulation Reduce Inflammation.” While the products are labeled to contain \u003Cstrong>(b)(4)\u003C\u002Fstrong> as active ingredients, which are permitted by M017 to be active ingredients in counterirritant external analgesics, “natural herbs”; however, are not permitted as active ingredients in M017 in combination or as sole ingredients. Although the products’ Drug Facts Panel do not specifically list natural herb ingredients as active ingredients, the claim that the products are formulated with “Natural herbs to Promote Healing Improve Circulation Reduce Inflammation” purports the natural herbs furnish pharmacological activity, demonstrating that natural herbs are “active ingredients” as defined in 21 CFR 201.66(b)(2).\u003Cem>\u003Cstrong>\u003Csup>3\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Thus, as formulated and labeled, your “Bamboo Pharmacy® Mobility penetrating muscle &amp; joint rub” and “Bamboo Pharmacy® Relief + Recovery deep tissue pain relieving rub” products do not comply with the applicable conditions specified in M017 and have not otherwise been found GRASE.\u003Cem>\u003Cstrong>\u003Csup>4\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> Accordingly, these products are new drugs within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), and there is no basis under section 505G of the FD&amp;C Act under which these products would be legally marketed without an approved application. Because there are no applications in effect for these products, these products are unapproved new drugs.\u003C\u002Fp>\u003Cp>The introduction or delivery for introduction of these unapproved new drug products into interstate commerce violates sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C. 355(a) and 331(d).\u003C\u002Fp>\u003Cp>\u003Cstrong>Misbranded Drug Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Additionally, “Bamboo Pharmacy® Mobility penetrating muscle &amp; joint rub” and “Bamboo Pharmacy® Relief + Recovery deep tissue pain relieving rub” are misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee), because these products are nonprescription drugs subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, but do not comply with the requirements for marketing under that section and are not the subject of an application approved under section 505 of the FD&amp;C Act, 21 U.S.C. 355.\u003C\u002Fp>\u003Cp>The introduction or delivery for introduction of a misbranded drug into interstate commerce violates section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>FDA placed all drugs and drug products offered for import into the United States from your firm on Import Alert 66-40 on March 24, 2026.\u003C\u002Fp>\u003Cp>Correct any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\u003C\u002Fp>\u003Cp>Failure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at Macau-Union Pharmaceutical Limited, at 3-3A Rua Cinco Do Bairro Da Areia Preta, Room B 1\u002FF, Industrial Veng Fong, into the United States under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated or misbranded may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B) and are misbranded under section 502 of the FD&amp;C Act, respectively.\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3011219786 and ATTN: Rory Geyer.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>\u002FS\u002F\u003C\u002Fp>\u003Cp>Tina Smith\u003Cbr>Captain, U.S. Public Health Service\u003Cbr>Director\u003Cbr>Office of Unapproved Drugs &amp; Labeling Compliance\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>__________________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> M017 reflects the conditions in the relevant final order established and in effect under Section 505G of the FD&amp;C Act; see Order ID OTC000033, available at FDA’s website OTC Monographs@FDA, https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fomuf\u002Findex.cfm?event=OrderDetail&amp;orderid=OTC000033.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> See 21 CFR 201.66(b)(2).\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> Under 21 CFR 201.66(b), an active ingredient is a component of a drug intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> FDA is not aware of any adequate and well-controlled clinical trials in the published literature that support a determination that “Bamboo Pharmacy® Mobility penetrating muscle &amp; joint rub” and “Bamboo Pharmacy® Relief + Recovery deep tissue pain relieving rub” are GRASE for use under the conditions prescribed, recommended, or suggested in their labeling, nor has FDA determined these drug products to be GRASE pursuant to an order issued under section 505G(b).\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Electronic Mail - Return Receipt Requested\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Kin Va Choi\n\nRecipient Title\n\nGeneral Manager\n\nMacau-Union Pharmaceutical Limited\n\n3 - 3A Rua Cinco Do Bairro Da Areia Preta\n\nRoom B 1\u002FF, Industrial Veng Fong\n\nMacao SAR China\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-26-83\nMay 29, 2026\nDear Mr. Choi:\nThe United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Macau-Union Pharmaceutical Limited, FEI 3011219786, at 3-3A Rua Cinco Do Bairro Da Areia Preta, Room B 1\u002FF, Industrial Veng Fong, from December 15 to 17, 2025.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nIn addition, “Bamboo Pharmacy® Mobility penetrating muscle & joint rub” and “Bamboo Pharmacy® Relief + Recovery deep tissue pain relieving rub” are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of section 505(a) and 301(d) of the FD&C Act, 21 U.S.C. 355(a), 331(d). Additionally, these products are misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee). Introduction or delivery for introduction of misbranded products into interstate commerce is prohibited under section 301(d) and (a) of the FD&C Act, 21 U.S.C. 331(d) and (a). These violations are described in more detail below.\nWe reviewed your February 2, 2026, response to our Form FDA 483 in detail.\nCGMP Violations\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n1. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release, and for each batch of drug product required to be free of objectionable microorganisms, appropriate laboratory testing, as necessary (21 CFR 211.165(a) and 211.165(b)).\nYour firm did not adequately test your over-the-counter (OTC) drug products prior to release and distribution to the U.S. market. Specifically, your firm failed to test the identity and strength of each active ingredient before releasing the drug products. Your firm also failed to perform adequate microbiological testing on each batch of your drug products prior to release. You confirmed to our investigator that you lacked procedures for testing your finished drug products, and you could only provide evidence of finished drug product testing for appearance and weight.\nIn your response, you commit to requiring testing for all drug products for the U.S. market, including identity verification, assay, microbial limits, and critical quality attributes. You also included summary test reports for batches shipped to the U.S. These reports contained both chemical and microbial test results.\nYour response is inadequate because you failed to provide supporting documentation for corrective actions. Additionally, the analytical reports provided lack specifications and show results for your active ingredients (b)(4). The analyses found that these active ingredients were below the drug product labeled concentrations but offered no scientific justification or explanation. Sub potency versus the labeled concentration is also a violation of section 501(c) in that the drug product’s quality falls below that which it purports to possess. Further, your microbiological reports reference “Modified United States Pharmacopeia” (USP) methods (e.g. \u003C61> and \u003C62>); however, your response lacks adequate documentation describing the specific modifications made to the compendial USP methods.\nTesting is essential to ensure that the drug products you manufacture conform to all pre-determined quality attributes appropriate for their intended use. Because your firm lacked adequate testing of each batch of your drug products, you do not know whether the drug products conform to all appropriate finished drug product specifications and are suitable for release to consumers.\nIn response to this letter, provide:\nA list of chemical and microbial specifications, including test methods used to analyze each batch of your drug products before a batch disposition decision.\no An action plan and timelines for conducting full chemical and microbiological testing of retain samples to determine the quality of all batches of drug product distributed to the United States that are within expiry as of the date of this letter.\no A summary of all results obtained from testing retain samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and drug product recalls.\no Complete microbiological testing results per USP \u003C61> and \u003C62> as written. Provide justification for any modified microbiological test method with validation data.\no A comprehensive objectionable organism testing panel appropriate for topical OTC drug products including scientific rationale for microbiological specifications\no Corrective actions to ensure no drug product is released without complete finished drug product testing.\n2. Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).\nYour firm failed to test incoming active pharmaceutical ingredients (APIs) (e.g. (b)(4)) and other components used to manufacture your OTC drug products to determine their identity, purity, strength, and other appropriate quality attributes. Additionally, you relied on your suppliers’ certificates of analysis (COA) without verifying your supplier’s test results at appropriate intervals.\nIn your response, you committed to implementing an identity testing program for all incoming components to align with USP requirements and to retrospectively verify the identity of the active ingredients (b)(4). In addition, you will establish a supplier audit procedure to verify that suppliers’ test methods and COA results to ensure compliance with USP standards.\nYour response is inadequate because you failed to provide supporting documentation demonstrating adequate implementation of the proposed corrective actions. You also do not mention retrospective testing for the active ingredients (b)(4). Additionally, you did not include your interim plans to mitigate risks to drug products during the implementation of these corrective actions.\nWithout adequate testing, you do not have scientific evidence that the components conform to appropriate specifications prior to use in the manufacture of your drug products. As a manufacturer, you have a responsibility to sample, test, and examine drug components before use in production to assure adequate quality.\nIn response to this letter, provide:\nA comprehensive, independent review of your material system including, but not limited to:\no evaluating all suppliers of materials (components, containers, and closures) to determine if they are reliable and appropriately qualified\no an assessment of all materials to determine if they are consistently of acceptable quality\no a review to ensure assigned expiration or retest dates are appropriate (supported by data)\no adequacy of the supplier qualification program and its selection, qualification, and disqualification provisions.\nBased on a thorough review, provide a summary of your systems corrective action and preventive action (CAPA) plan to remediate the vendor qualification program and prevent use of unsuitable components, containers, and closures.\nThe chemical and microbiological quality control specifications you use to test and release each incoming batch of component for use in manufacturing.\nA description of how you will test each component batch for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COA instead of testing each component batch for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component batch.\nA summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your SOP that describes this COA validation program.\nA summary of your program for qualifying and overseeing contract facilities that test the components and drug products you manufacture.\n3. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess, and your firm’s quality control unit did not review and approve those procedures, including any changes (21 CFR 211.100(a)).\nYour firm lacks process validation studies to demonstrate reproducibility and control of your manufacturing processes to ensure uniform drug product quality. Additionally, your cleaning procedures for shared equipment are inadequate. You have not demonstrated that they enable operators to clean each equipment type reproducibly and effectively.\nIn your response, you committed to conducting full process validation for U.S. drug products along with establishing a comprehensive in-process testing program. You will develop a shared equipment cleaning validation protocol to validate cleaning effectiveness. Additionally, you will install a new (b)(4) system with monitoring capabilities and revise your (b)(4) management procedure to ensure that cleaning water meets (b)(4) USP standards.\nYour response is inadequate because you failed to provide supporting documentation demonstrating adequate implementation of the proposed corrective actions. Additionally, you did not include a risk assessment of released drug products or provide any interim manufacturing plans to mitigate risks to drug products during the implementation of your corrective actions.\nProcess validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies include intensive monitoring and testing throughout each significant process stage to characterize intra-batch variation and evaluate batches to determine whether an initial state of control has been established.\nSee FDA’s guidance document Process Validation: General Principles and Practices for general principles and approaches that FDA considers appropriate elements of process validation at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload.\nIn response to this letter, provide:\nA detailed summary of your validation program for ensuring a state of control throughout the drug product lifecycle, along with associated procedures. Describe your program for process performance qualification (PPQ), and ongoing monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control.\nA timeline for performing appropriate PPQ for each of your marketed drug products. Also provide a risk assessment and any follow-up actions to be taken for the distributed drug products produced without performing any process validation studies.\nProcess performance protocol(s) and written procedures for qualification of equipment and facilities.\nA detailed program for designing, validating, maintaining, controlling and monitoring each of your manufacturing processes that include vigilant monitoring of intra-batch and inter-batch variation to ensure an ongoing state of control. Also, include your program for qualification of your equipment and facility.\nAppropriate improvements to your cleaning validation program, with special emphasis on incorporating conditions identified as worst case in your drug manufacturing operation. This should include but not be limited to identification and evaluation of all worst-case:\no Drugs with higher toxicities\no Drugs with higher drug potencies\no Drugs of lower solubility in their cleaning solvents\no Drugs with characteristics that make them difficult to clean\no Swabbing locations for areas that are most difficult to clean\no Maximum hold times before cleaning\nIn addition, describe the steps that must be taken in your change management system before introduction of new manufacturing equipment or a new drug product.\nA summary of updated standard operating procedures that ensure an appropriate program is in place for verification and validation of cleaning procedures for drug products, processes, and equipment.\n4. Your firm failed to assure that the drug product bore an expiration date that was supported by appropriate stability testing (21 CFR 211.137(a)).\nYou failed to establish an adequate stability testing program to support the labeled expiration date on your distributed drug products in the U.S. market. There is no assurance that your OTC drug products will remain acceptable throughout the labeled (b)(4) expiry period without an ongoing stability program.\nIn your response, you committed to establishing a stability testing program “in compliance with USP \u003C1150>.” You also commit to test identity and strength of the active ingredients, related substances, microbial limits, appearance, and viscosity at designated time intervals.\nYour response is inadequate because your it lacked sufficient scientific evidence to ensure that your drug products will meet proposed specifications and retain their quality attributes throughout labeled expiry. Additionally, you did not conduct or provide a risk assessment for drug products currently on the market without adequate stability testing to support the labeled expiration date.\nWithout appropriate stability data, you cannot ensure your drug products meet established specifications and all pre-determined quality criteria throughout their assigned shelf-life.\nIn response to this letter, provide a comprehensive, independent assessment CAPA plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\nStability-indicating methods\nStability studies for each drug product in its marketed container-closure system before distribution is permitted\nAn ongoing program in which representative batches of each drug product are added each year to the program to determine if the shelf-life claim remains valid\nDetailed definition of the specific attributes to be tested at each station (timepoint)\nAll procedures that describe these and other elements of your remediated stability program\nCGMP Consultant Recommended\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your CAPAs before you pursue resolution of your firm’s compliance status with FDA.\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\nUnapproved New Drug and Misbranding Violations\n“Bamboo Pharmacy® Mobility penetrating muscle & joint rub” and “Bamboo Pharmacy® Relief + Recovery deep tissue pain relieving rub” are drugs as defined by section 201(g)(1)(B) of the FD&C Act, 21 U.S.C. 321(g)(1)(B) because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&C Act, 21 U.S.C. 321(g)(1)(C) because they are intended to affect the structure or any function of the body.\nExamples from the product labels that provide evidence of the intended uses (as defined in 21 CFR 201.128) of the products as drugs include, but may not be limited to, the following:\n“Bamboo Pharmacy® Mobility penetrating muscle & joint rub”\n“DRUG FACTS . . . Uses: For the temporary relief of minor aches and pains of muscles and joints due to ■arthritis ■strains ■bruises ■sprains ■simple backache” [from the product label]\n“Natural herbs to Promote Healing Improve Circulation Reduce Inflammation” [from the product label]\n“Bamboo Pharmacy® Relief + Recovery deep tissue pain relieving rub”\n“DRUG FACTS . . . Uses: For the temporary relief of minor aches and pains of muscles and joints due to■¦arthritis ■strains ■bruises ■sprains ■simple backache” [from the product label]\n“Natural herbs to Promote Healing Improve Circulation Reduce Inflammation” [from the product label]\nUnapproved New Drug Violations\nBased on the above labeling evidence, “Bamboo Pharmacy® Mobility penetrating muscle & joint rub” and “Bamboo Pharmacy® Relief + Recovery deep tissue pain relieving rub” are intended for use as external analgesic drug products, among other intended uses. As described below, these drug products are unapproved new drugs marketed in violation of sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C 355(a) and 331(d).\nA drug product is a “new drug” within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p), if it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a). No FDA-approved applications pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, are in effect for these drug products identified above.\nUnder section 505G of the FD&C Act, certain nonprescription drugs marketed without an approved application —commonly referred to as \"OTC monograph drugs\"—may be legally marketed if they meet applicable requirements. With respect to nonprescription external analgesic drug products, such as your “Bamboo Pharmacy® Mobility penetrating muscle & joint rub” and “Bamboo Pharmacy® Relief + Recovery deep tissue pain relieving rub,” in order to be GRASE and not new drugs, the products must, among other things, conform to the conditions in the applicable OTC monograph, here M017: External Analgesic Drug Products for Over-the-Counter Human Use.1 However, “Bamboo Pharmacy® Mobility penetrating muscle & joint rub” and “Bamboo Pharmacy® Relief + Recovery deep tissue pain relieving rub” do not conform to the conditions specified in M017 for the reasons described below.\nSpecifically, the labeling for “Bamboo Pharmacy® Mobility penetrating muscle & joint rub” and “Bamboo Pharmacy® Relief + Recovery deep tissue pain relieving rub” includes intended use claims that are not permitted under M017. For example, claims that the products “…Promote Healing Improve Circulation Reduce Inflammation” go beyond the allowed general intended uses for an external analgesic drug product and do not conform with M017.50(b).\nFurthermore, as formulated “Bamboo Pharmacy® Mobility penetrating muscle & joint rub” and “Bamboo Pharmacy® Relief + Recovery deep tissue pain relieving rub” includes active ingredients that are not permitted by M017.2 For example, the product labels for “Bamboo Pharmacy® Mobility penetrating muscle & joint rub” and “Bamboo Pharmacy® Relief + Recovery deep tissue pain relieving rub” state that the products are formulated with “Natural herbs to Promote Healing Improve Circulation Reduce Inflammation.” While the products are labeled to contain (b)(4) as active ingredients, which are permitted by M017 to be active ingredients in counterirritant external analgesics, “natural herbs”; however, are not permitted as active ingredients in M017 in combination or as sole ingredients. Although the products’ Drug Facts Panel do not specifically list natural herb ingredients as active ingredients, the claim that the products are formulated with “Natural herbs to Promote Healing Improve Circulation Reduce Inflammation” purports the natural herbs furnish pharmacological activity, demonstrating that natural herbs are “active ingredients” as defined in 21 CFR 201.66(b)(2).3\nThus, as formulated and labeled, your “Bamboo Pharmacy® Mobility penetrating muscle & joint rub” and “Bamboo Pharmacy® Relief + Recovery deep tissue pain relieving rub” products do not comply with the applicable conditions specified in M017 and have not otherwise been found GRASE.4 Accordingly, these products are new drugs within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p), and there is no basis under section 505G of the FD&C Act under which these products would be legally marketed without an approved application. Because there are no applications in effect for these products, these products are unapproved new drugs.\nThe introduction or delivery for introduction of these unapproved new drug products into interstate commerce violates sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C. 355(a) and 331(d).\nMisbranded Drug Violations\nAdditionally, “Bamboo Pharmacy® Mobility penetrating muscle & joint rub” and “Bamboo Pharmacy® Relief + Recovery deep tissue pain relieving rub” are misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee), because these products are nonprescription drugs subject to section 505G of the FD&C Act, 21 U.S.C. 355h, but do not comply with the requirements for marketing under that section and are not the subject of an application approved under section 505 of the FD&C Act, 21 U.S.C. 355.\nThe introduction or delivery for introduction of a misbranded drug into interstate commerce violates section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nFDA placed all drugs and drug products offered for import into the United States from your firm on Import Alert 66-40 on March 24, 2026.\nCorrect any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\nFailure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at Macau-Union Pharmaceutical Limited, at 3-3A Rua Cinco Do Bairro Da Areia Preta, Room B 1\u002FF, Industrial Veng Fong, into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated or misbranded may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B) and are misbranded under section 502 of the FD&C Act, respectively.\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3011219786 and ATTN: Rory Geyer.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research\n\u002FS\u002F\nTina Smith\nCaptain, U.S. Public Health Service\nDirector\nOffice of Unapproved Drugs & Labeling Compliance\nOffice of Compliance\nCenter for Drug Evaluation and Research\n__________________________\n1 M017 reflects the conditions in the relevant final order established and in effect under Section 505G of the FD&C Act; see Order ID OTC000033, available at FDA’s website OTC Monographs@FDA, https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fomuf\u002Findex.cfm?event=OrderDetail&orderid=OTC000033.\n2 See 21 CFR 201.66(b)(2).\n3 Under 21 CFR 201.66(b), an active ingredient is a component of a drug intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\n4 FDA is not aware of any adequate and well-controlled clinical trials in the published literature that support a determination that “Bamboo Pharmacy® Mobility penetrating muscle & joint rub” and “Bamboo Pharmacy® Relief + Recovery deep tissue pain relieving rub” are GRASE for use under the conditions prescribed, recommended, or suggested in their labeling, nor has FDA determined these drug products to be GRASE pursuant to an order issued under section 505G(b).","Macau-Union Pharmaceutical Limited","macau-union-pharmaceutical-limited-724506-05292026","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmacau-union-pharmaceutical-limited-724506-05292026","2026-10-26T08:09:18.024742+00:00","2026-06-09","724506","Mr. Kin Va Choi","2026-08-19T04:38:02.357+00:00","Via Electronic Mail - Return Receipt Requested","2026-05-29",{"id":329,"raw":330,"subject":80,"body_html":334,"body_text":335,"firm_name":336,"letter_id":337,"created_at":260,"fei_number":19,"letter_url":338,"updated_at":339,"action_type":22,"case_status":23,"posted_date":340,"marcs_cms_no":341,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":342,"body_fetched_at":343,"delivery_method":29,"recipient_title":19,"reference_number":344,"action_taken_date":345,"medical_device_id":19,"response_letter_date":19},688,[331,332,333,11,80,13,13,13],"\u003Ctime datetime=\"2025-09-02T04:00:00Z\">09\u002F02\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-08-27T04:00:00Z\">08\u002F27\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Famneal-pharmaceuticals-llc-709894-08272025\">Amneal Pharmaceuticals, LLC \u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-25-104\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Chintu Patel\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Co-Chief Executive Officer \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Amneal Pharmaceuticals, LLC \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>50 Horseblock Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Brookhaven\u003C\u002Fspan>, \u003Cspan>NY\u003C\u002Fspan> \u003Cspan>11719-9509\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:chintu@amneal.com\"> chintu@amneal.com  \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-25-104\u003C\u002Fp>\u003Cp>August 27, 2025\u003C\u002Fp>\u003Cp>Dear Mr. Patel:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Amneal Pharmaceuticals Private Limited, FEI 3018907202, located at 506 Survey No., near Sachana Kalyanpura Road Palli, Gujarat, India, from March 10 to 19, 2025.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>We reviewed your April 3, 2025, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondences.\u003C\u002Fp>\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm failed to conduct an adequate investigation into recurring problems with visible particulate matter contamination. In 2024, your firm initiated an investigation when two batches of ropivacaine hydrochloride injection, supplied in polypropylene bags, exceeded your acceptance criteria for visual inspection. You identified the polypropylene bags as the source of the inordinately high levels of particulate contamination (predominately, white fibers). You performed an additional visual inspection and conducted a risk assessment that you believed justified releasing these batches. However, your risk assessment was inadequate as it minimized the severity associated with particle contamination in a sterile injectable drug product that can be administered into the epidural space. Your assessment failed to properly evaluate the potential impact of visible particulates on patient safety, as it did not adequately consider the route of administration and patient population receiving the product.\u003C\u002Fp>\u003Cp>The presence of particulate matter in epidural injectable products can pose significant health risks to patients. These risks are of particular concern for patients receiving long-term epidural therapy. There is a reasonable probability that particulate matter in the epidural space may cause an epidural inflammatory process, epidural abscess, or meningitis. Depending on the location of the epidural injection, the particles could potentially cause damage to the spinal cord including spinal cord infarction or permanent nerve injury.\u003C\u002Fp>\u003Cp>Your firm was aware of the risk of particulate contamination from the polypropylene bags purchased from your vendor for more than a year prior to your 2024 investigation. You had rejected several batches of a sterile drug product after investigating particulate contamination in late 2022 and early 2023. Your investigations found that the polypropylene bags were the source of the visible white fibers and noted difficulties in detecting these fibers when performing visual inspection. Notably, for multiple batches, your firm continued to detect visible fiber particles during acceptable quality limit inspections of limited sample sizes following performance of visual inspections.\u003C\u002Fp>\u003Cp>However, you continued to use these polypropylene bags to produce sterile injectable drug products and did not implement appropriate corrective action and preventive action (CAPA) to prevent recurrence.\u003C\u002Fp>\u003Cp>Based on your investigations into particulate contamination, you relaxed the “major defects” rate from no more than (NMT) \u003Cstrong>(b)(4)\u003C\u002Fstrong>% to NMT \u003Cstrong>(b)(4)\u003C\u002Fstrong>%, and the overall rejection limit from NMT \u003Cstrong>(b)(4)\u003C\u002Fstrong>% to NMT \u003Cstrong>(b)(4)\u003C\u002Fstrong>%. You implemented these significantly relaxed limits due to the high rate of particulate contamination in polypropylene bag lots received from your unreliable vendor. The inappropriately high tolerance for defective polypropylene bags accommodated the use of poor-quality polypropylene bags in the production of parenteral drug product batches.\u003C\u002Fp>\u003Cp>It is unacceptable to increase lot acceptance specifications to excessive levels to enable use of unsuitable polypropylene bags received from your supplier.\u003C\u002Fp>\u003Cp>In your response, you indicate that, on March 26, 2025, you filed a Field Alert Report for two lots of ropivacaine hydrochloride injection, USP, 500 mg\u002F100 mL infusion bags due to particulate contamination. You also initiated a recall of these two lots on April 18, 2025. The company announcement was posted to the FDA website: https:\u002F\u002Fwww.fda.gov\u002Fsafety\u002Frecalls-market-withdrawals-safety-alerts\u002Famneal-pharmaceutical-llc-issues-nationwide-recall-ropivacaine-hydrochloride-injection-usp. However, these actions were initiated only after FDA identified these problems during the current inspection.\u003C\u002Fp>\u003Cp>You also indicate that you will be revising your major defect and total defect limits for polypropylene bag visual inspection from NMT \u003Cstrong>(b)(4)\u003C\u002Fstrong>% to NMT \u003Cstrong>(b)(4)\u003C\u002Fstrong>%, and NMT \u003Cstrong>(b)(4)\u003C\u002Fstrong>% to NMT \u003Cstrong>(b)(4)\u003C\u002Fstrong>%, respectively, and will reject batches that fail to meet your acceptable quality limit after visual inspection. These defect levels remain unacceptably high.\u003C\u002Fp>\u003Cp>Furthermore, the health hazard assessment included in your response minimized the severity of risks associated with particle contamination in a sterile injectable drug product that can be administered into the epidural space.\u003C\u002Fp>\u003Cp>We encourage the use of suitable \u003Cstrong>(b)(4)\u003C\u002Fstrong> visual inspection methods for particulates to augment the 100% \u003Cstrong>(b)(4)\u003C\u002Fstrong> visual inspection program. \u003Cstrong>(b)(4)\u003C\u002Fstrong> methods should be rigorously studied and qualified to assess their capability and robustness under various conditions, including machine settings, container-closure sizes, defect types, product characteristics, and other variables. In addition, any use of \u003Cstrong>(b)(4)\u003C\u002Fstrong> particulate inspection as an adjunct method does not supplant the need for 100% \u003Cstrong>(b)(4)\u003C\u002Fstrong> visual inspection. It is essential that a final visual inspection program ensures reliable detection of not only particulates, but various other defects (e.g., container or closure abnormalities, cracks, volume, crimping issues, atypical \u003Cstrong>(b)(4)\u003C\u002Fstrong>, discoloration, bubbles, and any other appearance defects).\u003C\u002Fp>\u003Cp>It is important that significant quality defects, including visible particulate contamination, are appropriately evaluated and investigated. Visible particulates in injectable products should be avoided through appropriate preventive measures built into your process design and production controls.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive assessment of your overall system for investigating deviations, discrepancies, complaints, out-of-specification results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, quality unit (QU) oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\u003C\u002Fli>\u003Cli>A comprehensive, independent review of your materials system, including but not limited to:\u003Cbr>o An evaluation of all suppliers of materials (components, containers, and closures) to determine if they are reliable and appropriately qualified.\u003Cbr>o An assessment of all materials to determine whether they are consistently of acceptable quality.\u003Cbr>o A review to ensure assigned expiration or retest dates are appropriate (supported by data).\u003Cbr>o An assessment of the adequacy of the supplier qualification program, and its selection, qualification, and disqualification provisions.\u003C\u002Fli>\u003Cli>Based on a thorough review, provide a summary of your systemic CAPA to remediate the vendor qualification program and prevent use of unsuitable components, containers, and closures.\u003C\u002Fli>\u003Cli>A commitment to have a third-party review your firm’s defect categorization pertaining to the visual inspection program, including defining critical, major, and minor defects.\u003C\u002Fli>\u003Cli>A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003Cbr>o A determination of whether procedures used by your firm are robust and appropriate.\u003Cbr>o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\u003Cbr>o A complete and final review of each batch and its related information before the QU disposition decision.\u003Cbr>o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Also describe how top management supports quality assurance and reliable operations, including but not limited to timely provision of resources to proactively address emerging manufacturing\u002Fquality issues and to assure a continuing state of control.\u003C\u002Fp>\u003Cul>\u003Cli>Identification of interim steps and controls to ensure lots being produced and distributed into U.S. commerce are essentially free of visible particulate matter.\u003C\u002Fli>\u003Cli>Revision of your risk assessment procedures to ensure thorough evaluation of potential patient impact, and address factors including but not limited to route of administration, patient population, and particle characteristics.\u003C\u002Fli>\u003Cli>Training for all relevant personnel on revised policies, procedures, and other associated items.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity (21 CFR 211.160(b)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>During our inspection, we observed the preparation and reading of bacterial endotoxin tests and identified numerous deficiencies:\u003C\u002Fp>\u003Cul>\u003Cli>Failure to completely discharge the micropipette solution during preparation of water for injection samples, which may compromise the accuracy and reproducibility of the test results.\u003C\u002Fli>\u003Cli>Transfer of gel-clot sample tubes from the incubator to the waste container in a single rapid motion during microbiological analysis, without the crucial pause required to inspect the firmness of the gel for endotoxin detection.\u003C\u002Fli>\u003Cli>The analyst responsible for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> verification of the gel-clot assessment was unable to adequately observe or verify the process due to the primary microbiologist’s rapid assessment. Despite this basic deficiency, the secondary analyst signed off on the verification.\u003C\u002Fli>\u003Cli>Inadequate documentation practices when recording sample results of bacterial endotoxin tests for water for injection, including non-contemporaneous documenting of negative sample results and assigning a passing result to a positive control sample prior to the actual observation and confirmation of the result.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>In your response, you state that you revised various procedures, provided associated training, retested reserve samples of potentially impacted drug products, and purchased new equipment to increase laboratory automation.\u003C\u002Fp>\u003Cp>Your response is inadequate due to its limited scope, which primarily addressed the specific deficiencies identified during the FDA inspection. You did not conduct a comprehensive evaluation to determine if similar deficiencies exist in other laboratory operations or address additional opportunities for laboratory equipment automation.\u003C\u002Fp>\u003Cp>It is imperative that your organization conducts a more thorough and systemic review of all laboratory processes, testing methodologies, equipment capabilities, and documentation practices to ensure compliance with CGMP and prevent recurrence of similar issues in the future.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\u003C\u002Fli>\u003Cli>A complete assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Quality Unit Authority\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Significant findings in this letter indicate that your QU is not fully exercising its authority and\u002For responsibilities. Your firm must provide the QU with the appropriate authority and sufficient resources to carry out its responsibilities and consistently ensure drug quality.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>If you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(b). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\u003C\u002Fp>\u003Cp>Correct any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\u003C\u002Fp>\u003Cp>Failure to address any violations may also result in the FDA refusing admission of articles manufactured at Amneal Pharmaceuticals Private Limited, FEI 3018907202, located at 506 Survey No., near Sachana Kalyanpura Road Palli, Gujarat, India, into the United States under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days.\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3018907202 and ATTN: CDR Frank Verni, Compliance Officer.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>cc:&nbsp;\u003C\u002Fp>\u003Cp>Mr. Sandeep Raktate, President (Operations)\u003Cbr>Sandeep.Rakate@amneal.com\u003C\u002Fp>\u003Cp>_______________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Under program enhancements for the Generic Drug User Fee Amendments (GDUFA) reauthorization for fiscal years (FYs) 2023-2027, also known as the GDUFA III Commitment Letter, your facility may be eligible for a Post-Warning Letter Meeting to obtain preliminary feedback from FDA on the adequacy and completeness of your corrective action plans.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nReference #:\n\n320-25-104\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Chintu Patel\n\nRecipient Title\n\nCo-Chief Executive Officer\n\nAmneal Pharmaceuticals, LLC\n\n50 Horseblock Road\n\nBrookhaven, NY 11719-9509\n\nUnited States\n\nchintu@amneal.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-25-104\nAugust 27, 2025\nDear Mr. Patel:\nThe United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Amneal Pharmaceuticals Private Limited, FEI 3018907202, located at 506 Survey No., near Sachana Kalyanpura Road Palli, Gujarat, India, from March 10 to 19, 2025.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nWe reviewed your April 3, 2025, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondences.\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n1. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\nYour firm failed to conduct an adequate investigation into recurring problems with visible particulate matter contamination. In 2024, your firm initiated an investigation when two batches of ropivacaine hydrochloride injection, supplied in polypropylene bags, exceeded your acceptance criteria for visual inspection. You identified the polypropylene bags as the source of the inordinately high levels of particulate contamination (predominately, white fibers). You performed an additional visual inspection and conducted a risk assessment that you believed justified releasing these batches. However, your risk assessment was inadequate as it minimized the severity associated with particle contamination in a sterile injectable drug product that can be administered into the epidural space. Your assessment failed to properly evaluate the potential impact of visible particulates on patient safety, as it did not adequately consider the route of administration and patient population receiving the product.\nThe presence of particulate matter in epidural injectable products can pose significant health risks to patients. These risks are of particular concern for patients receiving long-term epidural therapy. There is a reasonable probability that particulate matter in the epidural space may cause an epidural inflammatory process, epidural abscess, or meningitis. Depending on the location of the epidural injection, the particles could potentially cause damage to the spinal cord including spinal cord infarction or permanent nerve injury.\nYour firm was aware of the risk of particulate contamination from the polypropylene bags purchased from your vendor for more than a year prior to your 2024 investigation. You had rejected several batches of a sterile drug product after investigating particulate contamination in late 2022 and early 2023. Your investigations found that the polypropylene bags were the source of the visible white fibers and noted difficulties in detecting these fibers when performing visual inspection. Notably, for multiple batches, your firm continued to detect visible fiber particles during acceptable quality limit inspections of limited sample sizes following performance of visual inspections.\nHowever, you continued to use these polypropylene bags to produce sterile injectable drug products and did not implement appropriate corrective action and preventive action (CAPA) to prevent recurrence.\nBased on your investigations into particulate contamination, you relaxed the “major defects” rate from no more than (NMT) (b)(4)% to NMT (b)(4)%, and the overall rejection limit from NMT (b)(4)% to NMT (b)(4)%. You implemented these significantly relaxed limits due to the high rate of particulate contamination in polypropylene bag lots received from your unreliable vendor. The inappropriately high tolerance for defective polypropylene bags accommodated the use of poor-quality polypropylene bags in the production of parenteral drug product batches.\nIt is unacceptable to increase lot acceptance specifications to excessive levels to enable use of unsuitable polypropylene bags received from your supplier.\nIn your response, you indicate that, on March 26, 2025, you filed a Field Alert Report for two lots of ropivacaine hydrochloride injection, USP, 500 mg\u002F100 mL infusion bags due to particulate contamination. You also initiated a recall of these two lots on April 18, 2025. The company announcement was posted to the FDA website: https:\u002F\u002Fwww.fda.gov\u002Fsafety\u002Frecalls-market-withdrawals-safety-alerts\u002Famneal-pharmaceutical-llc-issues-nationwide-recall-ropivacaine-hydrochloride-injection-usp. However, these actions were initiated only after FDA identified these problems during the current inspection.\nYou also indicate that you will be revising your major defect and total defect limits for polypropylene bag visual inspection from NMT (b)(4)% to NMT (b)(4)%, and NMT (b)(4)% to NMT (b)(4)%, respectively, and will reject batches that fail to meet your acceptable quality limit after visual inspection. These defect levels remain unacceptably high.\nFurthermore, the health hazard assessment included in your response minimized the severity of risks associated with particle contamination in a sterile injectable drug product that can be administered into the epidural space.\nWe encourage the use of suitable (b)(4) visual inspection methods for particulates to augment the 100% (b)(4) visual inspection program. (b)(4) methods should be rigorously studied and qualified to assess their capability and robustness under various conditions, including machine settings, container-closure sizes, defect types, product characteristics, and other variables. In addition, any use of (b)(4) particulate inspection as an adjunct method does not supplant the need for 100% (b)(4) visual inspection. It is essential that a final visual inspection program ensures reliable detection of not only particulates, but various other defects (e.g., container or closure abnormalities, cracks, volume, crimping issues, atypical (b)(4), discoloration, bubbles, and any other appearance defects).\nIt is important that significant quality defects, including visible particulate contamination, are appropriately evaluated and investigated. Visible particulates in injectable products should be avoided through appropriate preventive measures built into your process design and production controls.\nIn response to this letter, provide:\nA comprehensive assessment of your overall system for investigating deviations, discrepancies, complaints, out-of-specification results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, quality unit (QU) oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\nA comprehensive, independent review of your materials system, including but not limited to:\no An evaluation of all suppliers of materials (components, containers, and closures) to determine if they are reliable and appropriately qualified.\no An assessment of all materials to determine whether they are consistently of acceptable quality.\no A review to ensure assigned expiration or retest dates are appropriate (supported by data).\no An assessment of the adequacy of the supplier qualification program, and its selection, qualification, and disqualification provisions.\nBased on a thorough review, provide a summary of your systemic CAPA to remediate the vendor qualification program and prevent use of unsuitable components, containers, and closures.\nA commitment to have a third-party review your firm’s defect categorization pertaining to the visual inspection program, including defining critical, major, and minor defects.\nA comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\no A determination of whether procedures used by your firm are robust and appropriate.\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\no A complete and final review of each batch and its related information before the QU disposition decision.\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\nAlso describe how top management supports quality assurance and reliable operations, including but not limited to timely provision of resources to proactively address emerging manufacturing\u002Fquality issues and to assure a continuing state of control.\nIdentification of interim steps and controls to ensure lots being produced and distributed into U.S. commerce are essentially free of visible particulate matter.\nRevision of your risk assessment procedures to ensure thorough evaluation of potential patient impact, and address factors including but not limited to route of administration, patient population, and particle characteristics.\nTraining for all relevant personnel on revised policies, procedures, and other associated items.\n2. Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity (21 CFR 211.160(b)).\nDuring our inspection, we observed the preparation and reading of bacterial endotoxin tests and identified numerous deficiencies:\nFailure to completely discharge the micropipette solution during preparation of water for injection samples, which may compromise the accuracy and reproducibility of the test results.\nTransfer of gel-clot sample tubes from the incubator to the waste container in a single rapid motion during microbiological analysis, without the crucial pause required to inspect the firmness of the gel for endotoxin detection.\nThe analyst responsible for the (b)(4) verification of the gel-clot assessment was unable to adequately observe or verify the process due to the primary microbiologist’s rapid assessment. Despite this basic deficiency, the secondary analyst signed off on the verification.\nInadequate documentation practices when recording sample results of bacterial endotoxin tests for water for injection, including non-contemporaneous documenting of negative sample results and assigning a passing result to a positive control sample prior to the actual observation and confirmation of the result.\nIn your response, you state that you revised various procedures, provided associated training, retested reserve samples of potentially impacted drug products, and purchased new equipment to increase laboratory automation.\nYour response is inadequate due to its limited scope, which primarily addressed the specific deficiencies identified during the FDA inspection. You did not conduct a comprehensive evaluation to determine if similar deficiencies exist in other laboratory operations or address additional opportunities for laboratory equipment automation.\nIt is imperative that your organization conducts a more thorough and systemic review of all laboratory processes, testing methodologies, equipment capabilities, and documentation practices to ensure compliance with CGMP and prevent recurrence of similar issues in the future.\nIn response to this letter, provide:\nA comprehensive assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\nA complete assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.\nQuality Unit Authority\nSignificant findings in this letter indicate that your QU is not fully exercising its authority and\u002For responsibilities. Your firm must provide the QU with the appropriate authority and sufficient resources to carry out its responsibilities and consistently ensure drug quality.\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nIf you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(b). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\nCorrect any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\nFailure to address any violations may also result in the FDA refusing admission of articles manufactured at Amneal Pharmaceuticals Private Limited, FEI 3018907202, located at 506 Survey No., near Sachana Kalyanpura Road Palli, Gujarat, India, into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days.1 Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3018907202 and ATTN: CDR Frank Verni, Compliance Officer.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research\ncc:\nMr. Sandeep Raktate, President (Operations)\nSandeep.Rakate@amneal.com\n_______________\n1 Under program enhancements for the Generic Drug User Fee Amendments (GDUFA) reauthorization for fiscal years (FYs) 2023-2027, also known as the GDUFA III Commitment Letter, your facility may be eligible for a Post-Warning Letter Meeting to obtain preliminary feedback from FDA on the adequacy and completeness of your corrective action plans.","Amneal Pharmaceuticals, LLC","amneal-pharmaceuticals-llc-709894-08272025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Famneal-pharmaceuticals-llc-709894-08272025","2026-10-26T08:07:55.421238+00:00","2025-09-02","709894","Mr. Chintu Patel","2026-08-19T16:26:25.704+00:00","320-25-104","2025-08-27",{"id":347,"raw":348,"subject":80,"body_html":352,"body_text":353,"firm_name":354,"letter_id":355,"created_at":65,"fei_number":19,"letter_url":356,"updated_at":357,"action_type":22,"case_status":23,"posted_date":358,"marcs_cms_no":359,"product_type":26,"closeout_date":19,"issuing_office":58,"recipient_name":360,"body_fetched_at":361,"delivery_method":72,"recipient_title":19,"reference_number":19,"action_taken_date":362,"medical_device_id":19,"response_letter_date":19},1917,[349,350,351,58,80,13,13,13],"\u003Ctime datetime=\"2023-08-22T13:20:00Z\">08\u002F22\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-08-14T04:00:00Z\">08\u002F14\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fk-boeun-pharmaceutical-co-ltd-665099-08142023\">K. Boeun Pharmaceutical Co., Ltd.\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Yoon Ki Jung\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>K. Boeun Pharmaceutical Co., Ltd.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>114 Jangjagyeongje-ro\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Sinbuk-myeon\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Pocheon\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>11138\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>South Korea\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:nuttin@naver.com\"> nuttin@naver.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter 320-23-35\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>August 14, 2023\u003C\u002Fp>\n\n\u003Cp>Dear Yoon Ki Jung:\u003C\u002Fp>\n\n\u003Cp>Your facility is registered with the United States Food and Drug Administration (FDA) as a manufacturer of over-the-counter (OTC) drug products. FDA has reviewed the records you submitted in response to our March 3, 2023 request for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) for your facility, K. Boeun Pharmaceutical Co., Ltd., FEI 3016756938, 114 Jangjagyeongje-ro, Sinbuk-myeon, Pocheon, South Korea.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations, parts 210 and 211 (21 CFR, parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding of drugs as described in your response to our 704(a)(4) request do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the FD&amp;C Act (21 U.S.C. 351(a)(2)(B)).\u003C\u002Fp>\n\n\u003Cp>Following review of records and other information provided pursuant to section 704(a)(4) of the FD&amp;C Act, significant violations were observed, including, but not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm failed to conduct at least one test to verify the identity of each component of a drug product (21 CFR 211.84(d)(1)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You manufacture OTC drug products including \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Based on the records and information you provided, you did not demonstrate that you adequately tested each shipment of each lot of the incoming components at high-risk of diethylene glycol (DEG) or ethylene glycol (EG) contamination. These include, but are not limited to, testing of glycerin and sorbitol solution you used in manufacturing drug products to determine their appropriate identity. Identity testing for\u003Cbr>\n\u003Cbr>\nthese and certain other high-risk drug components\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> includes a limit test in the United States Pharmacopeia (USP) to ensure that the component meets the relevant safety limits for levels of DEG or EG. Because you did not perform identity testing on each shipment of each lot using the USP identification test that detects these hazardous impurities, you failed to assure the acceptability of these components for use in manufacture of your drug products.\u003C\u002Fp>\n\n\u003Cp>The use of ingredients contaminated with DEG or EG has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document \u003Cem>Testing of Glycerin, Propylene Glycol, Maltitol Solution, Hydrogenated Starch Hydrolysate, Sorbitol Solution, and Other High-Risk Drug Components for Diethylene Glycol and Ethylene Glycol\u003C\u002Fem> to help you meet the CGMP requirements when manufacturing drugs containing ingredients at high-risk for DEG or EG contamination at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F167974\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A commitment to provide DEG and EG test results, no later than 30 calendar days from the date of this letter, from testing retains for all lots of high-risk drug components used in the manufacture of drug products. Alternatively, if a retain of a component lot is unavailable, perform retain sample testing of all implicated finished drug product batches for the presence of DEG and EG.\u003C\u002Fli>\n\t\u003Cli>A full risk assessment for drug products that are within expiry which contain any ingredient at risk for DEG or EG contamination. Take prompt and appropriate actions to determine the safety of all lots of the component(s) and any related drug product that could contain DEG or EG, including customer notifications and product recalls for any contaminated lots. Identify additional appropriate corrective action and preventive action (CAPA) that secure supply chains in the future, including, but not limited to, ensuring that all incoming raw material lots are from fully qualified manufacturers and free from unsafe impurities. Detail these actions in your response to this letter.\u003C\u002Fli>\n\t\u003Cli>A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s certificate of analysis (COA) instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic revalidation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot. In the case of glycerin, propylene glycol, and certain additional high- risk components we note that this includes the performance of parts A, B, and C of the USP monograph.\u003C\u002Fli>\n\t\u003Cli>The chemical quality control specifications you use to test each incoming lot of high-risk drug components to determine acceptability for use in manufacturing.\u003C\u002Fli>\n\t\u003Cli>A comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\u003C\u002Fli>\n\t\u003Cli>A summary of your program for qualifying and overseeing contract facilities that test the drug products you manufacture.\u003C\u002Fli>\n\t\u003Cli>A summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your standard operating procedure (SOP) that describes this COA validation program.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>2. Your firm failed to establish an adequate quality control unit with the responsibility and authority to approve or reject all components, drug product containers, closures, in-process materials, packaging materials, labeling, and drug products (21 CFR 211.22(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The records and information you provided demonstrate that your quality unit (QU) did not effectively exercise its responsibilities to oversee the quality of your drug manufacturing operations. Specifically, your QU did not adequately exercise its authority in the approval or rejection of components in your Materials System.\u003C\u002Fp>\n\n\u003Cp>Your QU is responsible for fully exercising its authority and responsibilities. FDA is concerned that your QU may also not be conducting appropriate oversight regarding other CGMP operations, including Production, Facilities &amp; Equipment, Laboratory Controls, and Packaging &amp; Labelling Systems.\u003C\u002Fp>\n\n\u003Cp>See FDA’s guidance document \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem> for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o A determination of whether procedures used by your firm are robust and appropriate\u003Cbr>\n&nbsp; &nbsp; o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\u003Cbr>\n&nbsp; &nbsp; o A complete and final review of each batch and its related information before the QU disposition decision\u003Cbr>\n&nbsp; &nbsp; o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements if your firm intends to resume manufacturing drugs for the U.S. market. The qualified consultant should also perform a comprehensive six-system audit\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> of your entire operation for CGMP compliance and evaluate the completion and efficacy of your CAPA before you pursue resolution of your firm’s compliance status with FDA.\u003C\u002Fp>\n\n\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>FDA placed your firm on Import Alert 66-40 on August 11, 2023.\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\u003C\u002Fp>\n\n\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may inspect your facility to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 30 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with 3016756938 and ATTN: Kevin Maguire.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Francis Godwin\u003Cbr>\nDirector\u003Cbr>\nOffice of Manufacturing Quality\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003C\u002Fp>\n\n\u003Cp>CC: U.S. Agent:\u003Cbr>\nOnbix Corp US\u003Cbr>\n102 North G. Street\u003Cbr>\nUnit 105\u003Cbr>\nTacoma, WA 98403\u003Cbr>\nonbixus@gmail.com\u003C\u002Fp>\n\n\u003Cp>____________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Components with higher risk of DEG or EG contamination compared to other drug components.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> i.e., Quality System, Facilities &amp; Equipment System, Materials System, Production System, Packaging &amp; Labeling System, and Laboratory Control System per FDA’s guidance document \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem>.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nYoon Ki Jung\n\nK. Boeun Pharmaceutical Co., Ltd.\n\n114 Jangjagyeongje-ro\n\nSinbuk-myeon\n\nPocheon\n\n11138\n\nSouth Korea\n\nnuttin@naver.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nWarning Letter 320-23-35\n\nAugust 14, 2023\n\nDear Yoon Ki Jung:\n\nYour facility is registered with the United States Food and Drug Administration (FDA) as a manufacturer of over-the-counter (OTC) drug products. FDA has reviewed the records you submitted in response to our March 3, 2023 request for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) for your facility, K. Boeun Pharmaceutical Co., Ltd., FEI 3016756938, 114 Jangjagyeongje-ro, Sinbuk-myeon, Pocheon, South Korea.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations, parts 210 and 211 (21 CFR, parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding of drugs as described in your response to our 704(a)(4) request do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act (21 U.S.C. 351(a)(2)(B)).\n\nFollowing review of records and other information provided pursuant to section 704(a)(4) of the FD&C Act, significant violations were observed, including, but not limited to, the following:\n\n1. Your firm failed to conduct at least one test to verify the identity of each component of a drug product (21 CFR 211.84(d)(1)).\n\nYou manufacture OTC drug products including (b)(4). Based on the records and information you provided, you did not demonstrate that you adequately tested each shipment of each lot of the incoming components at high-risk of diethylene glycol (DEG) or ethylene glycol (EG) contamination. These include, but are not limited to, testing of glycerin and sorbitol solution you used in manufacturing drug products to determine their appropriate identity. Identity testing for\n\nthese and certain other high-risk drug components1 includes a limit test in the United States Pharmacopeia (USP) to ensure that the component meets the relevant safety limits for levels of DEG or EG. Because you did not perform identity testing on each shipment of each lot using the USP identification test that detects these hazardous impurities, you failed to assure the acceptability of these components for use in manufacture of your drug products.\n\nThe use of ingredients contaminated with DEG or EG has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document Testing of Glycerin, Propylene Glycol, Maltitol Solution, Hydrogenated Starch Hydrolysate, Sorbitol Solution, and Other High-Risk Drug Components for Diethylene Glycol and Ethylene Glycol to help you meet the CGMP requirements when manufacturing drugs containing ingredients at high-risk for DEG or EG contamination at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F167974\u002Fdownload.\n\nIn response to this letter, provide:\n\nA commitment to provide DEG and EG test results, no later than 30 calendar days from the date of this letter, from testing retains for all lots of high-risk drug components used in the manufacture of drug products. Alternatively, if a retain of a component lot is unavailable, perform retain sample testing of all implicated finished drug product batches for the presence of DEG and EG.\n\nA full risk assessment for drug products that are within expiry which contain any ingredient at risk for DEG or EG contamination. Take prompt and appropriate actions to determine the safety of all lots of the component(s) and any related drug product that could contain DEG or EG, including customer notifications and product recalls for any contaminated lots. Identify additional appropriate corrective action and preventive action (CAPA) that secure supply chains in the future, including, but not limited to, ensuring that all incoming raw material lots are from fully qualified manufacturers and free from unsafe impurities. Detail these actions in your response to this letter.\n\nA description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s certificate of analysis (COA) instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic revalidation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot. In the case of glycerin, propylene glycol, and certain additional high- risk components we note that this includes the performance of parts A, B, and C of the USP monograph.\n\nThe chemical quality control specifications you use to test each incoming lot of high-risk drug components to determine acceptability for use in manufacturing.\n\nA comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\n\nA summary of your program for qualifying and overseeing contract facilities that test the drug products you manufacture.\n\nA summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your standard operating procedure (SOP) that describes this COA validation program.\n\n2. Your firm failed to establish an adequate quality control unit with the responsibility and authority to approve or reject all components, drug product containers, closures, in-process materials, packaging materials, labeling, and drug products (21 CFR 211.22(a)).\n\nThe records and information you provided demonstrate that your quality unit (QU) did not effectively exercise its responsibilities to oversee the quality of your drug manufacturing operations. Specifically, your QU did not adequately exercise its authority in the approval or rejection of components in your Materials System.\n\nYour QU is responsible for fully exercising its authority and responsibilities. FDA is concerned that your QU may also not be conducting appropriate oversight regarding other CGMP operations, including Production, Facilities & Equipment, Laboratory Controls, and Packaging & Labelling Systems.\n\nSee FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\n\nIn response to this letter, provide:\n\nA comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\n\no A determination of whether procedures used by your firm are robust and appropriate\n\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\n\no A complete and final review of each batch and its related information before the QU disposition decision\n\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\n\nCGMP Consultant Recommended\n\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements if your firm intends to resume manufacturing drugs for the U.S. market. The qualified consultant should also perform a comprehensive six-system audit2 of your entire operation for CGMP compliance and evaluate the completion and efficacy of your CAPA before you pursue resolution of your firm’s compliance status with FDA.\n\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nFDA placed your firm on Import Alert 66-40 on August 11, 2023.\n\nCorrect any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\n\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may inspect your facility to verify that you have completed corrective actions to address any violations.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 30 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with 3016756938 and ATTN: Kevin Maguire.\n\nSincerely,\n\n\u002FS\u002F\n\nFrancis Godwin\n\nDirector\n\nOffice of Manufacturing Quality\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nCC: U.S. Agent:\n\nOnbix Corp US\n\n102 North G. Street\n\nUnit 105\n\nTacoma, WA 98403\n\nonbixus@gmail.com\n\n____________________________\n\n1 Components with higher risk of DEG or EG contamination compared to other drug components.\n\n2 i.e., Quality System, Facilities & Equipment System, Materials System, Production System, Packaging & Labeling System, and Laboratory Control System per FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations.","K. Boeun Pharmaceutical Co., Ltd.","k-boeun-pharmaceutical-co-ltd-665099-08142023","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fk-boeun-pharmaceutical-co-ltd-665099-08142023","2026-10-26T08:09:07.083748+00:00","2023-08-22","665099","Yoon Ki Jung","2026-08-20T00:46:07.026+00:00","2023-08-14",{"id":364,"raw":365,"subject":80,"body_html":369,"body_text":370,"firm_name":371,"letter_id":372,"created_at":18,"fei_number":19,"letter_url":373,"updated_at":374,"action_type":22,"case_status":23,"posted_date":375,"marcs_cms_no":376,"product_type":26,"closeout_date":19,"issuing_office":58,"recipient_name":377,"body_fetched_at":378,"delivery_method":92,"recipient_title":19,"reference_number":19,"action_taken_date":379,"medical_device_id":19,"response_letter_date":19},1397,[366,367,368,58,80,13,13,13],"\u003Ctime datetime=\"2024-07-02T13:20:00Z\">07\u002F02\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-06-18T04:00:00Z\">06\u002F18\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsun-pharmaceutical-industries-limited-677337-06182024\">Sun Pharmaceutical Industries Limited\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA EMAIL WITH READ RECEIPT\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Dilip Shanghvi\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Managing Director\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Sun Pharmaceutical Industries Limited\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Sun House, Plot No. 201 B\u002F1\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>West Express Highway Goregaon East\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Mumbai\u003C\u002Fspan> \u003Cspan>400063\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Maharashtra\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>India\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:Dilip.Shanghvi@sunpharma.com\"> Dilip.Shanghvi@sunpharma.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-24-48\u003C\u002Fp>\n\n\u003Cp>June 18, 2024\u003Cbr>\n\u003Cbr>\nDear Mr. Shanghvi:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Sun Pharmaceutical Industries Limited, FEI 3004561553, at Survey No. 1012, Dadra-396 193, U.T. of Dadra and Nagar Haveli and Daman and Diu, from December 4 to 15, 2023.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>We reviewed your January 9, 2024 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigator observed specific violations including, but not limited to, the following.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm failed to clean, maintain, and, as appropriate for the nature of the drug, sanitize and\u002For sterilize equipment and utensils at appropriate intervals to prevent malfunctions or contamination that would alter the safety, identity, strength, quality, or purity of the drug product beyond the official or other established requirements (21 CFR 211.67(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You failed to adequately clean and maintain your equipment used for drug product manufacturing. For example, our investigator observed approximately 450 mL of a \u003Cstrong>(b)(4)\u003C\u002Fstrong> stagnant liquid within the \u003Cstrong>(b)(4)\u003C\u002Fstrong> of your nondedicated \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your chemical analysis of the unknown liquid using liquid chromatography mass spectrometry (LC\u002FMS) showed numerous peaks. In addition, the microbiological analysis identified too numerous to count (TNTC) colony forming units for total aerobic microbial count (TAMC) and total yeast and mold count (TYMC) testing. You used this nondedicated \u003Cstrong>(b)(4)\u003C\u002Fstrong> to manufacture over \u003Cstrong>(b)(4)\u003C\u002Fstrong> different drug products.\u003C\u002Fp>\n\n\u003Cp>In your response, you state that a faulty \u003Cstrong>(b)(4)\u003C\u002Fstrong> valve was the root cause for the observed \u003Cstrong>(b)(4)\u003C\u002Fstrong> liquid accumulating in the \u003Cstrong>(b)(4)\u003C\u002Fstrong>. The \u003Cstrong>(b)(4)\u003C\u002Fstrong> valve failed to completely close and seal when you last disassembled it on June 26, 2023. You acknowledge you discovered this equipment malfunction after initiating an investigation as a result of our investigator’s findings. You state that previously manufactured drug products, including \u003Cstrong>(b)(4)\u003C\u002Fstrong> active pharmaceutical ingredient (API) and its degradants, as well as \u003Cstrong>(b)(4)\u003C\u002Fstrong> API, were identified in the liquid. You also identified microorganisms \u003Cem>Sphingomonas paucimobilis, Bordetella bronchiseptica\u003C\u002Fem>, and \u003Cem>Pseudomonas stutzeri\u003C\u002Fem> in the liquid.\u003C\u002Fp>\n\n\u003Cp>We acknowledge you recalled \u003Cstrong>(b)(4)\u003C\u002Fstrong> batches and rejected \u003Cstrong>(b)(4)\u003C\u002Fstrong> batches of drug products manufactured on the \u003Cstrong>(b)(4)\u003C\u002Fstrong> between June 2023 and December 2023.\u003C\u002Fp>\n\n\u003Cp>However, your response does not sufficiently address the cross-contamination issue. You failed to provide a full characterization of each unknown peak from your chemical analysis. It remains imperative that your investigations are comprehensive to prevent recurrence of inadequate equipment maintenance. We also understand from your recent correspondence that a third-party consultant identified numerous gaps in your equipment maintenance program, but you conclude no critical or major findings were noted.\u003C\u002Fp>\n\n\u003Cp>It is your responsibility to ensure your equipment maintenance program is comprehensive and includes appropriate assessment of equipment failures and their impact to product quality.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive, independent retrospective assessment of your cleaning effectiveness to evaluate the scope of cross-contamination hazards. Include other manufacturing equipment that may have been improperly cleaned, evaluate the identity of any residues, and assess whether cross-contaminated products may have been released for distribution. The assessment should identify any inadequacies of cleaning procedures and practices, and encompass each piece of manufacturing equipment used to manufacture more than one product.\u003C\u002Fli>\n\t\u003Cli>A corrective action and preventive action (CAPA) plan, based on the retrospective assessment of your cleaning program, that includes appropriate remediations to your cleaning processes and practices, and timelines for completion. Provide a detailed summary of vulnerabilities in your process for lifecycle management of equipment cleaning. Describe improvements to your cleaning program, including enhancements to cleaning effectiveness; improved ongoing verification of proper cleaning execution for all products and equipment; and all other needed remediations.\u003C\u002Fli>\n\t\u003Cli>Your CAPA plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, and improved systems for ongoing management review. Your plan should also ensure that appropriate actions are taken throughout the company network.\u003C\u002Fli>\n\t\u003Cli>Your CAPA plan to comprehensively address any gaps identified by your third-party consultant from the assessment of your equipment maintenance program including, but not limited to, inadequate quality unit (QU) oversight, inadequate trending of preventive maintenance, and lack of detailed procedures.\u003C\u002Fli>\n\t\u003Cli>Your specific activities that are being undertaken to ensure effective remediation of the conditions that caused the specific cross-contamination incidents discussed above. Provide an independent review by your consultant that determines the effectiveness of your CAPA, including but not limited to:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>o Enhancements to cleaning and maintenance procedures including determination of specific frequencies and locations to be cleaned in all relevant equipment (e.g., \u003Cstrong>(b)(4)\u003C\u002Fstrong>)\u003Cbr>\no Adequacy of analysis of equipment maintenance and repair history for all \u003Cstrong>(b)(4)\u003C\u002Fstrong> equipment\u003Cbr>\no Sufficiency of the evaluation of all significant manufacturing equipment including, but not limited to, the \u003Cstrong>(b)(4)\u003C\u002Fstrong> equipment, to identify other sources of contamination\u003Cbr>\no Whether improvements to your analytical methodology to identify residual carryover were adequate\u003Cbr>\no Whether adequate investigations into other unknown (unidentified) peaks detected in the unknown liquid in the \u003Cstrong>(b)(4)\u003C\u002Fstrong> were performed\u003Cbr>\no Assessment whether the scope of the investigation and its related CAPA were sufficient\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your investigations of out-of-specification (OOS) results were inadequate because they lacked scientific rationale for root cause determinations. For example, you initiated an OOS investigation for an unknown impurity detected during related substances testing of a 12-month stability sample of \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> tablets. The specification for any unknown impurity for \u003Cstrong>(b)(4)\u003C\u002Fstrong> is not more than \u003Cstrong>(b)(4)\u003C\u002Fstrong>%, however, your initial test yielded a result of \u003Cstrong>(b)(4)\u003C\u002Fstrong>%. Your investigation concluded, without adequate scientific justification, that dirty glassware was the probable root cause. Upon discussion with our investigator, you reopened your investigation and concluded the root cause to be contamination from another product, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, that was also tested during the same time period. However, this conclusion was not scientifically justified because the retention time of \u003Cstrong>(b)(4)\u003C\u002Fstrong> did not match that of the unknown impurity peak.\u003Cbr>\n\u003Cbr>\nIn your response, you state you performed additional testing of more drug products tested in the same laboratory during the same time period when the OOS result occurred. You identified the root cause as laboratory contamination and the unknown impurity to be \u003Cstrong>(b)(4)\u003C\u002Fstrong>. In addition, you state you have hired a third-party consultant to review invalidated OOS results generated between April 1, 2019, and December 26, 2023, to determine if the decisions made to invalidate those results were scientifically justified.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate. You did not explain why root cause determinations in the OOS investigation were accepted by your firm multiple times, although insufficiently justified.\u003C\u002Fp>\n\n\u003Cp>Your quality system failed to ensure appropriate investigations to determine root causes, evaluate the impact of OOS results, and ensure effective CAPA. We recommend that the retrospective review also includes an evaluation of the data associated with pending and approved drug application submissions.\u003C\u002Fp>\n\n\u003Cp>Your OOS investigations conclusions fail to include sufficient rigor and scope in determining root causes and the extent of deviations and drug product impact.\u003C\u002Fp>\n\n\u003Cp>For more information about handling failing, out-of-specification, out-of-trend, or other unexpected results and documentation of your investigations, see FDA’s current guidance document \u003Cem>Investigating Out-of-Specification (OOS) Test Results for Pharmaceutical Production\u003C\u002Fem> at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Finvestigating-out-specification-oos-test-results-pharmaceutical-production-level-2-revision.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A retrospective, independent review of all invalidated OOS (including in-process and release\u002Fstability testing) results for U.S. products for the last three years from the initial date of inspection and a report summarizing the findings of the analysis, including the following for each OOS:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>o Determine whether the scientific justification and evidence relating to the invalidated OOS result conclusively or inconclusively demonstrates causative laboratory error.\u003Cbr>\no For investigations that conclusively establish laboratory root cause, provide rationale and ensure that all other laboratory methods vulnerable to the same or similar root cause are identified for remediation.\u003Cbr>\no For all OOS results found by the retrospective review to have an inconclusive or no root cause identified in the laboratory, include a thorough review of production (e.g., batch manufacturing records, adequacy of the manufacturing steps, suitability of equipment\u002Ffacilities, variability of raw materials, process capability, deviation history, complaint history, batch failure history). Provide a summary of potential manufacturing root causes for each investigation, and any manufacturing operation improvements.\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive review and remediation plan for your OOS result investigation systems. The CAPA should include but not be limited to addressing the following:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>o QU oversight of laboratory investigations\u003Cbr>\no Identification of adverse laboratory control trends\u003Cbr>\no Resolution of causes of laboratory variation\u003Cbr>\no Initiation of thorough investigations of potential manufacturing causes whenever a laboratory cause cannot be conclusively identified\u003Cbr>\no Adequately scoping of each investigation and its CAPA\u003Cbr>\no Revised OOS investigation procedures with these and other remediations\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, OOS results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, QU oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\u003C\u002Fli>\n\t\u003Cli>An independent assessment and remediation plan for your CAPA program. Provide a report that evaluates whether the program includes effective root cause analysis, ensures CAPA effectiveness, analyzes investigations trends, improves the CAPA program when needed, implements final QU decisions, and is fully supported by executive management.\u003C\u002Fli>\n\t\u003Cli>A comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>Repeat Observation at Facility\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>On March 29, 2019, your firm was cited for inadequate cleaning and maintenance of manufacturing equipment. On April 13, 2017, your firm was cited for inadequate investigations of laboratory events regarding the recurrence of extraneous unidentified peaks. As a result of your 2017 inspection, you were issued a Response Letter dated September 29, 2017, that stated contaminated glassware should not be a frequent justification for rejecting or discarding aberrant result. Furthermore, the letter stated you should assess and identify additional CAPA to ensure clean laboratory glassware is utilized.\u003C\u002Fp>\n\n\u003Cp>You described specific remediations for these observations in your responses.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Repeat Violations at Multiple Sites\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA also cited a similar CGMP violation at other facilities in your company’s network. Sun Pharmaceutical Industries Ltd., (Halol site), FEI 3002809586, was issued a warning letter dated December 15, 2022 (later amended and dated October 16, 2023), for violation of, among other items, 21 CFR 211.67(a) for inadequate cleaning and maintenance of a \u003Cstrong>(b)(4)\u003C\u002Fstrong>. You committed to conduct a comprehensive assessment of your global manufacturing operations across your company’s network to ensure conformance to FDA requirements.\u003C\u002Fp>\n\n\u003Cp>These repeated failures at multiple sites demonstrate that management oversight and control over the manufacture of drugs is inadequate.\u003C\u002Fp>\n\n\u003Cp>We note the initial steps that you outlined in your written response to this inspection, including changes in key senior leaders at corporate and site levels, and modifications to your corporate structure that are intended to enhance quality oversight.\u003C\u002Fp>\n\n\u003Cp>Your executive management remains responsible for fully resolving all deficiencies and ensuring ongoing CGMP compliance.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Ineffective Quality Systems\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Significant findings in this letter demonstrate that your firm does not operate an effective quality system in accord with CGMP. In addition to the lack of effective management oversight of your production and laboratory operations, we found your QU is not enabled to exercise proper authority and\u002For has insufficiently implemented its responsibilities. Executive management should immediately and comprehensively assess your company’s global manufacturing operations to ensure that your systems, processes, and products conform to FDA requirements.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP Consultant Recommendation\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>We strongly recommend that your firm engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements.\u003C\u002Fp>\n\n\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>If you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(b). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\u003C\u002Fp>\n\n\u003Cp>Failure to address any violations may also result in the FDA refusing admission of articles manufactured at Sun Pharmaceutical Industries Ltd., Dadra, into the United States under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3004561553 and ATTN: Christina Alemu-Cruickshank.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Francis Godwin\u003Cbr>\nDirector\u003Cbr>\nOffice of Manufacturing Quality\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA EMAIL WITH READ RECEIPT\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Dilip Shanghvi\n\nRecipient Title\n\nManaging Director\n\nSun Pharmaceutical Industries Limited\n\nSun House, Plot No. 201 B\u002F1\n\nWest Express Highway Goregaon East\n\nMumbai 400063\n\nMaharashtra\n\nIndia\n\nDilip.Shanghvi@sunpharma.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nWarning Letter 320-24-48\n\nJune 18, 2024\n\nDear Mr. Shanghvi:\n\nThe U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Sun Pharmaceutical Industries Limited, FEI 3004561553, at Survey No. 1012, Dadra-396 193, U.T. of Dadra and Nagar Haveli and Daman and Diu, from December 4 to 15, 2023.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\n\nWe reviewed your January 9, 2024 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\n\nDuring our inspection, our investigator observed specific violations including, but not limited to, the following.\n\n1. Your firm failed to clean, maintain, and, as appropriate for the nature of the drug, sanitize and\u002For sterilize equipment and utensils at appropriate intervals to prevent malfunctions or contamination that would alter the safety, identity, strength, quality, or purity of the drug product beyond the official or other established requirements (21 CFR 211.67(a)).\n\nYou failed to adequately clean and maintain your equipment used for drug product manufacturing. For example, our investigator observed approximately 450 mL of a (b)(4) stagnant liquid within the (b)(4) of your nondedicated (b)(4). Your chemical analysis of the unknown liquid using liquid chromatography mass spectrometry (LC\u002FMS) showed numerous peaks. In addition, the microbiological analysis identified too numerous to count (TNTC) colony forming units for total aerobic microbial count (TAMC) and total yeast and mold count (TYMC) testing. You used this nondedicated (b)(4) to manufacture over (b)(4) different drug products.\n\nIn your response, you state that a faulty (b)(4) valve was the root cause for the observed (b)(4) liquid accumulating in the (b)(4). The (b)(4) valve failed to completely close and seal when you last disassembled it on June 26, 2023. You acknowledge you discovered this equipment malfunction after initiating an investigation as a result of our investigator’s findings. You state that previously manufactured drug products, including (b)(4) active pharmaceutical ingredient (API) and its degradants, as well as (b)(4) API, were identified in the liquid. You also identified microorganisms Sphingomonas paucimobilis, Bordetella bronchiseptica, and Pseudomonas stutzeri in the liquid.\n\nWe acknowledge you recalled (b)(4) batches and rejected (b)(4) batches of drug products manufactured on the (b)(4) between June 2023 and December 2023.\n\nHowever, your response does not sufficiently address the cross-contamination issue. You failed to provide a full characterization of each unknown peak from your chemical analysis. It remains imperative that your investigations are comprehensive to prevent recurrence of inadequate equipment maintenance. We also understand from your recent correspondence that a third-party consultant identified numerous gaps in your equipment maintenance program, but you conclude no critical or major findings were noted.\n\nIt is your responsibility to ensure your equipment maintenance program is comprehensive and includes appropriate assessment of equipment failures and their impact to product quality.\n\nIn response to this letter, provide:\n\nA comprehensive, independent retrospective assessment of your cleaning effectiveness to evaluate the scope of cross-contamination hazards. Include other manufacturing equipment that may have been improperly cleaned, evaluate the identity of any residues, and assess whether cross-contaminated products may have been released for distribution. The assessment should identify any inadequacies of cleaning procedures and practices, and encompass each piece of manufacturing equipment used to manufacture more than one product.\n\nA corrective action and preventive action (CAPA) plan, based on the retrospective assessment of your cleaning program, that includes appropriate remediations to your cleaning processes and practices, and timelines for completion. Provide a detailed summary of vulnerabilities in your process for lifecycle management of equipment cleaning. Describe improvements to your cleaning program, including enhancements to cleaning effectiveness; improved ongoing verification of proper cleaning execution for all products and equipment; and all other needed remediations.\n\nYour CAPA plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, and improved systems for ongoing management review. Your plan should also ensure that appropriate actions are taken throughout the company network.\n\nYour CAPA plan to comprehensively address any gaps identified by your third-party consultant from the assessment of your equipment maintenance program including, but not limited to, inadequate quality unit (QU) oversight, inadequate trending of preventive maintenance, and lack of detailed procedures.\n\nYour specific activities that are being undertaken to ensure effective remediation of the conditions that caused the specific cross-contamination incidents discussed above. Provide an independent review by your consultant that determines the effectiveness of your CAPA, including but not limited to:\n\no Enhancements to cleaning and maintenance procedures including determination of specific frequencies and locations to be cleaned in all relevant equipment (e.g., (b)(4))\n\no Adequacy of analysis of equipment maintenance and repair history for all (b)(4) equipment\n\no Sufficiency of the evaluation of all significant manufacturing equipment including, but not limited to, the (b)(4) equipment, to identify other sources of contamination\n\no Whether improvements to your analytical methodology to identify residual carryover were adequate\n\no Whether adequate investigations into other unknown (unidentified) peaks detected in the unknown liquid in the (b)(4) were performed\n\no Assessment whether the scope of the investigation and its related CAPA were sufficient\n\n2. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\n\nYour investigations of out-of-specification (OOS) results were inadequate because they lacked scientific rationale for root cause determinations. For example, you initiated an OOS investigation for an unknown impurity detected during related substances testing of a 12-month stability sample of (b)(4) and (b)(4) tablets. The specification for any unknown impurity for (b)(4) is not more than (b)(4)%, however, your initial test yielded a result of (b)(4)%. Your investigation concluded, without adequate scientific justification, that dirty glassware was the probable root cause. Upon discussion with our investigator, you reopened your investigation and concluded the root cause to be contamination from another product, (b)(4), that was also tested during the same time period. However, this conclusion was not scientifically justified because the retention time of (b)(4) did not match that of the unknown impurity peak.\n\nIn your response, you state you performed additional testing of more drug products tested in the same laboratory during the same time period when the OOS result occurred. You identified the root cause as laboratory contamination and the unknown impurity to be (b)(4). In addition, you state you have hired a third-party consultant to review invalidated OOS results generated between April 1, 2019, and December 26, 2023, to determine if the decisions made to invalidate those results were scientifically justified.\n\nYour response is inadequate. You did not explain why root cause determinations in the OOS investigation were accepted by your firm multiple times, although insufficiently justified.\n\nYour quality system failed to ensure appropriate investigations to determine root causes, evaluate the impact of OOS results, and ensure effective CAPA. We recommend that the retrospective review also includes an evaluation of the data associated with pending and approved drug application submissions.\n\nYour OOS investigations conclusions fail to include sufficient rigor and scope in determining root causes and the extent of deviations and drug product impact.\n\nFor more information about handling failing, out-of-specification, out-of-trend, or other unexpected results and documentation of your investigations, see FDA’s current guidance document Investigating Out-of-Specification (OOS) Test Results for Pharmaceutical Production at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Finvestigating-out-specification-oos-test-results-pharmaceutical-production-level-2-revision.\n\nIn response to this letter, provide:\n\nA retrospective, independent review of all invalidated OOS (including in-process and release\u002Fstability testing) results for U.S. products for the last three years from the initial date of inspection and a report summarizing the findings of the analysis, including the following for each OOS:\n\no Determine whether the scientific justification and evidence relating to the invalidated OOS result conclusively or inconclusively demonstrates causative laboratory error.\n\no For investigations that conclusively establish laboratory root cause, provide rationale and ensure that all other laboratory methods vulnerable to the same or similar root cause are identified for remediation.\n\no For all OOS results found by the retrospective review to have an inconclusive or no root cause identified in the laboratory, include a thorough review of production (e.g., batch manufacturing records, adequacy of the manufacturing steps, suitability of equipment\u002Ffacilities, variability of raw materials, process capability, deviation history, complaint history, batch failure history). Provide a summary of potential manufacturing root causes for each investigation, and any manufacturing operation improvements.\n\nA comprehensive review and remediation plan for your OOS result investigation systems. The CAPA should include but not be limited to addressing the following:\n\no QU oversight of laboratory investigations\n\no Identification of adverse laboratory control trends\n\no Resolution of causes of laboratory variation\n\no Initiation of thorough investigations of potential manufacturing causes whenever a laboratory cause cannot be conclusively identified\n\no Adequately scoping of each investigation and its CAPA\n\no Revised OOS investigation procedures with these and other remediations\n\nA comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, OOS results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, QU oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\n\nAn independent assessment and remediation plan for your CAPA program. Provide a report that evaluates whether the program includes effective root cause analysis, ensures CAPA effectiveness, analyzes investigations trends, improves the CAPA program when needed, implements final QU decisions, and is fully supported by executive management.\n\nA comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\n\nRepeat Observation at Facility\n\nOn March 29, 2019, your firm was cited for inadequate cleaning and maintenance of manufacturing equipment. On April 13, 2017, your firm was cited for inadequate investigations of laboratory events regarding the recurrence of extraneous unidentified peaks. As a result of your 2017 inspection, you were issued a Response Letter dated September 29, 2017, that stated contaminated glassware should not be a frequent justification for rejecting or discarding aberrant result. Furthermore, the letter stated you should assess and identify additional CAPA to ensure clean laboratory glassware is utilized.\n\nYou described specific remediations for these observations in your responses.\n\nRepeat Violations at Multiple Sites\n\nFDA also cited a similar CGMP violation at other facilities in your company’s network. Sun Pharmaceutical Industries Ltd., (Halol site), FEI 3002809586, was issued a warning letter dated December 15, 2022 (later amended and dated October 16, 2023), for violation of, among other items, 21 CFR 211.67(a) for inadequate cleaning and maintenance of a (b)(4). You committed to conduct a comprehensive assessment of your global manufacturing operations across your company’s network to ensure conformance to FDA requirements.\n\nThese repeated failures at multiple sites demonstrate that management oversight and control over the manufacture of drugs is inadequate.\n\nWe note the initial steps that you outlined in your written response to this inspection, including changes in key senior leaders at corporate and site levels, and modifications to your corporate structure that are intended to enhance quality oversight.\n\nYour executive management remains responsible for fully resolving all deficiencies and ensuring ongoing CGMP compliance.\n\nIneffective Quality Systems\n\nSignificant findings in this letter demonstrate that your firm does not operate an effective quality system in accord with CGMP. In addition to the lack of effective management oversight of your production and laboratory operations, we found your QU is not enabled to exercise proper authority and\u002For has insufficiently implemented its responsibilities. Executive management should immediately and comprehensively assess your company’s global manufacturing operations to ensure that your systems, processes, and products conform to FDA requirements.\n\nCGMP Consultant Recommendation\n\nWe strongly recommend that your firm engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements.\n\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nIf you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(b). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\n\nCorrect any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\n\nFailure to address any violations may also result in the FDA refusing admission of articles manufactured at Sun Pharmaceutical Industries Ltd., Dadra, into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3004561553 and ATTN: Christina Alemu-Cruickshank.\n\nSincerely,\n\n\u002FS\u002F\n\nFrancis Godwin\n\nDirector\n\nOffice of Manufacturing Quality\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research","Sun Pharmaceutical Industries Limited","sun-pharmaceutical-industries-limited-677337-06182024","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsun-pharmaceutical-industries-limited-677337-06182024","2026-10-26T08:10:07.086028+00:00","2024-07-02","677337","Mr. Dilip Shanghvi","2026-08-20T00:00:11.659+00:00","2024-06-18",{"id":381,"raw":382,"subject":12,"body_html":387,"body_text":388,"firm_name":389,"letter_id":390,"created_at":65,"fei_number":19,"letter_url":391,"updated_at":392,"action_type":22,"case_status":23,"posted_date":393,"marcs_cms_no":394,"product_type":26,"closeout_date":19,"issuing_office":58,"recipient_name":377,"body_fetched_at":395,"delivery_method":110,"recipient_title":19,"reference_number":19,"action_taken_date":393,"medical_device_id":19,"response_letter_date":19},1796,[383,384,385,58,386,13,13,13],"\u003Ctime datetime=\"2023-10-16T13:20:00Z\">10\u002F16\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-10-16T04:00:00Z\">10\u002F16\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsun-pharmaceutical-industries-ltd-636199-10162023\">Sun Pharmaceutical Industries Ltd.\u003C\u002Fa>","CGMP\u002FActive Pharmaceutical Ingredient (API)\u002FAdulterated\u003Cbr \u002F>\r\n","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Dilip Shanghvi\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Managing Director\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Sun Pharmaceutical Industries Ltd.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Sun House, Plot No. 201 B\u002F1\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Western Express Highway Goregaon East\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Mumbai\u003C\u002Fspan> \u003Cspan>400063\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Maharashtra\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>India\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:Dilip.Shanghvi@sunpharma.com\"> Dilip.Shanghvi@sunpharma.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-23-08\u003C\u002Fp>\n\n\u003Cp>October 16, 2023\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>AMENDED\u003C\u002Fstrong>\u003Cbr>\n(This letter replaces Warning Letter No. 320-23-08 dated December 15, 2022.)\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Shanghvi:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Sun Pharmaceutical Industries Ltd., FEI 3002809586, at Halol-Baroda Highway, Dist. Panchmahal, Halol 389350, Gujrat, India, from April 26 to May 9, 2022.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>We reviewed your May 31, 2022, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes (21 CFR 211.113(b)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Inadequate Media Fills\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>Your media fills failed to accurately simulate commercial operations. Our inspection found the aseptic operations simulated during your media fills were not sufficiently representative of commercial aseptic manufacturing operations for medroxyprogesterone acetate injectable suspension USP, 150 mg\u002FmL, 1 ml prefilled syringes and vials. For example, data from the inspection indicated:\u003C\u002Fp>\n\n\u003Cp>A. Personnel simulated the manual addition of approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> grams of sterile \u003Cstrong>(b)(4)\u003C\u002Fstrong> to the compounding tank for up to \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, for commercial manufacturing, approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> grams of sterile active pharmaceutical ingredient (API) was added to the compounding tank. This hand \u003Cstrong>(b)(4)\u003C\u002Fstrong> operation took up to \u003Cstrong>(b)(4)\u003C\u002Fstrong> and included a \u003Cstrong>(b)(4)\u003C\u002Fstrong> change during routine commercial manufacturing.\u003C\u002Fp>\n\n\u003Cp>B. Approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> grams of sterile \u003Cstrong>(b)(4)\u003C\u002Fstrong> was hand-\u003Cstrong>(b)(4)\u003C\u002Fstrong> from \u003Cstrong>(b)(4)\u003C\u002Fstrong> sealed \u003Cstrong>(b)(4)\u003C\u002Fstrong> container into \u003Cstrong>(b)(4)\u003C\u002Fstrong> or more \u003Cstrong>(b)(4)\u003C\u002Fstrong>. This process was not consistent with commercial manufacturing, where approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> grams of sterile API was hand-\u003Cstrong>(b)(4)\u003C\u002Fstrong> from \u003Cstrong>(b)(4)\u003C\u002Fstrong> different \u003Cstrong>(b)(4)\u003C\u002Fstrong> pouches into \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Pouches used in commercial manufacturing may also have been previously opened and re-sealed.\u003C\u002Fp>\n\n\u003Cp>The dispensing and compounding steps were high-risk steps, and there were no additional sterilization steps following these operations.\u003C\u002Fp>\n\n\u003Cp>Your operators performed lengthy, highly manually intensive aseptic operations. As such, the duration of process simulation should closely resemble the actual manufacturing process. If a media fill program fails to incorporate contamination risk factors and closely simulate actual drug product exposure, the state of process control and sterility assurance cannot be accurately assessed.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Poor Aseptic Behavior\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>Media fill and smoke studies of your manually intensive aseptic operations, such as dispensing of sterile API, and addition of sterile API to the compounding tank, revealed poor aseptic techniques by your operators. Examples include, but are not limited to:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>An operator inserted his gloved hand inside the \u003Cstrong>(b)(4)\u003C\u002Fstrong> to \u003Cstrong>(b)(4)\u003C\u002Fstrong> out sterile \u003Cstrong>(b)(4)\u003C\u002Fstrong> with a \u003Cstrong>(b)(4)\u003C\u002Fstrong> utensil.\u003C\u002Fli>\n\t\u003Cli>An operator touched the product contact surface of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> stopper prior to placing it back on the \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fli>\n\t\u003Cli>Operator movements in the critical areas were not always slow and deliberate.\u003C\u002Fli>\n\t\u003Cli>An operator blocked \u003Cstrong>(b)(4)\u003C\u002Fstrong> air during various activities, including but not limited to, reaching over the open sterile \u003Cstrong>(b)(4)\u003C\u002Fstrong> container multiple times, and tilting the \u003Cstrong>(b)(4)\u003C\u002Fstrong> towards his body to visualize its interior while \u003Cstrong>(b)(4)\u003C\u002Fstrong> out the sterile \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Your response is inadequate. You experienced a significant media fill failure in November 2021, which revealed serious flaws and risks in your operation. You failed to perform a timely risk assessment to evaluate if the quality and sterility of your distributed drug products were affected by these deficiencies. You waited over five months to initiate a recall of the affected batches. The failure to proactively identify deficiencies and implement timely and sustainable corrective actions and preventive actions (CAPA) is unacceptable because it puts patients at risk.\u003C\u002Fp>\n\n\u003Cp>We acknowledge you discontinued medroxyprogesterone acetate injectable suspension pre-filled syringe and vial manufacturing operations in Block \u003Cstrong>(b)(4)\u003C\u002Fstrong> as of November 30, 2021. This decision was based on the risks identified through your media fill failure investigation. You recalled all batches of the drug product following the FDA inspection. We also acknowledge that you intend to move the manufacturing operations to a new block equipped with \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>See FDA’s guidance document \u003Cem>Sterile Drug Products Produced by Aseptic Processing - Current Good Manufacturing Practice\u003C\u002Fem> to help you meet the CGMP requirements when manufacturing sterile drugs using aseptic processing, at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71026\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Your plan to ensure appropriate aseptic practices and cleanroom behavior during production. Include steps to ensure routine and effective supervisory oversight for all production batches. Also describe the frequency of quality unit (QU) oversight (e.g., audit) during aseptic processing and its support operations.\u003C\u002Fli>\n\t\u003Cli>A thorough retrospective review and risk assessment that evaluates how poor aseptic technique and cleanroom behavior may have affected the quality and sterility of your drug products.\u003C\u002Fli>\n\t\u003Cli>A comprehensive review of your media fill program, and CAPA to ensure an accurate simulation, including appropriately incorporating the worst-case conditions of commercial manufacturing.\u003C\u002Fli>\n\t\u003Cli>A list of the third parties performing consulting functions for your firm. Include their responsibilities and an estimated time frame for completion of their activities.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>2. Your firm failed to perform operations within specifically defined areas of adequate size and to have separate or defined areas or such other control systems necessary to prevent contamination or mix-ups in aseptic processing areas (21 CFR 211.42(c)(10)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Cleanroom Design\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>Your ISO 5 cleanroom areas used for aseptic compounding and filling were poorly designed and lacked adequate protection. For example, your ISO 5 area in Room \u003Cstrong>(b)(4)\u003C\u002Fstrong> lacked physical barriers to prevent potential contamination of your sterile components, including the sterile API, during manually intensive dispensing and compounding operations. Operators’ bodies and hands were in immediate proximity to the sterile API during dispensing, compounding, and syringe-loading in the filling station. Additionally, operators hand-\u003Cstrong>(b)(4)\u003C\u002Fstrong> sterile components into a compounding tank through a large funnel with a wide opening. Your smoke studies demonstrated non-unidirectional, recirculating airflow on and around the funnel.\u003C\u002Fp>\n\n\u003Cp>The ISO 5 area is critical because sterile drug products are exposed and therefore vulnerable to contamination. Your aseptic manufacturing process should be designed and operations should be executed to minimize contamination hazards to your sterile drug product. Basic design deficiencies and manually intensive interventions in your operation undermine the ability to maintain asepsis.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Environmental Monitoring\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>You failed to establish an adequate system for monitoring environmental conditions. For example, you did not perform viable (surface and air) environmental monitoring in close proximity to aseptic dispensing operations in Room \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Likewise, no environmental monitoring was performed where sterile API was manually added to the compounding tank. Data reviewed during the inspection noted this aseptic operation lasted up to \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your protocol failed to identify these locations as “high-risk” sampling points for environmental monitoring. Furthermore, personnel monitoring data was not captured appropriately.\u003C\u002Fp>\n\n\u003Cp>Vigilant and responsive environmental and personnel monitoring programs should be designed to provide meaningful information on the state of control of your aseptic processing environment. Operations that include highly manually intensive aseptic activities warrant a more extensive environmental and personnel monitoring program, including but not limited to emphasis on well-timed sampling that appropriately monitors batch manufacturing conditions.\u003C\u002Fp>\n\n\u003Cp>In your response you acknowledge the inadequacies of your environmental and personnel monitoring program. You state the drug products impacted by the observation are being recalled, and the specific filling line (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) involved in the observation is no longer in use. You provide a high-level overview of an action plan with assurance to map the manufacturing process from a contamination prevention perspective.\u003C\u002Fp>\n\n\u003Cp>You fail to adequately explain how your quality and operations management will ensure appropriate cleanroom design, control, aseptic practices, and cleanroom behavior during production.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive, independent risk assessment of all contamination hazards with respect to your aseptic processes, equipment, and facilities, including an independent assessment that includes, but is not limited to:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o All human interactions within the ISO 5 area\u003Cbr>\n&nbsp; &nbsp; o Equipment placement and ergonomics\u003Cbr>\n&nbsp; &nbsp; o Air quality in the ISO 5 area and surrounding room\u003Cbr>\n&nbsp; &nbsp; o Facility layout\u003Cbr>\n&nbsp; &nbsp; o Personnel Flows and Material Flows (throughout all rooms used to conduct and support sterile operations)\u003C\u002Fp>\n\n\u003Cp>Provide this comprehensive assessment for each of your aseptic operations.\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A detailed remediation plan with timelines to address the findings of the contamination hazards risk assessment. Describe specific tangible improvements to be made to aseptic processing operation design and control.\u003C\u002Fli>\n\t\u003Cli>A comprehensive, independent review of your personnel and environmental monitoring programs, including but not limited to a plan to fully remediate these programs. For example, describe changes to equipment, procedures, and practices that will ensure meaningful ongoing data is collected to promptly detect and respond to emerging risks in your classified areas. Also include your plan to perform appropriate non-viable particulate monitoring to sufficiently support manufacturing of aseptically filled powdered drug products. Provide an updated timeline for implementation of your program, including a summary of the CAPA steps you will be undertaking to ensure effective remediation.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>3. Your firm failed to use equipment in the manufacture, processing, packing, or holding of drug products that is of appropriate design, adequate size, and suitably located to facilitate operations for its intended use and for its cleaning and maintenance (21 CFR 211.63).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You failed to identify and use equipment suitable for the filling of your viscous parenteral drug product. Inappropriately designed vial filling equipment led to substantial extraneous matter contamination in testosterone cypionate injection 200 mg\u002FmL, 1 ml vials. Further, your production department failed to establish adequate personnel practices and supervisory oversight to prevent the use of damaged equipment.\u003C\u002Fp>\n\n\u003Cp>You determined the design of the filling equipment (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) in combination with the viscous nature of your drug product generated friction. This friction caused an abrasive effect on the surface of \u003Cstrong>(b)(4)\u003C\u002Fstrong> during \u003Cstrong>(b)(4)\u003C\u002Fstrong> movement which introduced blackish fine metallic particles into your vial during filling. You explained that these \u003Cstrong>(b)(4)\u003C\u002Fstrong> could not be fixed once damaged. Although reportedly removed from service, the damaged \u003Cstrong>(b)(4)\u003C\u002Fstrong> were listed as approved equipment in your master manufacturing batch record approved on April 5, 2022, approximately two years after they were identified as the root cause for cross-contamination.\u003C\u002Fp>\n\n\u003Cp>Notably, one of the damaged \u003Cstrong>(b)(4)\u003C\u002Fstrong> (H102) was used to fill numerous batches of testosterone cypionate injection.\u003C\u002Fp>\n\n\u003Cp>It is your responsibility to ensure that only appropriately designed and maintained equipment are used in the manufacture of your drug products.\u003C\u002Fp>\n\n\u003Cp>We acknowledge that after our inspection you voluntarily recalled five marketed testosterone cypionate injection lots associated with the \u003Cstrong>(b)(4)\u003C\u002Fstrong> investigations.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate. Your response fails to address the flaws in your change management system that permitted continued use of damaged and inappropriately designed \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your response states that damaged \u003Cstrong>(b)(4)\u003C\u002Fstrong> were isolated and not used in filling testosterone cypionate injection but were inadvertently not removed from the manufacturing batch record. You also state that an associated \u003Cstrong>(b)(4)\u003C\u002Fstrong> (H102) was reconditioned and was acceptable for use. However, your firm indicated during the inspection that these damaged \u003Cstrong>(b)(4)\u003C\u002Fstrong> could not be reconditioned and acknowledged that they were not suitably designed. Your response also did not include a risk assessment that thoroughly evaluates the design and lifecycle control of manufacturing equipment including \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Your CAPA plan to implement routine, vigilant operations management oversight (corporate and local) of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, appropriately qualified production management personnel, and improved systems for ongoing management review. Your plan should also ensure that appropriate actions are taken throughout the company network.\u003C\u002Fli>\n\t\u003Cli>A thorough evaluation and risk assessment that addresses the suitability of your equipment for its intended use. You should include a determination of whether equipment is of appropriate design and a robust program for ongoing control and maintenance. Also describe how Quality Assurance will oversee the efficacy of systems used by operations to accomplish these critical objectives.\u003C\u002Fli>\n\t\u003Cli>An independent retrospective review of your manufacturing batch records to ensure that defective \u003Cstrong>(b)(4)\u003C\u002Fstrong> manufactured by \u003Cstrong>(b)(4)\u003C\u002Fstrong> or \u003Cstrong>(b)(4)\u003C\u002Fstrong> were not used during filling operations.\u003C\u002Fli>\n\t\u003Cli>An independent retrospective review of all complaints, including the associated investigations, for discoloration and particulates, for sterile drug products within expiry as of the date of this letter. Include the drug product name, batch number, and date of manufacture, line number, along with a summary of the complaint, description of likely root cause(s), CAPA plan, and status of CAPA.\u003C\u002Fli>\n\t\u003Cli>An independent, comprehensive review of your complaint system that identifies deficiencies in the system and corresponding CAPA that are needed.\u003C\u002Fli>\n\t\u003Cli>A comprehensive, independent assessment of your change management system. This assessment should include, but not be limited to, your procedure(s) to ensure changes are appropriately justified, evaluated, and reviewed to a final determination of acceptability by your QU. Your change management program should include provisions for determining change effectiveness.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>4. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your investigations into water leaks in your cleanroom were inadequate because they lacked appropriate CAPA and failed to extend to other potentially affected batches.\u003C\u002Fp>\n\n\u003Cp>For example, water leaked from the service floor through the heating, ventilation, and air conditioning (HVAC) duct floor and into the ceiling directly above the ISO 5 filling area. Your investigation report noted water accumulated on the service floor due to a leak from an old, punctured \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Water then collected over the \u003Cstrong>(b)(4)\u003C\u002Fstrong> partition ceiling prior to entering the aseptic filling room where medroxyprogesterone acetate injectable suspension USP, was manufactured. Your personnel confirmed there was substantial water accumulation on the service floor.\u003C\u002Fp>\n\n\u003Cp>Although you sealed gaps in the ceiling, you did not sufficiently inspect the service floor, \u003Cstrong>(b)(4)\u003C\u002Fstrong> LAF ceiling, and HVAC duct floor for mold growth and water damage after the repairs were made. You also failed to extend the scope of your investigation to potentially impacted batches of medroxyprogesterone acetate injectable suspension USP manufactured in this room since the last preventive maintenance of the \u003Cstrong>(b)(4)\u003C\u002Fstrong>, approximately two months before the leak was observed.\u003C\u002Fp>\n\n\u003Cp>In your response, you state the leak was isolated to the day it was observed. You acknowledge that your investigation did not evaluate the impact of the leak to other batches. You initiated a recall on May 17, 2022, for all marketed batches of medroxyprogesterone acetate injectable suspension USP, 150 mg\u002FmL, 1 mL vials manufactured on this line, for events unrelated to this investigation.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate. While we acknowledge you initiated actions to address this specific leak, your investigation failed to sufficiently address facility damage and the potential for microbial (i.e., particularly fungal) contamination that could persist in the facility due to water leaks and moisture.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide a comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, OOS results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, quality assurance unit oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>5. Your firm failed to clean, maintain, and, as appropriate for the nature of the drug, sanitize and\u002For sterilize equipment and utensils at appropriate intervals to prevent malfunctions or contamination that would alter the safety, identity, strength, quality, or purity of the drug product beyond the official or other established requirements (21 CFR 211.67(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You failed to adequately clean and maintain your equipment used for drug product manufacturing. For example:\u003C\u002Fp>\n\n\u003Cp>A. Our investigators observed visible residue on \u003Cstrong>(b)(4)\u003C\u002Fstrong> 1 after it was identified as clean. Also, colored particles and pellets were observed inside a crevice where the \u003Cstrong>(b)(4)\u003C\u002Fstrong> was attached to \u003Cstrong>(b)(4)\u003C\u002Fstrong> 1. During the inspection your analytical testing identified that the pellets contained \u003Cstrong>(b)(4)\u003C\u002Fstrong> API.\u003C\u002Fp>\n\n\u003Cp>The equipment cleaning record indicated a Type-B cleaning was performed on \u003Cstrong>(b)(4)\u003C\u002Fstrong> 1, which is defined as complete removal of previous drug product and involves dismantling of \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>B. Our investigators observed numerous scratches and dents on product contact surfaces of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> 1 bowl-II. Additionally, shiny metal fragments were observed on the top of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> gaskets that connected the \u003Cstrong>(b)(4)\u003C\u002Fstrong> in \u003Cstrong>(b)(4)\u003C\u002Fstrong> 4.\u003C\u002Fp>\n\n\u003Cp>Inadequately cleaned and maintained equipment can lead to cross contamination and poor quality drug products.\u003C\u002Fp>\n\n\u003Cp>Your response states that the \u003Cstrong>(b)(4)\u003C\u002Fstrong> was not disassembled during the cleaning process because engineering staff was not available. The residue and powder were from the previously manufactured drug product (which was the same drug). You also confirm the shiny fragments on the \u003Cstrong>(b)(4)\u003C\u002Fstrong> gaskets are \u003Cstrong>(b)(4)\u003C\u002Fstrong> and stated that the shedding of metal fragments most likely occurred during the assembly and disassembly process. You state that your protocol-based visual inspection of \u003Cstrong>(b)(4)\u003C\u002Fstrong> performed in response to this observation did not result in any similar findings.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate. You state that your impact assessment is ongoing, and the batches manufactured since the last campaign are on hold. However, you do not provide information on how long the damaged and inadequately cleaned equipment has been used. You also do not provide a risk assessment for drug products manufactured and distributed using such equipment.\u003C\u002Fp>\n\n\u003Cp>Your response fails to sufficiently address the confirmed complaints you received since January 2020 pertaining to stains, specks, and spots in your \u003Cstrong>(b)(4)\u003C\u002Fstrong> tablets, \u003Cstrong>(b)(4)\u003C\u002Fstrong> mg, and \u003Cstrong>(b)(4)\u003C\u002Fstrong> tablets \u003Cstrong>(b)(4)\u003C\u002Fstrong>mg drug products.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive, independent retrospective assessment of your cleaning effectiveness to evaluate the scope of cross-contamination hazards. Include the identity of residues, other manufacturing equipment that may have been improperly cleaned, and an assessment whether cross-contaminated drug products may have been released for distribution. The assessment should identify any inadequacies of cleaning procedures and practices and encompass each piece of manufacturing equipment used to manufacture more than one drug product.\u003C\u002Fli>\n\t\u003Cli>A CAPA plan, based on the retrospective assessment of your cleaning program, that includes appropriate remediations to your cleaning processes and practices, and timelines for completion. Provide a detailed summary of vulnerabilities in your process for lifecycle management of equipment cleaning. Describe improvements to your cleaning program, including enhancements to cleaning effectiveness; improved ongoing verification of proper cleaning execution for all products and equipment; and all other needed remediations.\u003C\u002Fli>\n\t\u003Cli>An independent review of your investigations and complaints of foreign matter contamination in your products. The review should comprehensively assess your program, including but not limited to sources of foreign matter, risks associated with the product, and appropriate investigations and CAPA.\u003C\u002Fli>\n\t\u003Cli>Your protocol to test any drug product, within expiry and manufactured on non-dedicated \u003Cstrong>(b)(4)\u003C\u002Fstrong> equipment, for contamination.\u003C\u002Fli>\n\t\u003Cli>A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to, evaluating:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o whether procedures used by your firm are robust and appropriate\u003Cbr>\n&nbsp; &nbsp; o sufficiency of provisions used for QU oversight throughout your operations to evaluate adherence to appropriate practices\u003Cbr>\n&nbsp; &nbsp; o whether an effective and complete final review of each batch and its related information is conducted before the QU disposition decision\u003Cbr>\n&nbsp; &nbsp; o implementation of oversight and approval of investigations, as well as discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Ineffective Quality Systems\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Significant findings in this letter demonstrate that your firm does not operate an effective quality system in accordance with CGMP. In addition to the lack of effective oversight of production operations to ensure reliable facilities and equipment, we found your QU is insufficiently resourced or enabled with authority to carry out its responsibilities. Furthermore, internal communications and systems were not implemented by management to ensure all levels of the company can effectively identify major quality risks so they are promptly escalated to senior management, whenever needed. You should immediately and comprehensively assess your company’s global manufacturing operations to ensure that systems, processes, and the products manufactured conform to FDA requirements.\u003C\u002Fp>\n\n\u003Cp>The role of senior management leadership is critical to ensure successful functioning of a robust and effective quality system. See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk-management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211, at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the violations we identified at your firm, we strongly recommend engaging a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements.\u003C\u002Fp>\n\n\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>If you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(b). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\u003C\u002Fp>\n\n\u003Cp>FDA placed your firm on Import Alert 66-40 on December 7, 2022.\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\u003C\u002Fp>\n\n\u003Cp>Failure to address any violations may also result in the FDA refusing admission of articles manufactured at Sun Pharmaceutical Industries Ltd, Halol, into the United States under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion. We request you email CDER-OC-OMQ-Communications@fda.hhs.gov, within five days of receipt of this letter to schedule a regulatory meeting.\u003C\u002Fp>\n\n\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3002809586 and ATTN: Ganesh Joshi, Compliance Officer.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Francis Godwin\u003Cbr>\nDirector\u003Cbr>\nOffice of Manufacturing Quality\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Dilip Shanghvi\n\nRecipient Title\n\nManaging Director\n\nSun Pharmaceutical Industries Ltd.\n\nSun House, Plot No. 201 B\u002F1\n\nWestern Express Highway Goregaon East\n\nMumbai 400063\n\nMaharashtra\n\nIndia\n\nDilip.Shanghvi@sunpharma.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nWarning Letter 320-23-08\n\nOctober 16, 2023\n\nAMENDED\n\n(This letter replaces Warning Letter No. 320-23-08 dated December 15, 2022.)\n\nDear Mr. Shanghvi:\n\nThe U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Sun Pharmaceutical Industries Ltd., FEI 3002809586, at Halol-Baroda Highway, Dist. Panchmahal, Halol 389350, Gujrat, India, from April 26 to May 9, 2022.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\n\nWe reviewed your May 31, 2022, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\n\nCGMP Violations\n\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n\n1. Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes (21 CFR 211.113(b)).\n\nInadequate Media Fills\n\nYour media fills failed to accurately simulate commercial operations. Our inspection found the aseptic operations simulated during your media fills were not sufficiently representative of commercial aseptic manufacturing operations for medroxyprogesterone acetate injectable suspension USP, 150 mg\u002FmL, 1 ml prefilled syringes and vials. For example, data from the inspection indicated:\n\nA. Personnel simulated the manual addition of approximately (b)(4) grams of sterile (b)(4) to the compounding tank for up to (b)(4). However, for commercial manufacturing, approximately (b)(4) grams of sterile active pharmaceutical ingredient (API) was added to the compounding tank. This hand (b)(4) operation took up to (b)(4) and included a (b)(4) change during routine commercial manufacturing.\n\nB. Approximately (b)(4) grams of sterile (b)(4) was hand-(b)(4) from (b)(4) sealed (b)(4) container into (b)(4) or more (b)(4). This process was not consistent with commercial manufacturing, where approximately (b)(4) grams of sterile API was hand-(b)(4) from (b)(4) different (b)(4) pouches into (b)(4). Pouches used in commercial manufacturing may also have been previously opened and re-sealed.\n\nThe dispensing and compounding steps were high-risk steps, and there were no additional sterilization steps following these operations.\n\nYour operators performed lengthy, highly manually intensive aseptic operations. As such, the duration of process simulation should closely resemble the actual manufacturing process. If a media fill program fails to incorporate contamination risk factors and closely simulate actual drug product exposure, the state of process control and sterility assurance cannot be accurately assessed.\n\nPoor Aseptic Behavior\n\nMedia fill and smoke studies of your manually intensive aseptic operations, such as dispensing of sterile API, and addition of sterile API to the compounding tank, revealed poor aseptic techniques by your operators. Examples include, but are not limited to:\n\nAn operator inserted his gloved hand inside the (b)(4) to (b)(4) out sterile (b)(4) with a (b)(4) utensil.\n\nAn operator touched the product contact surface of the (b)(4) stopper prior to placing it back on the (b)(4).\n\nOperator movements in the critical areas were not always slow and deliberate.\n\nAn operator blocked (b)(4) air during various activities, including but not limited to, reaching over the open sterile (b)(4) container multiple times, and tilting the (b)(4) towards his body to visualize its interior while (b)(4) out the sterile (b)(4).\n\nYour response is inadequate. You experienced a significant media fill failure in November 2021, which revealed serious flaws and risks in your operation. You failed to perform a timely risk assessment to evaluate if the quality and sterility of your distributed drug products were affected by these deficiencies. You waited over five months to initiate a recall of the affected batches. The failure to proactively identify deficiencies and implement timely and sustainable corrective actions and preventive actions (CAPA) is unacceptable because it puts patients at risk.\n\nWe acknowledge you discontinued medroxyprogesterone acetate injectable suspension pre-filled syringe and vial manufacturing operations in Block (b)(4) as of November 30, 2021. This decision was based on the risks identified through your media fill failure investigation. You recalled all batches of the drug product following the FDA inspection. We also acknowledge that you intend to move the manufacturing operations to a new block equipped with (b)(4).\n\nSee FDA’s guidance document Sterile Drug Products Produced by Aseptic Processing - Current Good Manufacturing Practice to help you meet the CGMP requirements when manufacturing sterile drugs using aseptic processing, at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71026\u002Fdownload.\n\nIn response to this letter, provide the following:\n\nYour plan to ensure appropriate aseptic practices and cleanroom behavior during production. Include steps to ensure routine and effective supervisory oversight for all production batches. Also describe the frequency of quality unit (QU) oversight (e.g., audit) during aseptic processing and its support operations.\n\nA thorough retrospective review and risk assessment that evaluates how poor aseptic technique and cleanroom behavior may have affected the quality and sterility of your drug products.\n\nA comprehensive review of your media fill program, and CAPA to ensure an accurate simulation, including appropriately incorporating the worst-case conditions of commercial manufacturing.\n\nA list of the third parties performing consulting functions for your firm. Include their responsibilities and an estimated time frame for completion of their activities.\n\n2. Your firm failed to perform operations within specifically defined areas of adequate size and to have separate or defined areas or such other control systems necessary to prevent contamination or mix-ups in aseptic processing areas (21 CFR 211.42(c)(10)).\n\nCleanroom Design\n\nYour ISO 5 cleanroom areas used for aseptic compounding and filling were poorly designed and lacked adequate protection. For example, your ISO 5 area in Room (b)(4) lacked physical barriers to prevent potential contamination of your sterile components, including the sterile API, during manually intensive dispensing and compounding operations. Operators’ bodies and hands were in immediate proximity to the sterile API during dispensing, compounding, and syringe-loading in the filling station. Additionally, operators hand-(b)(4) sterile components into a compounding tank through a large funnel with a wide opening. Your smoke studies demonstrated non-unidirectional, recirculating airflow on and around the funnel.\n\nThe ISO 5 area is critical because sterile drug products are exposed and therefore vulnerable to contamination. Your aseptic manufacturing process should be designed and operations should be executed to minimize contamination hazards to your sterile drug product. Basic design deficiencies and manually intensive interventions in your operation undermine the ability to maintain asepsis.\n\nEnvironmental Monitoring\n\nYou failed to establish an adequate system for monitoring environmental conditions. For example, you did not perform viable (surface and air) environmental monitoring in close proximity to aseptic dispensing operations in Room (b)(4). Likewise, no environmental monitoring was performed where sterile API was manually added to the compounding tank. Data reviewed during the inspection noted this aseptic operation lasted up to (b)(4). Your protocol failed to identify these locations as “high-risk” sampling points for environmental monitoring. Furthermore, personnel monitoring data was not captured appropriately.\n\nVigilant and responsive environmental and personnel monitoring programs should be designed to provide meaningful information on the state of control of your aseptic processing environment. Operations that include highly manually intensive aseptic activities warrant a more extensive environmental and personnel monitoring program, including but not limited to emphasis on well-timed sampling that appropriately monitors batch manufacturing conditions.\n\nIn your response you acknowledge the inadequacies of your environmental and personnel monitoring program. You state the drug products impacted by the observation are being recalled, and the specific filling line ((b)(4)) involved in the observation is no longer in use. You provide a high-level overview of an action plan with assurance to map the manufacturing process from a contamination prevention perspective.\n\nYou fail to adequately explain how your quality and operations management will ensure appropriate cleanroom design, control, aseptic practices, and cleanroom behavior during production.\n\nIn response to this letter, provide the following:\n\nA comprehensive, independent risk assessment of all contamination hazards with respect to your aseptic processes, equipment, and facilities, including an independent assessment that includes, but is not limited to:\n\no All human interactions within the ISO 5 area\n\no Equipment placement and ergonomics\n\no Air quality in the ISO 5 area and surrounding room\n\no Facility layout\n\no Personnel Flows and Material Flows (throughout all rooms used to conduct and support sterile operations)\n\nProvide this comprehensive assessment for each of your aseptic operations.\n\nA detailed remediation plan with timelines to address the findings of the contamination hazards risk assessment. Describe specific tangible improvements to be made to aseptic processing operation design and control.\n\nA comprehensive, independent review of your personnel and environmental monitoring programs, including but not limited to a plan to fully remediate these programs. For example, describe changes to equipment, procedures, and practices that will ensure meaningful ongoing data is collected to promptly detect and respond to emerging risks in your classified areas. Also include your plan to perform appropriate non-viable particulate monitoring to sufficiently support manufacturing of aseptically filled powdered drug products. Provide an updated timeline for implementation of your program, including a summary of the CAPA steps you will be undertaking to ensure effective remediation.\n\n3. Your firm failed to use equipment in the manufacture, processing, packing, or holding of drug products that is of appropriate design, adequate size, and suitably located to facilitate operations for its intended use and for its cleaning and maintenance (21 CFR 211.63).\n\nYou failed to identify and use equipment suitable for the filling of your viscous parenteral drug product. Inappropriately designed vial filling equipment led to substantial extraneous matter contamination in testosterone cypionate injection 200 mg\u002FmL, 1 ml vials. Further, your production department failed to establish adequate personnel practices and supervisory oversight to prevent the use of damaged equipment.\n\nYou determined the design of the filling equipment ((b)(4)) in combination with the viscous nature of your drug product generated friction. This friction caused an abrasive effect on the surface of (b)(4) during (b)(4) movement which introduced blackish fine metallic particles into your vial during filling. You explained that these (b)(4) could not be fixed once damaged. Although reportedly removed from service, the damaged (b)(4) were listed as approved equipment in your master manufacturing batch record approved on April 5, 2022, approximately two years after they were identified as the root cause for cross-contamination.\n\nNotably, one of the damaged (b)(4) (H102) was used to fill numerous batches of testosterone cypionate injection.\n\nIt is your responsibility to ensure that only appropriately designed and maintained equipment are used in the manufacture of your drug products.\n\nWe acknowledge that after our inspection you voluntarily recalled five marketed testosterone cypionate injection lots associated with the (b)(4) investigations.\n\nYour response is inadequate. Your response fails to address the flaws in your change management system that permitted continued use of damaged and inappropriately designed (b)(4). Your response states that damaged (b)(4) were isolated and not used in filling testosterone cypionate injection but were inadvertently not removed from the manufacturing batch record. You also state that an associated (b)(4) (H102) was reconditioned and was acceptable for use. However, your firm indicated during the inspection that these damaged (b)(4) could not be reconditioned and acknowledged that they were not suitably designed. Your response also did not include a risk assessment that thoroughly evaluates the design and lifecycle control of manufacturing equipment including (b)(4) and (b)(4).\n\nIn response to this letter, provide:\n\nYour CAPA plan to implement routine, vigilant operations management oversight (corporate and local) of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, appropriately qualified production management personnel, and improved systems for ongoing management review. Your plan should also ensure that appropriate actions are taken throughout the company network.\n\nA thorough evaluation and risk assessment that addresses the suitability of your equipment for its intended use. You should include a determination of whether equipment is of appropriate design and a robust program for ongoing control and maintenance. Also describe how Quality Assurance will oversee the efficacy of systems used by operations to accomplish these critical objectives.\n\nAn independent retrospective review of your manufacturing batch records to ensure that defective (b)(4) manufactured by (b)(4) or (b)(4) were not used during filling operations.\n\nAn independent retrospective review of all complaints, including the associated investigations, for discoloration and particulates, for sterile drug products within expiry as of the date of this letter. Include the drug product name, batch number, and date of manufacture, line number, along with a summary of the complaint, description of likely root cause(s), CAPA plan, and status of CAPA.\n\nAn independent, comprehensive review of your complaint system that identifies deficiencies in the system and corresponding CAPA that are needed.\n\nA comprehensive, independent assessment of your change management system. This assessment should include, but not be limited to, your procedure(s) to ensure changes are appropriately justified, evaluated, and reviewed to a final determination of acceptability by your QU. Your change management program should include provisions for determining change effectiveness.\n\n4. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\n\nYour investigations into water leaks in your cleanroom were inadequate because they lacked appropriate CAPA and failed to extend to other potentially affected batches.\n\nFor example, water leaked from the service floor through the heating, ventilation, and air conditioning (HVAC) duct floor and into the ceiling directly above the ISO 5 filling area. Your investigation report noted water accumulated on the service floor due to a leak from an old, punctured (b)(4). Water then collected over the (b)(4) partition ceiling prior to entering the aseptic filling room where medroxyprogesterone acetate injectable suspension USP, was manufactured. Your personnel confirmed there was substantial water accumulation on the service floor.\n\nAlthough you sealed gaps in the ceiling, you did not sufficiently inspect the service floor, (b)(4) LAF ceiling, and HVAC duct floor for mold growth and water damage after the repairs were made. You also failed to extend the scope of your investigation to potentially impacted batches of medroxyprogesterone acetate injectable suspension USP manufactured in this room since the last preventive maintenance of the (b)(4), approximately two months before the leak was observed.\n\nIn your response, you state the leak was isolated to the day it was observed. You acknowledge that your investigation did not evaluate the impact of the leak to other batches. You initiated a recall on May 17, 2022, for all marketed batches of medroxyprogesterone acetate injectable suspension USP, 150 mg\u002FmL, 1 mL vials manufactured on this line, for events unrelated to this investigation.\n\nYour response is inadequate. While we acknowledge you initiated actions to address this specific leak, your investigation failed to sufficiently address facility damage and the potential for microbial (i.e., particularly fungal) contamination that could persist in the facility due to water leaks and moisture.\n\nIn response to this letter, provide a comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, OOS results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, quality assurance unit oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\n\n5. Your firm failed to clean, maintain, and, as appropriate for the nature of the drug, sanitize and\u002For sterilize equipment and utensils at appropriate intervals to prevent malfunctions or contamination that would alter the safety, identity, strength, quality, or purity of the drug product beyond the official or other established requirements (21 CFR 211.67(a)).\n\nYou failed to adequately clean and maintain your equipment used for drug product manufacturing. For example:\n\nA. Our investigators observed visible residue on (b)(4) 1 after it was identified as clean. Also, colored particles and pellets were observed inside a crevice where the (b)(4) was attached to (b)(4) 1. During the inspection your analytical testing identified that the pellets contained (b)(4) API.\n\nThe equipment cleaning record indicated a Type-B cleaning was performed on (b)(4) 1, which is defined as complete removal of previous drug product and involves dismantling of (b)(4).\n\nB. Our investigators observed numerous scratches and dents on product contact surfaces of the (b)(4) 1 bowl-II. Additionally, shiny metal fragments were observed on the top of the (b)(4) gaskets that connected the (b)(4) in (b)(4) 4.\n\nInadequately cleaned and maintained equipment can lead to cross contamination and poor quality drug products.\n\nYour response states that the (b)(4) was not disassembled during the cleaning process because engineering staff was not available. The residue and powder were from the previously manufactured drug product (which was the same drug). You also confirm the shiny fragments on the (b)(4) gaskets are (b)(4) and stated that the shedding of metal fragments most likely occurred during the assembly and disassembly process. You state that your protocol-based visual inspection of (b)(4) performed in response to this observation did not result in any similar findings.\n\nYour response is inadequate. You state that your impact assessment is ongoing, and the batches manufactured since the last campaign are on hold. However, you do not provide information on how long the damaged and inadequately cleaned equipment has been used. You also do not provide a risk assessment for drug products manufactured and distributed using such equipment.\n\nYour response fails to sufficiently address the confirmed complaints you received since January 2020 pertaining to stains, specks, and spots in your (b)(4) tablets, (b)(4) mg, and (b)(4) tablets (b)(4)mg drug products.\n\nIn response to this letter, provide:\n\nA comprehensive, independent retrospective assessment of your cleaning effectiveness to evaluate the scope of cross-contamination hazards. Include the identity of residues, other manufacturing equipment that may have been improperly cleaned, and an assessment whether cross-contaminated drug products may have been released for distribution. The assessment should identify any inadequacies of cleaning procedures and practices and encompass each piece of manufacturing equipment used to manufacture more than one drug product.\n\nA CAPA plan, based on the retrospective assessment of your cleaning program, that includes appropriate remediations to your cleaning processes and practices, and timelines for completion. Provide a detailed summary of vulnerabilities in your process for lifecycle management of equipment cleaning. Describe improvements to your cleaning program, including enhancements to cleaning effectiveness; improved ongoing verification of proper cleaning execution for all products and equipment; and all other needed remediations.\n\nAn independent review of your investigations and complaints of foreign matter contamination in your products. The review should comprehensively assess your program, including but not limited to sources of foreign matter, risks associated with the product, and appropriate investigations and CAPA.\n\nYour protocol to test any drug product, within expiry and manufactured on non-dedicated (b)(4) equipment, for contamination.\n\nA comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to, evaluating:\n\no whether procedures used by your firm are robust and appropriate\n\no sufficiency of provisions used for QU oversight throughout your operations to evaluate adherence to appropriate practices\n\no whether an effective and complete final review of each batch and its related information is conducted before the QU disposition decision\n\no implementation of oversight and approval of investigations, as well as discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\n\nIneffective Quality Systems\n\nSignificant findings in this letter demonstrate that your firm does not operate an effective quality system in accordance with CGMP. In addition to the lack of effective oversight of production operations to ensure reliable facilities and equipment, we found your QU is insufficiently resourced or enabled with authority to carry out its responsibilities. Furthermore, internal communications and systems were not implemented by management to ensure all levels of the company can effectively identify major quality risks so they are promptly escalated to senior management, whenever needed. You should immediately and comprehensively assess your company’s global manufacturing operations to ensure that systems, processes, and the products manufactured conform to FDA requirements.\n\nThe role of senior management leadership is critical to ensure successful functioning of a robust and effective quality system. See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk-management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211, at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\n\nCGMP Consultant Recommended\n\nBased upon the nature of the violations we identified at your firm, we strongly recommend engaging a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements.\n\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nIf you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(b). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\n\nFDA placed your firm on Import Alert 66-40 on December 7, 2022.\n\nCorrect any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\n\nFailure to address any violations may also result in the FDA refusing admission of articles manufactured at Sun Pharmaceutical Industries Ltd, Halol, into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion. We request you email CDER-OC-OMQ-Communications@fda.hhs.gov, within five days of receipt of this letter to schedule a regulatory meeting.\n\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3002809586 and ATTN: Ganesh Joshi, Compliance Officer.\n\nSincerely,\n\n\u002FS\u002F\n\nFrancis Godwin\n\nDirector\n\nOffice of Manufacturing Quality\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research","Sun Pharmaceutical Industries Ltd.","sun-pharmaceutical-industries-ltd-636199-10162023","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsun-pharmaceutical-industries-ltd-636199-10162023","2026-10-26T08:10:07.189023+00:00","2023-10-16","636199","2026-08-20T00:35:49.477+00:00",93,{"510k":398,"classification":399,"enforcement":400,"event":401,"event_backfill":402,"pma":403,"warning_letter":404},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-17T04:00:34.414+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]